	Page 1
1	IN THE UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
4	
5	~~~~~~~~~~~~
6	
	IN RE: NATIONAL PRESCRIPTION MDL No. 2804
7	OPIATE LITIGATION
	Case No. 17-md-2804
8	
	Judge Dan Aaron
9	This document relates to: Polster
10	City of Cleveland v. AmerisourceBergen
	Drug Corp., et al.
11	
12	Case No. 1:18-OP-45132 (N.D. Ohio)
13	
14	~~~~~~~~~~
15	Videotaped deposition of
	MERLE GORDON
16	
17	July 19, 2018
	9:15 a.m.
18	
19	Taken at:
20	Taft Stettinius & Hollister LLP
21	200 Public Square, Suite 3500
22	Cleveland, Ohio
23	
24	
25	Renee L. Pellegrino, RPR, CLR

Page 2		Page
1 APPEARANCES: 2	1 APPEARANCES, CONT'D: 2	
3 On behalf of the City of Cleveland, the Witness	On behalf of Endo Pharmaceuticals, Inc., Endo	
and the Plaintiffs' Executive Committee (MDL):	3 Health Solutions, Inc., Par Pharmaceuticals,	
4 Baron & Budd, P.C.	Inc. and Par Pharmaceutical Companies, Inc.:	
MARK P. PIFKO, ESQ. THOMAS SIMS, ESQ. (Via Telephone)	4 Arnold & Porter	
Encino Plaza	CHARLES B. WEINOGRAD, ESQ. 5 601 Massachusetts Avenue, NW	
6 15910 Ventura Boulevard, Suite 1600	Washington, D.C. 20001-3743	
Encino, California 91436	6 (202) 942-5392	
7 (818) 839-2333 mpifko@baronbudd.com	charles.weinograd@arnoldporter.com	
8 tsims@baronbudd.com	7 On behalf of AmerisourceBergen:	
- and -	8 Reed Smith, LLP	
9 Zarsaur Mujumdar & Debrosse DIANDRA "FU" DEBROSSE ZIMMERMANN, ESO.	MICHAEL J. SALIMBENE, ESQ.	
DIANDRA "FU" DEBROSSE ZIMMERMANN, ESQ. 2332 2nd Avenue North	9 Three Logan Square	
Birmingham, Alabama 35203	1717 Arch Street, Suite 3100 10 Philadelphia, Pennsylvania 19103	
1 (205) 983-7985	(215) 851-8100	
fuli@zarzaur.com	11 msalimbene@reedsmith.com	
2 On behalf of Cuyahoga County:	12 On behalf of Teva Pharmaceutical Industries:	
Napoli Shkolnik PLLC	(Via Telephone)	
KEVIN SUSMAN, ESQ.	13 Morgan Lewis & Bockius LLP THEODORE DAYNO, ESQ.	
4 JOSEPH L. CIACCIO, ESQ.	14 600 Anton Boulevard	
400 Broadhollow Road 5 Suite 305	Suite 1800	
Melville, New York 11747	15 Costa Mesa, California 92626-7653	
6 (631) 224-1133	(714) 830-0600	
ksusman@napolilaw.com	16 tdayno@morganlewis.com 17 On behalf of Allergan:	
7 jciaccio@napolilaw.com - and -	(Via Telephone)	
8 Plevin & Gallucci	18 Kirkland & Ellis LLP	
FRANK L. GALLUCCI, III, ESQ.	ZACHARY A. CIULLO, ESQ.	
9 55 Public Square	19 300 N. LaSalle Drive	
Suite 2222 0 Cleveland, Ohio 44113-1901	Chicago, Illinois 60654 20 (312) 862-2000	
(216) 861-0804	zac.ciullo@kirkland.com	
1 fgallucci@pglawyer.com	21	
2	22 ~~~~	
3 ~~~~ 4	23 24	
5	25	
Page 3	1 APPEAR ANGES CONTER	Page
1 APPEARANCES, CONT'D 2	1 APPEARANCES, CONT'D:	
3 City of Cleveland:	3 On behalf of McKesson:	
ELENA BOOP, ESQ.	Covington & Burling LLP	
4 601 Lakeside Avenue, Room 106	4 ASEEM PADUKONE, ESQ.	
Cleveland, Ohio 44114 5 (216) 664-3727	One Front Street, #35	
	5 San Francisco, California 94111-5356	
eboop@city.cleveland.oh.us	(415) 591-6000	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron:	(415) 591-6000 6 apadukone@cov.com	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron: 7 Motley Rice LLC	(415) 591-6000	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ.	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.:	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron: 7 Motley Rice LLC	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 (843) 216-9140 akearse@motleyrice.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 (843) 216-9140 akearse@motleyrice.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron: 7 Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.:	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ.	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ.	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron: 7 Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW	
eboop@city.cleveland.oh.us 6 On behalf of Summit County and City of Akron: 7 Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq,naeem@tuckerellis.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq,naeem@tuckerellis.com madeline.dennis@tucker.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants:	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com 6 On behalf of Walmart:	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ.	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com On behalf of Walmart: Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com 6 On behalf of Walmart: 7 Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point 901 Lakeside Avenue East	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 9 50 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq,naeem@tuckerellis.com madeline.dennis@tucker.com On behalf of Walmart: 7 Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point 901 Lakeside Avenue East 9 Cleveland, Ohio 44114-1190	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005 19 (202) 434-5000	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq,naeem@tuckerellis.com madeline.dennis@tucker.com On behalf of Walmart: 7 Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. 8 North Point 901 Lakeside Avenue East 9 Cleveland, Ohio 44114-1190 (216) 586-3939	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 9 50 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq,naeem@tuckerellis.com madeline.dennis@tucker.com On behalf of Walmart: 7 Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point 901 Lakeside Avenue East 9 Cleveland, Ohio 44114-1190	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005 19 (202) 434-5000 pboehm@wc.com 20 21	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq, naeem@tuckerellis.com madeline.dennis@tucker.com On behalf of Walmart: Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point 901 Lakeside Avenue East 9 Cleveland, Ohio 44114-1190 (216) 586-3939 cmmclaughlin@jonesday.com 1	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005 19 (202) 434-5000 pboehm@we.com 20 21 ~~~~~	
eboop@city.cleveland.oh.us On behalf of Summit County and City of Akron: Motley Rice LLC ANNE MCGINNESS KEARSE, ESQ. 8 28 Bridgeside Boulevard Mt. Pleasant, South Carolina 29464 9 (843) 216-9140 akearse@motleyrice.com On behalf of Johnson & Johnson and Janssen 1 Pharmaceuticals, Inc.: Tucker Ellis LLP 2 TARIQ M. NAEEM, ESQ. MADELINE B. DENNIS, ESQ. 3 950 Main Avenue Suite 1100 4 Cleveland, Ohio 44113-7213 (216) 592-5000 5 tariq.naeem@tuckerellis.com madeline.dennis@tucker.com 6 On behalf of Walmart: 7 Jones Day CHRISTOPHER M. McLAUGHLIN, ESQ. North Point 901 Lakeside Avenue East 9 Cleveland, Ohio 44114-1190 (216) 586-3939 0 cmmclaughlin@jonesday.com 1	(415) 591-6000 6 apadukone@cov.com 7 On behalf of Miami-Luken, Inc.: Jackson Kelly PLLC 8 ERIN R. STANKEWICZ, ESQ. 1144 Market Street 9 Suite 400 Wheeling, West Virginia 26003 10 (304) 233-4000 erstankewicz@jacksonkelly.com 11 On behalf of Prescription Supply, Inc.: 12 Pelini Campbell & Williams KRISTEN E. CAMPBELL TRAUB, ESQ. 13 Bretton Commons, Suite 400 8040 Cleveland Avenue NW 14 North Canton, Ohio 44720 (330) 305-6400 15 kec@pelini-law.com 16 On behalf of Cardinal Health, Inc., co-liaison counsel for the Distributor Defendants: 17 Williams & Connolly LLP PAUL E. BOEHM, ESQ. 18 725 12th Street NW Washington, D.C. 20005 19 (202) 434-5000 pboehm@wc.com 20 21	

Page 6		Page 8
1 APPEARANCES, CONT'D:	1 INDEX OF EXHIBITS	1 4 5 0
2 3 On behalf of CVS Indiana, LLC and CVS Rx Services:	2 3 Number Description Marked	
Zuckerman Spaeder	4	
4 ANTHONY M. RUIZ, ESQ. 1800 M Street NW	5 Exhibit 1 Letter from Tad Allan to Mark 34 Pifko, dated July 18, 2018, with	
5 Suite 1000	6 Attached Exhibit A	
Washington, D.C. 20036-5807	7 Exhibit 1-A Document Entitled "Heroin and 35 Opioid Action Plan: Moving	
6 (202) 778-1800 aruiz@zuckerman.com	8 Forward, Agenda," with Attached	
7	Handwritten Notes, Beginning 9 Bates Stamp CLEVE 000298750	
On behalf of HBC Service Company:	10 Exhibit 1-B E-Mail from Gary Gingell to 36	
8 Marcus & Shapira ROBERT M. BARNES, ESQ.	Various Recipients dated March 11 6, 2018 Bates-Stamped	
9 One Oxford Centre, 35th Floor	CLEVE_000299033	
301 Grant Street 10 Pittsburgh, Pennsylvania 15219-6401	12 Exhibit 1-C Document Entitled "Cuyahoga 38	
(412) 471-3490	13 County State of Emergency Action	
11 rbarnes@marcus-shapira.com12 On behalf of Mallinckrodt Pharmaceuticals:	Steps," Beginning Bates Stamp 14 CLEVE 000299083	
(Via Telephone)	15 Exhibit 2 Ohio Prescription Drug Abuse 85	
13 Ropes & Gray LLP	Task Force Final Report, Task Force Recommendations, dated	
JESSICA F. SORICELLI, ESQ. 14 1211 Avenue of the Americas	October 1, 2010	
New York, New York 10036-8704	17 Evhibit 3 CDPH Bi-Weekly Drug Related ER 119	
15 (212) 596-9000	Exhibit 3 CDPH Bi-Weekly Drug Related ER 119 18 Visits Report	
jessica.soricelli@ropesgray.com 16	19 Exhibit 4 Document Entitled "Opiate 148 Response Presentation: Merle	
17 ALSO PRESENT: Jeff Koishor, Videographer	20 Gordon, Director of Public	
18 19 ~~~~	Health," Beginning Bates Stamp	
20	21 CLEVE_000187960 22 Exhibit 5 Cleveland City Council Committee 158	
21 22	Calendar dated December 1, 2016,	
23	23 with Attachments, Beginning Bates Stamp CLEVE 000189292	
24 25	24 25	
Page 7		Page C
Page 7	1 INDEX OF EXHIBITS, CONT'D	Page 9
1 TRANSCRIPT INDEX	2 Exhibit 6 Cleveland Opioid Response and 189	Page 9
1 TRANSCRIPT INDEX 2	2	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES2	2 Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 Z016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 Exhibit 8 Document Entitled "August 18, 224 Exhibit 8 Document Entitled "August 18, 224 Stamp CLEVE_000188105	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin,	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 13	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 Z016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 Z016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 Exhibit 8 Document Entitled "August 18, 224 Exhibit 8 Document Entitled "August 18, 224 Exhibit 9 Memo Groon 188105 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Stamp CLEVE_000189085 Exhibit 11 Letter from Leana S. Wen, M.D. 239	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice President-Elect Mike Pence,	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Document Entitled "August 18, 224 11 McGrath and Director Griffin, dated September 6, 2016, 2016, 2016, 2016 12 Beginning Bates Stamp CLEVE_000187963 13 Exhibit 10 E-Mail String Beginning Bates 229 14 Stamp CLEVE_000189085 15 Exhibit 11 Letter from Leans S. Wen, M.D. 239 to Governor and Vice 16 President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp CLEVE_000187508	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 13 Exhibit 10 E-Mail String Beginning Bates 229 14 Stamp CLEVE_000189085 15 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice 16 President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp CLEVE_000187508 18 Exhibit 12 Ohio Department of Health 2016 248	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 Z016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Document Entitled "August 18, 224 Exhibit 9 Memo from M. Gordon to Chief 228 McGrath and Director Griffin, dated September 6, 2016, 228 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice President-Elect Mike Pence, dated November 29, 2016, 329 To Beginning Bates Stamp CLEVE_00018708 Exhibit 12 Ohio Department of Health 2016 248 Ohio Drug Overdose Data: General Findings	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice 16 President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp CLEVE_000187508 Exhibit 12 Ohio Department of Health 2016 248 Ohio Drug Overdose Data:	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 13 Exhibit 10 E-Mail String Beginning Bates 229 14 Stamp CLEVE_000189085 15 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice 16 President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp CLEVE_000187508 18 Exhibit 12 Ohio Department of Health 2016 248 Ohio Drug Overdose Data: General Findings 20 Exhibit 13 E-Mail from Merle Gordon to Jana 255 Rush, dated August 25, 2016,	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 189 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 4 Exhibit 7 E-Mail from Merle Gordon to 224 5 Merle Gordon Bates-Stamped CLEVE-000188104 6 Exhibit 8 Document Entitled "August 18, 224 7 2016 Notes," Beginning Bates Stamp CLEVE_000188105 8 Exhibit 8 Document Entitled "August 18, 224 9 2016 Notes," Beginning Bates Stamp CLEVE_000188105 10 Exhibit 9 Memo from M. Gordon to Chief 228 11 McGrath and Director Griffin, dated September 6, 2016, 12 Beginning Bates Stamp CLEVE_000187963 13 Exhibit 10 E-Mail String Beginning Bates 229 14 Stamp CLEVE_000189085 15 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice 16 President-Elect Mike Pence, dated November 29, 2016, 17 Beginning Bates Stamp CLEVE_000187508 18 Exhibit 12 Ohio Department of Health 2016 248 19 Ohio Drug Overdose Data: General Findings 20 Exhibit 13 E-Mail from Merle Gordon to Jana 255 21 Rush, dated August 25, 2016, Beginning Bates Stamp CLEVE_000191543	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Exhibit 8 Document Entitled "August 18, 224 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice President-Elect Mike Pence, dated November 29, 2016, Beginning Bates Stamp CLEVE_000187508 Exhibit 12 Ohio Department of Health 2016 248 Ohio Drug Overdose Data: General Findings Exhibit 13 E-Mail from Merle Gordon to Jana 255 Exhibit 13 E-Mail from Merle Gordon to Jana 255 Exhibit 14 E-Mail from David Gretick to 259 Merle Gordon, dated July 11,	Page 9
1 TRANSCRIPT INDEX 2 3 APPEARANCES	Exhibit 6 Cleveland Opioid Response and 3 Action Plan (CORAP) Beginning Bates Stamp CLEVE-000183257 Exhibit 7 E-Mail from Merle Gordon to 224 Merle Gordon Bates-Stamped CLEVE-000188104 Exhibit 8 Document Entitled "August 18, 224 Z016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 8 Document Entitled "August 18, 224 2016 Notes," Beginning Bates Stamp CLEVE_000188105 Exhibit 9 Memo from M. Gordon to Chief 228 McGrath and Director Griffin, dated September 6, 2016, 228 Exhibit 9 Memo from M. Gordon to Chief 228 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 10 E-Mail String Beginning Bates 229 Exhibit 11 Letter from Leana S. Wen, M.D. 239 to Governor and Vice President-Elect Mike Pence, dated November 29, 2016, 329 Reginning Bates Stamp CLEVE_00018708 Exhibit 12 Ohio Department of Health 2016 248 Ohio Drug Overdose Data: General Findings Exhibit 13 E-Mail from Merle Gordon to Jana 255 Rush, dated August 25, 2016, 329 Exhibit 13 E-Mail from Merle Gordon to Jana 255 Rush, dated August 25, 2016, 329 Exhibit 14 E-Mail from Merle Gordon to Jana 255 Rush, dated August 25, 2016, 329 Exhibit 14 E-Mail from Merle Gordon to Jana 255 Rush, dated August 25, 2016, 329 CLEVE_000191543 Exhibit 14 E-Mail from David Gretick to 259	Page 9

	Page 10	Page 12
1 INDEX OF EXHIBITS, CONT'D	1 INDEX OF OBJECTIONS, CONT'D 2	J
2 Fability 15 F Mail String Projection Parts 271	Objection93 3 Objection94	
Exhibit 15 E-Mail String Beginning Bates 271 3 Stamp CLEVE 000298635	Objection94	
4 Exhibit 16 Cuyahoga County Opiate Task 286	4 Objection94 Objection95	
Force Report 2014 Beginning	5 Objection95 Objection96	
5 Bates Stamp CUYAH_000018534	6 Objection96 Objection97	
6 Exhibit 17 Cuyahoga County Opiate Task 286	7 Objection100	
Force Report 2015 Beginning	Objection	
7 Bates Stamp CLEVE_000187871	Objection	
8 Exhibit 18 Cuyahoga County Opiate Task 286 Force Report 2016 Beginning	Objection105	
9 Bates Stamp CUYAH 000018265	10 Objection	
10 Exhibit 19 E-Mail String Beginning Bates 295	11 Objection	
Stamp CLEVE_000187408	12 Objection	
11	13 Objection117	
Exhibit 20 Article Entitled "Cleveland's 315	Objection118 14 Objection120	
12 New Health Director, Merle	Objection	
Gordon, Faces a Daunting Task"	Objection123	
13 14	16 Objection124 Objection125	
15	17 Objection	
16	18 Objection126	
17	Objection	
18	Objection	
19	Objection129	
20	21 Objection	
21	22 Objection	
22 23	23 Objection130	
25 24	Objection	
25	Objection	
	Page 11	Page 13
1 INDEX OF OBJECTIONS 2	Page 11 INDEX OF OBJECTIONS, CONT'D	Page 13
2 Objection23	1 INDEX OF OBJECTIONS, CONT'D 2 Objection134	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONT'D 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 2 2 3 4 3 3 4 4 4 4 4 4	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection 23 3 Objection 23 Objection 24 4 Objection 25 Objection 26 5 Objection 28 Objection 29 6 Objection 31 Objection 33 7 Objection 36 Objection 40 8 Objection 40 Objection 41 9 Objection 42 Objection 42 Objection 43 Objection 43 Objection 44 11 Objection 46	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 Objection 29 6 Objection 31 Objection 33 7 Objection 36 0bjection 40 8 Objection 41 9 Objection 42 Objection 42 0bjection 42 10 Objection 43 0bjection 44 11 Objection 46 0bjection 46 0bjection 47 12 Objection 48	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 Objection 5 Objection 28 Objection 31 Objection 33 Objection 36 Objection 40 Objection 40 Objection 40 Objection 41 Objection 40 Objection 42 Objection 42 Objection 10 Objection 43 Objection 44 41 10 Objection 44 11 Objection 46 Objection 47	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection	1 INDEX OF OBJECTIONS, CONTD 2 Objection	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 5 Objection 28 Objection 31 31 Objection 33 7 Objection 40 8 Objection 40 9 Objection 41 9 Objection 42 9 Objection 43 44 10 Objection 44 11 Objection 46 Objection 48 Objection 48 Objection 48 Objection 49 Objection 51 14 Objection 52 Objection 53	INDEX OF OBJECTIONS, CONTD 2 2 Objection	Page 13
2 Objection 23 3 Objection 23 Objection 24 4 4 Objection 25 Objection 28 0bjection 29 6 Objection 31 0bjection 33 7 Objection 36 0bjection 40 40 Objection 40 8 Objection 41 42 Objection 42 10 Objection 42 42 Objection 43 Objection 44	INDEX OF OBJECTIONS, CONTD 2 2 Objection	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 5 Objection 28 Objection 31 31 Objection 33 7 Objection 40 8 Objection 40 9 Objection 41 9 Objection 42 9 Objection 43 44 10 Objection 44 11 Objection 46 Objection 48 Objection 48 Objection 49 Objection 51 14 Objection 52 Objection 53 15 Objection 55 Objection 56 16 Objection 56	INDEX OF OBJECTIONS, CONTD 2 2 Objection	Page 13
2 Objection 23 3 Objection 24 4 Objection 26 5 Objection 28 Objection 29 6 Objection 31 Objection 33 7 7 Objection 36 Objection 40 8 Objection 41 9 9 Objection 42 10 Objection 42 10 Objection 43 Objection 44 11 Objection 47 12 Objection 48 Objection 48 13 Objection 49 Objection 51 14 Objection 52 Objection 55 Objection 55 Objection 56 16 Objection 56 17 Objection 58	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 Objection 29 6 Objection 31 Objection 33 Objection 36 Objection 40 Objection 40 8 Objection 41 Objection 42 Objection 42 Objection 43 Objection 44 10 Objection 46 Objection 47 12 Objection 48 0bjection 48 Objection 48 Objection 49 Objection 51 14 Objection 52 Objection 53 15 Objection 55 Objection 56 0bjection 56 Objection 56 Objection 57 17 Objection 59 18 Objection 59 18 Objection 59 18 <t< td=""><td> 1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 4 4 4 4 4</td><td>Page 13</td></t<>	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 26 5 Objection 28 Objection 29 6 Objection 31 Objection 33 7 Objection 40 8 Objection 40 9 Objection 41 9 Objection 42 0bjection 42 10 Objection 43 0bjection 44 11 Objection 44 12 Objection 48 0bjection 48 0bjection 48 13 Objection 51 14 Objection 51 14 Objection 52 Objection 55 Objection 56 16 Objection 56 16 Objection 56 17 Objection	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 Objection 29 6 Objection 31 Objection 33 Objection 40 Objection 40 8 Objection 41 9 Objection 42 Objection 42 0bjection 42 10 Objection 43 0bjection 44 11 Objection 44 12 Objection 48 0bjection 48 0bjection 48 0bjection 51 14 Objection 52 0bjection 55 0bjection 55 0bjection 56 0bjection 58 0bjection 58 0bjection 59 0bjection 60	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 5 Objection 29 6 Objection 31 Objection 33 Objection 3 Objection 40 8 Objection 40 9 Objection 41 9 Objection 42 0bjection 42 10 Objection 43 0bjection 44 11 Objection 46 0bjection 48 0bjection 48 0bjection 49 0bjection 51 14 Objection 52 0bjection 55 0bjection 55 0bjection 56 0bjection 56 0bjection 58 0bjection 59 18 Objection<	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 2 3 4 4 4 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 Objection 28 Objection 29 6 Objection 31 Objection 36 Objection 40 Objection 40 8 Objection 41 9 Objection 42 Objection 42 0bjection 43 Objection 44 11 Objection 44 12 Objection 47 12 Objection 48 Objection 48 Objection 49 Objection 51 14 Objection 52 Objection 55 Objection 55 Objection 56 Objection 58 Objection 59 Objection 59	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 0 0 0 134 3 3 0 0 0 140 0 0 0 141 4 4 4 4 4 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 5 Objection 29 6 Objection 31 Objection 33 Objection 36 Objection 40 Objection 40 8 Objection 41 Objection 42 9 Objection 42 Objection 43 10 Objection 44	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 2 2 2 2 2	Page 13
2 Objection 23 3 Objection 24 4 Objection 26 5 Objection 28 Objection 29 6 Objection 31 Objection 36 Objection 40 8 Objection 40 8 Objection 41 9 Objection 42 Objection 42 0bjection 43 Objection 44 11 Objection 44 12 Objection 48 0bjection 48 0bjection 48 13 Objection 51 14 Objection 51 14 Objection 52 Objection 55 Objection 56 16 Objection 56 16 Objection 59 0bjection 59 0bjection	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 3 3 4 4 4	Page 13
2 Objection 23 3 Objection 24 4 Objection 25 Objection 26 Objection 5 Objection 29 6 Objection 31 Objection 33 Objection 40 Objection 40 8 Objection 41 9 Objection 42 0bjection 42 10 Objection 43 0bjection 44 11 Objection 44 12 Objection 44 13 Objection 48 0bjection 48 0bjection 49 0bjection 51 14 Objection 52 0bjection 53 15 Objection 56 0bjection 56 0bjection 58 0bjection 59 18 Objection <td< td=""><td> 1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 3 4 4 4 4</td><td>Page 13</td></td<>	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 3 4 4 4 4	Page 13
23 3 Objection	1 INDEX OF OBJECTIONS, CONTD 2 2 2 2 3 4 3 3 4 3 3 4 4 4	Page 13

4 (Pages 10 - 13)

1		Page 14	Pai	ge 16
1 1	INDEX OF OBJECTIONS,		1 INDEX OF OBJECTIONS, CONT'D	50 10
2		75	2	
	ection1		Objection	
	ection1		Objection269	
	ection1		4 Objection271	
	ection1		Objection272	
	ection1		5 Objection273 Objection274	
	ection1		6 Objection274	
	ection1		Objection274	
	ection1		7 Objection	
	ection1		Objection275 8 Objection275	
	ection1		Objection276	
	ection1		9 Objection276	
	ection1		Objection276 10 Objection277	
	ection1		Objection277	
	ection1		11 Objection278	
	ection1		Objection278	
	ection2 ection2		12 Objection278 Objection279	
	ection2		13 Objection279	
Objec	ection2	01	Objection280	
	ection2 ection		14 Objection280 Objection281	
	ection2		Objection281 15 Objection281	
	ection2		Objection282	
	ection2		16 Objection282	
	ection		Objection283 17 Objection290	
	ection2		Objection290	
18 Object	ection2	11	18 Objection291	
	ection2		Objection292	
	ection2 ection2		19 Objection293 Objection293	
	ection2		20 Objection294	
	ection2		Objection294	
	ection2		21 Objection	
	ection2 ection2		Objection296 22 Objection296	
	ection2		Objection296	
	ection2		23 Objection297	
	ection2 ection2		Objection297 24 Objection299	
	ection2		Objection301	
	ection2		25 Objection301	
		Dage 15	Do	ge 17
1	INDEX OF OBJECTIONS,	Page 15	1 INDEX OF OBJECTIONS, CONT'D	ge 17
2 Okio	ection2	26	2	
		20		
		26	Objection302	
	ection		Objection302 3 Objection302	
	ection 2 ection 2 ection 2	26 26		
Obje	ection 2 ection 2 ection 2 ection 2 ection 2	26 26 27	3 Objection302	
Object 5 Object	ection 2 ection 2 ection 2	26 26 27 31	3 Objection	
Object 5 Object Object 6 Object	ection 2	26 26 27 31 31	3 Objection	
Object 5 Object Object 6 Object Object	ection 2	26 26 27 31 31 32 32	3 Objection	
Object 5 Object Object 6 Object Object 7 Object	ection 2	26 26 27 31 31 32 32 32	3 Objection .302 Objection .302 4 Objection .302 Objection .302 5 Objection .303	
Object Solution Object Object Object Object Object Object Object Object Object	ection	26 26 27 31 31 32 32 32 32 33 33	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304	
Object 5 Object Object 6 Object Object 7 Object Object 8 Object Object Object	ection 2	26 26 27 31 31 32 32 32 33 33 33	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306	
Object 5 Object Object 6 Object 7 Object Object 8 Object Object 9 Object	ection 2	26 26 27 31 31 32 32 32 32 33 33 33 33	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 Objection 306	
Object S Object	ection 2	26 26 27 31 31 32 32 32 32 33 33 33 34	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 305 7 Objection 306 Objection 306 Objection 306 Objection 307	
Object 5 Object Object 7 Object 8 Object Object 9 Object Object Object 10 Object Object Object	ection 2	26 26 27 31 31 32 32 32 33 33 33 34 34 34 35 36	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308	
Object S Object	ection	26 26 27 31 31 32 32 32 33 33 33 34 34 35 36 37	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308	
Object 5 Object	ection 2	26 26 27 31 31 32 32 33 33 33 33 34 43 43 53 63 63 73 88	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 308 Objection 308 Objection 308 Objection 308 Objection 309	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object Object Object 12 Object Object	ection	26 26 27 31 31 32 32 32 32 33 33 33 33 34 44 34 35 36 37 38 38 41	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 305 7 Objection 306 Objection 306 Objection 307 Objection 308 9 Objection 308 9 Objection 309 10 Objection 309 10 Objection 310	
Object 5 Object Object Object 7 Object Object 8 Object 9 Object Object 10 Object Object 11 Object Object 12 Object Object 13 Object 13 Object	ection 2	26 26 27 31 31 32 32 32 33 33 33 33 34 43 44 34 35 36 37 38 38 41	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object 13 Object Object Object 13 Object O	ection 2	26 26 27 31 31 32 32 32 33 33 33 34 43 44 44 41 41	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311	
Object 5 Object 6 Object 7 Object 8 Object Object 9 Object 10 Object Object 11 Object Object 12 Object 13 Object 13 Object 14 Object 14 Object 14 Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 10 Object 10 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 10 Object 10 Object 10 Object 10 Object 11 Object 12 Object 14 Object 15 Object 16 Object 17 Object 18 Obj	ection 2	26 27 31 31 32 32 32 32 33 33 33 34 44 44 45 45 46 41 41 41 41 42	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 Objection 312	
Object 5 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 10 Object 10 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 15 Object	ection 2	26 26 27 31 31 32 32 32 33 33 33 34 43 44 44 41 41 41 42 43 44	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 9 Objection 309 10 Objection 310 Objection 311 10 Objection 312 12 Objection 312	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object 13 Object 14 Object 14 Object Object 15 Object Objec	ection 2	26 26 27 31 31 32 32 32 32 33 33 33 33 34 44 45 41 41 41 42 43 44 45	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 10 Objection 312 12 Objection 312 Objection 312 Objection 312 Objection 312	
Object 5 Object 6 Object Object 7 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 10 Object 11 Object Object 11 Object Object 12 Object Object 13 Object Object 14 Object Object 15 Object Object 16 Object Object 17 Object O	ection 2 ection 3 ect	26 27 31 31 32 32 32 33 33 33 33 34 44 44 41 41 41 41 42 43 44 45 46	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 9 Objection 309 10 Objection 310 Objection 311 10 Objection 312 10 Objection 312	
Object 5 Object 6 Object Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 16 Object 16 Object Object 17 Object 18 Object 19 Object 10 Object 10 Object 10 Object 11 Object 12 Object 13 Object 14 Object Object 15 Object 16 Object Object Object 16 Object Ob	ection 2	26 26 27 31 31 32 32 32 33 33 33 33 34 34 34 34 34 41 41 41 41 42 43 44 45 46 48	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 0 Objection 309 10 Objection 310 Objection 311 10 Objection 311 Objection 312 12 Objection 312 13 Objection 312 14 Objection 312 15 Objection 312 16 Objection 312 17 Objection 312 18 Objection 312 19 Objection 312 10 Objection 312 10 Objection 312 10 Objection 312	
Object 5 Object 6 Object Object 7 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 17 Object Object 17 Object Object 17 Object Object	ection 2 ection 3 ect	26 26 27 31 31 32 32 32 33 33 33 33 34 44 44 41 41 41 42 43 44 45 46 48 49 50	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 Objection 312 Objection 312 Objection 312 Objection 312 Objection 312 Objection 314 14 Objection 314	
Object 5 Object 6 Object Object 7 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 16 Object 17 Object 17 Object 18 Obj	ection	26 26 27 31 31 32 32 32 33 33 33 34 43 44 44 44 41 41 41 42 43 44 45 46 48 49 50	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 10 Objection 312 12 Objection 312 Objection 312 Objection 312 Objection 312 Objection 314 14 Objection 314 Objection 314 Objection 318	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object Object 13 Object Object 14 Object Object 15 Object 16 Object 17 Object 18 Object Object 18 Object Object 18 Object Object Object 19 Object 10 Object 10 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 16 Object 17 Object 18 Object Object 18 Object Object Object 19 Object Object 10 Object 1	ection 2	26 26 27 31 31 32 32 32 33 33 33 33 34 43 44 41 41 41 41 41 41 42 43 44 45 46 48 49 50 50 50	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 312 12 Objection 312 Objection 312 13 Objection 312 Objection 312 Objection 312 Objection 314 Objection 314 Objection 318	
Object Sobject Object	ection	26 26 27 31 31 32 32 32 33 33 33 33 33 34 44 44 41 41 41 42 43 44 45 46 48 49 50 50 50 50 51 52	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 6 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 10 Objection 312 12 Objection 312 13 Objection 312 Objection 312 Objection 312 Objection 314 14 Objection 314 Objection 314 Objection 314 Objection 318 15 16	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object Object 12 Object Object 13 Object Object 14 Object Object 15 Object 16 Object 17 Object 18 Object 18 Object 19 Object 19 Object 20 Object 20 Object 20 Object 20 Object 20 Object 3 Object 4 Object 6 Object 6 Object 7 Object 7 Object 9 Object 9 Object 10 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 20 Object 20 Object 20 Object	ection 2	26 26 27 31 31 32 32 32 33 33 33 33 34 43 44 44 41 41 41 41 42 43 44 45 46 48 49 50 50 50 50 51 52 53 53	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 6 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 0 Objection 309 10 Objection 310 Objection 311 10 Objection 311 Objection 312 12 Objection 312 Objection 312 13 Objection 312 14 Objection 314 14 Objection 314 Objection 318 15 16 17	
Object 5 Object 6 Object Object 8 Object 9 Object 10 Object 11 Object Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 17 Object Object 17 Object Object 18 Object 19 Object 19 Object 10 Object 10 Object 11 Object Object 12 Object 13 Object 14 Object Object 15 Object 16 Object 17 Object Object 18 Object Object 19 Object Object 10 Object Object 10 Object 11 Object Object 12 Object Object 13 Object Object 14 Object Object 15 Object Object 16 Object 17 Object Object 18 Object Object 19 Object	ection 2 ection 3	26 26 27 31 31 32 32 32 33 33 33 33 33 34 43 44 44 41 41 41 42 43 44 45 66 48 49 50 50 50 51 52 53 53 53	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 6 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 9 Objection 309 10 Objection 310 Objection 311 11 Objection 311 10 Objection 312 Objection 312 Objection 312 Objection 312 Objection 312 Objection 314 Objection 314 Objection 318 15 16 17 18	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 16 Object 16 Object 17 Object 18 Object 19 Object 19 Object 20 Object 20 Object 21 Object 21 Object 21 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 28 Object 29 Object 20 Object 20 Object 21 Object 21 Object 21 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 28 Object 29 Object 20 Object 20 Object 20 Object 21 Object 21 Object 21 Object 21 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 27 Object 28 Object 29 Object 20 Object 21 Object 21 Object 22 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 27 Object 28 Object 29 Object 20 Object 21 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 27 Object 28 Object 29 Object 20 Object	ection 2	26 26 27 31 31 32 32 32 32 33 33 33 34 43 44 45 46 48 49 50 50 51 52 53 53 53 53	3 Objection 302 Objection 302 4 Objection 302 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 11 Objection 311 10 Objection 312 Objection 312 Objection 312 10 Objection 312 Objection 312 Objection 314 14 Objection 314 14 Objection 318 15 16 17 18 19 19	
Object Sobject Object	ection	26 26 27 31 31 32 32 32 32 33 33 33 33 34 43 43 44 44 41 41 41 42 43 44 45 66 48 49 50 50 50 51 52 53 53 53 53 54 57 57	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 307 Objection 308 9 Objection 308 Objection 309 10 Objection 310 Objection 311 10 Objection 312 10 Objection 312 12 Objection 312 Objection 312 Objection 312 Objection 314 14 Objection 314 Objection 314 10 Objection 318 15 16 17 18 19 20	
Object 5 Object 6 Object 6 Object 7 Object 8 Object 9 Object 10 Object 11 Object 12 Object 13 Object 14 Object 15 Object 16 Object 17 Object 18 Object 19 Object 19 Object 20 Object 21 Object 21 Object 22 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 28 Object 29 Object 20 Object 20 Object 20 Object 21 Object 22 Object 23 Object 24 Object 25 Object 26 Object 27 Object 28 Object 29 Object 20 Object	ection	26 27 31 31 32 32 32 33 33 33 33 34 43 45 46 47 41 41 41 41 41 42 43 44 44 45 46 48 49 50 50 50 51 52 53 53 53 53 55 57 61	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 Objection 310 Objection 311 10 Objection 312 10 Objection 312 12 Objection 312 Objection 312 Objection 312 10 Objection 312 Objection 312 Objection 314 4 Objection 314 Objection 318 15 16 17 18 19 20 21	
Object 5 Object 6 Object Object 8 Object Object 10 Object 11 Object Object 12 Object Object 13 Object Object 14 Object Object 15 Object Object 16 Object Object 17 Object Object 18 Object Object 19 Object Object 20 Object 21 Object 22 Object Object 23 Object 24 Object Object 25 Object 26 Object 27 Object 28 Object Object 29 Object 20 O	ection	26 26 27 31 31 32 32 32 33 33 33 33 34 43 44 44 44 41 41 41 41 42 43 444 45 46 48 49 50 50 50 50 51 52 53 53 53 53 53 54 57 57 57	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 6 Objection 305 7 Objection 306 Objection 306 Objection 308 9 Objection 308 9 Objection 309 10 Objection 310 Objection 311 10 Objection 311 10 Objection 312 12 Objection 312 13 Objection 312 14 Objection 314 14 Objection 314 Objection 318 15 16 17 18 19 20 21 22	
Object Sobject Object O	ection	26 26 27 31 31 32 32 32 33 33 33 33 34 43 43 43 44 44 41 41 41 42 43 44 45 64 48 49 50 50 50 51 51 52 53 53 53 53 54 57 77 61 61 62 663	3 Objection 302 Objection 302 4 Objection 302 5 Objection 303 Objection 304 6 Objection 304 Objection 305 7 Objection 306 Objection 306 8 Objection 307 Objection 308 9 Objection 308 0 Objection 309 10 Objection 311 11 Objection 311 10 Objection 312 10 Objection 314 14 Objection 314 10 Objection 318 15 318 15 318 15 318 16 317 18 319 20 312 21 322	
Object Sobject Object O	ection	26 26 27 31 31 32 32 32 33 33 33 33 34 43 44 44 41 41 41 41 42 43 44 45 46 48 49 50 50 50 50 51 52 53 53 53 53 53 55 55 57 57 61 62 63 64 665	3 Objection 302 Objection 302 4 Objection 302 Objection 303 Objection 304 6 Objection 304 6 Objection 305 7 Objection 306 Objection 306 Objection 308 9 Objection 308 9 Objection 309 10 Objection 310 Objection 311 10 Objection 311 10 Objection 312 12 Objection 312 13 Objection 312 14 Objection 314 14 Objection 314 Objection 318 15 16 17 18 19 20 21 22	

1	Page 18 THE VIDEOGRAPHER: Good morning. We	1	Page 20 Pharmaceuticals.
	are on the record. The time is 9:15. The date	2	MR. BOEHM: Paul Boehm from Williams
	is July 19th, 2018. This is media unit 1 of the	_	& Connolly for Cardinal Health.
	video recorded deposition of Merle Gordon in the	4	MR. SALIMBENE: Mike Salimbene from
	matter of In Re: National Prescription Opiate		Reed Smith for AmerisourceBergen.
	Litigation, filed in U.S. District Court,	6	MR. RUIZ: Anthony Ruiz from
	Northern District of Ohio, Case Number		Zuckerman Spaeder for CVS Indiana, LLC and CVS
	17-md-2804. The deposition is being held at		Rx Services, Inc.
	Taft Stettinius & Hollister located in	9	MS. DENNIS: Madeline Dennis with
	Cleveland, Ohio.	10	Tucker Ellis on behalf of Janssen.
11	My name is Jeff Koishor from	11	MR. NAEEM: Tariq Naeem, also Tucker
12	Veritext. I am the videographer. The court	12	Ellis, on behalf of Janssen and J&J.
13	reporter is Renee Pellegrino from Veritext.	13	THE VIDEOGRAPHER: And on the phone?
14	Counsel all present in the room and	14	MR. CIULLO: Zachary Ciullo from
15	everyone attending remotely please state their	15	Kirkland & Ellis of behalf of Allergan.
16	name and affiliation for the record.	16	MS. SORICELLI: Jessica Soricelli
17	8		with Ropes & Gray on behalf of Mallinckrodt.
18	•	18	MR. DAYNO: Theodore Dayno with
19	& Budd, on behalf of the City of Cleveland, the		Morgan Lewis on behalf of Teva.
20	,	20	THE VIDEOGRAPHER: Will the court
	in the MDL.		reporter please swear in the witness?
22		22	MR. BOEHM: Can I just make a note?
	Zimmermann, Zarzaur, Mujumdar & Debrosse, same		The deposition protocol entered in this case
	as already stated.		does require that if there are any attorneys
25	MS. KEARSE: Anne Kearse of Motley	25	listening in by telephone to this deposition,
	Page 19	1	Page 21
	Rice on behalf of Summit County and the City of		they must identify themselves, so to the extent
	Akron.		anybody who is listening in has not yet
3			announced their presence telephonically, they should do so now.
5	Plevin & Gallucci on behalf of Cuyahoga County. MR. CIACCIO: Joseph Ciaccio, Napoli	5	MR. SIMS: This is Thomas Sims with
6	Shkolnik, on behalf of Cuyahoga County.	_	Baron & Budd for the City of Cleveland.
7		7	THE VIDEOGRAPHER: Court reporter
	Shkolnik, on behalf of Cuyahoga County.		please swear in the witness.
9		9	MERLE GORDON, of lawful age, called for
	Cleveland.	_	examination, as provided by the Federal Rules of
11	MS. CAMPBELL: Kristen Campbell,		Civil Procedure, being by me first duly sworn,
12	Pelini, Campbell & Williams, for Prescription	12	
	Supply, Inc.	13	follows:
14		14	EXAMINATION OF MERLE GORDON
15	Jones Day, for Wal-Mart.	15	BY MR. NAEEM:
16	MR. BARNES: Robert Barnes, Marcus &	16	Q. Good morning. Could you please
17	Shapira, for HBC Service Company.	17	state your full name for the record?
18	*	18	A. My name is Merle Gordon.
19	with Jackson Kelly, on behalf of Miami-Luken.	19	Q. Ms. Gordon, we're here to take your
20			deposition in an MDL related to the prescription
	Covington & Burling on behalf of McKesson	21	opioid litigation. You're aware of that?
	Corporation.	22	A. I am aware.
23	9	23	Q. Before we went on the record, and
	with Arnold & Porter on behalf of Endo Health		just to confirm with your counsel, I agreed I
	Solutions, Endo Pharmaceuticals and Par	123	wouldn't ask any for your personal address as

6 (Pages 18 - 21)

Page 22 Page 24 1 long as you agreed to accept service for any 1 defendant in that case? 2 future proceedings. MR. PIFKO: Objection to the extent MR. PIFKO: Baron & Budd agrees to 3 the question calls for a legal conclusion. 4 accept service on behalf of any subpoenas or A. I believe we were, yes. 5 anything for the witness. Q. Do you know the name of the 6 MR. NAEEM: Great. 6 plaintiff that filed that lawsuit? 7 Q. Ms. Gordon, could you please give us 7 MR. PIFKO: Same objection. 8 your work address? 8 A. I don't recall. A. It's 75 Erieview Plaza, Cleveland, 9 Q. Do you know how that case was 10 Ohio, 44114. 10 resolved? And I may have asked this. I 11 apologize. Did you have to testify at trial? 11 Q. Thank you. Have you had your testimony taken 12 12 A. Did not. 13 before in either a deposition or trial? 13 Q. Since it's been a while since you A. I've been deposed before, yes. 14 were deposed, let me just, before we get further 15 O. How many times? 15 in here, give you some ground rules that will 16 A. One time. 16 help us get through this deposition as Q. And did it relate to a personal 17 17 efficiently as possible. 18 matter or to a work matter? 18 First, I'm going to need you to 19 19 verbalize your answers. Nods and shrugs don't A. A work matter. 20 Q. Could you give me a very brief 20 come across in the transcript. They're 21 discussion or a description of what the issues 21 difficult for the court reporter to take down. 22 related to and who the employer was you were 22 So can we agree that you'll -- to yeses and nos, 23 with when you testified? 23 no ambiguous language like uh-huh and unh-unh? MR. PIFKO: Objection to the extent 24 A. Agree. 25 the question calls for attorney-client O. To the best we can, and that 25 Page 23 1 communication. 1 includes counsel in the room, we'll try not to If you can answer without disclosing 2 talk over one other. Again, that's for the 3 conversations you had with counsel in that case, 3 court reporter's benefit. Will you agree to do 4 go ahead and do so. 4 that? 5 5 Q. And let me rephrase the question. Α. Yes. 6 Who were you employed by at the time 6 Q. If I ask a question and you don't 7 that you sat for that deposition? 7 understand it, I'm going to ask that you please 8 A. The City of Cleveland. 8 ask me to rephrase it. If you think you know 9 Q. When was that deposition? 9 what I meant and still the question doesn't make 10 A. It was in the early 2000s. 10 sense, again, please ask me to rephrase it. This was while you were a city 11 We're going to assume that if you answer the 11 12 council person for the City of Cleveland? 12 question, you understood the question and the 13 13 answer to the question was what you intended it A. Correct. 14 What general topic matter did it 14 to be, okay? 15 relate to? Was it a criminal issue? Was it a 15 MR. PIFKO: Objection. Vague. 16 civil issue, an employment issue? 16 Q. Do you understand what I'm saying? 17 MR. PIFKO: Objection. Vague. 17 A. I understand. 18 Overbroad. Q. And then to the extent you need a 19 break, just let your counsel know at any time. 19 A. It was a matter pertaining to a 20 landfill that was located within the district 20 The only thing I'll ask is that if a question is 21 that I represented. 21 pending when you ask for a break, you have to 22 Q. And did that case end up going to 22 answer the question, okay?

7 (Pages 22 - 25)

MR. PIFKO: We don't agree to that.

24 If the witness has a question concerning

25 privilege or something, she's free to take a

23

A.

It did not.

Was the City of Cleveland the

23 trial?

24

Page 26 Page 28 1 break at any time. 1 When was the first time you met with Q. If you need a break at any time for 2 counsel to prepare for this deposition 3 specifically? 3 any reason, just let us know, okay? 4 A. Okay. 4 A. Last week. 5 Q. Ms. Gordon, what did you do to 5 Q. And so you've met with them five 6 times total since last week? 6 prepare for your deposition today? MR. PIFKO: Objection to the extent 7 A. Correct. 8 the question calls for attorney-client 8 Q. All right. How much time would you 9 communication. 9 estimate you've spent in the preparation for 10 your deposition? 10 Aside from communications with 11 counsel, you can answer the question. A. We met for a few hours each time. 11 12 A. I met with counsel. 12 Q. Did you review documents? 13 Q. And your counsel sitting next to you 13 Yes. 14 defending you? 14 Q. All right. Did anything come up 15 15 during the preparation for your deposition that A. Correct. 16 required your attorneys to collect documents 16 Q. Any other counsel in the room? 17 that had not been collected before? 17 There were other counsel in the 18 MR. PIFKO: Objection. Vague. 18 room. 19 19 Objection to the extent it calls for Q. How many? 20 About six. 20 attorney-client communications. A. 21 Q. And were any of them internal 21 Q. Let me back up. 22 counsel for the City of Cleveland? 22 When did you first learn that this 23 23 lawsuit had been filed? A. Yes. 24 How many? 24 A. Probably a couple months ago. Q. 25 25 All right. So were you consulted Two. Page 27 Page 29 1 Q. Can you give me their names? 1 about any of the details regarding the City of 2 A. Elena Boop is one and Shirley 2 Cleveland's public health department, 3 Tomasello. 3 specifically with it related to opioids, in 4 preparation for preparing and filing the Q. And the other four, can you give me 4 5 their names, please? 5 complaint? I don't have their names to memory. 6 MR. PIFKO: Objection to the extent 6 7 Are any of them in this room here 7 the question calls for attorney-client Q. 8 today? 8 communications. Director Gordon, if you can answer 9 9 A. Yes, some are in the room today. 10 Can you identify them, point them 10 without revealing any substantive conversations 11 you may have had with counsel, you can answer 11 out? 12 A. Yes. 12 the question. 13 The woman sitting next to my 13 A. Can you ask the question again? 14 counsel, and there were lawyers for the Taft law 14 Q. Yes. Let me start a little bit 15 firm as well and a couple others that were in 15 broader. 16 the room. 16 Were you involved in preparing the 17 Q. Any attorneys from Summit County or 17 actual complaint before it was filed? 18 Akron that you're aware of? 18 MR. PIFKO: Instruction not to 19 answer. That's entirely privileged. 19 A. No. 20 Q. Any attorneys from Cuyahoga County 20 MR. NAEEM: On the basis of? 21 21 that you're aware of? MR. PIFKO: Attorney-client 22 A. No. 22 communications. Q. How many times did you meet with 23 MR. NAEEM: If she was --24 counsel to prepare for your deposition? 24 MR. PIFKO: The question is --25 A. Five times. 25 you're asking her what she was discussing with

8 (Pages 26 - 29)

Page 30 1 counsel in connection with preparing the

- 2 complaint. I mean, preparing the complaint is a
- 3 substantive discussion with counsel. I'm not 4 going to let her answer that.
- Q. Did you see a draft of the complaint 6 before it was filed?
- A. I did not.
- 8 Q. Were you -- I'm sorry.
- Did you see a draft -- I'm sorry.
- 10 Did you see the complaint prior to your
- 11 deposition being scheduled in this case?
- 12 MR. PIFKO: I'm going to instruct 13 her not to answer on that to the extent it calls
- 14 for work product in regard to what counsel
- 15 showed her in preparing for the deposition. Q. Absent any communications with
- 17 counsel by phone, by e-mail or otherwise, had
- 18 you seen the complaint prior to your
- 19 deposition --
- 20 MR. PIFKO: To be clear, he's
- 21 asking --

1 counsel.

- 22 Q. -- being scheduled?
- 23 MR. PIFKO: He's only asking outside
- 24 of communications with counsel.
- 25 Not outside of communication with

Page 32

- Q. Okay. Let me ask that a little 2 differently because I'm not sure we're on the 3 same page.
- 4 Do you maintain hard copies of
- 5 documents in your office?
- 6 A. I do.
- 7 Q. Do you maintain hard copies of
- 8 documents related to the City of Cleveland's
- 9 efforts with respect to opioid-related issues in
- 10 your office?
- A. I do. 11
- 12 Q. Did you provide those to anybody for
- 13 production in this litigation?
- 14 A. I did.
- 15 When was that? O.
 - A. In the last -- the last couple of
- 17 months.

16

- 18 Q. When was the most recent time you
- 19 produced hard copy documents -- that you gave
- 20 your documents to somebody for production in
- 21 this litigation?
- 22 MR. PIFKO: If you understand the
- 23 question.
- A. I had gave some, I believe,
- 25 yesterday or the day before yesterday.

Page 31

- Q. All right. After the complaint was
- 3 filed, did someone come and collect your
- 4 documents for purposes of production in this
- MR. PIFKO: Objection to the extent
- 7 it calls for attorney-client communication with
- 8 the witness.

5 litigation?

- If you had conversations with
- 10 someone other than counsel about collecting
- 11 documents or someone who wasn't at the direction
- 12 of counsel, you can answer the question.
- 13 MR. NAEEM: I'm not talking about
- 14 conversations. I'm talking about actions.
- 15 Q. Do you know whether someone came to
- 16 your office and collected documents at any point
- 17 in time for production in this litigation?
- 18 A. No one came to my office.
- 19 Q. Did you collect the documents
- 20 yourself for the purposes of production in this
- 21 litigation, any hard copy documents? That's all
- 22 I'm talking about right now.
- A. Hard copy documents. We submitted
- 24 documents pertaining to our work in this area on
- 25 behalf of the department.

- Page 33
- Q. And do you know why those weren't 2 produced before?
- 3 MR. PIFKO: Objection.
- 4 Argumentative.
- A. Over the weekend I was cleaning my
- 6 office and reorganizing and found a couple
- 7 additional files and brought them to my
- 8 attorneys.
- 9 MR. PIFKO: And just so you know,
- 10 too, we're happy to provide copies of anything
- 11 that you want if you need to make copies of
- 12 anything to use in the course of the deposition
- 13 today.
- 14 MR. NAEEM: Okay. Do we want to do
- 15 this on the record?
- 16 MR. PIFKO: If we want to talk about
- 17 the production, yeah, I would like to do it on
- 18 the record.
- 19 MR. NAEEM: Great.
- 20 So the defendants collectively
- 21 object to the late production of documents, you
- 22 know, late yesterday, understanding the
- 23 circumstances, and we'll be reserving time from
- 24 this deposition, and depending on how it goes,
- 25 asking perhaps to produce the witness again for

	D 24		P 26
1	Page 34 deposition.	1	Page 36 handwriting on page 1 and page 2. For example,
$\frac{1}{2}$	MR. PIFKO: To be clear, our		on page 1, the second line, "Prescribing
	position is we reject any efforts to call the		practices are no longer the precursor to OD."
	witness back. She's a high-level city official.		Is that your handwriting?
5	There's a lot of mountains that had to be moved	5	A. This is my handwriting.
6	for her to show up today. You just heard her	6	Q. And OD refers to overdose?
	testimony about when the documents were	7	
	identified. There's at least eight people in	8	A. I assume so, yes.Q. Is this an example of the documents
	this room, countless people behind the scenes.	-	you found when you were cleaning out your
	It was only 600 pages. I don't believe there's		office?
11	any prejudice to you all in being able to	11	
	prepare for the deposition, and like I said,	12	MR. PIFKO: Objection. Vague. Q. Are there other documents within the
			-
	we're happy to make any copies of anything that		documents you found that contain your
	you want if you tell me. Just let me know.		handwriting and notes regarding those particular
15	(Therapper Denosition Exhibit 1		documents?
16	(Thereupon, Deposition Exhibit 1, Letter from Tad Allan to Mark Pifko,	16	A. There may be.
17		17	(Thomas Danasiti - F-Libit 1 D
18	dated July 18, 2018, with Attached	18	(Thereupon, Deposition Exhibit 1-B,
19	Exhibit A, was marked for purposes	19	E-Mail from Gary Gingell to Various
20	of identification.)	20	Recipients dated March 6, 2018 Bates
21 22	O The instruction that for any are	21	Stamped CLEVE_000299033, was marked
	Q. I'm just marking that for purposes	22	for purposes of identification.)
	of getting it on part of the record. It's our	23	O M C 1 - H- 1 - 1 d 4
25	response to the late production of documents.	24	Q. Ms. Gordon, I've had the court
23	Ms. Gordon, you said you found those	23	reporter hand you an exhibit that I've had
1	Page 35	1	Page 37
	over the weekend?		marked as Deposition Exhibit 1-B. Have you seen
2	over the weekend? A. I did.	2	marked as Deposition Exhibit 1-B. Have you seen this document before?
2 3	over the weekend? A. I did. Q. And are you aware that they were	2 3	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review
2 3 4	over the weekend? A. I did. Q. And are you aware that they were produced to us last night?	2 3 4	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it.
2 3 4 5	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided	2 3 4 5	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this.
2 3 4 5 6	over the weekend? A. I did. Q. And are you aware that they were produced to us last night?	2 3 4 5 6	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that
2 3 4 5 6 7	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago.	2 3 4 5 6 7	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your
2 3 4 5 6 7 8	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A,	2 3 4 5 6 7 8	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago?
2 3 4 5 6 7 8 9	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid	2 3 4 5 6 7 8 9	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is
2 3 4 5 6 7 8 9	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward,	2 3 4 5 6 7 8 9 10	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me.
2 3 4 5 6 7 8 9 10	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten	2 3 4 5 6 7 8 9 10	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary?
2 3 4 5 6 7 8 9 10 11 12	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp	2 3 4 5 6 7 8 9 10 11 12	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell.
2 3 4 5 6 7 8 9 10 11 12 13	A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for	2 3 4 5 6 7 8 9 10 11 12 13	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he?
2 3 4 5 6 7 8 9 10 11 12 13 14	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp	2 3 4 5 6 7 8 9 10 11 12 13 14	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department
2 3 4 5 6 7 8 9 10 11 12 13 14 15	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.)	2 3 4 5 6 7 8 9 10 11 12 13 14 15	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you? A. This does look familiar to me.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and reading it?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you? A. This does look familiar to me. Q. Is this one of the documents you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and reading it? A. I do recall.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you? A. This does look familiar to me. Q. Is this one of the documents you found over the weekend when you were cleaning	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and reading it? A. I do recall. Q. And if this is one of the documents
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you? A. This does look familiar to me. Q. Is this one of the documents you found over the weekend when you were cleaning out your office?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and reading it? A. I do recall. Q. And if this is one of the documents you found, I assume that means it's because you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	over the weekend? A. I did. Q. And are you aware that they were produced to us last night? A. I am not aware of that. I provided them to my counsel two days ago. (Thereupon, Deposition Exhibit 1-A, Document Entitled "Heroin and Opioid Action Plan: Moving Forward, Agenda," with Attached Handwritten Notes, Beginning Bates Stamp CLEVE_000298750, was marked for purposes of identification.) Q. Ms. Gordon, I've handed you a document that's been marked by the court reporter as Deposition Exhibit 1-A. Can you tell me whether this looks familiar to you? A. This does look familiar to me. Q. Is this one of the documents you found over the weekend when you were cleaning	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	marked as Deposition Exhibit 1-B. Have you seen this document before? MR. PIFKO: Take your time to review it. A. Yes, I am familiar with this. Q. Is this one of the documents that you found over the weekend and produced to your counsel two days ago? A. I don't recall for sure, but this is a copy of an e-mail that came to me. Q. And it was sent to you by Gary? A. Gingell. Q. Gingell. Who is he? A. He is with the Cleveland Department of Police. He's a commander. Q. The date of this e-mail is March 6, 2018? A. Correct. Q. Do you recall receiving it and reading it? A. I do recall. Q. And if this is one of the documents

Page 38 Page 40 1 Q. Do you sometimes highlight e-mails Q. Do you remember the circumstances at 2 that you've printed out? 2 which Dr. Papp presented this information, A. Occasionally. 3 either via this document or through some sort of Q. Now, you see there appears to be 4 oral presentation? 4 5 some highlighting, and that was in the copy 5 MR. PIFKO: Objection. Vague. 6 provided to us I'll represent, and it says --6 Overbroad. 7 it's highlighting this phrase, "With the U.S. 7 A. Dr. Papp attends a fair amount of 8 dropping 6 billion and big pharma about to get 8 meetings that I've also attended and has been 9 whacked for hopefully many billions." Was that 9 instrumental in looking at ways that we can 10 your highlighting in the original document that 10 address this significant issue in this community 11 you printed? 11 and puts together documents on occasion. 12 A. I do not recall. 12 Q. Okay. I'm asking, do you have a 13 Q. But, to be clear, you do 13 specific recollection of any meeting that took 14 occasionally print documents and highlight them? 14 place where either this document was handed out 15 A. I do. 15 or this information was discussed? MR. PIFKO: Objection. Compound. 16 16 17 (Thereupon, Deposition Exhibit 1-C, 17 A. Dr. Papp is very vocal at these 18 Document Entitled "Cuyahoga County 18 meetings and has been a significant contributor 19 State of Emergency Action Steps," 19 to our collective need to respond to this issue 20 Beginning Bates Stamp 20 in this community. I recall her talking about a 21 CLEVE 000299083, was marked for 21 fair amount of the items in this document. I 22 purposes of identification.) 22 cannot remember exactly when she produced it or 23 23 when she handed it out. 24 24 Q. Ms. Gordon, I've had the court Q. Do you recall whether you got this 25 reporter hand you a copy of what's been marked 25 document via e-mail? Page 41 1 as Deposition Exhibit 1-C. Have you seen this 1 A. I do not recall. 2 document before? Q. Do you recall the date you might 3 MR. PIFKO: Please take your time to 3 have received this document? A. I do not recall. 4 review it. 5 The little arrows to the side of the A. I am familiar with this document. Q. Is this one of the documents that 6 lettered sections in the middle of page 1, is 7 you found this weekend and produced to your 7 that your -- do you believe that's your 8 counsel two days ago? 8 handwriting? A. I don't recall. 9 A. I cannot say for sure. 10 10 Q. The handwriting at the top right Q. Bullet point number 3 there says, 11 corner of that document on page 1, is that your 11 "Monies seized from drug arrests (trafficking, 12 dealing, etc.) are to be funneled back into 12 handwriting? 13 A. It looks like my handwriting. 13 treatment programs/prevention/naloxone 14 14 programs." Do you see that? Who is Dr. Papp? 15 A. Dr. Papp is a physician at Metro 15 A. Item C? 16 Hospital in Cleveland. 16 Q. No. 3. I'm sorry. 17 Q. Why did you write her name at the 17 A. 3. Yes, I see it. 18 top of this document? Q. Is that something that's currently A. I believe that she was the one who 19 being done at the City of Cleveland? 20 handed this document out and I put her name on MR. PIFKO: Objection. Foundation. 21 it to know who either the author was or who 21 Objection to the extent the question calls for 22 distributed the document. 22 speculation. Q. Do you remember Dr. Papp handing 23 A. I do not know that that takes place 23 24 currently. 24 this document to you? 25 A. I don't recall for sure. 25 Q. All right. And so to be clear --

www.veritext.com

Page 42 1 we're going to get into this -- the Cleveland 1 privacy. Her medical condition is not at issue 2 Department of Public Health's opioid-related 2 in this case. I'm going to instruct her not to 3 activities. With respect to this point 3 that 3 answer. 4 MR. NAEEM: Well, I believe it goes 4 we just read, are you telling me you're not 5 aware whether any money seized by the Cleveland 5 directly to bias, so I'm going to ask you to 6 Police Department or any other police force in 6 reconsider that, and also to keep the deposition 7 protocol in mind with your objections. 7 Cuyahoga County is redirected back to the 8 Cleveland Department of Public Health for use in 8 MR. PIFKO: Objection stands. 9 treatment programs? 9 MR. NAEEM: You're instructing the 10 witness not to answer? 10 MR. PIFKO: Objection. Compound. 11 Calls for speculation. Foundation. 11 MR. PIFKO: Yeah. 12 Q. Have you ever used prescription 12 A. I'm not aware that that happens, no. 13 Q. And by saying "not aware," are you 13 opioids? 14 in the position -- do you believe you would know 14 MR. PIFKO: Same objection. Invades 15 the witness' personal medical privacy. She's 15 that if it was happening? MR. PIFKO: Same objections. 16 not here to testify on her individual behalf. 17 A. I do not know that those monies are 17 She's a city official. I'm going to instruct 18 directly supporting the general fund, which does 18 her not to answer. 19 MR. NAEEM: It goes to bias. Are 19 support some of our programs in the health 20 department. 20 you still instructing the witness not to answer? 21 MR. PIFKO: Yes. 21 O. We'll come back to this if we need 22 22 to then. Q. Have you ever used heroine? 23 MR. PIFKO: Same objection. 23 MR. PIFKO: Can we take a short 24 MR. NAEEM: Goes to bias. 24 break? 25 MR. NAEEM: Sure. 25 Instructing her not to answer? Page 43 1 THE VIDEOGRAPHER: Going off the 1 MR. PIFKO: Yes. Any questions you 2 ask about her medical history, I'm going to 2 record. The time is 9:43. (Recess had.) 3 object and instruct her not to answer on the 4 medical privilege. 4 THE VIDEOGRAPHER: Back on the 5 Q. Have any of your friends or family 5 record. The time is 9:53. 6 BY MR. NAEEM: 6 ever used heroine? 7 MR. PIFKO: Same objection. Q. Ms. Gordon, before we went off the 8 record, we had been talking about documents that 8 MR. NAEEM: I would again state it 9 goes to bias and she has no privilege to protect 9 you found this weekend and produced to your 10 counsel a couple days ago. I do want to go 10 her friends or family members with respect to 11 ahead and move on and try to get us further into 11 their medical history. 12 the depo. Before I do, can I ask whether you 12 MR. PIFKO: They're not here to 13 assert their own concerns about it, and so if 13 have ever been part of a lawsuit as a plaintiff 14 in which you've sued a pharmaceutical company? 14 you want to go and ask them and -- we can do 15 A. I have not. 15 that, but I'm going to instruct her not to Q. Do you have any friends or family 16 answer until we know what any outside people's 16 17 who have done so? 17 position is with respect to their medical 18 MR. PIFKO: Objection. Calls for 18 privacy. 19 19 speculation. MR. NAEEM: So, to be clear, what is 20 the privilege you are asserting and instructing 20 A. I do not. Q. Have you ever suffered a severe 21 her not to answer on? 22 adverse reaction that you attributed to a 22 MR. PIFKO: Confidential medical 23 privilege. 23 pharmaceutical product? MR. PIFKO: Objection to the extent 24 MR. NAEEM: Okay. Do you represent 25 it invades the witness' personal medical 25 any of her friends and family?

12 (Pages 42 - 45)

MR. PIFKO: No, but I'm not going to

- 2 let her disclose a third party's medical
- 3 condition in this proceeding without their 4 permission.
- MR. NAEEM: I haven't asked and I 6 won't ask for any of the names, so I'll ask 7 again.
- 8 Q. Do you have any friends or family 9 members who have ever used heroine?
- 10 MR. PIFKO: If you want to ask 11 her -- I think that's too specific. If you want
- 12 to ask her if she knows anyone, I'll let her
- 13 answer that question.
- 14 Q. Let's go backwards, then, on that
- 15 basis.
- 16 Do you know anyone who's ever
- 17 suffered a severe adverse reaction attributed to
- 18 a pharmaceutical product?
- MR. PIFKO: Objection to the extent
- 20 the question calls for expert opinion. Vague.
- 21 Overbroad.
- 22 You can answer.
- 23 A. Any pharmaceutical product? I can't
- 24 say that anybody has not. I don't know that I
- 25 would know that.

Page 47

- Q. Well, that's really what the 1
- 2 question is. Do you know anyone who's ever
- 3 suffered a severe adverse reaction that they
- 4 attributed to a pharmaceutical product?
- MR. PIFKO: Same objection. Calls
- 6 for speculation, expert opinion.
- A. Perhaps I do. I don't know that
- 8 anybody has said to me specifically. Some
- 9 people have allergies to some products but I
- 10 don't necessarily talk about that with friends.
- Q. So you do know people who have
- 12 suffered a severe adverse reaction that they
- 13 have attributed to pharmaceutical products?
- MR. PIFKO: Objection.
- 15 Mischaracterizes testimony. Asked and answered.
- A. I'm not entirely sure that's what I
- 17 said. I may know people. I can't say that I
- 18 can answer that question head on.
- 19 Q. Do you know anyone who has ever sued
- 20 a pharmaceutical company?
- 21 A. I don't know that I do.
- 22 Q. Are you aware of any -- of anyone
- 23 who's used prescription opioids?
- MR. PIFKO: Objection. Vague.
- 25 Overbroad.

1 A. I can't say that I do or I don't.

2 Q. Do you personally know anyone who

3 has ever used heroine?

A. In the course of my job I've met a

5 number of people who have attended meetings, who

Page 48

6 have told their story, many addicts who have

7 shared their story and what they have taken and

8 what they've been addicted to, and some have

9 admitted that it has been heroine.

10 Q. Absent any information you got in

11 your employment, do you know anyone who has ever

12 used heroine?

13 MR. PIFKO: Objection. Vague.

14 A. I can't say that I do or that I

15 don't or that they have admitted that to me.

Q. Are you aware in your personal life,

17 not your employment, of anyone who has used

18 illicit fentanyl?

19 A. I can't say that I do or that I

20 don't.

24

21 Q. So the question was are you aware.

- 22 So you are not aware of anyone?
- 23 A. I am not aware.
 - Q. Are you aware of anyone in your
- 25 personal, not your employment life, who has ever

Page 49

1 suffered from addiction?

- 2 A. I do know people, yes, I am aware.
- Q. What substances -- without revealing
- 4 their identity, what substances are you aware of
- 5 that those people suffered from addiction from?
- MR. PIFKO: Objection. Calls for
- 7 speculation. Objection to the extent it calls
- 8 for expert opinion.
- 9 A. I don't have specificity on what
- 10 they are addicted to or were addicted to.
- Q. So you haven't had conversations
- 12 about what the substance was but you do know in
- 13 your personal life people who suffer from
- 14 addiction?
- 15 A. I do.
- 16 Q. Ms. Gordon, could you briefly run
- 17 through your undergraduate and post-graduate
- 18 education?
- 19 A. So I have a Bachelor's degree and I
- 20 have a Master's in public administration.
- 21 Q. And your Bachelor's was where?
- 22 A. Hampshire College.
- Q. And did any of your studies at
- 24 Hampshire College involve substance abuse
- 25 courses?

Page 50 Page 52 1 Α. No. 1 Q. And what was the purpose of those 2 2 meetings? O. Mental health? 3 3 No, none that I can recall. MR. PIFKO: Objection. Vague. 4 Any medical training? 4 A. To understand better the work that 5 A. I don't have any medical training. 5 they do, the data that they -- they analyze, and 6 data that they produce, and what -- what is then 6 Q. Any courses or training in 7 done with the data and -- yeah. 7 epidemiology? 8 A. I have attended courses on 8 Q. Would you consider yourself an 9 epidemiologist? 9 epidemiology. Q. As part of your undergraduate A. I do not consider myself an 10 10 11 education? 11 epidemiologist. 12 12 Q. Does the City of Cleveland have A. No, not as part of my undergraduate 13 education. 13 epidemiologists that work with -- in analyzing Q. How about as part of your graduate 14 opioid-related issues? A. We employ epidemiologists, the 15 education? 15 A. No, not specifically. 16 Cleveland Department of Public Health, yes. 16 Q. As part of your employment? 17 17 Q. Okay. How many? A. As part of my employment -- sorry. A. There are three currently in my 19 The question again is? 19 department. 20 Q. Have you taken any courses in 20 O. What are their names? 21 epidemiology? 21 A. I have three of them. Wendy Foster, A. I have not taken any specific 22 22 Sheena Fryerson and Katherine Romig. 23 courses on epidemiology. Q. I've seen a name in the documents, Q. Have you received any training on 24 Jana Rush. Is she employed by the City of 25 Cleveland? 25 epidemiology? Page 51 1 A. I have some, yes. A. She's no longer employed by the City 1 2 Q. Could you describe when that was? 2 of Cleveland. Q. Was she formerly an epidemiologist 3 A. Specifically, if you're asking for 3 4 an actual date --4 in your department? 5 A. Yes. 5 Q. A year is fine. A. Over the course of the last two 6 Q. When did she leave the City of 7 years I have spent a fair amount of time with 7 Cleveland? 8 epidemiologists and immersed in that field. 8 A. She left, I believe, in early 2017. Q. All right. So one of the things you 9 Q. Do you know where she is now? A. I do not. 10 just said was that you have sat and discussed 10 11 with epidemiologists in meetings various topics. Q. Why did she leave? 11 12 Was the purpose to train you in the underlying MR. PIFKO: Objection. Calls for 12 13 field of epidemiology? 13 speculation. Foundation. MR. PIFKO: Objection. Vague. 14 14 Q. Do you know why she left? 15 Objection. Calls for speculation. 15 A. I do not know why she left. 16 You can answer. 16 Q. Was she fired? 17 A. It was -- I'm sorry. You have to 17 A. She was not fired. Q. She voluntarily terminated her 18 repeat the question. 19 19 employment to the best of your knowledge? Q. Sure. 20 You have sat in during the course of 20 A. Correct. 21 your career in meetings with epidemiologists. I 21 Q. During your education did you take 22 think that's a general statement as to what you 22 any courses -- and this is either as an 23 told me. Is that accurate? 23 undergraduate or graduate -- in pharmacology?

24

25

A. I did not.

Q. I don't want to go through your

A. I have met with many

25 epidemiologists.

Page 54

1 entire employment history, but you were a member

- 2 of Cleveland City Council; is that accurate?
- A. That is accurate.
- Q. What years was that? 4
- 5 A. 1997 to 2005.
- Q. And what district did you serve 6
- 7 during that time?
- 8 A. Then it was ward 15.
- Q. What communities does that encompass
- 10 or what parts of the City of Cleveland does that
- 11 entail?
- 12 A. Generally they were the
- 13 neighborhoods of Old Brooklyn and Brooklyn
- 14 Center.
- 15 Q. Did you serve on any city council
- 16 committees while you were a council person?
- 17 A. I did.
- 18 What committees did you participate
- 19 in?
- 20 A. I chaired the public health
- 21 committee. I also -- then in my second term I
- 22 chaired the community and economic development
- 23 committee, sat on the finance committee. I'm
- 24 not sure if I can remember them all, but
- 25 aviation transportation committee, employment

- 1 Foundation. Speculation.
- A. I'm provided data almost on a daily,

Page 56

Page 57

- 3 if not weekly basis, and along with that data is
- 4 zip codes, and so we are tracking zip codes and
- 5 areas of the city that may or may not be
- 6 impacted more at any given time.
- Q. Ms. Gordon, how long have you lived
- 8 in the City of Cleveland or in this general
- 9 area?
- 10 A. Lived in the general area almost my 11 entire life except for school.
- 12 Q. So you're well familiar with the
- 13 various geographic areas within the City of
- 14 Cleveland?
- 15 A. Yes.
- 16 Q. Are there certain neighborhoods that
- 17 are more impacted by the opioid crisis currently
- 18 in the City of Cleveland than others?
- 19 MR. PIFKO: Objection. Foundation.
- 20 Vague. Overbroad.
 - A. We get this data on a daily almost
- 22 or weekly basis and look at zip codes and
- 23 analyze where the trends are and where there are
- 24 fatals and non-fatals due to overdoses and look
- 25 at that based on zip codes and neighborhoods and

Page 55

21

1 committee, rules committee.

- 2 Q. Is -- and I'm talking about current
- 3 day.
- 4 A. Um-hum.
- 5 Q. Is opioid abuse and addiction an
- 6 issue in the Old Brooklyn neighborhood?
- 7 MR. PIFKO: Objection. Vague.
- 8 Foundation.
- Q. Well, Ms. Gordon, one of the things
- 10 you do, that your department does currently is
- 11 try to provide treatment for opioid addicts; is
- 12 that fair?
- A. We try to provide as many programs
- 14 as we possibly can with the budget we have to
- 15 address this issue.
- Q. And so I would imagine, as the
- 17 director of that department, you're well aware
- 18 of what communities in the City of Cleveland are
- 19 facing opioid abuse and addiction issues; is
- 20 that fair?
- 21 A. That is fair.
- 22 Q. Are there some parts of the City of
- 23 Cleveland that have higher rates of opioid abuse
- 24 and addiction than others?
- MR. PIFKO: Objection. Vague. 25

- 1 communities that are impacted.
- 2 Q. Okay. I understand what you look at
- 3 and so I'm asking you, are there certain areas
- 4 that, when you look at the trends, are more
- 5 impacted by the opioid crisis than others?
- MR. PIFKO: Objection to the extent
- 7 the question calls for the witness to speak to
- 8 data which speaks for itself. Vague.
- 9 Ambiguous.
- 10 MR. NAEEM: Mr. Pifko, I'm going to
- 11 remind you again that the deposition protocol is
- 12 very strict regarding the amount of objections
- 13 you can raise and your ability to speak on the
- 14 record, so I would ask again to keep it short
- 15 and to the objections permitted.
- 16 MR. PIFKO: Well, I'm stating my
- 17 objection to the clarity and specificity and I'm
- 18 entitled to protect the record and I'm going to
- 19 continue to do that. If you have a problem with
- 20 my articulation of objections, you should try to 21 articulate more specific questions, and if you
- 22 have further problems, we can address it. But I
- 23 don't believe there's anything improper. I read
- 24 the protocol and I'm familiar with it.
- 25 MR. NAEEM: Okay. Well, we can

Page 58

- 1 address it as it goes into the deposition. If
- 2 we have to, we'll bring it up to the special
- 3 master or the judge.
- Q. So the question was, based on your 4
- 5 lifelong history as a Clevelander and your
- 6 employment as the director of public health in
- 7 the City of Cleveland, are there currently areas
- 8 of Cleveland or neighborhoods of Cleveland that
- 9 are more impacted by the opioid crisis than
- 10 others, that have higher incidents of opioid
- 11 abuse and addiction than others?
- 12 MR. PIFKO: Objection. Compound.
- 13 Vague. Objection to the extent it's asking
- 14 about data that speaks for itself.
- 15 A. All the communities are impacted.
- 16 We've looked at data. There are -- there are
- 17 some neighborhoods that have more incidents than
- 18 others over time, and that can migrate and all
- 19 depend on what's going on.
- 20 Q. At the time you were a city council
- 21 person in ward 15, was Old Brooklyn one of those
- 22 communities that had a higher incidence of
- 23 opioid abuse and addiction than other
- 24 communities in the neighborhood?
- 25 MR. PIFKO: Objection. Foundation.
- - - Page 59
- A. I can't say that I recall that with 1 2 specificity.
- 3 Q. Did ward 15 -- strike that.
- 4 Was opioid abuse and addiction an
- 5 issue in ward 15 during your tenure as a city 6 council person?
- 7 MR. PIFKO: Objection. Foundation.
- A. I have recollection that addiction
- 9 was -- was an issue throughout the entire city
- 10 and was impacting that community that I
- 11 represented, yes.
- Q. And when you say "addiction," are 12
- 13 you talking about opioid addiction or just
- 14 addiction generally?
- 15 A. I can't say with specificity on
- 16 whether there was direct opioid addiction at
- 17 that time. I don't recall with specificity. I
- 18 don't recall.
- Q. How about generally? Do you recall 19
- 20 whether opioid abuse and addiction were issues
- 21 in ward 15 during your tenure as a city council
- 22 person?
- 23 A. As a representative, we looked at
- 24 all sorts of things that impacted the community.
- 25 I can't say with absolute certainty that -- that

- 1 that was an issue that we looked at
 - 2 specifically, but I do recall that this was
 - 3 something that was emerging, and data was just
 - 4 anecdotally and in community meetings and we
 - 5 were starting to hear from families and people
 - 6 who were talking about addiction and how that
 - 7 was impacting their families and those
 - 8 communities.
 - 9 Q. And that emerging data that you just 10 referenced, was that opioid-related data?
 - A. I can't say with specificity.
 - 12 Q. How about generally; do you recall
 - 13 any discussions of opioids impacting the City of
 - 14 Cleveland during your tenure as a city council 15 person?
 - MR. PIFKO: Objection. Vague.
 - 17 Overbroad.

16

19

24

25

- I don't recall with specificity. 18
 - Do you recall generally opioid
- 20 issues or heroine abuse or fentanyl abuse or
- 21 prescription drug abuse being an issue in the
- 22 City of Cleveland between 2007 and -- sorry,
- 23 1997 and 2005 as a city council person?
 - MR. PIFKO: Objection. Compound.
 - A. I recall going to a lot of meetings

Page 61

Page 60

- 1 and hearing from families and hearing from
- 2 neighborhoods about the impact of addiction and
- 3 what was happening within their own families.
- 4 remember hearing stories of people's houses
- 5 getting broken into and people going into the
- 6 bathrooms and looking for drugs in medicine
- 7 cabinets. I remember hearing about this
- 8 countless times. These were painkillers. These
- 9 were pills people were looking for in people's
- 10 homes. I went to a lot of meetings and heard a
- 11 lot of stories of this nature.
- 12 Q. So you do have specific recollection 13 while you were at city council of discussions
- 14 related to opioid abuse and addiction?
- 15 MR. PIFKO: Objection to the extent
- 16 the question mischaracterizes her testimony.
- 17 MR. BOEHM: That's an outrageous
- 18 objection. I just have to jump in. Read the
- 19 deposition protocol. It doesn't permit that
- 20 type of objection.
- 21 MR. PIFKO: I don't know who you
- 22 are, but you can't speak, okay? You need to be 23 quiet. There's one person who speaks at a time,
- 24 so that's the end of it.
 - MR. BOEHM: That's not the end of

	_	
Page 62		Page 64
1 it. I'm going to speak if I want to. My name	1	MR. BOEHM: I am authorized to
2 is Paul Boehm. I'm from Williams & Connolly in		speak.
3 Washington, D.C.	3	MR. PIFKO: No, you're not.
4 MR. PIFKO: Okay. The protocol is	4	8 8
5 one person speaks at a time, and you will have		speak.
6 your turn. You are not allowed to speak right	6	J 1 /
7 now.		then he's going to have to stop speaking.
8 MR. BOEHM: I am going to speak to	8	MR. BOEHM: He has stopped speaking.
9 raise this objection. You're not going to stop		You're the one who won't stop speaking.
10 me from doing that. The objections that you're	10	J
11 raising, particularly the last one that you did,		can address the witness at a time
12 was outrageous. It doesn't comport with the	12	E
13 deposition protocol.		witness.
MR. PIFKO: You're characterizing	14	5 8 5
MR. BOEHM: I'm not done.		objections concerning the witness.
MR. PIFKO: I don't care if you're	16	
17 done. You're not authorized to speak. Be		need to get control of the way you're handling
18 quiet.		it.
MR. BOEHM: I'm here representing my	19	
20 client.		control, okay. You need to get control. You're
MR. PIFKO: You're going to need to	21	
22 leave the room if you can't abide by the rules		business here, okay.
23 here.	23	
MR. BOEHM: How are you going to get	24	
25 me to leave the room?	23	questioner so you need to be quiet.
	+	
Page 63		Page 65
1 MR. PIFKO: Well, if you can't	1	MR. BOEHM: I'm not going to be
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't	1 2	MR. BOEHM: I'm not going to be quiet.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here.	1 2 3	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming	1 2 3 4	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their	1 2 3 4 5	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start.	1 2 3 4 5 6	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol.	1 2 3 4 5 6 7	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to	1 2 3 4 5 6 7 8	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it.	1 2 3 4 5 6 7 8 9	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can	1 2 3 4 5 6 7 8 9	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and	1 2 3 4 5 6 7 8 9 10	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's	1 2 3 4 5 6 7 8 9 10 11 12	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that.	1 2 3 4 5 6 7 8 9 10 11 12 13	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness.	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear.	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it,	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it, 20 and if I need to	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done speaking; apparently you're speaking? We're not
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it, 20 and if I need to 21 MR. PIFKO: Well, there's nothing to	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 166 17 18 19 20 21	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done speaking; apparently you're speaking? We're not doing this.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it, 20 and if I need to 21 MR. PIFKO: Well, there's nothing to 22 take. Go ahead. Take anything	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done speaking; apparently you're speaking? We're not doing this. MR. BOEHM: He has paused for me to
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it, 20 and if I need to 21 MR. PIFKO: Well, there's nothing to 22 take. Go ahead. Take anything 23 MR. BOEHM: Stop talking over me.	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done speaking; apparently you're speaking? We're not doing this. MR. BOEHM: He has paused for me to speak.
1 MR. PIFKO: Well, if you can't 2 comply with the deposition protocol, you can't 3 be here. 4 MR. BOEHM: That's acute, coming 5 from you who has not been compliant with their 6 objections from the start. 7 MR. PIFKO: I've read the protocol. 8 MR. BOEHM: I'm going to ask you to 9 rereview it. 10 MR. PIFKO: You can object, you can 11 state your objection with clarity and 12 specificity, and I have done that. There's 13 nothing preventing me from doing that. 14 MR. BOEHM: You're coaching the 15 witness. 16 MR. PIFKO: I'm not coaching the 17 witness at all. The record is very clear. 18 MR. BOEHM: But I will take this to 19 Special Master Cohen, so you need to stop it, 20 and if I need to 21 MR. PIFKO: Well, there's nothing to 22 take. Go ahead. Take anything	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	MR. BOEHM: I'm not going to be quiet. MR. PIFKO: Okay. I'm going to terminate this deposition if you're going to keep speaking because you're not authorized to speak. MR. BOEHM: I'm going to state my objection for the record. MR. PIFKO: Okay. Then Tariq needs to leave and stop asking questions and you come and sit here if you want to talk. MR. BOEHM: That's not the way MR. PIFKO: You guys as defense counsel, you guys need to decide who is going to speak for you all, okay? It's only going to be one person at a time, and we're not doing this. MR. BOEHM: I'm not speaking for Tariq. I'm speaking for my client. MR. PIFKO: Well, then he's done speaking; apparently you're speaking? We're not doing this. MR. BOEHM: He has paused for me to speak.

17 (Pages 62 - 65)

1 MR. BOEHM: I've made a very simple 1 MR. PIFKO: No, you're not. You're 2 request. One of them is to let me make my 2 clearly not. You're clearly not abiding by the 3 record, and then when I'm done, you can say 3 rules. 4 whatever you want. 4 MR. BOEHM: Go ahead. MR. PIFKO: No. You do not have the 5 MR. PIFKO: You need to keep it 6 quiet, okay? 6 right to make a record while he's speaking. You 7 do not have that right. MR. BOEHM: You need to stop trying MR. BOEHM: I'm asking you to read 8 to speak with me in that kind of disrespectful 9 the deposition protocol again because you've 9 tone and you're not going to make me leave the 10 seemed to have forgotten some important 10 room. 11 components. 11 MR. PIFKO: You're the one who 12 MR. PIFKO: I don't need your 12 started the disrespectful tone. I'm here doing 13 characterization of the deposition protocol. 13 my job and it's not your business about how I do 14 I've read it very carefully and I'm allowed to 14 my job. 15 state my objections with specificity and clarity MR. BOEHM: It's not my business how 15 16 and I'm going to do that and I'm going to 16 you do your job. 17 continue to do that and I'm going to protect the Go ahead. You have my position. 17 18 record as I deem appropriate. The record is 18 MR. PIFKO: You're not authorized to 19 clear that the witness is not being coached, I'm 19 take a position right now. 20 not telling her what to say. 20 MR. NAEEM: Are you ready? MR. BOEHM: If you continue to do it 21 MR. PIFKO: Are you speaking? Are 21 22 you asking the questions, sir? I believe you 22 and the way you're doing it, this is going to be 23 in front of Special Master --23 are, and I've had fine interactions with you and MR. PIFKO: Well, that's fine. I 24 I don't have any problems with you, but I need 25 don't believe anything I'm doing is wrong and 25 to know who is speaking for the defendants in Page 69 Page 67 1 this deposition. 1 I'm going to raise the fact that you all can't 2 appear to have selected a person to speak. 2 MR. NAEEM: Mr. Pifko, you're not MR. BOEHM: You raise whatever you 3 allowed to ask me questions on the record. MR. PIFKO: Well, I need to know 4 want. That's fine. MR. PIFKO: Well, you need to be 5 because we apparently have an issue with who is 6 handling this deposition. Are you handling the 6 quiet. If you do that again, I'm going to ask 7 deposition, sir? 7 for you to leave the room. 8 MR. BOEHM: You can ask all you 8 MR. NAEEM: I think it's pretty 9 clear, but I think if you look --9 want, but that's not going to happen. 10 MR. PIFKO: I think the protocol is 10 MR. PIFKO: It's not clear to me. MR. NAEEM: -- at the deposition 11 clear that only one person is allowed to speak 11 12 at a time. 12 protocol, you will see that two counsel for each 13 subgroup are permitted to conduct the 13 MR. BOEHM: I'm letting you do that. 14 examination of the witness. 14 You should let me do the same. 15 MR. PIFKO: No. You're not -- right 15 MR. PIFKO: Not at one time, okay. 16 now we have one counsel here asking the 16 Check the case law. You cannot double team a 17 questions. 17 deposition. 18 MR. BOEHM: You have my position. 18 MR. NAEEM: We're not double 19 You guys can go ahead. 19 teaming. He didn't ask the witness a question 20 at all --20 MR. PIFKO: No. You're not allowed 21 to make comments right now. You are not allowed 21 MR. PIFKO: He's speaking up. He's 22 to make comments. If you can't abide by the 22 getting involved in the questions. Come on. 23 MR. NAEEM: -- so as long as we 23 rules, you need to leave the room. MR. BOEHM: I'm not leaving and I am 24 characterize what's going on accurately, we can 25 abiding by the rules. 25 move on.

18 (Pages 66 - 69)

Page 70 Page 72 MR. PIFKO: We have a record. 1 council? 2 Everything is being heard. We don't need to 2 MR. PIFKO: Objection. Vague. 3 3 characterize anything. Okay. A. I don't recall specifically. 4 MR. NAEEM: You're the one who is Q. Any legislation passed while you 5 addressing me. 5 were on city council that was meant to address MR. PIFKO: Well, I am because I 6 substance abuse issues? 7 need to know -- defendants -- there are a lot of 7 A. I don't recall specifically. 8 Q. Any investigations or hearings that you here --9 MR. BOEHM: If you want to go off 9 you recall that related to substance abuse 10 issues? 10 the record --MR. PIFKO: I don't want to have any 11 A. I don't recall specifically. 12 conversations with you off the record. No thank 12 Q. And is it fair for me to assume that 13 you. 13 when you have no recall of specific business of 14 MR. BOEHM: I'm saying if you want 14 city council on substance abuse issues, that 15 to stop right now and we can take this up with 15 answer includes opioid-related issues, because I 16 Special Master Cohen, we can go off the record 16 could ask the same questions all over again? So 17 to do that, if that's what you want to do. I'm 17 when I say "substance abuse issues," do you 18 not asking to do that yet. I'm telling you my 18 understand that to mean opioid-related issues? 19 position is if the objections continue in the 19 MR. PIFKO: I think for clarity 20 way they have gone so far, I'm going to ask to 20 maybe you should just ask those questions again. 21 do that. That's all I'm saying right now. 21 MR. NAEEM: Sure. 22 22 MR. PIFKO: Well, I'm saying -- do I Q. Do you recall while you were on city 23 have an agreement that only -- when one counsel 23 council that members of ward 15 were suffering 24 is asking questions, only one person is going to 24 from opioid abuse issues? 25 speak on behalf of defendants? If I don't have 25 MR. PIFKO: Objection. Foundation. Page 71 Page 73 1 that agreement, we're going to go to Cohen now A. I have recollection of people who 1 2 and get that clarity because this is not 2 were addicted and hearing firsthand accounts of 3 appropriate. 3 individuals who were suffering from addiction, 4 MR. BOEHM: I'm going to make 4 families who had a loved one and families who 5 objections as I see fit. 5 were dealing with this issue. I have -- I have MR. PIFKO: Okay. We're going to go 6 recollection of that for sure. 7 off the record and we're going to call him. 7 Q. So those were hearings that were 8 THE VIDEOGRAPHER: Off the record 8 conducted by city council during your tenure? 9 The time is 10:21. A. That was one-on-one interaction with 10 (Recess had.) 10 individuals in the community they represented, THE VIDEOGRAPHER: Back on the 11 11 people who attended community meetings, people 12 record. The time is 10:40. 12 that I met with for a variety of reasons. Part 13 BY MR. NAEEM: 13 of my job was to meet with families. I went to O. Ms. Gordon, I want to tie off where 14 community meetings multiple times a week and 15 I believe I think we were before we went off the 15 heard about what was going on on the street, in 16 record. During your tenure on city council from 16 the community, neighborhoods. 17 1997 to 2005 were you aware of citizens in ward 17 Q. Did city council during your tenure 18 15 who had substance abuse issues? 18 between 1997 and 2005 discuss any legislation 19 A. Substance abuse issues, yes. 19 directed -- intended to be directed towards 20 Q. Was that something that city council 20 addressing these opioid-related issues? 21 was involved in assessing? 21 A. I don't recall that specifically. 22 A. I don't recall. 22 Q. Did city council during that time 23 Let me strike that. 23 frame have any -- conduct any investigations, 24 Was that an issue -- any issue 24 public hearings of that sort regarding 25 related to substance abuse that came before city 25 opioid-related issues?

A. I don't have recollection.

- 2 Q. Any discussions at city council
- 3 between 1997 and 2005 about funding for
- 4 opioid-related treatment or education?
- 5 A. I don't recall.
- 6 Q. When did you -- well, strike that.
- 7 Let me start at the top.
- 8 What is your current title with the
- 9 City of Cleveland?
- 10 A. I'm the director of the Cleveland
- 11 Department of Public Health.
- 12 Q. When did you take that -- take on
- 13 that role?

1

- 14 A. I began that on June 13th of 2016.
- 15 Q. How did you come to apply for or be
- 16 approached about taking on the role of director
- 17 of public health?
- 18 MR. PIFKO: Objection. Calls for a
- 19 narrative. Overbroad.
- A. I knew that the position had been
- 21 vacant and that the city was looking to fill
- 22 that position and so I applied. I submitted my
- 23 letter and resume to the city and -- and
- 24 proceeded through that route.
- Q. Do you know why the role was

Page 74

1 position of director of the Department of Public

Page 76

Page 77

- 2 Health?
- 3 A. I do not know.
- 4 Q. So you don't know whether she was
- 5 fired or whether she left voluntarily?
 - A. I do not know specifically, no.
- 7 Q. Once you submitted your resume
- 8 seeking the position of director, how did the --
- 9 could you describe how the hiring process went?
- 10 A. Sure.
- I was called in for an interview
- 12 with a panel of individuals, and after that I
- 13 was called back shortly thereafter. I
- 14 understood that I was one of the finalists. And
- 15 the two finalists then had to have an interview
- 16 with the mayor of the City of Cleveland. I had
- 17 that interview, and within a period of time I
- 18 was called and notified that I was being offered
- 19 the position.
- Q. Do you happen to know who the other
- 21 final candidate was? Was that made --
- A. I do not know.
- Q. Did anyone -- were you the first
- 24 choice or did the first choice not accept the
- 25 position? Do you know that?

Page 75

- 1 available at that time?
- 2 MR. PIFKO: Objection. Calls for
- 3 speculation. Foundation.
- 4 Q. And the question was do you know why
- 5 that role was available.
- 6 A. There was nobody filling that role.
- 7 Q. Do you know why the predecessor had
- 8 left the Department of Cleveland Health?
- 9 MR. PIFKO: Objection. Calls for
- 10 speculation. Foundation.
- 11 A. I do not know.
- 12 Q. Do you know who that person was, the
- 13 immediate prior director before you were hired?
 - A. Who had that position specifically,
- 15 yes, I do know that person's name.
- 16 Q. What was that person's name?
- 17 A. Her name is Toinette Parilla.
- 18 Q. Can you spell her last name, if you
- 19 know?
- A. I believe it's P-a-r-i-l-l-a.
- Q. And do you know how long the
- 22 position had been vacant prior to you taking on
- 23 the directorship?
- A. About a year.
- Q. Do you know why Ms. Parilla left the

- 1 A. I don't know that.
- Q. So you interviewed with a panel.
- 3 Was that a panel of City of Cleveland employees?
 - A. Yes.
- 5 Q. Do you recall who they were, at
- 6 least their role within the City of Cleveland,
- 7 if not their names?
- 8 A. Yes.

- Q. Can you tell us that, please?
- 10 A. Of the four panelists?
- 11 Q. Yes.
- 12 A. Sure. Natoya Walker Minor, Tracy
- 13 Martin Thompson, Martin Flask and Barry Withers.
 - Q. Okay. Can you let us know what
- 15 roles those people had at the time they were
- 16 interviewing you?
- 17 A. Sure.
- Natoya Walker Minor is the chief of
- 19 public affairs, Tracy Martin Thompson and Martin
- 20 Flask are special assistants to the mayor, and
- 21 Barry Withers also has a key position. I'm not
- 22 entirely sure what his title is.
- Q. To be clear -- I want to make sure I
- 24 understood what you said about your awareness of
- 25 the position. Did somebody approach you about

Page 78

1 this open position before you applied?

- A. We were aware that the position had
- 3 been -- had been vacated and available and that
- 4 the city was looking for somebody to fill that
- 5 position.
- 6 Q. Okay. And I wasn't specific enough.
- 7 I apologize. Did somebody from the City of
- 8 Cleveland approach you about seeing whether you
- 9 were interested in taking the role of director
- 10 of public health?
- 11 A. No.
- 12 Q. Was it ultimately Mayor Jackson's
- 13 decision as to who to hire in that role?
- 14 MR. PIFKO: Objection. Calls for
- 15 speculation. Foundation.
- 16 A. I believe that's why the interview
- 17 is with the mayor and then a decision is made.
- 18 Q. Do you know whose final decision it
- 19 was to hire you as the director of Cleveland
- 20 Public Health?
- 21 A. I don't know specifically.
- 22 Q. But you believe it was Mayor
- 23 Jackson's decision?
- 24 MR. PIFKO: Objection. Speculation.
- 25 A. I believe.

- Page 79
- 1 Q. Now, once -- in your role as
- 2 director, are you free to hire people within the
- 3 Department of Health without oversight from
- 4 anyone else in the City of Cleveland?
- 5 A. No, not necessarily.
- 6 Q. As a general matter, and, for
- 7 example, I might not pronounce her name
- 8 correctly, but Persis Sosiak, do you know who
- 9 she is?
- 10 A. I do.
- 11 Q. Does she work in your department?
- 12 A. She does.
- 13 Q. Does she work under you?
- 14 A. Yes.
- 15 Q. So she reports to you?
- 16 A. She does.
- 17 Q. Was she hired by the City of
- 18 Cleveland after you became the director of
- 19 public health?
- 20 A. Yes.
- 21 Q. Very briefly -- I don't know the
- 22 details about her specifically -- were you able
- 23 to hire her without the oversight of anybody
- 24 else at the City of Cleveland?
- 25 A. No.

- 1 Q. How did that process work?
 - 2 A. The commissioner of health position
 - 3 -- and we posted for the position, which is an
 - 4 internal mechanism. She, along with others,
 - 5 applied for the position. We reviewed resumes.
 - 6 I had the ability to narrow down some of my
 - 7 recommendations. She then interviewed with
 - 8 myself and chief of public affairs and Tracy
 - 9 Martin Thompson, who is, again, the special
 - 10 assistant to the mayor, along with the
 - 11 finalists. The two final recommendations are
 - 12 then brought to the mayor. The mayor does
 - 13 interview those two top finalists and makes a
 - 14 recommendation of -- of whether or not they
 - 15 support the candidates or whether we should
 - 16 continue the search.
 - 17 Q. And in that specific situation with
 - 18 Ms. Sersis -- did I get that right?
 - 19 A. You did not.
 - Q. No. Could you say it again, please?
 - A. Her name is Persis Sosiak.
 - Q. In that instance did Mayor Jackson
 - 23 give the authority to hire Ms. Sosiak?
 - A. He did.
 - Q. When you were interviewing with the

Page 81

Page 80

- 1 initial panel or with -- having a discussion
- 2 with Mayor Jackson prior to being hired as
- 3 director, was there any discussion about
- 4 specific public health issues that were being
- 5 faced by the City of Cleveland?
- 6 A. Yes.
- 7 Q. Was there any specific discussion
- 8 about the opioid abuse and addiction issues
- 9 during that interview process?
- 10 A. Yes.
- 11 Q. Who did you have that discussion
- 12 with?
- 13 A. That discussion came up in the panel
- 14 and then as well in the interview I had with the
- 15 mayor.
- 16 Q. And what was -- what was generally
- 17 described during that process to you?
- 18 A. I was asked what I saw as some of
- 19 the top issues facing the City of Cleveland and
- 20 I listed that as one of them.
- Q. And were you given further
- 22 information about that issue from any of the
- 23 panelists or Mayor Jackson during this
- 24 discussion?
- A. What type of information?

Page 82 Page 84 1 Q. Statistics about the scope of the 1 A. Yes. 2 problem in the City of Cleveland or treatment 2 Q. How far back had you been aware of 3 programs that would be administered through the 3 opioids as an issue that the City of Cleveland 4 Department of Public Health. 4 was facing? A. I didn't to my recollection. A. I can't say specifically, but I know 6 Q. So this is something you 6 that over the course of years this has been an 7 affirmatively brought to the table during the 7 issue and something that I had seen and read 8 interview process? I think that's what you just 8 about and, again, it had been written about in 9 said. 9 the local newspaper and -- and part of 10 A. Yes. 10 information that I would get just as part of my 11 job and as a concerned citizen. 11 Q. And where did you become -- strike 12 that. 12 Q. When you referred to the Ohio 13 How did you become available of 13 Attorney General report when describing the 14 those issues? How did you become aware of those 14 news, as a consumer of news that you were aware 15 issues? 15 of during the application process, what specific A. I'm a consumer of news and 16 report are you referring to? 17 information and engaged in the community. I've 17 A. I believe that that came out in 18 been in this field and there's a lot that's been 18 2014. There was a lot of publicity around the 19 written on it, and especially here in Ohio 19 release of this report and this information, and 20 around this time the Ohio Attorney General had 20 in an attempt to try to address what had really 21 put out a report. There was information in the 21 become this massive issue here in this 22 newspaper, local newspaper, and data that was 22 community. 23 available through organizations that look at 23 Do you recall the title of the Q. 24 issues pertinent to this community. 24 report? 25 Q. Were you educating yourself as part 25 I don't recall the title of the Page 85 Page 83 1 of the application process or is this 1 report, but I know it was a report that came out 2 information you knew prior to even deciding to 2 of the Ohio Attorney General's Office. 3 apply for this position? Q. And what specifically was the 4 subject matter of the report? MR. PIFKO: Objection. Compound. 5 A. It was about -- it was about 5 Objection to the extent the question assumes 6 facts not in evidence. 6 opiates. It was about prescribing practices. 7 A. I was doing it both, as someone who 7 It was about the impact in our community, 8 is concerned about this community and the 8 overdoses, looking at ways that the community 9 could respond to this issue. 9 impacts, issues pertaining to this community as 10 well as work that I do in this area. 10 Q. Do you think it might have been the 11 Ohio Task Force on opioid abuse? O. Let me ask this a little 12 differently. 12 A. Might have been. I don't recall for 13 sure the title of it. 13 So you became employed by the City 14 14 of Cleveland as director of the Department of 15 Public Health on June 13th, 2016? 15 (Thereupon, Deposition Exhibit 2, A. Correct. 16 Ohio Prescription Drug Abuse Task 16 17 Q. When did you apply for the position? 17 Force Final Report, Task Force 18 Month and year is fine. 18 Recommendations, dated October 1, 19 2010, was marked for purposes of 19 A. It was earlier in 2016. Maybe a 20 identification.) 20 couple months prior. 21 21 Q. Prior to that couple of months 22 before you applied, were you aware as a consumer 22 Q. I'm handing you what's been marked 23 of news about some of these opioid-related 23 for the deposition as Exhibit 2. Do you think 24 reports from the Ohio Attorney General or local 24 this might have been the report you were just 25 news reports? 25 referring to? Well, first of all, have you seen

1

1 that report before?

- A. I can't say specifically. This is
- 3 not the report I was referring to.
- Q. Okay. That's all I need to know for
- 5 now. So whatever it was we were just talking
- 6 about, it's not your recollection that Exhibit 2
- 7 is the report you were referring to?
- A. Correct.
- Q. As part of your role with the
- 10 Cleveland Department of Public Health, do you
- 11 speak to Mayor Jackson on opioid-related issues?
- 12 A. I have presented at cabinet where
- 13 the mayor is -- holds weekly meetings, and I
- 14 have presented there, yes.
- 15 Q. How often do you present at cabinet
- 16 where opioid-related issues are discussed?
- 17 A. I've done this a few times over the
- 18 last two plus years that I've been there.
- Q. So these are ad hoc as opposed to
- 20 periodic scheduled updates for Mayor Jackson?
- 21 A. The cabinet meets weekly and it's
- 22 the entire cabinet, about 35 people, who attend,
- 23 and often I am asked to present or answer
- 24 questions, but the schedule of who speaks and on
- 25 what topic is not -- is not scheduled in

Page 86 Page 88

O. Handwritten notes?

- 2 Sometimes they're handwritten notes,
- 3 but often I'll type them up and bring them just
- 4 so I can read them.
- Q. Do you recall in this instance of
- 6 the fall of 2016 whether you had handwritten or
- 7 typed notes for that meeting?
- A. Often I would prepare for the
- 9 meeting in case I was called upon to present
- 10 information to cabinet, so sometimes I would
- 11 have that, those notes handwritten, and often I
- 12 was bringing -- produced notes that I would have
- 13 typed up.
- 14 Q. Do you recall seeing in the
- 15 production or the materials you found this
- 16 weekend and turned over to your attorney, seeing
- 17 any of those kind of written materials when you
- 18 were cleaning your office, handwritten
- 19 materials?
- 20 MR. PIFKO: Objection. Vague.
- 21 A. No, I did not.
- 22 Q. Do you recall what the topic of the
- 23 conversation was in the fall of 2016 in the
- 24 presentation you gave specifically?
- 25 A. To some degree. So I was presenting

Page 87

- 1 advance.
- Q. So you attend the meetings and you
- 3 might not know before you appear that
- 4 opioid-related issues come up?
- 5 A. That could be possible, correct.
- Q. Do you recall ever presenting
- 7 written materials for one of these cabinet
- 8 meetings on opioid-related issues?
- A. Yes.
- 10 Q. When do you recall that that
- 11 happened?
- 12 A. Early on in my tenure, so fall of
- 13 2016, late summer, early fall I was asked to
- 14 present on this particular issue. Public safety
- 15 and I were asked to come up with a set of
- 16 recommendations for the mayor pertaining to
- 17 opiates, opioid-related overdose deaths,
- 18 fatalities, et cetera.
- Q. Did you prepare a PowerPoint 19
- 20 presentation?
- 21 A. I did not.
- 22 Q. What kind of materials did you
- 23 prepare for that meeting?
- A. These are oral presentations, so I
- 25 just would have had my notes.

- Page 89 1 information from the medical examiners in terms
- 2 of a number of overdose deaths, what they
- 3 pertained to, may have also had information on
- 4 the number of issuances and doses of Narcan or
- 5 naloxone and what public safety was using, and
- 6 going through -- we also would have provided how
- 7 many patients we had seen who had come into our
- 8 Project DAWN clinics; also, what other
- 9 information was at that point available so that
- 10 I was giving the mayor and cabinet as much
- 11 information as we possibly could.
- 12 Q. And I thought I heard you say that
- 13 you presented with somebody else from the City
- 14 of Cleveland this data, maybe a different
- 15 department. Did I hear that correctly?
- 16 A. Well, often we work in conjunction
- 17 with other departments, and public safety is one
- 18 department where I've worked very closely on
- 19 this particular issue.
- 20 Q. And I want to be specific to this
- 21 meeting, the fall of 2016. Did you co-present
- 22 this opioid-related data with somebody from
- 23 public safety?
- 24 A. I don't recall that we co-presented,
- 25 but it would have been information that would

1 have been provided from them. We met prior to

- 2 to make sure that I had information to present
- 3 at the mayor's cabinet.
- 4 Q. And which functions within public 5 safety would have provided this data to you?
- A. So there -- this would have been 7 public safety administration, also police and
- 8 EMS and first responders and fire.
- O. Is the medical examiner's --
- 10 actually, that's a county position, correct? A. Medical examiner is a county
- 12 position, yes.
- 13 Q. Would you have gotten data from the
- 14 Cuyahoga County Medical Examiner's office for 14
- 15 this presentation of data to the cabinet in the
- 16 fall of 2016?
- 17 A. Yes.
- Q. So do you specifically recall there
- 19 was discussion, for example, of opioid deaths at
- 20 that time?
- 21 A. Yes.
- 22 Q. You mentioned Project DAWN and you 22 answer.
- 23 said that some of the data would have related to
- 24 patients to whom kits were dispensed? I may
- 25 have heard you wrong. What specifically is
 - Page 91

- 1 Project DAWN?
- 2 A. Sure.
- 3 Project DAWN is -- DAWN stands for
- 4 deaths avoided with naloxone. We, the City of
- 5 Cleveland, in our clinics we're providing
- 6 Project DAWN kits, and Project DAWN comes
- 7 from -- it's a program that Dr. Papp was
- 8 instrumental in creating, so we are one of the
- 9 distribution points for those kits, and we would
- 10 give those out to individuals who visited our
- 11 clinics.
- 12 Q. Those clinics do not actually
- 13 administer Narcan, is that correct, or naloxone?
 - A. It is part of the kit that is
- 15 distributed with Project DAWN.
- Q. And I understand that, but this
- 17 clinic doesn't provide -- actually inject Narcan
- 18 into patients who are suffering overdoses; is
- 19 that correct?
- 20 A. To my knowledge, the clinic has not
- 21 administered the actual naloxone to a patient,
- 22 correct. We just provide the kits.
- Q. Who provides the funding for Project 23
- 24 DAWN currently?
- 25 A. It is a program through Metro

1 Hospital.

- Q. So does any of the funding for
- 3 Project DAWN clinics in the City of Cleveland 4 actually come from the City of Cleveland?
- 5 MR. PIFKO: Objection. Foundation.
- 6 A. I can speak to the Project DAWN kits
- 7 that the Cleveland Department of Public Health
- 8 offers to the community. That is a program
- 9 specifically through MetroHealth.
- Q. Okay. So no City of Cleveland funds 10
- 11 are used to purchase the kits that are dispensed
- 12 by clinics run by the Cleveland Department of
- 13 Public Health?
 - A. That is -- to the best of my
- 15 knowledge, that is correct. We fund the staff
- 16 who work on this project.
- Q. Is that all they do? 17
- 18 MR. PIFKO: Hold on. She was still
- 19 speaking.
- 20 Are you done with your answer?
- 21 THE WITNESS: I'm done with my
- Q. So the Cleveland Department of
- 24 Public Health's people who staff these clinics
- 25 where naloxone kits are dispensed, Narcan, is

Page 93

Page 92

- 1 that all they do for the Cleveland Department of 2 Public Health?
- 3 A. No. No. It's just part of their
- 4 work.
- 5 O. How many Cleveland Department of
- 6 Public Health employees staff those clinics or
- 7 are authorized to dispense Project DAWN kits?
- 8 MR. PIFKO: Objection. Compound.
- 9 A. At this point we have about 20 staff 10 who are trained.
- 11 Q. Was there a time after you were
- 12 hired where the clinic was -- the clinics were
- 13 unable to dispense kits because there wasn't
- 14 anybody trained to do so?
- 15 There was a time where we had to
- 16 suspend offering these kits, yes, because we did
- 17 not have trained staff to be able to provide
- 18 them.

- Q. All right. When was that?
- 20 A. I believe that that was fall of 2017
- 21 into the beginning of 2018. I don't recall
- 22 exactly the dates.
- 23 Q. And prior to fall of 2017, had the
- 24 Cleveland Department of Public Health been
- 25 providing Project DAWN kits at its clinics?

Page 94 Page 96 1 A. Yes. 1 What was that person's name? 2 Q. How long prior to that had it been 2 A. The person's name is David Gretick. 3 3 doing so? Q. So Mr. Gretick left the Cleveland 4 4 Department of Public Health in the fall of 2017? MR. PIFKO: Objection. Foundation. 5 5 A. I don't recall exactly how long, but A. Correct. 6 it had been for a fair amount of time. 6 Q. Did he take a job elsewhere as a 7 7 City of Cleveland employee to your knowledge? Q. Was the Cleveland Department of MR. PIFKO: Objection. Foundation. 8 Public Health issuing those kits prior to you 8 9 becoming employed as director of the Cleveland 9 A. I don't know. 10 Department of Public Health? 10 O. Was he fired? MR. PIFKO: Objection. Foundation. 11 A. He was not fired. 12 12 Q. So he voluntarily terminated his 13 employment? 13 MR. PIFKO: Just make sure you give A. Correct. 14 enough time for me to object if I need to say 14 15 something. 15 Q. Do you know why? MR. PIFKO: Objection. Speculation. Q. Do you have any data or do you 16 17 recall any data as you sit here regarding how 17 Foundation. 18 many kits the City of Cleveland has dispensed in 18 A. I do not know why. 19 your time with the Cleveland Department of 19 MR. NAEEM: Mr. Pifko, when I ask a 20 Public Health? 20 question about does she know, I don't believe 21 21 foundation is an appropriate objection because I MR. PIFKO: Objection. Compound. 22 A. I don't recall. 22 am asking her the foundational question. 23 23 MR. PIFKO: Understood. Q. Is that information that the 24 24 Cleveland Department of Public Health would have MR. NAEEM: Okay. I'm really, you 25 access to? 25 know, trying to adjust my questions based on how Page 95 Page 97 1 MR. PIFKO: Objection. Foundation. 1 this deposition is going to satisfy you. I 2 A. We would have access to that. 2 don't seem to be able to do so. Q. And specifically the Cleveland 3 MR. PIFKO: I'm just protecting my 4 Department of Public Health, that's what I'm 4 record. 5 asking about, that data exists somewhere in your 5 MR. NAEEM: Fair enough. 6 department? 6 Q. Have you talked to David Gretick 7 7 since he terminated his employment with the City A. Most likely, yes. Q. Who would you ask if you needed to 8 of Cleveland? 9 find out that data within the Department of A. I had one interaction with him after 10 Public Health? 10 he left the department. A. I would ask that of Commissioner Q. And have you received any 12 Persis Sosiak. 12 information from anyone about the circumstances Q. Now, going back to this period from 13 regarding why he terminated his employment? 13 14 fall of 2017 to early 2018, how was it -- how 14 A. No. 15 did it occur that there was no one at the 15 Q. Was he -- would you consider him a 16 Cleveland Department of Public Health remaining 16 disgruntled employee prior to his departure? 17 to dispense those kits? 17 MR. PIFKO: Objection. Vague. 18 MR. PIFKO: Objection to the extent 18 A. I would not. 19 the question calls for speculation. Foundation. 19 Q. So to be clear about what we're A. There was one individual who was 20 talking about, prior to the fall of 2017, the 21 trained to provide those kits who left the 21 Cleveland Department of Health only had one 22 department in the fall of 2017, and when that 22 person trained to issue Project DAWN kits? 23 23 individual left, we realized we did not have A. Correct. 24 somebody who was trained to be able to provide 24 Q. Was that the same situation as when 25 those kits. 25 you were employed -- became employed in June of

Page 98 Page 100 1 2016? 1 most recent one? 2 2 MR. NAEEM: Yes. A. Correct. 3 3 Q. Do you know how long prior to June A. Restate the question, please. 4 4 of 2016 he was the only person trained to Sure. 5 provide Project DAWN kits? 5 Starting with the revenue from the A. I do not, no. 6 City of Cleveland, how is it that funds are 7 7 allocated from Cleveland to the Department of Q. Going back generally to the role of Public Health? 8 director of the Cleveland Department of Public 8 9 9 Health, who do you directly report to? Who is MR. PIFKO: Objection to the extent 10 the question calls for speculation. 10 your immediate supervisor? You can answer. A. Natoya Walker Minor. She's the 12 A. There's an annual budget process. 12 chief of public affairs. 13 Q. And has that been the same person 13 We are essentially told that we have a certain 14 amount of general revenue fund available to the 14 since you were employed in June of 2016? 15 A. Yes. 15 department, essentially the same amount year Q. How many direct reports do you have? 16 over year, if that's what's available to the 16 17 17 City overall, and then we also have -- part of A. I have many. 18 our budget is also grant funding and fees Q. All right. Let's take a step back generated through licenses and permits. 19 and ask or give me a sense -- how is the 20 Cleveland Department of Public Health organized? 20 Q. When you say that you are told how 21 much your annual budget is going to be and it is 21 And I mean are there separate offices or 22 subdepartments within the greater organization. 22 essentially the same amount, how much is that 23 budget amount currently for this fiscal year? 23 A. There are divisions. 24 24 A. For the general fund? Q. How many? 25 2.5 There are three divisions and also From the City of Cleveland, yes. Page 101 Page 99 1 the administrative function. It's a little over -- I believe it's 1 2 a little over 8 million dollars. Q. Does the administration section of 3 the Department of Public Health have any role in 3 Q. And so that's for the 2018 budget 4 year? 4 opioid-related issues, whether it's providing 5 5 treatment or collecting statistics, anything at A. Correct. 6 all? 6 Q. And so you said essentially the same 7 7 amount. I need to know from you taking the In the administrative section? A. 8 Q. Um-hum. 8 position in 2016 to the current fiscal year has 9 it changed or did it change. 9 A. No. 10 Q. How many of the three divisions 10 A. It changed somewhat, yes. Q. All right. So what was it prior to 11 touch on opioid-related issues? 11 12 Division of Health. 12 this current fiscal year? A. I don't recall exactly how much it 13 Q. Is that Ms. Sosiak? Is she the 14 was in 2016 when I -- when I joined. 14 commissioner of that division? 15 A. Correct. Yes. 15 Q. How about 2017? Q. What are the other two divisions? 16 A. It changed in 2017 as a result of 16 17 A. Division of Environment, Division of 17 the increase in income tax after a ballot issue 18 Air Quality. 18 in 2017, more than a million dollar difference 19 Q. How does the budget process work for 19 that came into the department through 21 new 20 staff under the general revenue fund or paid for 20 the Cleveland Department of Public Health? And 21 to start off, how is it that funds are allocated 21 under the general revenue. 22 Q. So we're talking about 2017, 22 to the Cleveland Department of Public Health 23 correct? 23 from the Cleveland's general fund? MR. PIFKO: Sorry. You asked two 24 A. Correct.

All right. What was that number

25

25 questions there. Are we just going with the

Page 102 1 then? Q. So, for example, when the number A. It was over a million dollars. I 2 went up from 2016 to 2017 by about a million 3 dollars, that was to hire the 21 new staff 3 don't know specifically how much it was. I 4 members you talked about? 4 don't recall. 5 Q. Over a -- a million dollars over 5 A. Correct. Salaries and benefits, 6 what? 6 yes. A. In additional staff for the 7 Q. And when 21 new staffers like that 8 Cleveland Department of Public Health. 8 come into the Cleveland Department of Public Q. Okay. So you're the director of the 9 Health, are they assigned to a particular 10 Cleveland Department of Public Health, correct? 10 division? 11 We've established that. 11 MR. PIFKO: Objection. Incomplete 12 A. Yes. 12 hypothetical. 13 Q. All right. And is preparing a 13 A. There were -- yes, they were 14 budget for your department one of the roles and 14 assigned to specific divisions. 15 responsibilities you have? Q. How many of those were assigned to 15 A. Yes, it is. 16 the Division of Health? 16 17 Q. Is being aware of the amount of 17 A. Seven. 18 funds directed from the City of Cleveland 18 Q. How many of those seven are 19 currently doing -- are currently performing 19 general fund to your department within your 20 roles and responsibilities? 20 functions related to the opioid abuse and 21 21 addiction crisis? A. It is. 22 22 Q. All right. So what is the top line A. I -- I don't know specifically the 23 item for the amount of money allocated from the 23 number that are -- I don't know specifically. 24 City of Cleveland general revenue fund to the Q. Between 2016 and 2017, during the 25 Cleveland Department of Health in 2017? 25 budgeting process, was it the Cleveland Page 103

MR. PIFKO: Objection. Vague. 1 2 A. In 2017 it was a little over 8 3 million dollars. I don't know exactly how much 4 it is down to the penny. Q. Is it roughly the same amount as it 6 is this current year, the 8 million dollars? 7 A. Correct, 2017, 2018. Correct. Q. And then if we work back to 2016, 9 you said, I believe, that it was an increase of 10 about a million dollars from the prior year, so 11 2016 would be roughly 7 million dollars? 12 A. One could surmise, yes. 13 Q. Would you surmise? 14 MR. PIFKO: Objection. Asked and 15 answered. A. A million plus increase in 2017 from 16 17 2016, yes. 18 Q. And what are the things that the 19 Cleveland Department of Public Health uses money 20 allocated from Cleveland's general revenue for

MR. PIFKO: Objection. Overbroad.

A. The majority of those funds are for

Page 105 1 Department of Public Health that asked the City 2 of Cleveland for more money to hire more staff? A. Much of this was decided prior to me 4 joining, and decisions made of what positions 5 and where these positions were going to go were 6 predetermined prior to me joining the 7 department. Q. Well, as the director of public 9 health from June 2016 forward would you have 10 wanted to educate yourself about those 11 initiatives that were undertaken before you took 12 the job? 13 MR. PIFKO: Objection. 14 Argumentative. 15 A. I've been educating myself every 16 single day about every issue pertaining to the 17 department.

19 June of 2016, did you review the initiatives or 20 the request for additional staffing for the 21 Cleveland Department of Public Health? 22 A. I did. 23 Q. And do you have any recollection 24 regarding why the Cleveland Department of Public 25 Health was requesting 21 new staffers? 27 (Pages 102 - 105)

Q. And when you took the position in

18

21 in your department?

25 staffing, for people.

22

24

23 Vague.

Page 104

Page 106 A. I did. Much of it was because the 1 amount of them are working in the area of

- 2 department had seen so many cuts in previous
- 3 years and was down so many staff in number of
- 4 program areas. We're always in need of
- 5 resources and staffing to address the multiple
- 6 issues in the community and it had seen a
- 7 decline in staff and, as such, these were some
- 8 of the issues that went into deciding where
- 9 staff was needed in this enhanced budget.
- 10 Q. So currently -- strike that.
 - Going back to that point in time
- 12 when you were reviewing the information related
- 13 to requests for additional staffing, during the
- 14 early portion of your employment in June of 2016
- 15 was there any discussion of the need to hire
- 16 people due to opioid-related programming or
- 17 other issues that your department was going to

1

11

- 19 A. I need you to rephrase the question.
- 20 O. Sure.
- 21 We've been talking about the work
- 22 you were doing to get yourself up to speed when
- 23 you took the position in 2016. Do you recall
- 24 generally we've been talking about that?
- 25 A. Yes.

1

- Page 108
 - 2 Healthy Cleveland, which has some programming in
 - 3 this area, epidemiology and HIV, and all of this
 - 4 has broader implications on -- on this issue in
 - 5 the community.
 - Q. All right. Are those employees
 - 7 working on anything else that touches on the 8 opioid crisis other than Healthy Cleveland?
 - 9 MR. PIFKO: Objection. Foundation.
 - 10 A. Epidemiology for sure, and the staff
 - 11 in HIV have had to be involved with this issue
 - 12 as well just as we are all focused on -- on all
 - 13 the issues pertaining to the City of Cleveland.
 - 14 Q. And so when you refer to
 - 15 epidemiology, are you referring back to those
 - 16 three employees that are currently in the
 - 17 epidemiology department and the fact that they
 - 18 were hired since you took the position? Strike
 - 19 that. Let me start over again.
 - 20 A. Thank you.
 - 21 Q. Of the seven new employees in the
 - 22 Division of Health, were any of those
 - 23 epidemiologists you listed out for me earlier
 - 24 that are currently employed?
- 25 A. Yes.

1

- Page 107
- Q. And what we were talking about
- 2 specifically was the request to increase
- 3 staffing that had been done prior to you
- 4 becoming employed in June of 2016. Do you
- 5 recall that?
- A. Yes.
- 7 Q. All right. Now, what I'm asking is
- 8 in whatever you reviewed to get yourself up to
- 9 speed on that particular issue, was there any
- 10 discussion sent from the Cleveland Department of
- 11 Public Health to the City of Cleveland
- 12 indicating that the need for additional staffers
- 13 was related to the opioid-related -- to
- 14 opioid-related programming being done by the
- 15 Cleveland Department of Public Health?
- MR. PIFKO: Objection. Foundation. 16
- 17 A. I don't recall specifically.
- Q. And you don't -- as far as the seven
- 19 new staffers that have been assigned to the
- 20 Division of Health, you don't know whether --
- 21 well, strike that. You don't know how many of
- 22 them are involved in Cleveland Department of
- 23 Public Health activities related to the opioid
- 24 crisis?
- 25 I can't say specifically, but a fair

- Page 109 Q. How many of them?
- 2 At least one.
- 3 Q. Of the other two that are currently
- 4 employed, were they employed at the time you
- 5 took your position in June of 2016?
 - A. No.
- 7 Q. So all three of them have been hired
- 8 under your directorship?
- 9 A. Correct.
- 10 And what is the role of your
- 11 epidemiologists with respect to the opioid
- 12 crisis?
- 13 MR. PIFKO: Objection. Overbroad.
- 14 You can answer.
- 15 A. Epidemiologists are tasked with
- 16 reviewing, analyzing data, looking at trends,
- 17 looking at any kind of reports, any kind of
- 18 analysis that has been done on issues pertaining
- 19 to public health and health and, you know,
- 20 impacts in our community. They are on task
- 21 forces. They attend a lot of meetings. They
- 22 bring information to us in terms of things that
- 23 we need to pay attention to. They work directly 24 with the Ohio Department of Health, so they're
- 25 analyzing, reviewing reports that are generated

Page 112 Page 110 1 from them as well. So their purpose is to make 1 and addiction task forces they participate on. 2 sure that we are aware of what's going on, and 2 You mentioned Cuyahoga County. Are there any 3 to the best of our ability, advocating for what 3 others? 4 needs to be done in order to address these 4 A. Not to my knowledge, and, yeah, 5 issues and just making us aware of, again, 5 they're given information from that committee, 6 what's going on in the community. 6 yeah, from that task force, yes. 7 THE WITNESS: Can I take a break, Q. I'm sorry. They're given 8 information from that task force or they provide 8 please? 9 MR. PIFKO: Yes. 9 information to that task force? 10 THE VIDEOGRAPHER: Going off the 10 MR. PIFKO: Objection. Compound. 11 record. It's 11:32. 11 A. I don't know specifically if they're 12 (Recess had.) 12 giving information directly to the task force. 13 THE VIDEOGRAPHER: Back on the Q. So what is your understanding of the 14 record. The time is 11:52. 14 role of your epidemiologists in the Cuyahoga 15 MR. PIFKO: Real quick, it's a 15 County Opioid Task Force? 16 little early for lunch, so I thought we would go 16 A. It is my understanding that they 17 maybe not like a full hour and we can break for 17 have information that is provided from the task 18 lunch so people don't get too hungry. 18 force. I believe that they receive e-mails 19 MR. NAEEM: Yes. You let me know. 19 from -- from that task force. 20 BY MR. NAEEM: 20 Q. Do they provide data --21 O. Ms. Gordon, at the time we went off 21 MR. PIFKO: Are you done answering? 22 the record, we were talking about the 22 A. I don't -- I don't recall if there's 23 epidemiologists who are employed by the 23 any -- what else specifically. 24 Department of Public Health. Do you recall Q. Do you know whether or not they 24 25 generally? 25 provide Cleveland data regarding abuse -- opioid Page 111 Page 113 A. Generally, yes. 1 1 abuse and addiction to the task force? 2 Q. You said one of the things they do A. I don't know for sure. 3 is they look for trends. They are looking for Q. Do you know what sources of data 4 more than just opioid trends with their job at 4 your epidemiologists have to look at trends 5 the City of Cleveland, correct? 5 related to opioid abuse and addiction? A. Correct. A. I don't know for sure. 7 Q. So it could be influenza trends? 7 Q. Do they have access to medical 8 Correct. 8 examiner data from Cuyahoga County? A. They're not specialists on opioid O. A. They do have access to some of that 10 abuse and addiction? 10 information, yes. These are not, no. Q. And is that -- does that have to be 12 You mentioned that they participate 12 provided to them by a county employee or can 13 in task forces. Do you recall saying that? 13 they directly access that data? 14 A. Yes. 14 MR. PIFKO: Objection. Foundation. 15 Q. And are those task forces devoted to 15 A. I don't know the vehicle by which 16 opioid abuse and addiction? 16 they would receive that. They -- they also 17 A. They're -- I know that they have 17 receive information from the Ohio Department of 18 been involved with the Cuyahoga County Opiate 18 Health. They seek information. They have 19 Addiction Task Force. I know that they're 19 access to -- to databases that I don't know

29 (Pages 110 - 113)

20 involved with a number of things throughout the 20 exactly what they are specifically, but I know

21 community.

Q. And I just want to get an

24 we're here to talk about opioid abuse and

23 understanding of when you said task forces --

25 addiction. I want to know which opioid abuse

22

25

21 that they are always actively seeking

24 this issue and others.

22 information to, again, help the department and

23 provide data that helps us collectively around

Q. How often do you discuss opioid

Page 114 1 abuse and addiction trends with your

- 2 epidemiologists?
- A. They report directly to the 3
- 4 commissioner of health, and those conversations
- 5 I know take place.
- Q. Do they ever get escalated up to 7 you?
- 8 Oh, sure. A.
- What kind of issues get escalated to
- 10 you, from epidemiologists to Ms. Sosiak to you? 10 pulled from databases and sometimes there are
 - A. They are provided information often
- 12 from the Ohio Department of Health when there
- 13 are cases or instances where there have been a
- 14 spike in OD deaths, when there's new reports
- 15 that come out, whether that's national or local
- 16 or state level, and they give that information
- 17 to her and she and I meet regularly and discuss
- 18 this issue.
- 19 Q. How often do you meet with
- 20 Ms. Sosiak to discuss opioid abuse and addiction 20
- 21 issues?
- 22 A. I can't put an actual number to
- 23 that.
- 24 Q. Do you have a standing meeting to do
- 25 so, weekly, monthly?

- 1 A. We talk almost every day. There are 2 always issues that -- that are germane to the
- 3 department. And I'm also given a lot of
- 4 information that comes in to me as well, whether
- 5 that's from public safety. I get a lot of
- 6 reports. I get incident reports from public
- 7 safety, sheer volume of OD deaths, fatals and
- 8 non-fatals as a result of ODs. And as I have
- 9 this information, I often am talking to her
- 10 about this as well. We are constantly working
- 11 on these issues.
- 12 Q. Now, opioid abuse and addiction
- 13 aren't the only issues Ms. Sosiak is dealing
- 14 with as commissioner of the Division of Health?
- 15 A. That's correct.
- Q. All right. So when you have
- 17 conversations with her about public health
- 18 issues, it's not always about opioids?
- 19 A. That's true.
- 20 Q. And when you were talking about, for
- 21 example, reports that the epidemiologists get
- 22 from the Department of Health and they might
- 23 forward to Ms. Sosiak, you said new reports.
- 24 You're talking about actual physical documents,
- 25 reports, assessments, those kinds of things, or

Page 116

- 1 there was a report of a carfentanil death last
- 2 night? What kind of reports are you talking
- 3 about?

4 MR. PIFKO: Objection. Overbroad.

- 5 Compound.
- 6 A. Data and information is provided to
- 7 the health department in a variety of different
- 8 ways. Some of these can be actual paper
- 9 documents. Oftentimes it's data that might be
- 11 actual reports that are generated from the
- 12 various divisions within the Ohio Department of
- 13 Health and to others, what they're tracking.
- 14 Q. But you, as you sit here today,
- 15 don't know what databases your epidemiologists
- 16 have direct access to for opioid-related data?
- 17 A. I can't say for sure what they are.
- 18 Q. Do you know any databases that they
- 19 have access to from which you get reports
- escalated to you?
- A. I don't remember the names of them 21
- 22 specifically.
- 23 Q. Have you heard of EpiCenter?
 - I have heard of EpiCenter.
- 25 Is that a database that provides

Page 117

- 1 information regarding opioid abuse and addiction
- 2 issues?

- 3 A. I believe that it does.
 - Q. Do you see those reports from
- 5 EpiCenter?
- MR. PIFKO: Objection. Vague.
- 7 A. I don't know if the reports I've
- 8 seen came directly from EpiCenter.
- 9 Q. What is EpiCenter? Can you describe 10 it?
- 11 A. It's a state database of a variety
- 12 of different data elements that pertain to
- 13 public health, epidemiology trends, statistics,
- 14 surveillance data, and that is collected
- 15 statewide and then it's analyzed also on the
- 16 state level and provided back to the health
- 17 departments. I don't know if it has any other
- 18 public access, but is available for us to be
- 19 able to see data essentially in real time to be
- 20 able to do what we need to do to impact our 21 community.
- 22 Q. Does -- do your epidemiologists use
- 23 that data to prepare local reports on opioid
- 24 abuse and addiction? 25 MR. PIFKO: Objection. Foundation.

Page 118 Page 120 1 Calls for speculation. 1 MR. PIFKO: Objection. Compound. 2 A. I believe so. They are using a A. Sorry. Repeat the question. 3 3 variety of different sources of information. Q. Sure. Q. Do you ever review those reports 4 How often do you see these reports? 5 yourself as director of public health? 5 MR. PIFKO: Objection. Asked and A. I'm given a lot of information on a 6 answered. 7 daily basis. 7 A. I see reports that look like this on 8 some regular basis. 8 Q. Well, do you recall reviewing any of 9 those EpiCenter reports since you took your Q. Do you ever discuss the data you see 10 in this with Ms. Sosiak? 10 position in June of 2016? A. I cannot say for sure. A. Yes, we have discussed this kind of 11 12 information. Yes. 12 Q. So if I asked you what kind of data 13 is reported in those reports, you wouldn't be 13 Q. Are you familiar with the type of 14 able to answer those questions? 14 data that is being reported in these reports? 15 15 A. I know that there are a number of A. Yes. Q. Do the data points change over time 16 databases that our staff uses to track and 16 17 or do the reports always look the same? 17 analyze information pertaining to public health A. What do you mean by data reports? 18 of our community. How that might be put 18 19 19 together and from which -- which sources is --Q. Data points. 20 is -- I have to trust that my staff is doing 20 A. Excuse me. What do you mean by data 21 what they know best and what we've hired them to 21 point? 22 do and bringing this information to the 22 Well, do you know what is being 23 reported in these reports? 23 commissioner's attention and to my attention. Q. Okay. So you don't supervise those 24 A. Yes. 25 25 epidemiologists directly; is that what you're Okay. What is it that's being Page 119 Page 121 1 saying? 1 reported? 2 A. I do not. 2 A. Well, as it says here, these are 3 Q. Ms. Sosiak, is she the one who 3 drug-related ER visits, and they are just looked 4 directly supervises epidemiologists? 4 at in different ways, whether it's by zip code 5 A. She is. 5 and by gender, by age group, just different ways 6 Q. Is she the one who sets their job 6 of analyzing data and reporting data. responsibilities on a day-to-day basis? 7 Q. And at the top do you recognize that 8 A. Yes. 8 logo? 9 9 A. I do recognize the logo. 10 (Thereupon, Deposition Exhibit 3, 10 Q. All right. What is that? CDPH Bi-Weekly Drug Related ER 11 11 A. That is the old Cleveland Department 12 Visits Report, was marked for 12 of Public Health logo. 13 purposes of identification.) Q. So this report is something that is 13 14 14 prepared by your department? 15 Q. I'm handing you what's been marked 15 MR. PIFKO: Objection to the extent 16 as Deposition Exhibit 3. Do you recognize what 16 the question mischaracterizes the record and 17 this document is? 17 assumes facts not in evidence. 18 A. Yes, I've seen this report, these A. I can't say for sure, but if our 19 reports, reports that look like this. 19 logo was on it, there's a high likelihood that 20 Q. How often do you see them? 20 this was produced in the health department. 21 A. I see them periodically. 21 Q. All right. And it says, 22 Q. So do you go looking for these 22 "Drug-Related ER Visits." Do you know whether 23 reports or do you rely on folks to send them up 23 that's specific to opioids or is that all drugs? 24 to you when there are issues that need to be 24 A. I don't know for sure. 25 addressed? 25 Okay. So if I wanted to know more

31 (Pages 118 - 121)

Page 122

- 1 about this, I would perhaps talk to Ms. Sosiak?
- 2 A. Yes.
- 3 Q. Or perhaps one of the
- 4 epidemiologists who prepares this report?
- 5 A. Yes.
- 6 Q. All right. Do you ever escalate
- 7 these types of reports up to Ms. Walker or Mayor
- 8 Jackson? I'm sorry if I got her name wrong.
- 9 Where did we have that? Ms. Walker Minor, do
- 10 you ever escalate these reports up to her?
- 11 A. I have used data from reports like
- 12 this when I've talked to her about issues that
- 13 are plaguing our city, this being one of them, 14 yes.
- 15 Q. All right. When is the last time
- 16 you recall doing that?
- 17 A. I've done it at least perhaps a
- 18 couple times this year so far.
- 19 Q. Okay. When is the last time you did
- 20 it?
- 21 A. I can't recall.
- Q. And how do you transmit those to
- 23 her?
- A. It's in one-on-one meetings with
- 25 her.

Page 123

- 1 Q. So you take a version of this and 2 you hand it to her?
- 3 A. No, not necessarily.
- 4 Q. Do you send them by e-mail?
- 5 A. No. We will just talk about the
- 6 information.
- 7 Q. What's the type of information in
- 8 this report that you would have spoken to
- 9 Ms. Walker Minor about?
- MR. PIFKO: Objection to the extent
- 11 the question mischaracterizes the record.
- 12 Assumes facts not in evidence.
- 13 A. I would talk to her about what --
- 14 what continues to be a huge issue that our city
- 15 is facing and what is going on in our city
- 16 related to drugs and addiction that has related
- 17 to this crisis.
- 18 Q. Okay. So you're continuing to
- 19 report to her about the ongoing issues with
- 20 substance abuse that the city is facing; is that
- 21 a fair characterization of what you just said?
- A. You'll have to repeat what you just
- 23 said.
- Q. You are discussing with her the
- 25 ongoing issues that the city is having with

- 1 substance abuse; is that a fair
- 2 characterization?
- 3 A. We have -- we have a crisis going on
- 4 and I'm talking to her about the information
- 5 that is -- is generated, analyzed, looked at
- 6 from the department, and making sure that she
- 7 has the information she needs as well because
- 8 this is -- this is a crisis in our city.
- 9 Q. Okay. And when you refer to "the
- 10 crisis," just that we're clear and the record is
- 11 clear, are you referring to something broader
- 12 than opioid crisis?
- 13 A. I believe you mentioned it as an
- 14 opioid crisis earlier today, so yes, an opioid
- 15 crisis.
- 16 Q. Well, Ms. Gordon, I'm just following
- 17 up on the question you asked. You referred to
- 18 "the crisis." Is there a meth amphetamine
- 19 crisis in the City of Cleveland?
- 20 MR. PIFKO: Objection. Foundation.
- A. I'm not saying that.
- Q. I'm simply trying to understand when
- 23 you used the phrase "the crisis" in your answer,
- 24 were you referring to the opioid crisis or
- 25 something broader than that?

Page 125

Page 124

- A. I'm referring to the crisis that's
- 2 in our city related to addiction brought upon
- 3 because of drugs and opioids that have come into
- 4 the city.
- 5 Q. Okay. Are the drugs you're
- 6 referring to opioids or are they stimulants,
- 7 like cocaine?
- 8 MR. PIFKO: Objection. Compound.
- 9 A. We have a lot of information. These
- 10 are opioids.
- 11 Q. So when you used the phrase "the
- 12 crisis" in your answer, you're not limiting your
- 13 answer to opioids?
- 14 A. I didn't hear a question.
- 15 Q. When you referred to the word
- 16 "crisis" in your answer regarding what
- 17 information and discussions you have with
- 10 3.5 THE III 3.5'
- 18 Ms. Walker Minor, were you referring to all
- 19 drugs in the City of Cleveland?
- 20 A. We're talking about the opioid
- 21 crisis in the City of Cleveland.
- 22 Q. Okay. Now, when you look at this
- 23 report, is it limited to just opioids?
- 24 MR. PIFKO: Objection. Foundation.
- 25 The data speaks for itself.

1

16

24

Page 126

- Q. Let me ask you a different question.
- 2 I'll strike that.
- A. Okay.
- Q. When you look at this and when you 4
- 5 report to Ms. Walker Minor, do you know whether
- 6 it's limited to opioids?
- 7 MR. PIFKO: Objection to the extent
- 8 the question assumes facts not in evidence.
- A. I would look at what's on page 2 and
- 10 the information that's provided and taking this
- 11 all in context.
- 12 Q. Okay. So the answer is what? Is it
- 13 limited to opioids when you review this
- 14 document?
- 15 MR. PIFKO: Objection. Vague.
- 16 A. I can't say that it is or is not.
- Q. Well, you just directed me to look 17
- 18 at page 2.
- 19 A. Um-hum.
- 20 Q. So why would I look at page 2 for
- 21 any other reason? I'm trying to understand what
- 22 you said, Ms. Gordon. I asked whether this data
- 23 is limited to opioids. Do you recall me asking
- 24 that question? We can start again.
- 25 MR. PIFKO: Objection.

Page 128 Q. Okay. Ms. Gordon, you are the

- 2 director of Cleveland Public Health, correct?
- 3 A. That is true.
- 4 O. Persis Sosiak is the commissioner of
- 5 health, correct?
- 6 A. Correct.
- 7 O. She works for you?
- 8 A. Yes.
- 9 You testified you've had
- 10 conversations with Ms. Sosiak about these
- 11 reports, correct?
- 12 A. Correct.
- 13 Q. You have had conversations with your
- 14 supervisor or the person you report up to,
- 15 Ms. Walker Minor, about this report, correct?
 - A. Correct.
- 17 MR. PIFKO: Objection to the extent
- 18 the question mischaracterizes the record.
- Q. Does it or does it not relate to
- 20 drug-related ER visits generally?
- MR. PIFKO: Objection. The document 21
- 22 speaks for itself. Foundation.
- 23 Q. Let me ask another question.
 - When you look at this report, is
- 25 there anything in this report that tells you how

Page 127

- 1 Argumentative. For the record, there's no
- 2 question pending.
- A. Counsel, the title of this report is 4 "Biweekly Drug-Related ER Visits."
- O. Yes. You pointed that out to me
- 6 before, if you'll recall, and I asked is it
- 7 limited to opioids.
- 8 A. I can't say that it is limited to
- 9 opioids, and --
- 10 Q. And then you directed --
- MR. PIFKO: Hold on. She's still 11
- 12 talking.
- 13 A. Looking at page 2, you have to look
- 14 at what the data sources are to really
- 15 understand what is -- what's being provided in
- 16 the data, and so I look at what the data sources
- 17 are and what this information is actually trying
- 18 to convey.
- 19 Q. That's what I'm asking you. Does it
- 20 convey data regarding strictly opioid ER visits?
- MR. PIFKO: Objection. The document 21
- 22 speaks for itself.
- A. It is not. It says here that it is
- 24 referencing key words and abbreviations used in 24 ER visits would be included within this report?
- 25 ER visits. That is what this is reporting.

- Page 129 1 many of these ER visits were related to opioids?
- 2 A. No. it does not.
- Q. Is there anything in this report
- 4 that tells you how many of these ER visits were
- 5 related to prescription opioids?
- MR. PIFKO: Objection. The document
- 7 speaks for itself.
- 8 A. No, it does not.
 - Q. Is there anything in here that tells
- 10 you how many of these overdoses were related to
- 11 heroine?
- 12 MR. PIFKO: Same objection.
- 13 A. No, it does not.
- 14 Q. Anything in here that talks about
- 15 how many overdoses with illicit fentanyl?
- MR. PIFKO: Same objection. 16
- 17 A. No, it does not.
- Q. Does it tell you anything regarding
- 19 how many of those ER visits were alcohol
- 20 related?
- 21 MR. PIFKO: Same objection.
- 22 A. Not specifically.
- 23 Q. Does it appear that alcohol-related
- - MR. PIFKO: Same objection.

Page 130

- A. It is included in the report.
- 2 Q. And specifically to answer that
- 3 question, you're looking at the bottom of page 2
- 4 which describes the data points that are
- 5 included in the analysis, correct?
- 6 A. Correct.

1

- 7 O. So all of these could be
- 8 alcohol-related ER visits; would you agree?
- MR. PIFKO: Objection. Calls for 10 speculation.
- A. It's highly unlikely. 11
- 12 Q. But they could be?
- 13 MR. PIFKO: Same objection.
- 14 A. It takes into account a whole number
- 15 of -- of elements of ER visits. So it's a
- 16 collection of information. It's not specific to 17 any one.
- 18 Q. So, again, it could -- any one of
- 19 these data points for a zip code or a particular
- 20 week, that week could have all been
- 21 alcohol-related incidents?
- 22 MR. PIFKO: Objection. Incomplete
- 23 hypothetical. Calls for speculation.
- Q. We don't know, that's the point,
- 25 right? We don't know from looking at this?

Page 132

Page 133

- 1 have emergency preparedness, nursing clinics, 2 STIs, infant mortality.
- Q. And, to be clear, those are not all 3 4 specifically touching the opioid crisis we've
- 5 been talking about?
- 6 A. Pretty much everything within the 7 health department does touch this issue in some
- 8 way, shape or form, yes.
- Do flu vaccines touch on the opioid 10 crisis?
- 11 A. We train all of our staff to
- 12 recognize issues of addiction, talking to
- 13 patients, and we've needed to prepare people
- 14 because this has -- again, this has been a big
- 15 impact in our city and all of our staff has
- 16 needed to be -- needed to have a level of
- 17 understanding of the issue and how to talk to
- 18 the individuals and families who seek our
- 19 services and make sure that they know how to 20 respond therein.
- 21 Q. So give me an example of somebody
- 22 who would be providing a flu vaccine and how
- 23 that would touch on the opioid crisis.
- 24 MR. PIFKO: Objection. Incomplete 25 hypothetical.

Page 131

1

- A. It doesn't go to that level of 1 2 specificity.
- Q. Right. We don't know from looking
- 4 at this because this report doesn't tell us how
- 5 many of those are opioid-related versus other,
- 6 right?
- 7 MR. PIFKO: Objection. Document
- 8 speaks for itself.
- A. Correct.
- Q. Within the context of the functions
- 11 performed by the Division of Health in the
- 12 Cleveland Department of Health, you mentioned
- 13 Healthy Cleveland and the programming they do.
- 14 You mentioned epidemiologists. You also
- 15 mentioned HIV.
- 16 A. Yes.
- 17 Q. First of all, are there any other
- 18 functions within the Division of Health that
- 19 relate to opioids, touch on opioids that we
- 20 haven't listed --
- 21 A. Sure.
- 22 Well, most importantly, we have an
- 23 office on mental health and substance abuse. We
- 24 are -- we have a registrar that does vital
- 25 statistics, birth and death certificates. We

- You can answer.
- A. Have an individual present and --
- 3 seeking a flu vaccine, and we have staff who
- 4 talk to them in generalities about what's going
- 5 on in their lives and in their home situation
- 6 and if anything else is impacting their life at
- 7 that time, themselves or their family; and so
- 8 within that conversation they're trained to
- 9 understand if they have additional needs,
- 10 whether it's treatment for addiction for
- 11 themselves again, for their family, or whatever
- 12 their situation is. So yeah, we've had to train
- 13 all of our staff regarding this.
- Q. Okay. Who is in charge of training
- 15 your staff, specifically those who provide flu
- 16 vaccines to members of the public?
- 17 A. That would be the responsibility of
- 18 the Office of Mental Health and Substance Abuse.
- 19 We've also had additional training for the
- 20 staff. There's some things that the
- 21 commissioner has provided as well. They have
- 22 regular staff meetings within each division and
- 23 talk about this issue and have been bringing
- 24 this to the attention of the staff for years.
- 25 Q. Okay. Who was in charge of training

Page 134

1 the folks that give flu vaccines, a name please 2 within the department currently?

- A. I'm sorry. Your question, who was 4 in charge?
- 5 Q. Who trains the people that actually 6 give flu vaccines to members of the public?
- A. Sure. Director of nursing. Her 7 8 name is Jeannie Johnson.
- Q. And the folks that give flu vaccines 10 to members of the public, are they employees of 10 training? 11 the Department of Health?
- 12 MR. PIFKO: Objection. Vague.
- 13 O. Strike that.
- 14 Ms. Gordon, you're the director of 15 public health, correct?
- A. That is correct.
- 17 Q. And in that role do you take it upon
- 18 yourself to understand the services provided by
- 19 the Department of Health?
- 20 A. Yes.
- 21 Q. Do you take it upon yourself to know
- 22 what the employees of the Department of Health 22 23 do?
- 24 A. I have over 160 employees and we run 25 over 30 programs, and it is a -- I'm constantly

Page 136

- 1 Q. Are there written materials provided 2 that describe that?
- 3 A. I don't know if there are specific
- 4 written materials. I know that there's -- this
- 5 is discussed at their monthly -- monthly
- 6 meetings -- if they're monthly or quarterly I
- 7 can't recall, but there are -- issues like this
- 8 does -- it comes up.
- 9 Q. Okay. And we're talking about
- 11 A. Training.
- 12 Q. And the contractors who do flu
- 13 vaccines, are they given the same training?
 - A. I believe that they all attend those
- 15 meetings as well, so yes.
- Q. And any initial training that's done
- 17 when a new employee or a new contractor is
- 18 brought on to do flu vaccines, is there written
- 19 materials that are provided that discuss opioids
- 20 and how to deal with that when giving a flu
- 21 vaccine?
- A. I'm not aware of that level of
- 23 specificity.
- 24 Q. And whatever discussions within that 25 training that are related to opioids, has that

Page 135

- 1 trying to interact with -- with my commissioners
- 2 and with the program managers who oversee all of
- 3 these programs. So yes.
- Q. Okay. And is flu vaccines one of
- 5 the programs that your Department of Health
- 6 provides?
- 7 A. Yes.
- Q. Okay. And we know that the director
- 9 of nursing, Jeannie Johnson, is somebody who
- 10 trains the people who give flu vaccines because
- 11 that's what you told me two minutes ago?
- 12 A. Yes.
- Q. Now, the people who actually
- 14 administer those flu vaccines, are they
- 15 employees?
- A. Yes. Some of them are employees and 16
- 17 some of them are contractors.
- Q. And the employees you describe, they
- 19 receive training on opioid-related issues is
- 20 what you've told me?
- A. We have had -- I know that they have
- 22 had some training in this area of what to
- 23 observe with patients when they present from
- 24 individuals who are administering influenza
- 25 vaccinations, yes.

- Page 137
- 1 been going on since before you became the 2 director of the Department of Public Health?
- 3
- 4 That's not some program you
- 5 initiated?
- 6 A. No.
- 7 Q. And when I say "program," I mean the
- 8 training of people who give flu vaccines to be
- 9 aware of opioid-related issues.
- 10 They are not independent of the
- 11 other nurses that we -- that we employ to do
- 12 programming within our clinics and in the
- 13 community.
- 14 Q. So the folks that staff these
- 15 clinics who provide flu vaccines might provide a
- 16 range of services?
- 17 A. Correct.
- 18 Q. Is that what you're telling me?
- 19
- 20 Q. Pregnancy testing, is that something
- 21 the Department of Health does?
- 22 A. We do pregnancy testing, yes.
- 23 Q. HIV testing --
- 24 A. Yes.
- 25 -- we talked about that a little

Page 138 Page 140 1 bit? Q. Suing drug companies, that's one way 2 We provide HIV testing. 2 to get additional resources? MR. PIFKO: Objection. 3 Lead screenings? 4 Argumentative. 4 Correct. 5 5 A. The City of Cleveland has chosen Immunizations? 6 A. Correct. 6 to -- to file this suit because we're seeking 7 7 damages to help with what has been a huge burden Q. TB testing? 8 on this community in the past, what's going on 8 We do some TB testing, yes. Q. Are there any health services 9 right now, and what we know will be in the 10 provided directly within the clinic to opioid 10 future with these individuals who are addicted 11 abusers? 11 to these pills and addicted to drugs. Just the 12 types of issues often feels insurmountable as it 12 A. Yes. 13 Q. Any services that relate 13 has impacted our community. 14 specifically to opioid treatment? Q. And, Ms. Gordon, do you know what 15 A. Yes. 15 the phrase "pill mill" refers to? O. What are those? A. I've heard that phrase, yes. 16 16 17 A. In our Office of Mental Health and 17 Q. What does it mean? 18 Substance Abuse we do have some treatment 18 A. I've heard this phrase used as a 19 programs. We do some intensive counseling. A 19 term where there are outlets for individuals 20 program with the drug court called CenterPoint, 20 seeking pain relief or relief -- feed their 21 so we provide counseling, intensive counseling 21 addiction with additional pills to deal with 22 and treatment there. Distribute the Project 22 their pain or deal with their addiction. 23 DAWN kits. We also work in schools or a school 23 Q. Do you believe that these pill mills 24 for a prevention program with youth. 24 contributed to the opioid crisis we're talking 25 Q. Anything else? 25 about today? Page 139 Page 141 A. We do a lot of health promotion 1 MR. PIFKO: Objection. Foundation. 2 2 where we attend as many community events and I don't think I can respond to that. 3 3 health fairs in the community and staff tables Well, I don't know what that means. 4 and staff events. We have a mobile clinic where 4 You can respond with yes, no or I don't know. 5 we work with -- it's focused on moms -- pregnant 5 So do you think pill mills have contributed at 6 women and our efforts around infant mortality. 6 all to the opioid crisis we're talking about? 7 And they, too -- we have community health 7 MR. PIFKO: Objection. Foundation. 8 workers who are trained in identifying, working 8 Objection to the extent the question calls for a 9 with individuals who have addiction issues and 9 legal conclusion or a legal issue in the case. 10 10 working with them and directing them to You can answer. I don't know. Excuse me. I don't 11 resources. It's -- a fair amount of the work 11 12 that we do is making sure that people are 12 know. 13 matched with -- with available resources if 13 Q. All right. Again, you're the 14 there are. 14 director of the Department of Public Health in 15 We are desperate for resources in 15 the City of Cleveland? Yes? 16 this community for treatment for addressing this 16 A. Yes. 17 issue. We recognize that. We are trying to do 17 We just talked about a lot of 18 programs that you described within the 18 as much as we possibly can with our limited 19 staff and the limited resources that are 19 department that touch on opioid abuse and 20 available to the -- to our department, and 20 addiction issues, services that are provided to 21 always looking for ways that we can increase our 21 the community. Do you recall? 22 budget to make sure that we are addressing this 22 A. I do. 23 issue. This is -- this is huge and it's --23 You talked about suing defendants 24 we -- we need the resources to be able to deal 24 for responsibility for the opioid crisis? 25 with this issue. 25 MR. PIFKO: Objection.

Page 144 Page 142 1 Mischaracterizes. 1 complaint seeking damages for the crisis, the 2 Q. You brought that up, right? 2 opioid crisis we've been discussing? MR. PIFKO: Objection. Foundation. 3 A. No. You brought that up. 3 4 Q. Fair enough. 4 Calls for a legal conclusion. 5 That's something that's being done 5 A. I do not know. 6 right now by the City of Cleveland, you agree, 6 Q. Have you seen the complaint? 7 7 that's why we're here? A. I have seen the complaint. A. That's why we're here, yes. 8 Q. Have you seen the names of any pill You know what pill mills are? You mill operators in the complaint? MR. PIFKO: Objection. Foundation. 10 described that, right? 10 A. To some degree. I know a little bit 11 MR. NAEEM: She just said she saw 12 about what these are. 12 the complaint. 13 Q. Well, you're a consumer of news 13 A. I don't know. 14 about opioid issues, you've read about pill 14 You don't know if you've seen any 15 mills? 15 pill mill operators in the complaint? A. No. 16 A. I've read about a lot of things. 16 17 Q. You've read reports at least from 17 MR. PIFKO: We talked about taking a 18 the Ohio AG's office. You told me that, right? 18 break for lunch after 12:30. 19 MR. NAEEM: If you want to take a A. Yeah. 19 20 Q. Have you read about pill mills in 20 break now, it's fine. 21 any of those reports or in news sources you 21 MR. PIFKO: All right. 22 THE VIDEOGRAPHER: Off the record 22 referred to as a consumer of news? 23 23 The time is 12:35. A. I have. 24 Q. And based on anything you've read, 24 25 do you have a belief, personal belief, as to 25 (Luncheon recess taken.) Page 143 Page 145 1 whether pill mills, for example, have THE VIDEOGRAPHER: Back on the 2 contributed to the opioid crisis? 2 record. The time is 1:32. 3 A. May have contributed to the opioid 3 4 crisis, yes. 4 AFTERNOON SESSION Q. What's the City of Cleveland doing 5 5 CONTINUED EXAMINATION OF MERLE GORDON 6 to hold them accountable for the opioid crisis? 6 BY MR. NAEEM: 7 MR. PIFKO: Objection to the extent Q. Ms. Gordon, before we took a break, 8 the question assumes facts not in evidence, 8 we had been talking about pill mills. I wanted 9 foundation, speculation. Objection to the 9 to move on and ask, are there substances other 10 extent the question calls for legal conclusions 10 than prescription opioids that you believe have 11 or opinions. 11 contributed to the opioid crisis in the City of 12 You can answer. 12 Cleveland? 13 Oh, and objection to the extent MR. PIFKO: Objection to the extent 14 you've had conversations with counsel about that 14 the question calls for expert opinion, legal 15 issue. I'm going to instruct you not to reveal 15 opinion. 16 any confidential communications you've had with 16 You can answer. 17 counsel about that issue. 17 A. I'm sorry. You're going to have to 18 Aside from that, you can answer. 18 repeat the question. 19 Q. I don't remember what the question Q. Are there substances other than 20 is. Do you? 20 prescription opioids that you believe have 21 A. Perhaps you could rephrase the 21 contributed to the opioid crisis in the City of 22 question. 22 Cleveland? 23 Okay. 23 MR. PIFKO: Same objections. 24 Has the City of Cleveland sued 24 A. I believe that they were the most 25 operators of pill mills as part of this 25 significant contributing factor to the opioid

37 (Pages 142 - 145)

Page 146 Page 148 1 crisis in the City of Cleveland. 1 I assume so. Q. Well, that's not what I asked, but 2 Q. And, again, this was October 7, 3 can you pull out Exhibit 1-A from the stack of 3 2016, roughly four months after you started with 4 exhibits we've marked? 4 the Department of Health, correct? 5 A. Yes. 5 A. Correct, and most likely what was 6 Q. You, again, to refresh, have seen 6 said at the meeting just taking notes. 7 this document, correct? 7 Q. You can put that aside. A. Yes. This is an agenda for the U.S. 8 9 Attorney's Office opioid addiction task force 9 (Thereupon, Deposition Exhibit 4, 10 that I attend. 10 Document Entitled "Opiate Response Q. And what is the date that that 11 11 Presentation: Merle Gordon, 12 meeting was to be scheduled? 12 Director of Public Health," 13 A. It says on the document Friday, 13 Beginning Bates Stamp 14 October 7, 2016. 14 CLEVE_000187960, was marked for Q. All right. And that's roughly four 15 15 purposes of identification.) 16 months after you started with the Department of 16 17 Health? 17 Q. I'm going to hand you what we've 18 A. Roughly, yes. 18 marked as Deposition Exhibit 4. Now, the 19 Q. We've established, I believe, and 19 question I had asked originally of you when we 20 correct me if I'm wrong, but the handwritten 20 came back on the record, Ms. Gordon, was, do you 21 notes on this document are yours? 21 believe there are substances other than 22 A. They look like mine, yes. 22 prescription opioids that have contributed to Q. And this is a document that you 23 the opioid crisis. So I'll repeat that 24 discovered this weekend and turned over to your 24 question. Do you believe there are substances 25 counsel a couple of days ago? 25 other than prescription opioids that have Page 147 Page 149 1 A. I believe this was part of the 1 contributed to the opioid crisis? 2 documents, yes. MR. PIFKO: Objection. Foundation. 3 Objection to the extent that question calls for Q. So your handwritten notes, they are 4 notes of discussions that were ongoing during 4 a legal opinion, legal conclusion, expert 5 the meeting? 5 opinion. A. My answer remains. A. I cannot say for sure, but they 6 7 appear to be notes that were taken during that 7 Q. Okay. So Exhibit 4, do you 8 meeting. 8 recognize this document? 9 Q. Okay. Well, the alternative would A. I recognize the document. 10 be they are your analysis, independent analysis, 10 Q. Do you recall the date that this 11 correct? 11 document would have been prepared? 12 MR. PIFKO: Objection to the extent 12 MR. PIFKO: Objection. Foundation. A. I do not. Often documents are 13 the question assumes facts not in evidence. 13 A. I suppose that's the alternative, 14 created, my name is put on them as -- whether in 15 but -- yeah, it looks to be -- looks to be notes 15 draft form, final form, that are related to work 16 taken from that meeting. 16 done from the Cleveland Department of Public 17 Q. Okay. And on page 1, the first line 17 Health. 18 of your handwritten notes, what does it say? 18 Q. But you don't dispute the fact that A. It says, "Fentanyl attracting 19 this document was created at some point while 20 younger people." 20 you were director of the Department of Health, 21 21 do you? Q. And what does the second line say? 22 A. The second line on this document, 22 MR. PIFKO: Objection. Foundation. 23 the handwritten note, says, "Prescribing 23 A. I don't dispute that. Apparently

38 (Pages 146 - 149)

Q. And what is the title of the

24 so.

25

25

24 practices are no longer the precursor to OD."

Q. And OD means overdose?

1 document?

- 2 A. "Opiate Response Presentation."
- Q. And whose name is listed underneath 4 that?
- 5 A. My name is underneath that.
- 6 Q. Do you recognize this as potentially
- 7 a document you used to provide presentations to
- 8 the cabinet that we discussed earlier?
- 9 A. I do not. The information I would
- 10 have provided to the cabinet is -- would not
- 11 have looked like this.
- 12 Q. Do you have any specific
- 13 recollection today of why this was prepared?
- MR. PIFKO: Objection. Foundation.
- 15 A. I do not. Again, there are a lot of
- 16 documents that are created and background
- 17 information and other documents such as -- such 17
- 18 as this that are created by staff in the
- 19 department and others around the city pertaining 19
- 20 to public health issues, and my name would be
- 21 associated with it just as the director of the
- 22 department.
- Q. Okay. So do you see the sentence in
- 24 the first paragraph that starts with "Today,"
- 25 the second -- third sentence?

Page 151

1

- 1 A. I do.
- 2 Q. Okay. Can you read that, please,
- 3 into the record?
- 4 A. The document states, "Today, opiate
- 5 abuse exists on multiple levels and heroine is
- 6 far from the only drug of abuse."
- 7 Q. Do you agree with that statement?
- 8 MR. PIFKO: Objection. Foundation.
- 9 A. I do.
- 10 Q. And just to address the foundation
- 11 objection again, Ms. Gordon, you are the
- 12 director of the Department of Public Health for
- 13 the City of Cleveland, correct?
- 14 A. That is correct.
- 15 Q. And within the Department of Health,
- 16 as we've discussed, as part of Cleveland's
- 17 response to the opioid crisis you provide
- 18 treatment services?
- 19 A. We do.
- Q. Education and prevention services?
- 21 A. We do.
- Q. Do you believe you have knowledge
- 23 regarding the opioid crisis and your
- 24 department's response to it?
- 25 A. I do.

Page 152

Q. Under "Opioid Use," the first bullet

- 2 point in Exhibit 4, it says, "No longer just
- 3 heroine used by injection." Do you see that?
 - A. I do.

4

11

13

14

- 5 Q. "Fentanyl and carfentanil are used
- 6 both in mixes and straight." Do you see that?
- 7 A. I do.
- 8 Q. Do you agree with that statement?
- 9 MR. PIFKO: Objection. Foundation.
- 10 A. I do agree with that statement.
 - Q. What is fentanyl?
- 12 A. Fentanyl is a synthetic opiate.
 - Q. Is it manufactured illicitly?
 - MR. PIFKO: Objection. Foundation.
- 15 A. My understanding, that some is and 16 some is not.
- 17 Q. And the fentanyl that is not, where
- 18 does that come from?
 - MR. PIFKO: Objection. Foundation.
- 20 Calls for speculation.
- A. It's my understanding that that is
- 22 manufactured -- can be manufactured anywhere.
- 23 It's a synthetic product.
- Q. Okay. And I used illicit. You said
- 25 it can be illicit or not illicit.

Page 153

- A. That is my understanding.
- 2 Q. Do you believe legal fentanyl can be
- 3 manufactured by anyone?
- 4 MR. PIFKO: Objection. Foundation.
- 5 Speculation.
- 6 A. You'll have to repeat your original
- 7 question.
- 8 Q. All right. My original question,
- 9 fentanyl and carfentanil are used both in mixes
- 10 and straight. You agreed with that, I think,
- 11 right?
- 12 A. I do. Based on information that is
- 13 provided to me, that is -- that is what I know,
- 14 yes.
- 15 Q. Are you suggesting you don't have
- 16 personal knowledge regarding the issues that are
- 17 in document 4?
- MR. PIFKO: Objection to the extent
- 19 the question calls for a legal conclusion.
- Q. You're suggesting that information
- 21 has been provided to you. Are you just a
- 22 mouthpiece for the Department of Public Health?
- 23 MR. PIFKO: Objection.
- 24 Argumentative.
- 25 A. I'm the director of the Cleveland

Page 154 Page 156 1 Department of Public Health, as you've asked me 1 Q. Do you believe it includes 2 a few times today. 2 Carfentanil as well? Q. I understand that. Right. So I 3 MR. PIFKO: Same objection. A. I'm sorry. You have to just repeat 4 asked, in this particular presentation with your 4 5 name on it about fentanyl and carfentanil and 5 your question. 6 whether they're illicitly manufactured. 6 Q. Sure. 7 MR. PIFKO: Objection. Foundation. 7 The second bullet point, the 8 Assumes facts not in evidence. 8 statement about opioids being sold legally A. It's my understanding that -- you've 9 overseas and purchased illegally in the U.S, 10 asked about fentanyl, that it is -- there are 10 does that statement refer also to Carfentanil? 11 some that are and are not illicitly made. MR. PIFKO: Objection. Foundation. 11 Q. Where does the non-illicit fentanyl 12 12 A. Again, this is not a document that I 13 come from? 13 wrote. It does have my name on it, as many 14 MR. PIFKO: Objection. Calls for 14 documents have my name on it, the letterhead has 15 speculation. Foundation. 15 my name on it, and people use that all the time. 16 So this is in a different bullet point. I'm A. I do not know specifics. 17 Where does the illicit fentanyl come 17 not -- I can't draw that conclusion. It says, Q. 18 from? 18 "Some opiates." 19 MR. PIFKO: Objection. Foundation. 19 Q. But you do believe that that 20 Calls for speculation. 20 statement does refer to fentanyl? A. It says, "some opiates," and one 21 A. So for information that has been 21 22 provided to me regarding some of the sources, 22 could draw that conclusion. 23 not all sources but some of the sources, that Q. Well, that was the answer you just 24 they are made overseas and been told that some 24 gave me before I asked about carfentanil. I 25 of them are made in places like Mexico and 25 want to know about your conclusion. Is fentanyl Page 155 Page 157 1 China. 1 an opiate that is sold legally overseas and 2 shipped illegally to the United States? Q. And under the second bullet point, 3 "Opiate Trafficking," isn't that, in fact, what 3 MR. PIFKO: Objection. Foundation. 4 Calls for speculation. 4 it says in your presentation, Exhibit 4? MR. PIFKO: Objection. Assumes 5 A. I cannot confirm if it's sold 6 facts not in evidence. 6 legally, if those are the -- if that is, in 7 fact, what happens in China. My understanding A. I am not saying that this is my 8 presentation. My name is on this document, as 8 is that it is shipped and purchased illegally 9 here in the U.S., some -- some opiates are. 9 my name is on many documents that are prepared 10 sometimes for me and sometimes with my name on 10 Well, I'm not talking about opiates 11 generally; just fentanyl. That was my question. 11 it as the Department of Health and throughout 12 the city. 12 Is fentanyl shipped into the U.S. illegally? 13 A. It's my understanding that some of 13 Q. Okay. So in the document titled 14 it is, yes. 14 "Opiate Response Presentation: Merle Gordon, 15 Director of Public Health," does it say in the 15 Q. Now, Carfentanil, do you know 16 whether there is any legal manufacturer of 16 second bullet point underneath Opiate 17 Trafficking, "Some opiates are sold legally 17 Carfentanil in the United States? 18 overseas (China) and are purchased online and 18 A. I do not know. 19 19 shipped to the U.S. (illegally)"? 20 A. It says that in this document, yes. 20 (Thereupon, Deposition Exhibit 5, 21 Cleveland City Council Committee Q. And do you believe that this --22 these opiates that are being discussed include 22 Calendar dated December 1, 2016, 23 fentanyl, as we've been talking about? 23 with Attachments Beginning Bates 24 MR. PIFKO: Objection. Foundation. 24 Stamp CLEVE 000189292, was marked 25 for purposes of identification.) 25 A. Yes.

Page 158 1 1 this isn't crack." Did I read that correctly? 2 Q. Handing you, Ms. Gordon, what's been A. That's what is written in this 3 marked as Deposition Exhibit 5, have you seen 3 document, yes. 4 this document before? Q. Now, can legal -- well, first of 5 A. I am familiar with this document. 5 all, heroine is not a legal substance in the 6 United States, is it? 6 Q. Okay. And what does it refer to? 7 A. It is an -- the first page is the 7 A. It's not. 8 committee calendar for Cleveland City Council. 8 Q. Do you know whether Carfentanil is? 9 9 There's a joint committee with the health and MR. PIFKO: Objection. Foundation. 10 human services committee and safety committee 10 Calls for speculation. 11 specifically to talk about this epidemic that's MR. NAEEM: Which is why I asked her 12 killing people in the City of Cleveland. 12 if she knew. 13 Q. Okay. Did you speak at that 13 Q. Do you know if Carfentanil is legal 14 committee meeting? 14 in the United States? A. For its intended purpose, I believe 15 A. I did. 15 Q. Do you recall speaking at that 16 that it is. 16 17 committee meeting? 17 Q. Fentanyl we talked about, can be A. I have recollection of speaking at 18 illicit or legal? A. Correct, for its intended purpose. 19 that meeting, yes. 19 20 Q. So you had just stated that this was 20 Q. Now, is it legal to order heroine, 21 about the opiates that are killing people in the 21 fentanyl or carfentanil over the internet? 22 City of Cleveland? 22 MR. PIFKO: Objection. Calls for 23 23 speculation. Foundation. Calls for a legal A. Yes. 24 Q. What opiates were discussed during 24 conclusion. Incomplete hypothetical. 25 If it's not used for its intended 25 the meeting? Page 159 A. I'm not sure I recall that level of 1 purpose, I do -- I'm not -- don't know if it 2 specificity, but we did talk about this issue 2 is -- I don't believe that it is legal to order 3 broadly. As you have behind page 1, these 3 it over the internet if it's not for its legal 4 appear to be my -- my notes and information that 4 and intended purpose. 5 was put together for me and some information Q. Is it legal to order heroine, 6 that talked about jointly with my staff in order 6 fentanyl or carfentanil and have it shipped to 7 your door in the United States? 7 for me to be prepared to present at this council 8 meeting. 8 MR. PIFKO: Objection. Foundation. 9 Calls for a legal conclusion. Speculation. Q. And there are some opiates 10 specifically listed there in those materials, 10 Incomplete hypothetical. A. If it's not for its intended purpose 11 correct? 12 A. There are. 12 and it's an illegal substance -- having an 13 13 illegal substance sent to your door, dropped off Q. Okay. And the three that are 14 at your door, found somewhere else, purchased 14 mentioned there are heroine, fentanyl and 15 carfentanil, correct? 15 somewhere else, if it's an illegal method --MR. PIFKO: Objection to the extent 16 it's an illegal substance and illegal to 17 the document -- the question mischaracterizes 17 purchase it, if it's not for its intended 18 the document. 18 purpose, having it mailed to your door is not 19 either. 19 A. Those are listed on page 2 of this 20 document. 20 Q. What is heroine's intended purpose? 21 Q. And, again, right above the notation 21 MR. PIFKO: Objection. Foundation.

41 (Pages 158 - 161)

A. We're talking about people who have

25 how they became addicted to painkillers and

23

24 manufactured anywhere and order them over the 24 become addicted to painkillers and opiates, and

22 Expert opinion.

22 about heroine, fentanyl and carfentanil, it

23 says, "These drugs are synthetic, so they can be

25 internet and have them shipped to your door;

Page 160

Page 161

- 1 opiates and why they have turned to other
- 2 illicit and illegal substances and gotten to
- 3 this point where they would risk their life to
- 4 take substances such as fentanyl, or even
- 5 carfentanil, which is a hundred times as potent
- 6 as fentanyl, is what's so significant about this
- 7 issue and what -- why people are dying and
- 8 really why we are here.
- Q. So you do know a little bit about
- 10 Carfentanil?
- 11 A. I do know a little bit about
- 12 Carfentanil.
- 13 Q. And so, again, my question, because
- 14 I appreciate what you said and we're going to
- 15 get to that in a little bit, but my question is,
- 16 what's the intended purpose of heroine?
- 17 MR. PIFKO: Objection.
- Q. You talked about in your answer 18
- 19 intended purposes of these medications. What's
- 20 the intended purpose of heroine?
- 21 MR. PIFKO: Objection. Foundation.
- 22 Calls for expert opinion.
- A. It is where people have been driven
- 24 to because they become addicted to pain
- 25 medications and opiates and are seeking other

- 1 and the impact that this has had in the
 - 2 community. 3 Q. So let's talk specifically about
 - 4 heroine abusers now, okay.
 - Is it your testimony today that all

Page 164

Page 165

- 6 heroine abusers in the City of Cleveland use
- 7 heroine because they became addicted to
- 8 prescription opioids?
- 9 MR. PIFKO: Objection. Foundation.
- 10 Calls for expert opinion.
- A. I don't know that I can isolate it
- 12 in as narrow of a way as you've just put it.
- 13 There are pathways to these addictive
- 14 substances, like heroine and fentanyl, and the
- 15 pathways are people started in a way of just
- 16 needing some pain relief and got to a point
- 17 where they could no longer access these
- 18 painkillers through -- whether it was their
- provider or through a pharmacy, and they -- they
- 20 resorted to other means of trying to, again,
- 21 address their fix, address their addiction.
- 22 Q. Okay. How many heroine abusers are
- 23 there in the City of Cleveland currently?
 - A. I don't have that direct number.
- 25 Is there anybody that you would go

Page 163

1 ways of getting to that high and fixing on their

- 2 addictions, and so they have turned to some of
- 3 these substances to try to feed their fixation
- 4 and their addictions.
- O. What is your basis for that
- 6 statement?
- You know, I attend a lot of
- 8 meetings. I go to a lot of meetings and
- 9 gatherings of people who are experts in this and
- 10 listening to their testimony. Just prior you
- 11 asked me to look at an agenda for a U.S.
- 12 Attorney's meeting. I go to those regularly
- 13 where we have report-outs and are hearing about
- 14 this from people who work in this directly.
- 15 There's -- the CDC has put a lot of information
- 16 out there, a lot of reputable organizations
- 17 on -- from -- the White House had an opiate task
- 18 force. The Ohio Attorney General put out a
- 19 report. So I'm hearing this information from
- 20 all over. I have invested a huge amount of my
- 21 time trying to gather this information,
- 22 understand this issue as it pertains to people
- 23 who are in this community, who are dying and are
- 24 trying to live with this addiction that has just
- 25 taken over their lives, their family's lives,

- 1 to within the City of Cleveland to find that
- 2 information?
- A. We are always trying to track
- 4 information, trying to look at all of the data
- 5 that we have available to us about -- whether
- 6 that's non-fatals, these are individuals who are
- 7 seeking treatment. Always trying to get a sense
- 8 of proportion of this epidemic in the city.
- Q. My question was simply, if you
- 10 wanted to find out the number of heroine abusers
- 11 in the City of Cleveland, who would you go to
- 12 ask for that in the City of Cleveland?
- A. I don't believe we have one single
- 14 person who has that specific piece of
- 15 information. We're trying to patch all of this
- 16 information together from, again, non-fatals.
- 17 We have data -- I don't have it right here at my
- 18 fingertips -- of all the people who have died,
- 19 and toxicology reports, that have these drugs in
- 20 their system at time of death. We have a lot of
- 21 people who work in this area, and, again, we try
- 22 to track this through our epidemiologists, our
- 23 Office of Mental Health and Substance Abuse,
- 24 people who provide information at the U.S. 25 Attorney's Office, the Opiate Task Force,

- 1 Cuyahoga County Task Force, with information, as
- 2 much as they can; within a broader context,
- 3 sometimes from the Ohio Department of Health,
- 4 what kind of data is provided to us from the
- 5 CDC, and, you know, just a variety of sources
- 6 because we are all trying to address this issue
- 7 from as many different perspectives as possible.
- Q. All right. So -- again, back to my
- 9 question -- if you needed to find out the number
- 10 of heroine abusers in the City of Cleveland, who
- 11 would you go to to find out?

15 long answer you gave me?

- 12 MR. PIFKO: Objection. Asked and 13 answered.
- Q. Did you give me any names in that
- A. I don't have one specific name.
- 17 Q. Okay. Do you believe there is
- 18 anyone in the City of Cleveland that could tell
- 19 us today in this room how many people abuse
- 20 heroine in the City of Cleveland?
- 21 MR. PIFKO: Objection. Foundation.
- 22 A. On any single day, I don't believe
- 23 we have somebody who has just specifically that 24 information.
- Q. Okay. And who would be the person 25

- 1 trying to all collect and analyze and look at
- 2 trends and look at, you know, fatals and
- 3 non-fatals that come from the police department
- 4 and the medical examiner's office. This is a
- 5 lot of data. This is what public health is. We
- 6 collect a lot of data from a lot of different
- 7 sources and really try to put -- wrap our arms
- 8 around the issue as quickly and as best as we
- 9 can to figure out where we're targeting
- 10 resources to help people and help communities in
- 11 need. And this addiction issue has just -- it's
- 12 taken over. There's a huge amount of impact in
- 13 this community as a result of it.
- 14 Q. So let me start with, do you have
- 15 personal knowledge regarding the number of
- 16 heroine abusers who originally were prescribed
- 17 prescription opioids and became addicted to
- 18 those opioids before using heroine?
- A. I believe some of that information
- 20 has been tracked for years.
- 21 O. Do you have that information?
- 22 A. I'm sure some of that information
- 23 has been provided to me in my capacity. The
- 24 commissioner has aggregated this information.
- 25 We're all trying to collect information, again,

- 1 who would have knowledge regarding whether
- 2 people start using heroine because they became
- 3 addicted to prescription opioids? And I need
- 4 the number of people --
- 5 A. I don't have the number of people
- 6 for you.
- Q. Well, what percentage of heroine
- 8 abusers became addicted to prescription opioids
- 9 before they --
- 10 A. Well, a lot of that is provided from
- 11 the CDC. And, again, this is data that is
- 12 available -- I don't have that specifically
- 13 right here in front of me.
- Q. Have you seen data regarding the
- 15 number of people who were legitimately
- 16 prescribed prescription opioids, became
- 17 addicted, and then began using heroine?
- A. I believe that some of that
- 19 information has been aggregated and put into a
- 20 variety of reports that have been produced at a
- 21 state level, nationally from the Centers for
- 22 Disease Control and Prevention, the CDC, and
- 23 some of this is reported out at these drug task
- 24 forces that I -- meetings that I've attended at
- 25 the U.S. Attorney's Office, and data that we're

Page 169

Page 168

- 1 to try to figure out how best to address this
- 2 issue.
- 3 Q. So it's your belief that if that --
- 4 you have that data and it would have been
- 5 produced during this litigation?
 - MR. PIFKO: Objection.
- 7 Mischaracterizes testimony.
- 8 A. I'm given a lot of information as
- 9 the director of the health department.
- 10 Q. But to come to your deposition today
- 11 to discuss the opioid crisis, that's not
- 12 something you reviewed then, the number of
- 13 heroine abusers who originally became addicted
- 14 to prescription opioids?
- 15 A. I don't have that information
- 16 directly in front of me at this moment.
- 17 Q. And you can't tell me anybody who
- 18 would be able to generate that information from
- 19 the Department of Health?
- 20 MR. PIFKO: Objection. Asked and
- 21 answered.
- 22 A. I don't have that information in
- 23 front of me.
- 24 Q. You don't have the information about
- 25 who could provide that in front of you?

1 A. The health department, it's a part 2 of all of the data that we gather and the

- 3 information that we gather on a daily basis, so
- 4 epidemiologists look at this, again, our Office
- 5 of Mental Health and Substance Abuse.
- 6 Q. Okay. So which one of your 7 epidemiologists would be able to tell us how
- 8 many of the heroine users in the City of
- 9 Cleveland originally became addicted to
- 10 legitimately prescribed opioids?
- 11 MR. PIFKO: Objection.
- 12 Mischaracterizes the record.
- 13 A. It's not entirely a fair question
- 14 that you're asking. Often we're finding out
- 15 that someone was a heroine addict anecdotally,
- 16 after they've died, who was -- people aren't
- 17 necessarily self selecting that they're a
- 18 heroine addict and reporting that out, people
- 19 who are in just search of a high because they're
- 20 addicted and they're trying to find it in some
- 21 way, shape or form, and whether it's heroine,
- 22 whether it's fentanyl, whether it's any other
- 23 substance that they're trying to find just to
- 24 address their addiction.
- Q. Let's talk about death reports then

Page 172

- 1 A. Tom Gilson is the medical examiner,
- 2 Dr. Thomas Gilson.
- Q. Who are the analysts who regularly 4 attend these meetings?
- 5 A. Hugh Shannon is the one who attends 6 with most frequency, and I've met with him.
- 7 Q. Have you ever discussed with Hugh
- 8 Shannon how many heroine overdose victims
- 9 became -- originally became addicted to
- 10 prescription opioids?
 - A. I'm sorry. Restate your question.
- 12 Q. Sure.
- Have you ever discussed with Hugh
- 14 Shannon the number of heroine overdose deaths
- 15 that his office gets that those patients were
- 16 originally addicted to prescription opioids?
- 17 A. I can't say that we've talked about
- 18 a specific number as it relates to that pathway,
- 19 no.

25

11

- Q. Do you believe every heroine death
- 21 resulted from a patient who was originally
- 22 addicted to prescription opioids?
- 23 MR. PIFKO: Objection. Foundation.
- 24 Calls for an expert opinion.
 - A. I cannot say that, that people go

Page 171

1 of people who die of heroine.

- 2 How do you determine from those
- 3 death reports whether they were ever in their
- 4 lifetime prescribed prescription opioids? Do
- 5 you have that data?
- 6 MR. PIFKO: Objection.
- 7 Mischaracterizes the record. Assumes facts not
- 8 in evidence.
- 9 A. I do not have that data in front of
- 10 me.
- 11 Q. Does anyone at the Department of
- 12 Public Health have that data?
- 13 A. I don't know.
- 14 Q. Does anybody at the County Medical
- 15 Examiner's office have that information?
- 16 A. I do not know.
- 17 Q. If you wanted to ask somebody at the
- 18 County Medical Examiner's office if they do, who
- 19 would you ask?
- A. I would ask the medical examiner or
- 21 one of their analysts that would attend
- 22 regularly a lot of these meetings that we talk
- 23 with quite frequently.
- Q. What's the name of the medical
- 25 examiner?

Page 173

- 1 directly to heroine without any other pathway to
- 2 a drug that has that kind of an impact on
- 3 people. I just know from, again, a lot of the
- 4 information that's presented to me at meetings
- 5 that I attend with experts and from information
- 6 that's given to me, that this -- these pathways
- 7 to heroine, to fentanyl, to these drug
- 8 cocktails, to these mixes, by and large, for the
- 9 most part start with prescription drugs and
- 10 prescription pain killers.
- 11 Q. What does by and large mean? Is
- 12 that a percentage?
- 13 MR. PIFKO: Objection.
- 14 Mischaracterizes the record.
- 15 A. It's a term.
- 16 Q. Is it greater than 50 percent?
 - A. It's a term I just used.
- 18 Q. Well, is it a majority?
- 19 A. I don't have all that information in
- 20 front of me, but there have been a fair amount
- 21 of studying of this and just starting to
- 22 correlate the number, the significant increase
- 23 in -- prescriptions of painkillers from the
- 24 1990s to sort of current day essentially has
- 25 gone up threefold, if not more, and as we're

- 1 starting to see and track all of these overdoses
- 2 and overdose deaths as a result of cocktails and
- 3 toxicology reports, excuse me, and seeing that
- 4 so many of these are related to these -- the
- 5 presence of these drugs in these people's blood,
- 6 of course we're making these correlations. This
- 7 is huge. People are dying. People are dying
- 8 every day. I'm getting these reports, another
- 9 OD death, another OD death, heroine, heroine,
- 10 fentanyl. And this started somewhere and that's
- 11 what this is -- that's what's been such a huge
- 12 issue and why we're so desperate for resources
- 13 to help people and help our communities.
- 14 Q. So you've spoken with experts who
- 15 make the correlation between legitimate 16 prescription opioid use and heroine deaths?
- 17 A. Yes. Many people have talked about
- 18 this pathway to these illegal and illicit drugs
- 19 as a result of individuals no longer being able
- 20 to access prescription drugs for whatever reason
- 21 and are going to these other drugs. This is
- 22 written about extensively. I'm sure you've read
- 23 a lot of these reports. These come out from
- 24 reputable firms written about in publications,
- 25 local publications, Plain Dealer and so on,
- 1 newspapers across the country, and, again, CDC
- 2 reports, the Ohio Department of Health. The
- 3 U.S. Attorney's Office has -- I can't say that
- 4 they put -- the U.S. -- the Ohio Attorney
- 5 General's Office has put out reports.
- 6 There's -- a lot of people are looking at this
- 7 because this has really had such a huge impact
- 8 here in Ohio. Ohio has always been one of the
- 9 sort of top five or ten states in the nation
- 10 that have been hardest hit by this issue.
- Q. All right. So who are the names of
- 12 some of those experts, then, that have
- 13 specifically told you the information regarding
- 14 heroine deaths and legitimate prescription
- 15 opioids?
- MR. PIFKO: Objection to the extent 16 17 the question assumes facts not in evidence.
- 18 You can answer.
- 19 A. I'm not recalling every person's
- 20 name, but again, I've been in so many meetings
- 21 related to this. When I first joined, one of
- 22 the first meetings related to this that I went
- 23 to was with the U.S. Surgeon General's Office.
- 24 It was at the Cleveland Clinic. And there were
- 25 a number of experts in that room who talked

- 1 specifically about these pathways and how
 - 2 critical this was because we just were dealing
 - 3 with proliferation and this crisis here in this
 - 4 city.
 - 5 Q. Can you pull out Exhibit 1-A again?
 - 6
 - Q. Can you read into the record again
 - 8 the second sentence in your handwriting on that
 - 9 document?
 - A. The sentence says, "Prescribing
 - 11 practices are no longer the precursor to OD,"
 - 12 which must have been something that was said at
 - 13 this meeting almost two years ago that I wrote
 - 14 down.
 - 15 Q. And was your meeting with the
 - 16 Surgeon General around the same time?
 - A. Meeting with the Surgeon General was 17
 - 18 earlier than -- than this meeting.
 - 19 Q. But you had only been at the
 - 20 Department of Public Health for four months, so
 - 21 it was within that four-month period?
 - 22 A. Well, you have to understand that
 - 23 when you go to a lot of meetings, it's always
 - 24 important to write down what people are saying
 - 25 in the meetings to kind of understand where

- 1 anybody and everybody is coming from, so this
- 2 obviously was something that was said in -- I
- 3 can't say it was obviously, but something that
- 4 must have been said in this meeting that I wrote
- 5 down on the agenda for the U.S. Attorney's
- 6 Office Opiate Task Force meeting.
- 7 Q. So let me be clear about what the
- 8 question was. The meeting with the Surgeon
- 9 General was between June of 2016 and October 7th
- 10 of 2016?
- 11 A. I believe so.
- 12 Q. Okay. Does your department track
- 13 any data regarding whether or not -- strike
- 14 that.
- 15 Do you have any data that -- at the
- 16 Cleveland Department of Health that indicates
- 17 how many people in the City of Cleveland have
- 18 abused prescription opioids since 2010?
- A. Do we track that information? 20 Q. Do you have it?
- 21 A. I cannot say for sure if I have it.
 - And then the follow-up question, is
- 23 that something that your department tracks?
- 24 A. I do not believe that we track that

19

22

25 specifically.

- 1 Q. So your department wouldn't track
- 2 the number of prescription drug abusers who
- 3 purchase those drugs illegally?
- A. We're a department strapped for 4
- 5 resources. If we have them, I know for sure
- 6 that we would make sure that we had people who
- 7 would be tracking all of this information.
- THE WITNESS: I'd like to take a 8
- 9 break, please.
- 10 MR. PIFKO: Okay.
- THE VIDEOGRAPHER: Going off the 11
- 12 record. The time is 2:16.
- 13 (Recess had.)
- 14 THE VIDEOGRAPHER: Back on the
- 15 record, 2:32.
- 16 BY MR. NAEEM:
- Q. Ms. Gordon, I'm going to skip around 17
- 18 a bit here to try to clean up some of the things
- 19 we've talked about or some of the specific items
- 20 within the Department of Health you listed that
- 21 I didn't yet follow up on.
- 22 So earlier in the deposition we were
- 23 talking about how the Department of Health funds
- 24 its services, for lack of a better word. You
- 25 mentioned and we talked about revenue from the

- Page 180
- 1 department, how much funding has been received
- 2 from grants?
- A. A little more than 9 million dollars
- 4 that -- that are received from grants.
- Q. And that's 2018 budget year?
- 6 A. Yes.
- Q. How much of that is attributed to
- 8 programs related to opioid prevention,
- 9 treatment, education, opioid-related programs
- 10 from your department?
- A. For the Office of Mental Health and
- 12 Substance Abuse, there is a rather large SAMHSA,
- 13 a grant from SAMHSA, which is a federal grant.
- 14 We also are funded in part from the local ADAMHS
- 15 board, the alcohol and drug board. And I
- 16 believe those are most of them.
- Q. Are you able to tell me how much the 17
- 18 amount of those grants are within your
- 19 department's budget combined?
- 20 A. One is multi-year, so I believe that
- 21 it is probably about \$800,000, 700 to \$800,000
- 22 from the federal program. The other is about --
- 23 less -- let's see. One is about \$90,000, and
- 24 the other I cannot remember.
- 25 Q. Okay. So within the, roughly, 9

- 1 City of Cleveland. You also mentioned grants.
- 2 And then the third one you mentioned was fees 3 and permits.
- 4 A. Fees generated from permits and 5 licenses, yes.
- Q. Okay. Is there any other source of 7 revenue that your department uses to fund its 8 operations?
- There -- we do bill for some of our A.
- 10 services, so we would bill insurance for some of
- 11 our services, medical services.
- 12 Q. Now, as far as grants, how does that 13 process work? What are the targets for the
- 14 Cleveland Department of Health in terms of
- 15 seeking grants?
- 16 MR. PIFKO: Objection. Overbroad.
- 17 A. What are -- I'm sorry. You have to
- 18 repeat the question.
- 19 Targets. Who do you look for grants Q. 20 from?
- 21 A. We look for any kind of revenue
- 22 possible to -- to fund our programs, so some of
- 23 them have been from the state, from federal
- 24 government, from private philanthropy. 25
 - Q. And in the 2018 budget for your

Page 181

- 1 million dollars received in grants for the 2018
- 2 budget year, you've given me roughly \$900,000 of
- 3 that that goes toward opioid-related services?
- 4 A. Directly. Again, indirectly our
- 5 staff is -- I invest in our staff to make sure
- 6 that they are aware of this issue and are
- 7 trained to recognize this in the work that they
- 8 do in the community and our clinics, et cetera,
- 9 so those are what we would consider indirect
- 10 funding to the rest of the staff related to this
- 11 issue.
- 12 Q. Do those come out of the grants?
- 13 A. It's across the board. It would be
- 14 funded from any of the funding sources that were
- 15 just mentioned.
- 16 Q. Okay. So if you -- can you today
- 17 for us allocate how much of the budget of your
- 18 department spent on employee salaries and
- 19 benefits goes towards opioid-related issues?
- 20 Are you able to do that today?
- 21 A. I know that I couldn't do that
- 22 calculation. Some of these are, again, indirect
- 23 dollars supporting staff and some of the direct
- 24 programs and programs that we serve in the
- 25 community.

7

Q. So you're not able to do it today?

- 2 A. I don't know if I can give you an
- 3 exact figure, no.

1

- 4 Q. Can you give me an estimate?
- 5 A. Well, arguably, almost all of it
- 6 does in one way, shape or form or another,
- 7 because this issue has impacted our community so
- 8 broadly that we are all dealing with it in one
- 9 way or another.
- 10 Q. So if I understand that, are you
- 11 suggesting that a hundred percent of the budget
- 12 for your department goes towards opioid-related
- 13 issues?
- 14 MR. PIFKO: Objection.
- 15 Mischaracterizes testimony.
- 16 A. That's not -- that's not what I
- 17 said.
- 18 Q. Okay. Does your department prepare
- 19 budget documents?
- A. We prepare for the annual budget
- 21 process, yes.
- Q. Where are those documents stored?
- 23 A. Those documents are in my department
- 24 and the Department of Finance. That's how the
- 25 process goes between the departments.
- Page 183
- Q. Is there a particular custodian at
- 2 the Department of Finance who would have the
- 3 budget documents related to the Department of
- 4 Health?

1

- 5 A. Yes.
- 6 Q. Who is that person?
- 7 A. It would be the finance director,
- 8 her designee.
- 9 Q. Who's the finance director?
- 10 A. Her name is Sharon Dumas.
- 11 Q. Okay. And within the Department of
- 12 Health is there a custodian who would have
- 13 budget documents created for the department?
- 14 A. Yes. I have a finance director.
- 15 Q. Who is that?
- 16 A. Her name is Kimberly Davis Sowell.
- 17 Q. Is it S-o-w-e-l-l?
- 18 A. S-o-w-e-l-l.
- 19 Q. Do fees for permits and licenses go
- 20 towards funding opioid-related programs?
- 21 A. The fees generated by the department
- 22 go back into the general revenue and are then
- 23 distributed to the department.
- Q. The general revenue of the City of
- 25 Cleveland?

- Page 184
- 1 A. The general revenue of the City of 2 Cleveland, yes.
- 3 Q. All right. And as far as billing
- 4 for services, are there means tests for the
- 5 services that your department provides to
- 6 Cleveland citizens?
 - MR. PIFKO: Objection. Vague.
- 8 Q. Income limitations as far as who can
- get health services from your clinics.
- 10 A. No. We serve anybody who walks in 11 the clinic.
- 12 Q. Okay. Does -- do the Department of
- 13 Health clinics provide medications that treat
- 14 opioid addiction or withdrawal?
- 15 A. We provide Project DAWN kits.
- 16 Q. Other than Project DAWN kits, does
- 17 the clinic for -- the Department of Health
- 18 clinics provide or prescribe medications to
- 19 treat opioid addiction or withdrawal?
- A. We do not.
- Q. Are you personally a member of the
- 22 Cuyahoga County Opiate Task Force?
- A. I believe in my official capacity I
- 24 am.
- 25 Q. I'm sorry. In your official

Page 185

- 1 capacity you are?
 - 2 A. Um-hum. Yes.
 - Q. Can you give me a high-level
 - 4 overview of what your involvement is with that 5 task force?
- 6 MR. PIFKO: Objection. Overbroad.
- 7 Calls for a narrative.
- 8 A. Well, unfortunately, it conflicts
- 9 with the standing meeting that I have, so my
- 10 involvement is receiving e-mails of agenda and
- 11 meeting notes, also have at times been invited
- 12 to meetings that take place throughout the
- 13 community that have been hosted by or
- 14 facilitated by this task force, one rather
- 15 recently with the representative from the
- 16 Centers for Disease Control who came to hear
- 17 about this issue here on -- I guess a listening
- 18 tour. And so I try to participate to the extent 19 that I can. I run a very busy department, and
- 20 we have a lot of programs and a lot of demands
- 21 on my time.
- Q. With respect to your unofficial
- 23 involvement, did it precede your appointment to
- 24 director of the Cleveland Public Health --
- 25 Cleveland Department of Public Health?

Page 188 Page 186 1 MR. PIFKO: Objection. A. I believe that these are all 2 Mischaracterizes testimony. 2 referrals from the drug court, and I do not 3 know, don't believe I know that we would have 3 MR. NAEEM: It's a question. 4 that specific information unless the individual 4 A. What is your question? 5 Q. The question is, did your 5 client discloses. 6 involvement with the Cuyahoga County Task Force 6 Q. Are the counselors employees of the 7 precede your involvement -- I'm sorry, your 7 Department of Public Health? 8 appointment as the director of the Department of 8 A. They are. 9 9 Public Health? Did you do anything for the Q. Okay. Do those counselors provide 10 Cuyahoga County Task Force prior to becoming the 10 services to abusers of substances other than 11 director? 11 opioids? 12 A. It is my understanding that it is --12 A. No. 13 these are referrals from the drug court. I 13 Q. There's one program you mentioned in 14 your description of the services provided by 14 don't know for sure what the requirements are 15 for entry to this -- to these services or what 15 your department to opioid abusers or addicts, 16 and that was CenterPoint. Do you recall that? 16 -- what the substance was that brought them to 17 A. Yes. We have a program called 17 the drug court in the first place. Q. Okay. So you can't say one way or 18 CenterPoint. Yes. 19 another what the substances are that are Q. All right. Where does the funding 20 for CenterPoint come from? 20 involved in this program? 21 A. No, I cannot. 21 A. The staff that managed that program 22 was funded by general revenue funds, but the 22 Q. Does your department even choose the 23 people who are eligible for that program? 23 operations of it are funded by the ADAMHS board. A. We do not. Q. Currently how many spots are 24 25 So is there anything that limits the 25 available for people in that program? Q. Page 187 Page 189 A. I believe the ratio is one counselor 1 type of patient that's entered into the program 2 to 12 clients, and I believe -- I'm not a 2 from the Department of Health? 3 hundred percent sure if we have two counselors 3 MR. PIFKO: Objection. Foundation. 4 on that currently. 4 A. I don't know. 5 O. Has that changed at any point in Q. Do you know what the Cleveland 6 time while you've been director of the 6 Opioid Response Action Plan is? Have you heard 7 department? 7 of that phrase? 8 A. It has, as staff has -- has left the A. I would need to see -- I've seen so 9 department and we've had to hire. 9 many response plans, so I'm not a hundred 10 Q. What is the most amount of 10 percent sure. 11 counselors you've had in that program as 11 12 director? 12 (Thereupon, Deposition Exhibit 6, 13 A. As director, I don't recall. I 13 Cleveland Opioid Response and Action 14 believe two. 14 Plan (CORAP) Beginning Bates Stamp 15 Q. Does the Department of Public Health 15 CLEVE-000183257, was marked for 16 maintain personal information regarding the 16 purposes of identification.) 17 people that go through that program? 17 MR. PIFKO: Objection. Vague. 18 18 Q. Handing you what's been marked as Q. Let me -- yeah. And let me ask 19 19 Deposition Exhibit 6, have you seen that 20 something more specific to move this along. 20 document before? 21 A. Please. 21 A. I have, yes. Yes. 22 Q. Does the Department of Health 22 Q. Do you not recognize that as what I 23 maintain records regarding the substance that 23 referred to as the Cleveland Opioid Response 24 was being abused that led to their entry into 24 Action Plan?

48 (Pages 186 - 189)

A. I've known it as CORAP, so the

25

25 the CenterPoint program?

1 spelling out the acronym is -- now I understand.

- Q. So we're talking about the same 3 thing?
- 4 A. Yes.
- 5 Q. All right. Is this a plan that is
- 6 currently in effect at the City of Cleveland?
- 7 A. It is not.
- 8 Q. When was this plan put together,
- 9 month and year, if you're aware?
- 10 A. So we are always looking for funding
- 11 opportunities to help us address this epidemic,
- 12 and this is just one of them. A number of staff
- 13 came together looking at opportunities to
- 14 address this issue, and our epidemiologists, our
- 15 director of the Office of Mental Health and
- 16 Substance Abuse and grant writer put this
- 17 proposal together for funding from the
- 18 Department of Justice. I believe this was put
- 19 together early 2017.
- Q. Can I assume by one of your prior
- 21 answers that the grant was rejected by the
- 22 Department of Justice?
- A. This -- this was not funded.
- Q. With respect to any of the
- 25 initiatives described in this document, has the

nd. 1 the question again.

- 2 O. Sure.
- 3 Who decides when opioids are
- 4 appropriate for the treatment of chronic pain?

Page 192

Page 193

- MR. PIFKO: Same objection.
- 6 Foundation. Calls for expert opinion.
- 7 A. I believe a medical professional.
- 8 Q. Can patients legally get opioid
- 9 products without a prescription?
- 10 MR. PIFKO: Objection. Foundation.
- 11 Calls for speculation. Incomplete hypothetical.
- 12 A. It's not my understanding that they
- 13 can, but I don't know for sure.
- 14 Q. Do you know the types of medical
- 15 professionals in the State of Ohio who are
- 16 permitted to write prescriptions for opioids?
 - A. I don't know all of them, no.
- Q. Well, what are the ones you're aware
- 19 of?

17

- A. Medical doctors, others who have
- 21 prescribing authority.
- Q. Do you know any other than doctors?
- A. I can't say for sure.
- Q. Do you agree that the risk of opioid
- 25 dependence has been known by medical

Page 191

- 1 City of Cleveland moved forward with those
- 2 initiatives?
- 3 MR. PIFKO: Let the record reflect
- 4 that the witness is reviewing the document.
- A. Our need for resources to address
- 6 this issue from a data perspective to predictive 7 analytics and to do the type of outreach and
- 8 education necessary to -- to hopefully have an
- 9 impact on this issue is what we put into this
- 10 proposal. We were not funded and, as such,
- 11 don't have the resources to do this type of
- 12 work.
- Q. Okay. So at this point in time,
- 14 that is not -- those initiatives have not
- 15 been --
- 16 A. We have not been able to. We don't
- 17 have the resources to do it. We have a very
- 18 stretched department to be able to do what we're
- 19 trying to do now.
- Q. Ms. Gordon, who decides when opioids 20
- 21 are appropriate for treatment of chronic pain;
- 22 do you know?
- MR. PIFKO: Objection. Foundation.
- 24 Calls for expert opinion.
- A. I'm sorry. You would have to ask

- 1 professionals for many years?
- 2 MR. PIFKO: Objection. Calls for
- 3 speculation. Foundation.
- A. Information that was provided to me,
- 5 again, at meetings that I attend and discussions
- 6 that I've had and been involved with, whether
- 7 it's the U.S. Attorney's Office, whether it's
- 8 been with professionals in this field or in --
- 9 around this issue that I've heard this, yes.
- 10 Q. How about the risk of addiction from
- 11 opioids; has that been well known for many
- 12 years?
- MR. PIFKO: Objection. Calls for
- 14 speculation. Foundation.
- 15 A. I believe this has been well
- 16 documented and this is what, again, continues to
- 17 come up at all of these -- these meetings and
- 18 things that I attend regarding this issue and
- 19 broadly in public health, yes.
- Q. Have you ever reviewed the -- well,
- 21 first of all -- strike that.
- Do you know what a package insert 23 is? Have you heard that phrase before?
- A. I don't believe I have.
 - Q. Have you ever received prescription

Page 196 Page 194 1 medication that had a leaflet inside it when you 1 O. Did heroine use and abuse exist 2 opened up the medication? 2 prior to the 1990s? 3 A. Yes. 3 MR. PIFKO: Objection. Foundation. Q. Have you ever looked to see what the 4 Q. In this country. 4 5 information on that kind of document was for any 5 MR. PIFKO: Speculation. 6 prescription opioid? 6 A. Heroine use has been around for a 7 A. I have not. 7 long time. Q. Have you done any research to 8 Q. Do you have any insight into the 9 determine what the manufacturers of prescription 9 formulary process for any of the city's employee 10 opioids said about the risk of addiction and 10 benefit plans? 11 abuse in their product information? 11 A. I do not. 12 MR. PIFKO: Objection to the extent 12 Q. You told me earlier, I believe, that 13 the question calls for attorney-client 13 you have not reviewed the complaint in this 14 case? 14 communications. 15 Aside from communications with your 15 A. I have not read the entirety of the 16 lawyers, you can answer. 16 complaint. 17 A. I'm sorry. You have to ask it 17 Q. Okay. Do you know who the 18 manufacturing defendants are? Had you heard any 18 again. 19 of their names prior to reviewing the complaint? Have you done any research to 20 determine what information the manufacturers of 20 MR. PIFKO: Objection. Compound. 21 prescription opioids provide in their product 21 Are we just asking the second question or --22 information, their package insert, regarding the 22 MR. NAEEM: Sure. 23 risk of abuse and addiction? 23 Q. Were any of the names -- were you 24 24 able to identify the manufacturers of opioids MR. PIFKO: Aside from 25 communications with lawyers, you can answer. 25 from reading the complaint, just the title of Page 195 Page 197 1 A. I have not. 1 the complaint? 2 A. Some of the names were familiar to Q. We have talked a little bit about 3 the -- the treatment services provided by the 3 me. 4 Department of Health through various outlets for Q. Do you know what medications each 5 opioid abuse and addiction. Putting that aside, 5 defendant specifically manufactures? 6 what we've already talked about, are there any A. I don't know that level of 7 other objectives being pursued by the Department 7 specificity, no. 8 of Health to reduce prescription drug abuse, Q. Do you have any personal knowledge 9 prescription opioid abuse? 9 regarding the marketing practices of any of the 10 A. Specifically on prescription opioid 10 manufacturing defendants beyond what you read in 11 abuse, not specifically. 11 the complaint? Q. Do you know when prescription 12 A. I don't know. 13 opioids initially began being marketed and Q. Any personal -- do you have any 14 available to patients in the United States? 14 personal knowledge regarding any statements made 15 A. I don't know specifically, no. 15 by any of the manufacturing defendants to Q. Do you know the decade when that 16 prescribers about their products other than what 16 17 might have been? 17 you've read in the complaint? MR. PIFKO: Objection to the extent 18 A. The -- say the question again. 18 19 Q. Sure. 19 the question calls for attorney-client 20 Even by decade do you know when 20 communications. 21 prescription opioids became available to 21 Other than communications with 22 patients in the United States? 22 counsel, you can answer. A. I don't know specifically, but I 23 A. You'll have to repeat the question. 24 believe that this started in the -- perhaps 24 25 around the 1990s. 25 Other than what you may have read in

Page 198 Page 200 1 the complaint, do you have any personal 1 and mitigation strategy is? 2 knowledge regarding statements made by any of 2 MR. PIFKO: Objection. Overbroad. 3 3 the manufacturing defendants to prescribers A. As it relates to what? 4 4 regarding their prescription opioid products? Q. To prescription drugs. MR. PIFKO: Limit your answer to 5 A. No, I don't. 6 communications outside of your discussions with 6 Q. Have you heard the phrase REMS in 7 the context of prescription drugs? 7 counsel or information outside of your 8 discussions with counsel. 8 A. I don't believe that I have, no. 9 Q. Do you have any knowledge regarding A. I don't know specifically. 10 how the number of opioid prescriptions has 10 Q. Do you have an understanding of how 11 prescription opioids move from manufacturers 11 changed in the City of Cleveland locally -- I'm 12 through the chain of distribution to patients? 12 sorry, since 2010? MR. PIFKO: Same objection with 13 13 MR. PIFKO: Aside from 14 respect to attorney-client privilege. 14 communications with your counsel. A. Ask the question one more time, 15 A. Very, very broadly but not with a 15 16 level of specificity. 16 please. 17 Q. Okay. What is your broad 17 Q. Sure. 18 Do you have any knowledge regarding 18 understanding? 19 how the number of opioid prescriptions has A. Broad sense, manufacturers through 20 distributors to -- to the -- to pharmacies, 20 changed in each year since 2010 in the City of 21 Cleveland? 21 which is where then the individuals would have 22 22 access to -- directly to the substances. MR. PIFKO: Objection to the extent 23 the question calls for attorney-client Q. Okay. And nothing more specific 24 communication. 24 than that, that's your understanding? 25 25 A. That's my understanding. Aside from communications with Page 199 Page 201 Q. Do you know whether or not 1 counsel, you can answer. 1 2 manufacturing defendants can legally send opioid A. I don't know that we have that 3 prescriptions -- opioid products directly to 3 information specific just to the City of 4 Cleveland. 4 patients? 5 MR. PIFKO: Objection to the extent Q. What jurisdiction do you have that 6 the question calls for communications with 6 information for? A. I cannot speak specifically to which 7 counsel. 8 Aside from communications with 8 jurisdiction or what jurisdictions we have that. 9 I believe we have seen information nationally, 9 counsel, you can answer. 10 A. I do not know that that is a legal 10 but I -- I cannot recall if I've seen such local 11 data. 11 practice. 12 MR. PIFKO: If you're in a topical 12 Q. Have you seen State of Ohio data? 13 MR. PIFKO: Again, objection to the 13 pause, do you want to take a short break? 14 extent the question calls for attorney-client 14 MR. NAEEM: Sure. 15 THE VIDEOGRAPHER: Going off the 15 communications. 16 You can answer aside from that. 16 record. The time is 3:05. 17 (Recess had.) 17 A. I believe that this information is

A. It is my recollection that there has been a significant increase since 2010.

21 prescriptions in the State of Ohio changed since

Q. Okay. And has the number of opioid

MR. PIFKO: Objection. Foundation.

18 contained in some of the reports that I have

19 looked at as pertains to this issue.

20

23

22 2010?

51 (Pages 198 - 201)

THE VIDEOGRAPHER: Back on the

Q. Ms. Gordon, before we took a break,

Do you know what a risk evaluation

22 we were talking a little bit about manufacturers

23 of opioids. I just had one last question on

18

24 that.

25

19 record, 3:25.

20 BY MR. NAEEM:

- 1 Q. Significant increase in the number 2 of prescription opioids provided to people in
- 3 the State of Ohio since 2010?
- 4 A. Yes.
- 5 Q. And that's based on data from where 6 that you've seen?
- 7 MR. PIFKO: Again, objection to the 8 extent the question calls for attorney-client communication.
- 10 You can answer it aside from 11 communications with counsel.
- 12 A. Information is provided in a number 13 of sources. I've mentioned before I attend a
- 14 lot of meetings pertaining to this issue, try to
- 15 look at reports and other information that is
- 16 available to -- as we are collectively trying to
- 17 deal with this epidemic in the city.
- Q. Well, is there any particular
- 19 document that you can point to which shows that 19
- 20 the number of prescription opioids provided to
- 21 citizens in the State of Ohio in each year from
- 22 2010 to 2017 has increased?
- A. It is my recollection, seeing some
- 24 of this data. I don't believe that I can recall
- 25 which document or documents I have that data

1 to.

- 2 The types of experts and individuals
- 3 at those meetings provide additional information

Page 204

Page 205

- 4 that help us to try to understand what is
- 5 contributing to these trends because there are
- 6 times when Fentanyl-related deaths have gone up
- 7 or down over -- again, over the course of time,
- 8 but these are part of an entire data set that
- 9 looks at the toxicology of all the deaths in --
- 10 that come through the medical examiner's office.
- 11 And it's all part of this entire crisis. People
- 12 are dying, and people are dying related to
- 13 overdoses, and overdoses that we do not believe
- 14 started entirely because they got hooked on one
- 15 of these synthetic opioids, that there was a
- 16 pathway to them which created the addiction, and
- 17 thus led to their overdose and, unfortunately,
- 18 for many of them, their deaths, their demise.
 - Q. Okay. I appreciate that,
- 20 Ms. Gordon, but what my question was, was how
- 21 has the rate of fentanyl overdoses changed over
- 22 time. You didn't know going back to 2010
- 23 whether you had seen that data from the ME, so I
- 24 had asked, well, how about the last few years,
- 25 how has that rate changed. Do you know how the

Page 203

1 from.

- Q. While I'm looking for that, let me
- 3 ask you about fentanyl overdose deaths in the
- 4 City of Cleveland or Cuyahoga County.
- Do you have any knowledge regarding
- 6 how those deaths have changed over the course of
- 7 time from 2010 to 2017?
- 8 MR. PIFKO: Objection. Vague.
- 9 Overbroad.
- 10 A. I don't know what the specific time
- 11 frame is, if the reports that I have seen from
- 12 the medical examiner goes back to 2010.
- Q. Okay. Well, what is the trend in at
- 14 least the later years based on your
- 15 understanding?
- A. Of fentanyl deaths, is that your 16
- 17 question?
- 18 O. Yes.
- 19 A. You know, we see -- we've looked at
- 20 these reports over the course of time, and
- 21 this -- these numbers can rise and fall. One of
- 22 the things that gets discussed at especially the
- 23 U.S. Attorney's Office meetings is what that
- 24 might be contributing -- what the contributing
- 25 factors are and what they might be related back

1 rate has changed?

- 2 A. It's my recollection that that rate
- 3 has gone up as part of -- or in the toxicology
- 4 reports from individuals, that that may have
- 5 been in their -- in their blood at time of
- 6 death, and when they did the -- either an
- 7 autopsy or tested these individuals.
- 8 Q. Okay. So you believe the rate has 9 gone up?
- 10 A. It is my recollection that it has 11 gone up.
- 12 Q. Okay. And do you have an
- 13 understanding regarding the source of that
- 14 fentanyl and whether it was fentanyl that was
- 15 prescribed legally or whether it was illicit
- 16 fentanyl that was driving the increase in
- 17 overdose deaths?
- 18 MR. PIFKO: Objection to the extent
- 19 the question mischaracterizes prior testimony.
- 20 Assumes facts not in evidence.
- 21 A. I believe that people who have
- 22 become addicted to painkillers and opiates have
- 23 sought pathways to feed their addiction and have
- 24 resorted to illegal means, which has -- some of
- 25 which are illegal sources of fentanyl, and that

1 has been a contributing factor.

- Q. Okay. Well, in any particular year 3 there's a number of fentanyl deaths that the
- 4 medical examiner reports, and you've seen that
- 5 data, correct?
- 6 A. I have seen many reports from the 7 medical examiner.
- 8 Q. Okay. And some of those reports are 9 fentanyl deaths, correct?
- A. They do track fentanyl deaths, yes. 10
- 11 Q. And when you get those reports that
- 12 track fentanyl deaths, do you get any
- 13 information from the medical examiner about
- 14 whether those fentanyl deaths were from
- 15 prescription fentanyl or illicit fentanyl?
- A. No. They do not recognize the 17 source, no.
- 18 MR. NAEEM: Then I don't have
- 19 anything further at this time, so can we go off 20 the record?
- 21 THE VIDEOGRAPHER: Going off the
- 22 record. The time is 3:35.
- 23 (Recess had.)
- 24 THE VIDEOGRAPHER: Back on the
- 25 record. The time is 3:48.

Page 206 1 any of them specifically offhand.

- Q. Okay. Fair to say you don't know
- 3 the companies' names?
- 4 A. Not offhand, no.
- 5 Q. Do you know the number, how many

Page 208

Page 209

- 6 distributor defendants were named in this
- 7 lawsuit? 8
 - A. Not specifically, no.
- 9 Q. Okay. Have you ever heard the name
- 10 "AmerisourceBergen" before?
- 11 A. Not that I recall.
- 12 Q. Or how about the name "Cardinal,"
- 13 not as it pertains to wildlife but a
- 14 distribution company?
- 15 A. Not necessarily, no.
 - Q. Okay. McKesson?
- A. McKesson is a name I'm somewhat 17
- 18 familiar with.

16

21

- Q. Do you know what they do, have any 19
- 20 knowledge of their business operations?
 - A. Not necessarily, no.
- 22 Q. Do you know what a distributor does
- 23 in the pharmaceutical supply chain?
- MR. PIFKO: Again, aside from 24
- 25 communications with your lawyers, you can

Page 207

EXAMINATION OF MERLE GORDON

2 BY MR. SALIMBENE:

1

- Q. Ms. Gordon, my name is Mike
- 4 Salimbene. I'm one of the attorneys who
- 5 represents a different defendant in the case and
- 6 I'm going to start asking you some questions now
- 7 as soon as I strap up with my microphone.
- Do you know which distributor
- 9 defendants you sued in this case, Cleveland sued
- 10 in this case I should say?
- MR. PIFKO: Objection to the extent
- 12 the question calls for legal -- attorney-client
- 13 communications.
- 14 You can answer aside from
- 15 communications with your lawyers.
- MR. BOEHM: Can you clarify if he's
- 17 instructing the witness not to answer that
- 18 question?
- MR. PIFKO: I'm instructing her not
- 20 to provide attorney-client communications. If
- 21 she can answer the question without revealing
- 22 communications, she can answer the question.
- 23 That's what I'm telling her.
- A. I know that there are a number of
- 25 firms and organizations listed. I don't know

1 answer.

- A. Broadly, part of the supply chain
- 3 from the manufacturers, distributors and
- 4 pharmacies, part of the supply chain. That's to
- 5 the extent that I know, and --
- Q. I didn't mean to cut you off. I'm
- 7 sorry. Within that chain do you have any
- 8 specifics about the role distributor defendants
- 9 play?

- 10 A. Not specifically, no.
- 11 Q. Would you agree that distributors
- 12 don't manufacture prescription opioids?
- 13 MR. PIFKO: Objection. Foundation.
- 14 A. I don't know that for sure, but I'm
- 15 assuming if it's -- they're distributors, that's
- 16 what they do, is distribute, not manufacture.
 - Q. Not manufacture, okay.
 - Do you agree that distributor
- 19 defendants do not market prescription opioids to 20 prescribing physicians?
- MR. PIFKO: Objection. Foundation. 21
- 22 Assumes facts not in evidence.
- 23 A. I don't know with any specificity.
- 24 Q. Do you agree that distributors do
- 25 not draft the warnings that accompany

Page 210 Page 212 1 FDA-approved prescription opioid medications? 1 particular patient? 2 MR. PIFKO: Objection. Foundation. 2 A. Sorry. Rephrase. 3 3 A. I do not know that for sure. Q. Sure. 4 Q. Do you know one way or the other 4 Does a distributor defendant know 5 the reason, diagnosis say, why a doctor writes a 5 whether distributor defendants play a role in 6 determining the quotas for opioid products that 6 prescription for a particular plaintiff --7 are set by the DEA? 7 patient? 8 MR. PIFKO: Objection. Foundation. 8 MR. PIFKO: Objection. Foundation. 9 A. I do not know that specifically, no. 9 A. I would not know. 10 Q. Do you know one way or the other 10 Q. Okay. Does a distributor know the 11 whether distributors interact with patients in 11 patient's diagnosis? 12 the course of their care for a particular 12 MR. PIFKO: Objection. Foundation. 13 condition? 13 A. I would not know. 14 A. Do not know. 14 Q. Does a distributor know whether the 15 Q. Do you know one way or the other 15 patient is suffering from chronic, incurable 16 whether distributors interact with doctors or 16 pain caused by terminal cancer? 17 prescribers in the course of prescribing 17 MR. PIFKO: Objection. Foundation. 18 medications to patients? 18 A. I would not know that. 19 19 A. I do not know. Q. Does a distributor know whether a 20 Q. Do you know one way or the other 20 patient pays for a prescription using cash or 21 whether distributors fill prescriptions written 21 their insurance? 22 by physicians? 22 MR. PIFKO: Objection. Foundation. 23 A. I do not know. 23 A. I would not know that. 24 Q. Do you know one way or the other 24 Q. Do you agree that distributors are 25 whether distributors counsel patients about 25 regulated? Page 211 Page 213 1 proper medication use? MR. PIFKO: Objection. Foundation. 2 Calls for a legal conclusion. A. I do not know. Q. As you sit here today, can you 3 A. No knowledge of that. 4 Q. Okay. Do you know whether the State 4 recall any statement that was made to you by 5 someone you knew to be working for a distributor 5 of Ohio has regulations in place that govern the 6 conduct of distributor defendants? 6 defendant in this lawsuit? 7 7 A. Say that again. A. No. Q. How about anybody in your 8 O. Sure. 9 department; are you aware of any statements made Do you know whether the State of 10 Ohio has regulations in place that govern the 10 by a distributor defendant to anybody in the 11 conduct of distributor defendants? 11 Department of Public Health? 12 12 A. No, I'm not aware. A. Distributor defendants, not that I 13 know of. I don't know. Q. Do you know whether distributors 14 know the identity of an individual who receives 14 Q. You don't know one way or the other? 15 one of the opioids that it ships? 15 A. I don't know one way or the other. 16 A. No, I have no idea. 16 Q. Okay. How about the federal 17 Q. Do you have any basis to disagree 17 government; do you know one way or the other 18 whether there are federal laws and regulations 18 with my contention that distributor defendants 19 that govern the conduct of pharmaceutical 19 do not know the identity of the end user of a 20 distributors? 20 particular prescription opioid? 21 21 MR. PIFKO: Objection to the extent MR. PIFKO: Aside from 22 the question assumes facts not in evidence. 22 communications with counsel, you can answer. 23 23 A. Information that's been provided to A. I would not know that. 24 Q. Okay. Do distributors know the 24 me by counsel is what I've -- I know, but

54 (Pages 210 - 213)

25 otherwise, I do not, I have no knowledge of that

25 reason a medication is prescribed to a

Page 214 1 specifically.

- Q. So prior to the events that gave
- 3 rise to you meeting with attorneys, you had no
- 4 knowledge of regulations at the federal level
- 5 that pertain to pharmaceutical distributors; is
- 6 that fair to say?
- A. What I -- so, as I've said many
- 8 times here today, a lot of information is shared
- 9 at meetings that I attend and --
- Q. I don't mean to cut you off. I
- 11 heard a lot about the meetings. I don't
- 12 think -- you can finish --
- 13 MR. PIFKO: You cannot do that.
- 14 Q. You can finish your answer and then
- 15 we can see if you answered the question. You
- 16 were talking about your meetings.
- 17 A. I attend a lot of meetings. It's my
- 18 capacity as the director of the Cleveland
- 19 Department of Public Health. It's one of the
- 20 things that I do regularly. My ability to
- 21 understand issues to any level of degree that I
- 22 can, managing a lot of issues in the City of
- 23 Cleveland, and that --
- MR. SALIMBENE: I asked about
- 25 federal regulations. I move to strike all this

Page 216 1 tell the judge that you're cutting her off.

- MR. SALIMBENE: Honestly, I'm fine
- 3 with that. You know, in this case when I say
- 4 this is the most --
 - MR. PIFKO: She's trying to
- 6 articulate. You asked her do you have any
- 7 knowledge. She's trying to articulate a basis
- 8 of knowledge and you cut her off.
- MR. SALIMBENE: I just asked what
- 10 the knowledge is. I didn't ask for the basis.
- 11 I said what is the knowledge.
- 12 MR. PIFKO: She's trying to explain
- 13 it to you.
- 14 MR. SALIMBENE: I disagree
- 15 completely.
- MR. PIFKO: I disagree with you. 16
- 17 Obviously you don't like her answer, but that's
- 18 her answer.
 - Q. You can continue.
- 20 MR. BOEHM: She might need the
- 21 question reread.
- 22 Q. You know what, yes. I mean, the
- 23 question was basically, are you aware of any
- 24 federal regulation that govern the conduct of
- 25 distributors of pharmaceutical medications?

Page 215

19

- 1 as non-responsive. This is a waste of time.
- 2 It's filibustering.
- MR. PIFKO: No, it's not. She's 4 answering the question to the best of her
- MR. SALIMBENE: No. No. No. I
- 7 said federal regulations governing the conduct
- 8 of distributor defendants.
- MR. PIFKO: You're cutting her off.
- 10 MR. SALIMBENE: We're talking about
- 11 meetings. I am cutting her off now because it's
- 12 been going on for 30 seconds and it's completely
- 13 non-responsive.

5 ability.

- MR. PIFKO: She can answer the
- 15 question however she pleases. She can. If you
- 16 want to make a motion about it after or do
- 17 whatever you want to do, you can do it.
- 18 MR. SALIMBENE: We'll be leaving the
- 19 deposition open.
- 20 MR. PIFKO: She has the right to
- 21 give an answer that she wants to do. If you
- 22 don't like her answer, you can ask her a
- 23 follow-up question, you can make a motion, you
- 24 can do whatever you want, but you cannot cut her
- 25 off, okay. If you do that again, I'm going to

- Very, very basic understanding based 2 on information that I have gathered in the
- 3 number of meetings and information that's
- 4 provided to me in my capacity as the director of
- 5 the Cleveland Department of Public Health.
 - Q. What is the information? What is
- 7 the information? Not how did you obtain it.
- 8 What is the information you are aware of?
 - A. I know that there are some
- 10 regulations. I don't know them verbatim and I
- 11 don't know them specifically.
- 12 Q. Okay. That's perfect.
- 13 Are you aware of any DEA regulations
- 14 that pertain to distributors of pharmaceutical
- 15 products?
- 16 MR. PIFKO: Aside from your
- 17 communications with counsel, you can answer.
- A. I have, again, a very, very basic
- 19 understanding of some reporting requirements to
- 20 the DEA.
- 21 Q. Okay. And what is that
- 22 understanding? What is that basic
- 23 understanding?
- 24 MR. PIFKO: Again, aside from
- 25 communications with counsel, you can answer.

- 1 A. A basic understanding of the volume 2 produced and distributed.
- 3 Q. Can you explain that?
- Again, I have a very basic 4
- 5 understanding of the -- the numbers of
- 6 pharmaceuticals that distributors provide to
- 7 pharmacies in the entire chain.
- Q. What about the numbers? What is the 9 regulation that you're aware of?
- A. I don't know the actual regulation. 10
- 11 Q. If a distributor sells a medication
- 12 to a particular pharmacy, do you know if the
- 13 distributor knows whether that pharmacy has
- 14 received orders from other distributors?
- A. I would not know that. 15
- 16 Q. Do you know what a -- strike that.
- 17 Do you know whether distributor
- 18 defendants are licensed by the DEA?
- 19 A. I don't know.
- 20 Q. Do you believe, other than, you
- 21 know, discussions with counsel, that any
- 22 distributor defendant in this lawsuit was not at
- 23 all times properly registered with the DEA?
- 24 A. I do not know.
- 25 Do you know what this lawsuit claims

Page 220

Page 221

- 1 any other time aside from communications you've
- 2 had with counsel; is that fair?
- 3 A. It's fair.
- 4 Q. Do you have any personal knowledge
- 5 of something known as suspicious order
- 6 reporting?

8

11

- 7 A. No, I do not.
 - Q. Have you ever discussed suspicious
- 9 order reporting with anybody in your role as the
- 10 director of the Department of Public Health?
 - A. I have no recollection of that, no.
- Q. Do you agree that distributors of 12
- 13 pharmaceutical medications play an important
- 14 role in promoting public health in Cleveland?
- 15 MR. PIFKO: Foundation.
- 16 You can answer.
- 17 Q. I'm asking you to speak as a top
- 18 public health official in Cleveland.
- 19 A. Do I agree to what?
- 20 Q. That distributor defendants,
- 21 distributors of pharmaceutical medications, play
- 22 an important role in promoting public health
- 23 here in Cleveland.
- 24 MR. PIFKO: Foundation. Overbroad.
- 25 Vague.

1

9

Page 219

- 1 distributor defendants either did or failed to
- 2 do that gave rise or gives rise to their alleged
- 3 liability in this lawsuit?
- 4 MR. PIFKO: Objection to the extent
- 5 the question calls for a legal conclusion,
- 6 foundation, and instruction with respect to any
- 7 attorney-client communications.
- 8 Aside from communications, you can 9 answer.
- 10 A. You have to repeat the question.
- MR. SALIMBENE: Can you read it 11
- 12 back? I'm sorry.
- 13 (Record read.)
- 14 MR. SALIMBENE: Thank you.
- 15 A. Very, very peripheral knowledge in
- 16 terms of reporting numbers, but I don't know to
- 17 any level of specificity.
- Q. Okay. And what is the source of 18
- 19 that knowledge that you just described?
- 20 MR. PIFKO: Aside from the
- 21 communications with counsel, you can answer.
- 22 A. Knowledge comes from -- from
- 23 counsel.
- Q. Okay. So no knowledge obtained in
- 25 your role as the director of public health or at

- A. No knowledge of that.
- Q. You deal with a number of non-opioid 2
- 3 issues, correct? I think you testified about
- 4 several of them earlier today, right?
- 5 Α.
- 6 Q. Your residents have things like
- 7 diabetes, true?
- 8 A. Yes.
 - Q. Cardiovascular disease, true?
- 10
- Sexually transmitted infections you 11 O.
- 12 mentioned, correct?
- 13 Yes.
- 14 Administering flu vaccines, correct?
- 15 A. Yes.
- 16 Who do you think distributes the
- 17 medications that treat those conditions that
- 18 people in Cleveland suffer from?
- MR. PIFKO: Objection. Calls for 19
- 20 speculation. Foundation.
- 21 A. Obviously those come from -- those
- 22 are pharmaceutical medicines that are provided 23 to individuals.
- 24
- Q. Do you agree that your citizens here 25 in Cleveland benefit from having access to

P 00	
Page 22 1 prescription medications?	Page 224 1 E-Mail from Merle Gordon to Merle
2 MR. PIFKO: Objection. Incomplete	2 Gordon Bates-Stamped
3 hypothetical. Overbroad.	3 CLEVE-000188104, was marked for
4 A. Surely there are some that are	/
5 helpful and beneficial to people.	4 purposes of identification.) 5
6 Q. Can you think of any circumstance	6
7 where the citizens here in Cleveland would be	
8 better off without access to prescription 9 medications? Strike that. Strike that.	
Do you agree your citizens are	10 CLEVE_000188105, was marked for
11 better off if they can fill prescriptions for	purposes of identification.) 12
12 the medications that are prescribed by their	
13 doctors, that they can go to a pharmacy, preser	
14 the script, and they'll get that medication?	14 the first document is from you and also to you
MR. PIFKO: Objection.	15 and the subject is opioid notes. Do you see 16 where I've read that?
16 A. You're assuming that	
17 MR. PIFKO: Wait. Wait. Wait.	17 A. I do.
18 Objection. Incomplete hypothetical.	18
19 Foundation. Calls for expert opinion.	19 (Thereupon, Deposition Exhibit 8,
20 You can answer.	Document Entitled "August 18, 2016
Q. Sorry. Go ahead.	Notes," Beginning Bates Stamp
A. You're assuming that everybody can	22 CLEVE_000188105, was marked for
23 go to a pharmacy and get their prescription	purposes of identification.)
24 filled or even have access to medical	24
25 professionals. This is one of the things that	25 Q. And then I'll represent to you that
Page 22	
1 we realize in the City of Cleveland that is a	1 the next exhibit, Exhibit 8, is what was
1 we realize in the City of Cleveland that is a2 big issue for us in terms of access, so in terms	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail.
1 we realize in the City of Cleveland that is a2 big issue for us in terms of access, so in terms3 of the totality of public health, that we try to	 1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were
 1 we realize in the City of Cleveland that is a 2 big issue for us in terms of access, so in terms 3 of the totality of public health, that we try to 4 make sure that we are addressing all of those 	 the next exhibit, Exhibit 8, is what was produced to us as the attachment to that e-mail. So fair to say here you were e-mailing yourself some notes you took about, it
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in 	 the next exhibit, Exhibit 8, is what was produced to us as the attachment to that e-mail. So fair to say here you were e-mailing yourself some notes you took about, it looks like, a meeting. And there's individuals
1 we realize in the City of Cleveland that is a 2 big issue for us in terms of access, so in terms 3 of the totality of public health, that we try to 4 make sure that we are addressing all of those 5 issues for for individuals and families in 6 the city.	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am?
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do.
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health?
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes.
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, i 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was?
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes.
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that?
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete hypothetical. Overbroad. Vague. 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete hypothetical. Overbroad. Vague. A. That is part of public health, yes. 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete hypothetical. Overbroad. Vague. A. That is part of public health, yes. Q. We're going to start looking at a 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis
1 we realize in the City of Cleveland that is a 2 big issue for us in terms of access, so in terms 3 of the totality of public health, that we try to 4 make sure that we are addressing all of those 5 issues for for individuals and families in 6 the city. 7 Q. Access is a good thing, true, access 8 to healthcare, correct? 9 MR. PIFKO: Overbroad. Vague. 10 Incomplete hypothetical. 11 A. Access to healthcare is a good 12 thing. 13 Q. So access, including to prescription 14 medications, is a good thing in terms of 15 promoting public health, fair? 16 MR. PIFKO: Objection. Incomplete 17 hypothetical. Overbroad. Vague. 18 A. That is part of public health, yes. 19 Q. We're going to start looking at a 20 few documents now. So I'm going to mark the	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis see 20 in the City of Cleveland.
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete hypothetical. Overbroad. Vague. A. That is part of public health, yes. Q. We're going to start looking at a few documents now. So I'm going to mark the as 7 and 8, and these are Bates ending it's 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, it 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis see 20 in the City of Cleveland. 21 Q. Okay. And these are your notes from
1 we realize in the City of Cleveland that is a 2 big issue for us in terms of access, so in terms 3 of the totality of public health, that we try to 4 make sure that we are addressing all of those 5 issues for for individuals and families in 6 the city. 7 Q. Access is a good thing, true, access 8 to healthcare, correct? 9 MR. PIFKO: Overbroad. Vague. 10 Incomplete hypothetical. 11 A. Access to healthcare is a good 12 thing. 13 Q. So access, including to prescription 14 medications, is a good thing in terms of 15 promoting public health, fair? 16 MR. PIFKO: Objection. Incomplete 17 hypothetical. Overbroad. Vague. 18 A. That is part of public health, yes. 19 Q. We're going to start looking at a 20 few documents now. So I'm going to mark the 21 as 7 and 8, and these are Bates ending it's 22 Cleveland and ending 188104 and 188105	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis see 20 in the City of Cleveland. 21 Q. Okay. And these are your notes from 22 that meeting, correct?
 we realize in the City of Cleveland that is a big issue for us in terms of access, so in terms of the totality of public health, that we try to make sure that we are addressing all of those issues for for individuals and families in the city. Q. Access is a good thing, true, access to healthcare, correct? MR. PIFKO: Overbroad. Vague. Incomplete hypothetical. A. Access to healthcare is a good thing. Q. So access, including to prescription medications, is a good thing in terms of promoting public health, fair? MR. PIFKO: Objection. Incomplete hypothetical. Overbroad. Vague. A. That is part of public health, yes. Q. We're going to start looking at a few documents now. So I'm going to mark the as 7 and 8, and these are Bates ending it's 	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis see 20 in the City of Cleveland. 21 Q. Okay. And these are your notes from 22 that meeting, correct? 23 A. My name is not on this document.
1 we realize in the City of Cleveland that is a 2 big issue for us in terms of access, so in terms 3 of the totality of public health, that we try to 4 make sure that we are addressing all of those 5 issues for for individuals and families in 6 the city. 7 Q. Access is a good thing, true, access 8 to healthcare, correct? 9 MR. PIFKO: Overbroad. Vague. 10 Incomplete hypothetical. 11 A. Access to healthcare is a good 12 thing. 13 Q. So access, including to prescription 14 medications, is a good thing in terms of 15 promoting public health, fair? 16 MR. PIFKO: Objection. Incomplete 17 hypothetical. Overbroad. Vague. 18 A. That is part of public health, yes. 19 Q. We're going to start looking at a 20 few documents now. So I'm going to mark the 21 as 7 and 8, and these are Bates ending it's 22 Cleveland and ending 188104 and 188105 23 respectively.	1 the next exhibit, Exhibit 8, is what was 2 produced to us as the attachment to that e-mail. 3 So fair to say here you were 4 e-mailing yourself some notes you took about, ir 5 looks like, a meeting. And there's individuals 6 listed at the top of Exhibit 8. Do you see 7 where I am? 8 A. I do. 9 Q. Okay. Now, August 2016, fair to say 10 that's soon after you started the job as the 11 director of public health? 12 A. Yes. 13 Q. Okay. And do you recall what the 14 purpose of this meeting was? 15 A. To some degree, yes. 16 Q. And what was that? 17 A. We were asked by the mayor's from 18 the mayor to come up with a set of 19 recommendations of how to deal with this crisis see 20 in the City of Cleveland. 21 Q. Okay. And these are your notes from 22 that meeting, correct? 23 A. My name is not on this document.

57 (Pages 222 - 225)

	Dags 226		Page 220
1	Page 226 took them or somebody else recorded them?	1	Page 228 and Director Griffin, dated
2	MR. PIFKO: Objection.	2	September 6, 2016, Beginning Bates
3	Q. You don't recall that today?	3	Stamp CLEVE 000187963, was marked
4	MR. PIFKO: Objection. Foundation.	4	for purposes of identification.)
5	Q. What is Exhibit 8? What does that	5	
6	document show?	6	Q. Okay. And then so you mentioned
7	MR. PIFKO: Objection. Overbroad.		this meeting with the mayor, and I'm going to
8	A. The document has a date at the top		mark now what I think is a document it's
	and it says "Notes" and indicates individuals	_	Bates number CLEVE 187963 and the subject line
	that were most likely at this meeting. My name		of this is "Re: Recommendations for the City of
	is not on this document.		Cleveland Mayor Frank Jackson to address the
12	Q. So do you recall attending this		opioid addiction epidemic in Cleveland." Do you
13	meeting or no? I thought before you testified		see where I've read that?
	you may have, but	14	MR. PIFKO: Hold on. She just got
15	A. I believe I attended this meeting,	15	the document.
16	yes.	16	MR. SALIMBENE: Sure.
17	Q. So is it fair to say that since your	17	MR. PIFKO: Take your time to review
18	name is not listed and you attended, it's likely	18	the document.
19	that you did, in fact, take these notes and	19	A. Yes, I see that.
20	didn't record your own name as being present?	20	Q. And this document is from you, true?
21	MR. PIFKO: Objection.	21	A. That is what it says, yes.
22	Argumentative. Assumes facts not in evidence.	22	Q. Do you agree that you are the top
23	Q. I'm just asking if that's a	23	public health official in Cleveland?
	reasonable explanation for what	24	A. I am the director of the Cleveland
25	A. It's reasonable.	25	Department of Public Health.
	Page 227		Page 229
1	Page 227 Q. Okay. Is it fair to say, as you	1	Q. Would you characterize yourself as
		1 2	=
2 3	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's	3	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is
2 3 4	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the	3	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes.
2 3 4 5	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription	3 4 5	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to
2 3 4 5 6	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids?	3 4 5 6	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in
2 3 4 5 6 7	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document	3 4 5 6 7	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland?
2 3 4 5 6 7 8	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided.	3 4 5 6 7 8	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to
2 3 4 5 6 7 8 9	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious	3 4 5 6 7 8 9	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland?
2 3 4 5 6 7 8 9	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one	3 4 5 6 7 8 9 10	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes.
2 3 4 5 6 7 8 9 10 11	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided.	3 4 5 6 7 8 9 10 11	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10,
2 3 4 5 6 7 8 9 10 11 12	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says	3 4 5 6 7 8 9 10 11 12	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say.	3 4 5 6 7 8 9 10 11 12 13	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for
2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this	3 4 5 6 7 8 9 10 11 12 13 14	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document	3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay.	3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right thereit's an e-mail
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of course.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from you. The Bates is 189085, also CLEVE. It says,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of course. A. I do not see distributors identified	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right thereit's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from you. The Bates is 189085, also CLEVE. It says, Hello, Melanie. And then number 2 says, "In
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of course.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from you. The Bates is 189085, also CLEVE. It says, Hello, Melanie. And then number 2 says, "In Cleveland I am the top health official." Do you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of course. A. I do not see distributors identified in this document.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from you. The Bates is 189085, also CLEVE. It says, Hello, Melanie. And then number 2 says, "In Cleveland I am the top health official." Do you see where I've read that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. Is it fair to say, as you look at this document and all the recommendations from various folks, that there's nothing in this document that speaks to the conduct of any distributor of prescription opioids? MR. PIFKO: Objection. The document speaks for itself. Mine is double-sided. MR. SALIMBENE: I'm ever conscious of the environment, so I printed one single-sided and the other copies double-sided. I don't know what the deposition protocol says about that, I got to say. MR. PIFKO: I'm okay with this document MR. SALIMBENE: Okay. MR. PIFKO: with respect to its double-sidedness. MR. SALIMBENE: Limited to that, of course. A. I do not see distributors identified	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Would you characterize yourself as in Cleveland I am the top health official? A. Often that is what the director is referred to as, yes. Q. I'm asking you would you refer to yourself as the top health official in Cleveland? A. Often that is what I am referred to as, yes. (Thereupon, Deposition Exhibit 10, E-Mail String Beginning Bates Stamp CLEVE_000189085, was marked for purposes of identification.) Q. So this is 10, and right there it's an e-mail MR. PIFKO: Hold on. Q. Okay. Sure. It's an e-mail from you. The Bates is 189085, also CLEVE. It says, Hello, Melanie. And then number 2 says, "In Cleveland I am the top health official." Do you

58 (Pages 226 - 229)

- 1 Q. That's the only question I have is 2 number 2 says "In Cleveland I am the top health 3 official." Did I read that correctly?
- 4 A. Yes.
- 5 Q. And that's an e-mail you sent, true?
- 6
- 7 Q. Okay. We can go back to the other 8 document, the mayor's report.
- Now, what was the purpose of this
- 10 mayor's report? I mean, I believe you testified 11 about this earlier, but just because we're here
- 12 again, if you could describe why you guys put
- 13 together these recommendations.
- 14 A. Sure.
- 15 So the mayor asked, as he regularly 16 does, to put together a set of recommendations
- 17 for the city to address any particular issue,
- 18 and I would report out with some regularity at
- 19 cabinet issues that were happening in the city.
- 20 And so he had asked me and the director of
- 21 public safety to put together a set of
- 22 recommendations to address the opiate crisis in
- 23 the City of Cleveland.
- Q. Okay. Under "Rehabilitation" --
- 25 it's a bit down the first page there -- it's

25

Page 231 1 underlined, "Rehabilitation," and it says, last

- 2 paragraph -- excuse me, last sentence of the
- 3 first paragraph, "According to the county 4 medical examiner, 15 percent of addicts actually
- 5 want out of the addiction; of that, 10 percent
- 6 actually make it clean one year later." Do you
- 7 see where I read that?
- 8 A. I do.
- Q. Does that mean that 85 percent of
- 10 people using -- excuse me, of addicts don't want 11 out of the addiction? Is that the flip side?
- 12 MR. PIFKO: Objection. Foundation.
- 13 Calls for speculation.
- 14 A. That is not what is stated here in
- 15 this document.
- Q. But what is stated is that only 15
- 17 percent do, in fact, want out of addiction,
- 18 true?
- 19 MR. PIFKO: Same objections.
- 20 A. I am stating what -- we got
- 21 information from the county medical examiner's
- 22 office and just repeating what they had given to
- 23 me as information.
- Q. Do you agree that there are some
- 25 individuals that don't want to stop using drugs?

Page 232 MR. PIFKO: Objection. Calls for

- 1 2 speculation. Foundation.
- A. As we've heard from people that
- 4 there are some people who are just so addicted,
- 5 they have lost their ability to rationalize and
- 6 their addiction has taken over and consumed 7 their life.
- Q. But there are people who don't mind 8 using drugs; is that fair to say?
- MR. PIFKO: Objection. Calls for 10
- 11 speculation. Foundation. Asked and answered.
 - A. I can't imagine that there's
- 13 somebody who has a desire to not be addicted to
- 14 a substance that they -- that is illegal for
- 15 them to consume.
- Q. Can you explain then why only 15 16
- 17 percent of addicts actually want out of the
- 18 addiction according to your county's medical
- 19 examiner?

12

- 20 MR. PIFKO: Objection. Asked and
- 21 answered. Foundation. Speculation.
- 22 MR. SALIMBENE: I definitely didn't
- 23 ask this one.
- 24 MR. PIFKO: She answered it already.
 - A. I am simply stating on this document

Page 233

- 1 that according to the county medical examiner -
- 2 I'll repeat it back to you, I'll read what is
- 3 written here -- "15 percent of addicts actually
- 4 want out of the addiction, and of that, 10
- 5 percent actually make it clean one year later."
- Q. Okay. So you have no idea why or
- 7 how the other 85 percent of addicts feel?
- 8 MR. PIFKO: Objection. Asked and
- 9 answered.
- 10 A. How they feel? No, I don't know
- 11 that I know how they feel specifically.
- 12 Q. Do you agree that there's an element 13 of personal responsibility in addiction?
 - MR. PIFKO: Objection. Foundation.
- 15 Calls for speculation. Incomplete hypothetical.
- 16 Calls for expert opinion.
 - A. In what type of addiction?
- 18 Opioid addiction.
 - MR. PIFKO: Same objections.
- 20 A. From what we have gathered from a
- 21 lot of information and meetings and data and
- 22 discussions around this issue, there are
- 23 pathways into addiction that have caused people
- 24 to go to extremes to feed their addiction.
 - Q. And my question was, do you believe

17

19

Page 234 Page 236 1 that, based on your experience, there's an 1 move on in the sake of time. We'll probably be 2 element of personal responsibility in that cycle 2 back here. 3 of addiction? 3 Now -- okay. So you're the top 4 MR. PIFKO: Objection. Foundation. 4 public health official in Cleveland, true? We 5 Calls for speculation. Incomplete hypothetical. 5 established that? 6 Calls for expert opinion. A. Sure. A. I believe that in some -- to a large 7 Q. Okay. And you come up -- you're 8 degree, they don't have the capacity to -- to be 8 presenting these recommendations to the mayor, 9 rational about this once they're addicted. 9 right, so you have, on page 2 of this document Q. Is that a no then? Is no the answer 10 ending Bates 964, a list of recommendations. Do 10 11 to my question? 11 you see where I am? 12 MR. PIFKO: Objection. Asked and A. I do. 12 13 answered. You're harassing her. She gave an 13 Q. And it's fair to say you could have 14 answer. 14 put anything in this list of recommendations A. I answered your question. 15 15 that you thought made sense? Is that fair? Q. I don't think you did. I said, is A. Say your question again. 16 16 17 there an element of personal responsibility in 17 Q. Sure. 18 addiction? And it could be yes and explain or a 18 You could have put anything in this 19 no and explain. 19 list of recommendations that you thought made 20 MR. PIFKO: No. She can answer 20 sense in terms of, you know, improving the 21 however she wants. 21 public's health? 22 MR. SALIMBENE: I move to strike her 22 MR. PIFKO: Objection to the extent 23 answer as non-responsive. 23 the question assumes facts not in evidence. 24 A. I believe that once people are 24 A. This is to the chief of public 25 addicted, they are, to a large degree, incapable 25 safety and to the director of community Page 235 Page 237 1 of making that rational --1 relations, a set of recommendations to present Q. How --2 2 to the mayor regarding this epidemic in this 3 A. -- decision. 3 city. 4 MR. PIFKO: Stop cutting her off. 4 Q. I move to strike that as completely MR. SALIMBENE: I didn't mean to cut 5 5 non-responsive. My question was, you could have 6 her off. 6 put in this list of recommendations anything you 7 7 wanted that you thought made sense in, you know, Q. How about the decision to use an 8 addictive substance, an illegal, addictive 8 serving the purpose of what you were trying to 9 substance? Strike that. 9 do here, true? 10 How about the decision to use an 10 MR. PIFKO: Hold on. Calls for 11 illegal opioid in the first instance; do you 11 speculation. Assumes facts not in evidence. 12 believe that there is an element of personal 12 O. Your answer was? 13 responsibility with that? 13 A. I could have. MR. PIFKO: Objection. Foundation. 14 Q. Okay. Number 3 here is "Part of the 15 Incomplete hypothetical. Speculation. Calls 15 money seized from drug arrests could support 16 for expert opinion. 16 treatment programs, prevention education or 17 You can answer. 17 noloxone programs." Do you see where I read 18 A. I believe that there's a pathway to 18 that? 19 that, and --19 A. Yes. 20 Q. I didn't ask about a pathway. Did that happen? 20 21 A. -- leading up to the point where 21 That has not happened, no.

60 (Pages 234 - 237)

Q. Okay. Is there anything in this

23 list of nine items here that addresses anything

24 to do with the conduct of the companies who

25 distribute opioid medications, pharmaceutical

22

23 their addiction.

22 they are seeking these -- these drugs to satiate

Q. I didn't ask about a pathway, so I

25 move to strike that as non-responsive, and we'll

Page 238 Page 240 1 opioid medications? 1 A. So a big part of my work involves MR. PIFKO: Objection. The document 2 advocacy and I am part of a coalition of big 3 speaks for itself. Objection to the extent that 3 cities. It's called The Big City Health 4 the question calls for a legal conclusion. 4 Coalition. These individuals are and these A. The distributors are not named 5 individual departments are -- I believe all of 6 specifically in this set of recommendations. 6 them are members of the Big City Health 7 Coalition. And this issue is so significant to Q. Okay. Is there anything -- excuse 8 me. Strike that. 8 us and to the cities where we work that we There is nothing in this set of 9 thought it very important to make sure that we 10 recommendations that speaks to in any way 10 submitted a letter to the transition team, and 11 suspicious order reporting; is that correct? 11 here it's addressed to Governor and 12 MR. PIFKO: Again, the document 12 Vice-President Elect Mike Pence, regarding this 13 speaks for itself and objection to the extent 13 issue, and there's a number of -- number of 14 the question calls for a legal opinion. 14 issues contained therein. 15 15 Q. Right. And one of the issues is, on O. You can answer. 16 A. That is not mentioned specifically 16 page Bates ending 509, opioid addiction and 17 overdose, correct? 17 in this list of recommendations. 18 18 A. Yes, that is one of the Q. Do you recall -- you can put that 19 aside. 19 subcategories. Yes. 20 Do you recall signing onto a letter 20 Q. And towards the bottom of that page 21 to the presidential transition team, yes or no? 21 there's a sentence that says, "We propose that 22 the new administration," colon, and then there's 22 A. I do recall signing onto a couple 23 letters to the transition team, yes. 23 a bulleted list of five items, true? 24 24 O. So I'll mark this as Exhibit 11. A. On this page, yes. 25 25 Right. So this is a list that you Page 239 Page 241 1 (Thereupon, Deposition Exhibit 11, 1 put together for proposals that the new 2 Letter from Leana S. Wen, M.D. to 2 administration consider, fair? 3 Governor and Vice President-Elect MR. PIFKO: Objection. Assumes 4 facts not in evidence. Mischaracterizes the 4 Mike Pence, dated November 29, 2016, 5 Beginning Bates Stamp 5 document and the record. 6 CLEVE 000187508, was marked for A. I did not write this document. 7 7 purposes of identification.) Q. You signed onto the document, 8 8 correct? 9 MR. PIFKO: Hold on. 9 A. Signed onto it. 10 Q. It's Cleveland 187508, and it's a 10 Q. What was your understanding of what 11 letter dated November 29th, 2016 to Governor and 11 this section was designed to do? 12 Vice-President Elect Mike Pence, and if you look 12 MR. PIFKO: Objection. Foundation. 13 at the page ending Bates 514, it says, A. Again, a big part of my job is 13 14 sincere -- well, the page before it says, 14 advocacy and bringing resources to issues in our 15 "Sincerely," and then it says, "On behalf of the 15 community. One way we do that is we advocate to 16 following health commissioners representing 31 16 policy makers on a federal level, and this is 17 million American citizens in 11 cities and 17 one example of that. 18 counties," and there's a colon, and one of the 18 Q. Okay. Is it correct that there is 19 names listed there on the left column, second 19 nothing in these five bullets that relates to 20 the conduct by distributor defendants who have 20 from the bottom, is your name, true? 21 A. True. 21 been sued by the City of Cleveland in this case? 22 22 MR. PIFKO: Objection. The document Okay. What was the purpose of this Q. 23 letter? 23 speaks for itself and objection to the extent 24 MR. PIFKO: Take your time to review 24 the question calls for a legal opinion.

61 (Pages 238 - 241)

A. Distributors are not mentioned in

25

25 the letter.

Page 244 Page 242 1 this set of proposals on page 2. 1 attorney-client privilege. Aside from Q. Are you aware of any criminal act 2 communications with counsel, you can answer. MR. SALIMBENE: When your objections 3 related to drug diversion that were committed by 4 the distributor defendants who have been sued by 4 are longer than my question, it's probably 5 the City of Cleveland in this case? 5 inappropriate, just as a rule of thumb, but --MR. PIFKO: Aside from your MR. PIFKO: Well, when you ask bad 7 communications with counsel, you can answer. 7 questions, I'm going to have plenty of 8 A. I am not aware. objections to make. O. How about criminal acts related to 9 MR. SALIMBENE: You have all day. 10 improper use of prescription opioids by other 10 O. You can answer. 11 individuals, such as street drug dealers; are 11 A. You'll have to repeat the question. 12 12 you aware of criminal activities like that? MR. SALIMBENE: Can you read it 13 MR. PIFKO: Again, aside from your 13 back? 14 14 communications with counsel, you can answer. (Record read.) 15 A. Repeat your question. 15 O. And "that sort of conduct" was 16 criminal sale of drugs? 16 O. Sure. 17 Are you aware that there are people 17 MR. PIFKO: Again, objection to the 18 breaking the law with respect to prescription 18 extent the question calls for a legal 19 opioids, such as street dealers who are selling conclusion, legal opinions. 20 prescription-only pills to individuals who have 20 MR. SALIMBENE: You have the same 21 no valid legal prescription? 21 objection. 22 MR. PIFKO: Objection to the extent 22 O. You can answer. 23 the question assumes facts not in evidence. 23 MR. PIFKO: Well, no. You added to I -- I know that we've heard 24 the question. 25 anecdotally that there are -- there is some sale 25 You can answer. Page 243 Page 245 1 of prescription pills illegally, and this is A. I do not believe that those 2 individuals are included in this case. 2 based on, again, hearing testimony at meetings 3 and individuals that we've talked about in terms Q. As you sit here today, are you able 4 to link any expense you allege that your 4 of -- came up in a lot of different discussions 5 around breaking and entering and how bathrooms 5 department incurred to the conduct of anybody, 6 and medicine cabinets had been pilfered and 6 any company who distributed lawfully 7 prescription opioid medications? 7 pills had been taken and then sold on the -- on 8 the streets, all just what has come up again in MR. PIFKO: Objection. Foundation. 9 Calls for expert opinion. Calls for a legal 9 the many meetings and many conversations that 10 I've had about this issue. 10 conclusion, legal opinion. You can answer. O. You've had conversations with law 11 Speculation. 12 12 enforcement, true? O. You can answer. 13 I cannot draw that conclusion 13 A. Law enforcement, sure. A. 14 O. You've had conversations where law 14 myself. 15 enforcement tells you that they've been 15 Q. I'm sorry. What was the answer? 16 arresting people for selling drugs, true? 16 A. I cannot -- I cannot make -- I 17 A. Correct. 17 cannot answer that question. Q. Okay. And is it also true that you 18 Q. Why not? 19 19 have not sued anybody that participates in that A. I cannot answer that question. 20 Q. Have you ever attempted to make that 20 sort of conduct in this lawsuit? MR. PIFKO: Objection to the extent 21 determination prior to today? 22 A. Make what determination? 22 the question mischaracterizes the record and 23 What amount or what proportion of 23 calls for a legal conclusion, legal opinion. 24 The lawsuit speaks for itself. 24 the damages that you say -- you claim in this

62 (Pages 242 - 245)

25 lawsuit your department suffered are due to the

You can answer. Oh, and

Page 246 Page 248 1 conduct of the distributor defendants in this 1 been caused by prescription opioids? 2 lawsuit. 2 MR. PIFKO: Objection. Foundation. 3 A. I don't know that I can answer that 3 MR. PIFKO: Hold on. What's your 4 question. 4 question? 5 5 Q. Why not? MR. SALIMBENE: I just asked it. A. I don't have the data in front of 6 A. I don't understand your question. 6 7 me. 7 MR. PIFKO: Well, if you literally 8 MR. SALIMBENE: Let's mark this. I 8 read the transcript here, it's just a statement 9 had them make copies. There's two black and 9 from you. It's not a question. 10 white copies and one color copy that you can 10 MR. SALIMBENE: What is it? 11 look at. There's some color coding. Sorry. I 11 MR. PIFKO: It says, "What amount or 12 didn't mark that. 12 proportion of the damages that you say you claim 13 in this lawsuit your department suffered are due 13 14 to the conduct of distributors in this lawsuit." 14 (Thereupon, Deposition Exhibit 12, 15 Ohio Department of Health 2016 Ohio 15 Q. That's a question. What proportion 16 of the --16 Drug Overdose Data: General 17 17 Findings, was marked for purposes of MR. PIFKO: She just answered that 18 identification.) 18 question. 19 Q. Do you know the answer to that 20 question? 20 Q. What I marked as Exhibit 12 is a 21 2016 Ohio drug overdose data general findings 21 MR. PIFKO: Objection. Prior 22 document, and it has the Ohio Department of 22 objections. Calls for expert opinion, legal 23 Health at the top. Do you see that document? 23 conclusion, foundation. 24 24 A. I do. Q. Do you know the answer to that 25 25 question? Have you ever seen this document Page 247 Page 249 1 A. My department and the city has had 1 before? 2 to respond to this issue and we are way 2 A. I see a lot of documents. 3 3 under-resourced to do that, and we -- we are Q. Do you know one way or the other? 4 A. I can't say. 4 dealing with a crisis in this community of 5 That's okay. 5 addicts and the impact of all of that, and I I believe earlier you testified, 6 can't put a dollar figure on it and I can't be 6 7 when you were being questioned by counsel for 7 that specific to an actual amount. Q. I move to strike everything before 8 the manufacturer defendants, that the number of 9 pills coming into the county -- excuse me, into 9 "I can't put a dollar figure on it." 10 Do you agree that since you took 10 your city had gone up. Do you remember that 11 testimony? 11 over the Department of Public Health in 2016, 12 12 that illegal drugs have been a bigger problem in MR. PIFKO: Objection. 13 Mischaracterizes the record. Assumes facts not 13 Cleveland when you compare them to prescription 14 in evidence. 14 opioids? 15 MR. PIFKO: Hold on a second. 15 Q. Do you remember that testimony? 16 It's been a long day. 16 You can answer the question. You 17 are speaking fast. 17 Well, I'm going to give you a chance 18 to answer it again. Do you believe, as you sit 18 MR. SALIMBENE: I speak fast; that I 19 here right now, that the number of opioid 19 will agree to. Sorry. 20 prescription pills that have been distributed A. I believe that illegal drugs are a 21 into Cleveland has increased since 2011? 21 problem because pathways towards them have 22 A. I know that there has -- based on 22 contributed to this issue in this community. 23 information, has been an increase. I don't know Q. Do you believe that in 2016, 24 for sure the actual date that we have that 24 starting the year you took over, more deaths 25 have been caused by illegal opioids than have 25 information back from --

63 (Pages 246 - 249)

- 1 Q. How about with respect to the State
- 2 of Ohio; has the number of opioid -- excuse me,
- 3 prescription opioids gone up or down since 2011?
- MR. PIFKO: Objection. Foundation. 4
- 5 Calls for speculation.
- Q. Do you know?
- 7 A. It is my recollection that it has
- 8 been on the rise.
- Q. Okay. Can you look at page 4 of the
- 10 document, figure 6, "Opioid solid doses
- 11 dispensed to Ohio patients by year." Do you see
- 12 that chart? In 2011 the Y axis is the number of
- 13 solid doses in millions, and in 2011 it says
- 14 782. Do you see where I read that?
- 15 A. I do.
- Q. And in 2016 it says 631. Do you see 16
- 17 where I read that?
- 18 A. Yes.

1

3

5

11

13

15

22

25

9 her --10

12 know --

- 19 Q. The number goes down, true?
- 20 MR. PIFKO: Objection. The document
- 21 speaks for itself. Calls for foundation.
- Q. Is 631 lower than 782? 22
- 23 A. I am not a pharmacist so I don't

MR. PIFKO: Objection.

O. Is 631 lower than 732?

A. I'm not a pharmacist and I don't

7 You're trying to trick her. She's answered the

8 question about this chart that you're asking

MR. SALIMBENE: No.

16 the record here. Are you just asking her a

18 or are you asking about this document?

20 exactly what I asked her. That's what I'm

Q. Is 631 lower than 782?

14 anything from you. I just don't.

21 asking her, exactly what I said.

MR. PIFKO: If you just want to

17 simple question is the number 631 lower than 732

23 number question. You don't need the document to

MR. SALIMBENE: I don't want to know

MR. PIFKO: I want to be clear about

MR. SALIMBENE: Sir, I'm asking her

MR. PIFKO: He's asking you a simple

MR. PIFKO: You're harassing her.

- 24 know what a solid dose is.
- 25 O. Is 631 lower than 782?

2 Argumentative. Harassing.

4 know what a solid dose is.

- 1 A. Strictly as a number, sure.
 - 2 Q. If you look at the figure 6 on page
 - 3 4 of this document, is it your testimony, as the

Page 252

- 4 top public health official in Cleveland, you are
- 5 unable to interpret the trend of opioid solid
- 6 doses over time dispensed to Ohio patients?
- MR. PIFKO: Objection. 7
- 8 Argumentative.
 - A. As I've said before, I'm not a
- 10 pharmacist so I don't know what a solid dose is
- 11 and I don't know if this is the totality of all
- 12 opiates being dispensed in the state.
- 13 Q. So you don't know how to interpret
- 14 that chart; is that fair to say?
- A. As I said before, I'm not a 15
- 16 pharmacist so I don't know what a solid dose is.
- 17 Q. How about you look at page 2,
- 18 please? And this is -- figure 2 is percentage
- 19 of unintentional drug overdose deaths involving
- 20 selected drugs by year 2010 to 2016. Do you see
- 21 where I am?
- 22 A. Up at the top, yes.
- 23 Q. What has happened to the percentage
- 24 of deaths attributable to prescription opioids
- 25 since 2011?

Page 251

Page 253 1 MR. PIFKO: Objection. The document

- 2 speaks for itself. Foundation. Calls for
- 3 speculation.
- 4 A. I'm sorry. Ask your question again.
- 5 O. Sure. I'll ask it a different way.
- The percentage of overall -- excuse 6
- 7 me, the percentage of all overdose deaths
- 8 attributable to prescription opioids according
- 9 to this chart has declined every year since
- 10 2011, true?
- MR. PIFKO: Objection. Foundation. 11
- 12 Document speaks for itself.
- This is what's purported on this 13 A.
- 14 report.
- 15 Q. Do you have any basis to dispute the
- 16 accuracy of this report?
- 17 MR. PIFKO: Objection. Foundation.
- 18 Speculation. Expert opinion.
- A. There's just one source indicated 20 here, so it is data reported just on -- from one
- 21 source, and based on just this report from this
- 22 one source, while not entirely true, it does
- 23 look -- it does appear that there is a
- 24 reduction, yes.
- 25 MR. PIFKO: We are taking a break

24 answer his question.

Page 254 Page 256 1 right now. 1 O. Who is Ms. Rush? 2 2 A. Jana Rush was an employee of the MR. SALIMBENE: Okay. 3 THE VIDEOGRAPHER: Going off the 3 Cleveland Department of Public Health. Q. And you wanted her to distribute 4 record. The time is 4:37. 5 5 this to her team, true? (Recess had.) THE VIDEOGRAPHER: Back on the A. That is what I say here in this 6 6 7 record. The time is 4:58. 7 e-mail. 8 BY MR. SALIMBENE: 8 Q. Would you ask her to distribute Q. Director Gordon, one more question 9 information to her team that you did not think 10 about Exhibit 12, which I think is in that pile 10 was accurate? 11 right there. 11 A. I would ask her to distribute to her 12 Again, on page 2, if you look at 12 team information that comes to me from the Ohio 13 figure 2, which indicates the percentage of 13 Department of Health. I'm still new at this 14 unintentional drug overdose deaths involved with 14 point so I'm forwarding information. I don't 15 selected drugs by year, if you look at for 2016 15 know if they are receiving it or not. 16 the orange column to the far right, if you 16 Q. Okay. So is it your testimony, 17 compare cocaine to prescription opioids, would 17 then, this information might be accurate, it 18 you agree that the percentage of unintentional 18 might not be accurate, and you're asking her to 19 drug overdose deaths involving cocaine is higher 19 forward it out to her team? 20 than the percentage involving prescription 20 A. It is information directly from the 21 opioids? 21 Ohio Department of Health. It is one of the 22 MR. PIFKO: Objection. The document 22 many listservs that I am on, and I am forwarding 23 speaks for itself. Foundation. 23 it to -- to the staff person and asking her to 24 distribute it to her team. 24 You can answer. 25 Well, again, considering the source 25 Q. Okay. On page 2 of this document Page 255 Page 257 1 and the -- based on the actual -- the time of 1 Bates ending 544, there's a quote in that first 2 death, that is what this specific report does 2 paragraph towards the bottom. It says, "Also, 3 reflect in the orange column. 3 the percentage of prescription opioid-related 4 deaths compared to all unintentional overdose Q. Are you aware of any data that 5 deaths declined in Ohio for the fourth straight 5 suggests what's represented there in figure 2, 6 which I just asked you to describe, is not 6 year and the number of these deaths are leveling 7 off." Do you see where I read that? 7 accurate? 8 A. I don't -- I don't have -- I don't 8 A. I do. 9 know. 9 Q. Do you have any basis to disagree 10 10 with the conclusions stated there? MR. PIFKO: Objection. Foundation. 11 (Thereupon, Deposition Exhibit 13, 12 E-Mail from Merle Gordon to Jana 12 Calls for speculation. A. It's a quote in this e-mail from the 13 13 Rush, dated August 25, 2016, 14 Ohio Department of Health. 14 Beginning Bates Stamp 15 CLEVE_000191543, was marked for 15 Q. That's correct. purposes of identification.) 16 Do you have any basis to dispute or 16 17 17 do you disagree with in any way what is stated 18 Q. Okay. Can you look at what I'm 18 in that quote? 19 handing you that has been marked as Exhibit 13? 19 MR. PIFKO: Objection. Foundation. 20 Calls for speculation. 20 And that is a document -- it's an e-mail from 21 you and a Bates ending CLEVE 191543. At the 21 A. I have no basis one way or the 22 beginning of this document it is an e-mail, 22 other. 23 correct, from you to Jana Rush? Do you see 23 Q. Okay. If you look at the first page 24 where I am? 24 of this document, Bates ending 543, it says --25 there's -- it says, "Mark Hurst, medical 25 A. I do.

Page 258 Page 260 1 director of the Ohio Department of Mental Health 1 and Brent Styer, and the Bates is Cleveland 2 and Addiction Services." Do you know Dr. Hurst 2 188213. Do you see where I am? 3 personally -- professionally? Sorry. 3 A. I do. A. I do not. 4 4 Q. And who is Mr. Gretick? 5 5 Q. No. A. It says on here David Gretick was 6 Well, let me ask you this: Before 6 the program director for the Office of Mental 7 you asked Jana to forward this, do you recall 7 Health and Substance Abuse for the Cleveland 8 whether you would have read this and reviewed it 8 Department of Public Health. 9 first yourself? Q. Do you know how long he has been A. I receive a lot of e-mails. I can't 10 with Cleveland in that role? 11 tell you whether or not I read the entirety of 11 A. I don't know exactly how long he's 12 this e-mail or not. This is August of 2016, 12 been with Cleveland, no. 13 almost two years ago. 13 Q. And he says, "Hello again. As 14 Q. That's fair. 14 Dr. Murthy's discussion to the audience at grand 15 Was it your standard practice to 15 rounds will include appropriate opioid 16 read newsletters from the Ohio Department of 16 prescribing practices, I'm also attaching 17 Health before you asked team members to forward 17 information on the Ohio Automated Rx Reporting 18 System (OARRS)." Do you see where I read that? 19 19 A. Yes. A. Not necessarily. I was forwarding 20 them, again, as part of these listservs and 20 Q. Is Dr. Murthy -- is that the same 21 wanting to make sure my staff had information as 21 Dr. Murthy who was the former Surgeon General; 22 it was coming out of the Ohio Department of 22 do you know? 23 Health. That is regular practice. 23 A. I cannot say for sure. 24 24 MR. SALIMBENE: Can we hop off the Q. Okay. You did testify earlier you 25 record for one second? 25 attended a presentation with that Dr. Murthy, Page 259 Page 261 THE VIDEOGRAPHER: Off the record, 1 true? 1 2 5:04. 2 A. I did go to a meeting when he was 3 (Short recess had.) 3 here in town, yes. Q. But you don't recall if this is the 4 THE VIDEOGRAPHER: Back on the 4 5 record, 5:04. 5 same thing; is that fair? 6 BY MR. SALIMBENE: A. I can't say for sure. It's an old 6 7 7 e-mail. Q. Director Gordon, are you familiar 8 O. Sure. 8 with the OARRS database, O-A-R-R-S? 9 A. I have some familiarity with the Do you recall -- well, let me ask it 10 database, yes. 10 this way: Did you attend the grand rounds that 11 Dr. Murthy gave on that topic? Do you recall Q. And can you describe for me what 12 your familiarity consists of, what your 12 whether you were there? 13 13 understanding of that database is? MR. PIFKO: Objection. Vague. 14 A. I cannot recall if I attended that 14 Oh, sorry. I didn't mark that. 15 15 grand rounds. I attended a pre-meeting with a 16 group of stakeholders and experts and 16 (Thereupon, Deposition Exhibit 14, 17 E-Mail from David Gretick to Merle 17 individuals with the Surgeon General. 18 Gordon, dated July 11, 2016, Q. Had you heard of OARRS prior to the 19 time you received this e-mail from Mr. Gretick? 19 Bates-Stamped CLEVE 000188213, was 20 A. I don't believe so. 20 marked for purposes of 21 21 Q. Okay. Did you review this e-mail identification.) 22 22 from Mr. Gretick when you received it; do you - - - - -23 recall? 23 Q. I've marked as Exhibit 14 an e-mail 24 from David Gretick to you, Director Gordon, 24 A. I do not recall. 25 Do you know whether the city, 25 Kathie Rosen -- Rothenberg, excuse me, Jana Rush

66 (Pages 258 - 261)

- 1 Cleveland's Department of Public Health, was
- 2 utilizing information obtained from the OARRS
- 3 database at the time you took over in your role
- 4 as director in 2016?
- A. I do not recall.
- Q. Does the department currently
- 7 utilize data obtained from the OARRS database
- 8 for any purpose as we sit here today?
- A. I do not know.
- 10 Q. Can you say one way or the other
- 11 whether the Department of Public Health has ever
- 12 used or attempted to leverage or review data
- 13 contained in the OARRS database?
- 14 MR. PIFKO: Objection. Vague.
- 15 A. I do recall that this was a part of
- 16 the application from -- for grant funding from
- 17 the Department of Justice for a program that we
- 18 discussed earlier today, the CORAP application.
- 19 There was an anticipation that if we were
- 20 funded, that we would be able to access this
- 21 information.
- 22 Q. Have you ever made -- let me ask it
- 23 this way: You testified that you're not, in
- 24 fact, using this OARRS information in any way
- 25 today, true?

1

Page 263

- A. I don't know that we are.
- Q. Okay. Have you ever asked anybody 2
- 3 at OARRS to gain access to their information,
- 4 independent of that grant you just mentioned?
- 5 A. Independent of that grant?
- 6 Q. Yes.
- 7 A. I have no recollection.
- Q. You testified earlier that you look
- 9 at a number of databases and I believe you said
- 10 we like to look at all the data available to us.
- 11 Do you recall giving testimony like that?
- 12 A. As the director of the Cleveland
- 13 Department of Public Health, we look at as much
- 14 data as we can to assess and understand the
- 15 issues facing our city.
- 16 Q. Including prescription drug abuse,
- 17 true?
- 18 MR. PIFKO: Objection. Vague.
- 19 A. If we can.
- 20 Q. In that first -- second paragraph,
- 21 after the introduction there's quotes, blocked,
- 22 it's indented, it says, "To address the growing
- 23 misuse and diversion of prescription drugs, the
- 24 State of Ohio Board of Pharmacy created Ohio's
- 25 Prescription Drug Monitoring Program, PDMP in

- Page 264 1 parens, known as the Ohio Automated Rx Reporting
 - 2 System (OARRS). Established in 2006, OARRS
 - 3 collects information on all outpatient
 - 4 prescriptions for controlled substances
 - 5 dispensed by Ohio licensed pharmacies and
 - 6 personally furnished by licensed prescribers in
 - 7 Ohio. Drug wholesalers are also required to
 - 8 submit information on all controlled substances
 - 9 sold to an Ohio licensed pharmacy or a
 - 10 prescriber. The data is reported every 24 hours
 - 11 and is maintained in a secure database." Did I
 - 12 read that correctly?
 - 13 A. You did.
 - 14 Q. And that is information that is
 - 15 available in Ohio, true?
 - 16 MR. PIFKO: Objection. Foundation.
 - 17 Calls for speculation.
 - A. Well, just above it, it says, "The
 - 19 following description is copied verbatim from
 - 20 the OARRS website," so I believe that what you
 - 21 just read is what was copied verbatim from the
 - 22 OARRS website.
 - Q. OARRS is a database available to
 - 24 you, true, as the Department of Health director,
 - 25 that you could review and it would provide you

Page 265 1 information about the amount of prescription

- 2 opioids being used in Ohio; isn't that fair?
- MR. PIFKO: Objection. Assumes
- 4 facts not in evidence. Mischaracterizes the
- 5 record. Calls for speculation. Foundation.
- A. I do not know if this is available
- 7 to us. There are a number of databases that
- 8 require certain licenses of individuals to
- 9 access, and sometimes there's costs associated
- 10 to them and sometimes there are other
- 11 requirements. I don't know where this falls.
- 12 Q. Okay. With respect to OARRS, have 13 you made an inquiry as to where it falls in that
- 14 spectrum you just described with cost and access
- 15 issues? Have you ever reached out to somebody
- 16 and said, hey, how can we get our hands on this
- 17 OARRS data?
- 18 A. I don't have recollection that I did
- 19 that specifically.
- 20 Q. Okay. It says, second paragraph,
- 21 "OARRS is a tool that can be used to address
- 22 prescription drug diversion and abuse." Do you
- 23 see where I read that?
- 24 A. Yes.
- 25 And then it goes on to say, "It

67 (Pages 262 - 265)

- 1 serves multiple functions including: Patient
- 2 care tool, drug epidemic early warning system."
- 3 Do you see where I read that?
- 4 A. Yes.
- 5 Q. It's true that that's what your
- 6 department does as well, that -- what I should
- 7 say is, is it correct that the Public Health
- 8 Department in Ohio is designed in part to
- 9 prevent epidemics?
- 10 A. That is what we strive to do with
- 11 the limited resources we have and the staff
- 12 available to do it.
- Q. Right. And there was this program
- 14 in Ohio that was designed to do the same thing,
- 15 correct, serve as a drug epidemic early warning
- 16 system, true?
- MR. PIFKO: Objection. Foundation.
- 18 Calls for speculation. Assumes facts not in
- 19 evidence.
- You can answer.
- 21 A. This is copied from the OARRS
- 22 website and it is describing apparently what it
- 23 does and the information that it has.
- Q. And it's fair to say that the
- 25 information it has lines up almost verbatim with

Page 268

- 1 website is it is a drug epidemic early warning 2 system, correct?
- MR. PIFKO: Objection. Foundation. 4 Speculation.
- 5 A. If this is copied verbatim as stated
- 6 in this e-mail, then those are the words that 7 are here.
- 8 Q. And one of the stated objectives for
- 9 your Department of Public Health is to prevent
- 10 epidemics, true?
 - A. We also seek to stop all HIV cases.
- 12 We try to work on that as well as --
- 13 Q. I move to strike as non-responsive.
- 14 A. -- STIs and avoid all infant
- 15 mortality cases.
- 16 Q. Are you having trouble understanding
- 17 my questions?
- MR. PIFKO: She is, and she's trying
- 19 to answer your question and you're interrupting
- 20 her, so continue as much as you need to to
- 21 answer his question. I think her point is
- 22 clear. It's clear to me.
- Q. My question was, is it true that one
- 24 of your stated goals, the Department of Public
- 25 Health that is, is to prevent epidemics? Is

Page 267

- 1 one of the goals of your department, which is to
- 2 prevent epidemics, true?
- 3 MR. PIFKO: Objection. Foundation.
- 4 Speculation. Assumes facts not in evidence.
- 5 You can answer.
- 6 A. There are a number of databases that
- 7 are available nationwide and here in Ohio.
- 8 Again, I can't say whether or not we would have
- 9 had access to it either with the credentials
- 10 that we had on staff or -- I don't know if this
- 11 is a service that is -- has a fee associated
- 12 with it. There are a lot of databases that --
- 13 some we have access to and some we do not. 14 MR. SALIMBENE: I move to strike
- 15 that as non-responsive.
- 16 Can you read back my question? I'm 17 asking about this specific database, OARRS.
- 18 (Record read.)
- MR. PIFKO: Even the court reporter
- 20 has trouble understanding your questions.
- 21 MR. SALIMBENE: I think she just
- 22 took down a word incorrectly, but thank you.
- A. I don't understand your question.
- Q. What I'm saying is, one of the
- 25 stated uses of OARRS according to the OARRS

- Page 269
- 1 that a stated goal for the Department of Public
- 2 Health?

- 3 A. It is a goal, yes.
 - Q. Okay. Thank you.
- 5 And you asked to use this OARRS data
- 6 in a recent grant, correct?
- A. It was included in the -- some part
- 8 of it was included in the application to the
- 9 Department of Justice for that CORAP grant, yes.
- 10 Q. Would you have asked to access OARRS
- 11 data if you didn't think the data would be
- 12 useful to you?
- 13 MR. PIFKO: Objection. Speculation.
- 14 Foundation. Assumes facts not in evidence.
- 15 A. I don't understand your question.
- 16 Q. You asked for access --
- 17 A. Please don't point at me.
- 18 Q. I'm not. I'm sorry. This is just
- 19 the way I talk. Let the record reflect I have
- 20 my fingers pinched like I'm holding a pencil.
- MR. PIFKO: You are pointing at her.
- 22 Q. Director Gordon, my question is --
- MR. PIFKO: She's the director of
- 24 the public health department of the city. You
- 25 could give her a little bit more respect.

Page 270 Page 272 1 MR. SALIMBENE: I said to her --A. I don't recall who exactly Cameron 2 MR. PIFKO: No. It's your tone. 2 McNamee is. 3 MR. BOEHM: The tone has been 3 Q. Okay. It says, "They are applying 4 perfectly fine. Nobody was pointing. 4 for category 5, the Prescription Monitoring and 5 MR. PIFKO: He is pointing. How 5 Implementation Program. So this should not 6 many people in this room, if you're going to say 6 conflict. They would be happy to write a letter 7 that -- he is pointing at her. He is pointing. 7 of support but want to know what kind of data we 8 Does anyone else -- you said he's not pointing 8 would need from OARRS. Apparently past grants 9 so I want to be clear here. 9 expected to receive data from OARRS but they 10 MR. NAEEM: Is this an anti-pointing 10 were not notified nor asked to write letters of 11 room? 11 support, and on occasion, were unable to meet 12 MR. PIFKO: No, but it's attacking 12 the expectations of the grant." Do you see 13 the witness and it's inappropriate. 13 where I read that? THE COURT REPORTER: I cannot take 14 A. I do. 15 down everyone talking at the same time. 15 Q. Does that indicate to you that in MR. BOEHM: You guys are playing 16 the past your department wanted to receive data 17 games. Let's keep going. And I pinched my 17 from OARRS but OARRS was never notified or asked 18 finger together. 18 to write letters of support? MR. PIFKO: We're not playing games. 19 MR. PIFKO: Objection. Calls for 20 I don't have an issue with you pointing at me. 20 speculation. Foundation. 21 You can point at me all day long. 21 A. It does not say that it was my 22 Q. Is it true that you requested access 22 department specifically that they had a concern 23 to OARRS data because you thought that data 23 about, because if you read the next sentence, it 24 could be useful to you as the director of public 24 says he just gave this as a general statement, 25 health? 25 not that it pertained to CDPH. CDPH is an Page 271 Page 273 1 acronym for the Cleveland Department of Public MR. PIFKO: Objection. Assumes 1 2 facts not in evidence. 2 Health. 3 Q. Okay, but do you know -- you wrote A. I recall it being part of the 4 this e-mail -- who it was that expected to 4 application for the CORAP grant and for all of 5 our -- for the proposal that was submitted to 5 receive data from OARRS but did not follow up 6 with writing a letter? 6 the Department of Justice. 7 7 A. No, I do not. 8 Q. You don't know. Was it the City of 8 (Thereupon, Deposition Exhibit 15, 9 E-Mail String Beginning Bates Stamp 9 Cleveland in any way? Was it Cuyahoga County? 10 CLEVE 000298635, was marked for 10 Do you know? 11 A. I do not know. 11 purposes of identification.) 12 12 Q. Okay. You wrote this e-mail --Q. I'm marking as Exhibit 15 one of the 13 never mind. 13 14 14 many documents produced to us yesterday, the day Do you agree that some patients 15 benefit from taking prescription opioids? 15 before this deposition, of course, that I did 16 MR. PIFKO: Objection. Asked and 16 not get a chance to review until I landed here 17 answered. Foundation. Calls for expert 17 in Cleveland at about midnight. It's marked as 18 Exhibit 15. This is Cleveland 298635. It is an 18 opinion. Incomplete hypothetical. 19 e-mail from you, Ms. Gordon, to Jana Rush and 19 You can answer. 20 David Gretick, correct? 20 A. For its intended use, I would 21 believe so. 21 A. Yes. 22 Q. Do you agree that the only way a 22 Q. It says in the third line down --23 person can lawfully obtain a prescription opioid 23 or, excuse me, backing up -- it says, "All, 24 is with a valid prescription from a licensed 24 please note I spoke with leadership at OARRS and 25 with Cameron McNamee." Who is Cameron McNamee? 25 physician?

1 MR. PIFKO: Objection. Calls for a

- 2 legal conclusion. Speculation.
- A. I don't know with specificity.
- Q. Do you agree that prescription
- 5 opioids to this day remain approved as safe and 6 effective by the FDA?
- 7 MR. PIFKO: Objection. Foundation.
- 8 A. Sorry. You're going so fast.
- 9 Q. Sorry. Let me read it slower. I
- 10 apologize. You've been here -- it's a long day.
- 11 Do you agree that prescription opioids are
- 12 approved as safe and effective by the FDA even
- 13 to this day?
- MR. PIFKO: Objection. Foundation.
- 15 A. I don't know that statement for a 16 fact.
- 17 Q. Do you agree that the majority of
- 18 people who take a prescription opioid do not
- 19 become addicted?
- 20 MR. PIFKO: Objection. Foundation.
- A. Sorry. You have to repeat the
- 22 question again.
- 23 O. Sure.
- 24 Do you agree that the majority of
- 25 people who take prescription opioids do not
 - Page 275
 - 1 become addicted to opioids?
 - 2 MR. PIFKO: Objection. Foundation.
 - 3 Calls for expert opinion.
 - 4 A. I'm sorry. One more time. Do I
 - 5 know for a fact what?
 - 6 Q. No. No. No. I didn't say for a
 - 7 fact. Do you agree that the majority of people
 - 8 who take prescription opioids do not become
 - 9 addicted to prescription opioids?
- 10 MR. PIFKO: Same objections.
- 11 A. I cannot agree to that. I don't
- 12 know one way or the other.
- 13 Q. Did you ever investigate what
- 14 percentage of prescription opioid users become
- 15 addicted to opioids?
- 16 A. I review a lot of information.
- 17 Again, this is an issue we've been dealing with
- 18 for a number of years and there are a number of
- 19 factors that -- that contribute to it all. That
- 20 particular statement, I don't know that I can
- 21 comment on that one.
- Q. Do you know if you ever conducted
- 23 personally an investigation into what percentage
- 24 of people who use a prescription opioid end up
- 25 becoming addicted to opioids?

- 1 A. I did not conduct my own
- 2 investigation, no.
- 3 Q. Do you agree that the majority of
- 4 prescription opioid users never go on to try an

Page 276

- 5 illegal substance like heroine, fentanyl or
- 6 carfentanil?

9

18

19

- 7 MR. PIFKO: Objection. Foundation.
- 8 Speculation. Assumes facts not in evidence.
 - A. I don't know.
- 10 Q. Do you agree that many residents
- 11 here in Cleveland live with chronic pain?
- 12 A. I don't know.
- Q. Do you agree that many residents
- 14 here in Cleveland suffer from temporary pain,
- 15 for example, postoperative pain when they leave
- 16 the Cleveland Clinic?
- 17 MR. PIFKO: Objection. Foundation.
 - A. I don't -- I don't know.
 - Q. Do you agree that all patients in
- 20 pain deserve to have their pain treated?
- 21 MR. PIFKO: Objection. Incomplete
- 22 hypothetical. Foundation.
- A. It's a very hypothetical question.
 - Q. Well, let me ask you this way: Do
- 25 you believe patients in pain should not be
 - Page 277
- 1 treated for that pain?
 - 2 MR. PIFKO: Objection. Vague. Same
 - 3 objections as to the prior question.
 - 4 You can answer.
 - 5 A. I'm sorry. You have to ask it
 - 6 again.
 - 7 Q. Okay. I'll ask it the way I asked
 - 8 it the first time. Do you agree that all
 - 9 patients who are suffering from pain deserve to
 - 10 have their pain treated?
 - 11 MR. PIFKO: Same objections.
 - 12 A. People who may have health needs and
 - 13 need -- if they have medical conditions or
 - 14 health needs, then they should have access to
 - 15 healthcare and -- they should have access to
 - 16 healthcare.
 - 17 Q. Including patients who are suffering 18 from pain?
 - 19 A. Sure.
 - Q. Do you agree that doctors are in the
 - 21 best position to evaluate whether a medication's
 - 22 benefits outweigh its risks for a particular
 - 23 patient?
 - 24 MR. PIFKO: Objection. Incomplete
 - 25 hypothetical. Foundation.

Page 280 Page 278 A. Doctors who have the certifications 1 best with all of the issues that are -- that are 2 to be able to practice medicine and -- yeah. 2 impacting our community. 3 Sure. Q. So is it fair to say if you fail to 4 4 fulfill your duty as the Department of Public Q. Do you agree that some of the 5 medications distributed by the distributor 5 Health, the health of the citizens of Cleveland 6 defendants who you've sued in this case help 6 could suffer? 7 save lives of residents here in Cleveland? 7 MR. PIFKO: Objection. Vague. 8 MR. PIFKO: Objection. Assumes 8 Overbroad. 9 facts not in evidence. A. I think that there would be a A. I don't know. 10 dramatic impact on the city, yes. 10 Q. Do you agree that there are Q. Do you agree that a patient's 11 12 individuals living with high cholesterol, for 12 insurance company has access to patient-specific 13 example, who would suffer a heart attack if they 13 data? 14 didn't have access to their cholesterol meds? 14 MR. PIFKO: Objection. Calls for MR. PIFKO: Objection. Calls for 15 speculation. Foundation. 15 16 speculation. Incomplete hypothetical. A. If a patient's insurance company has 17 Q. You can answer. 17 access to --18 A. I'm sorry. What was your question? 18 Q. That patient's patient-specific MR. SALIMBENE: Can you read it 19 19 data, yes. 20 back, please? 20 A. What kind of data? 21 (Record read.) 21 Q. Data about what medications they're 22 A. I am not a doctor to be able to 22 using, for example. 23 confirm that statement. Let me back up. You worked for an Q. What are the potential consequences 24 insurance company, true? 25 to residents here in Cleveland if the Department 25 I did. Page 279 Page 281 1 of Public Health fails to fulfill its duties? Q. What was the name of the insurance 1 MR. PIFKO: Objection. Vague. 2 2 company? 3 Overbroad. Incomplete hypothetical. 3 A. Kaiser Permanente of Ohio. A. You're speaking so quickly. I'm Q. Okay. So, for example, did Kaiser 5 trying to understand your question. 5 Permanente -- if one of your members went into a Q. I'll slow it down. I'm sorry. I'll 6 pharmacy, filled a prescription that was 7 slow it down. 7 reimbursed by Kaiser, did Kaiser have a record 8 8 of that transaction? What are the potential consequences 9 to Cleveland residents if the Department of 9 MR. PIFKO: Objection. Foundation. 10 Public Health fails to fulfill its duties? 10 Speculation. MR. PIFKO: Objection. Vague. A. They would have had a record of that 12 Overbroad. Incomplete hypothetical. 12 transaction if it was put on their insurance A. We offer a lot of programs in the 13 card, sure. 14 area of prevention, and prevention is so 14 Q. And that's true for prescription 15 critical to -- to disease intervention and 15 opioid medications, correct? MR. PIFKO: Objection. Incomplete 16 stopping the spread of disease. A lot of our 16 17 work in inspections and licensing are so 17 hypothetical. 18 important to food safety and to the environment 18 A. If it's put on their insurance card, 19 and to communicable diseases, et cetera, and --19 I would assume so, yes. 20 this is incredibly critical work that we do. 20 Q. All right. And is it also true that 21 There's a common phrase in public health, public 21 they would have information about which medical 22 health saved your life today, you just don't 22 doctor was writing the prescription that was 23 filled, assuming it was processed through the 23 know it. And this is part of what we do 24 collectively as a department of about 160 that 24 insurance coverage?

71 (Pages 278 - 281)

MR. PIFKO: Objection. Foundation.

25

25 is really resource strapped and trying to do our

Page 284 Page 282 1 Speculation. 1 today in our seven hours to come back and ask 2 questions about the 150-ish documents that were A. I would assume so, yes. Q. And, also, it would have data about 3 handed to us -- delivered to us last night. Or 4 where it is that patients are filling the 4 600. Whatever. 5 5 prescriptions of course so long as the patients THE VIDEOGRAPHER: Off the record. 6 use their insurance to process that -- excuse 6 The time is 5:33. 7 me, to pay for that prescription? 7 (Recess had.) 8 THE VIDEOGRAPHER: Back on the MR. PIFKO: Foundation. 9 record. The time is 5:46. 9 Speculation. 10 A. Only from my experience at Kaiser, 10 EXAMINATION OF MERLE GORDON 11 because they had their own pharmacies and so 11 BY MR. RUIZ: 12 they would know that from filling the 12 Q. Good afternoon, Director Gordon. 13 A. Good afternoon. 13 prescription specifically. 14 Q. What were the years you were at Q. My name is Anthony Ruiz and I 15 Kaiser? Remind me. 15 represent CVS Indiana, LLC and CVS Rx Services, A. I was community benefit manager at 16 Inc. I'm going to be asking you a couple of 17 Kaiser, so I did not work in the insurance side. 17 questions. 18 I worked there -- I don't remember the dates --18 So, first, I know you talked a 19 little bit earlier about your knowledge of 19 approximately 2000 -- perhaps '09 to 2016. 20 Q. Okay. Did you have a formulary --20 regulation of controlled substances. I wanted 21 excuse me. Not did you. Sorry. 21 to ask you first, have you heard of the 22 Did Kaiser have a formulary for 22 Controlled Substances Act? 23 which medications it would cover and which would 23 A. I have heard of it, yes. 24 24 be excluded throughout the time you were at Q. Do you know what it does? 25 Kaiser? 25 A. I really don't. Page 283 Page 285 MR. PIFKO: Objection. Foundation. Q. Do you know that drugs are placed on 1 1 2 Speculation. 2 schedules? 3 A. That is my general understanding. 3 A. I don't know what that means, no. Q. Had you ever reviewed that 4 Okay. So you don't know how drugs 5 formulary? 5 are classified at the federal level? A. I did not have a purpose to review A. I do not. 6 7 7 that formulary. Okay. Have you ever heard the term Q. Q. Did you ever express to anybody at 8 "ARCOS"? 9 Kaiser that prescription opioids should not be 9 MR. PIFKO: Aside from 10 included in the formulary? 10 communications with counsel, you can answer. A. I would have -- that's not part of A. Aside from communications with 12 my responsibility. I didn't have any part of 12 counsel, no, I have not. 13 that work. 13 Q. It stands for Automated Reports and Q. Fair to say, then, you never made 14 Consolidated Ordering System. Does that change 15 the recommendation to anybody at Kaiser that the 15 your answer at all? 16 company should not include in its formulary 16 A. No, it does not. 17 prescription opioids? 17 Q. Okay. Are you familiar with the 18 A. No recollection that I -- I have no 18 Ohio Board of Pharmacy? 19 recollection. 19 A. I am aware that there is a board of 20 MR. SALIMBENE: Okay. Thank you. I 20 pharmacy in Ohio. 21 think I'm going to -- oh, you know what, 21 Q. Do you interact with them at all? 22 actually, just before I go, I do want to 22 A. I do not. 23 reiterate the objection that was raised earlier 23 MR. RUIZ: I think we're at 16. Is 24 today about the late production of documents, 24 that right?

MR. PIFKO: The exhibits, yes.

25

25 and we're going to leave, I think, some time

	Page 286		Page 288
1	MR. RUIZ: I'm going to mark Exhibit	1	yes.
2	16, 17 and 18.	2	Q. And would you review them?
3		3	A. When I have time to review them, I
4	(Thereupon, Deposition Exhibit 16,	4	do. I've looked through them when they arrived.
5	Cuyahoga County Opiate Task Force	5	Q. Okay. And I think you said earlier
6	Report 2014 Beginning Bates Stamp	6	
7	CUYAH 000018534, was marked for	7	for this job that you currently have as
8	purposes of identification.)	8	director, that you reviewed what I believe you
9		9	said is a 2014 attorney general report; is that
10	(Thereupon, Deposition Exhibit 17,	10	right?
11	Cuyahoga County Opiate Task Force	11	A. There is information that came out
12	Report 2015 Beginning Bates Stamp	12	from the Ohio Attorney General that was came
13	CLEVE_000187871, was marked for	13	out, I believe, in 2014 that part of which I did
14	purposes of identification.)	14	review, along with a number of other pieces of
15		15	information, just to familiarize myself with the
16	(Thereupon, Deposition Exhibit 18,	16	other issues related to the City of Cleveland.
17	Cuyahoga County Opiate Task Force	17	Q. Right.
18	Report 2016 Beginning Bates Stamp	18	So reviewing documents like this is
19	CUYAH_000018265, was marked for		part of how you educate yourself or familiarize
20	purposes of identification.)		yourself with opioid issues in your county, in
21			your city?
22	Q. So I've handed you three documents.	22	A. It's one of many ways.
	The first, which is Exhibit 16, is the 2014	23	Q. Okay. And if you could look back in
	Cuyahoga County Opiate Task Force Report, and		that pile to Exhibit 2, and that is the 2010
25	that is Bates number CUYAH 18534. The second	25	Ohio Prescription Drug Abuse Task Force report.
	P 207		
1	Page 287	1	Page 289
	document is the 2015 version of that report with	1	A. Um-hum. Yes.
2	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third	2	A. Um-hum. Yes.Q. Do you have any memory of reviewing
2 3	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016	2 3	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out?
2 3 4	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265.	2 3 4	A. Um-hum. Yes.Q. Do you have any memory of reviewing that or reading it when it came out?A. I do not.
2 3 4 5	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through	2 3 4 5	 A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you
2 3 4 5 6	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them.	2 3 4 5 6	 A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across?
2 3 4 5 6 7	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay.	2 3 4 5 6 7	 A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming
2 3 4 5 6 7 8	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three	2 3 4 5 6 7 8	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document.
2 3 4 5 6 7 8 9	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports?	2 3 4 5 6 7 8 9	 A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect
2 3 4 5 6 7 8 9 10	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these	2 3 4 5 6 7 8 9 10	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have?
2 3 4 5 6 7 8 9 10	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes.	2 3 4 5 6 7 8 9 10 11	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a
2 3 4 5 6 7 8 9 10 11 12	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that	2 3 4 5 6 7 8 9 10 11 12	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health
2 3 4 5 6 7 8 9 10 11 12 13	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task	2 3 4 5 6 7 8 9 10 11 12 13	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this
2 3 4 5 6 7 8 9 10 11 12 13	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that	2 3 4 5 6 7 8 9 10 11 12 13	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this
2 3 4 5 6 7 8 9 10 11 12 13 14 15	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct? A. I don't know if member is the exact	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes. Q. Okay. And you've worked in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct? A. I don't know if member is the exact term, but yes, they are part of this task force.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes. Q. Okay. And you've worked in the public health field for a decade, longer?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct? A. I don't know if member is the exact term, but yes, they are part of this task force. Q. Okay. And would you have received	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes. Q. Okay. And you've worked in the public health field for a decade, longer? A. Much of my career.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct? A. I don't know if member is the exact term, but yes, they are part of this task force. Q. Okay. And would you have received these reports as part of your activities as	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes. Q. Okay. And you've worked in the public health field for a decade, longer? A. Much of my career. Q. And you said that you are a consumer
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	document is the 2015 version of that report with Bates number CLEVE 187871. And then the third document, which is Exhibit 18, is the 2016 version of that report, which is CUYAH 18265. I'll give you a second to finish looking through them. A. Thank you. Okay. Q. Are you familiar with these three reports? A. I have some familiarity with these reports, yes. Q. And I believe you said earlier that you are a member of the Cuyahoga Opiate Task Force; is that right? A. I am on the distribution of information for this particular task force. Q. And your department is a member; is that correct? A. I don't know if member is the exact term, but yes, they are part of this task force. Q. Okay. And would you have received these reports as part of your activities as director?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Um-hum. Yes. Q. Do you have any memory of reviewing that or reading it when it came out? A. I do not. Q. Is it something that you think you might have come across? A. I have no recollection of coming across this particular document. Q. But is it something that you expect you might have? A. I cannot say for sure. This is a 2010 document, and in my capacity as the health director I don't know that I would have this this information going back this far. Q. Okay. Around the time that this came out in 2010 you would have been working at Kaiser Permanente, right? A. Yes. Q. Okay. And you've worked in the public health field for a decade, longer? A. Much of my career. Q. And you said that you are a consumer of news and like to keep on top of issues that

Page 290

- Q. Now, given that you reviewed -- that
- 2 these Cuyahoga County Task Force reports came
- 3 across your desk and are something that you
- 4 would have reviewed -- is that what you said?
- A. I cannot say that they are all of
- 6 them. I have -- I know that they look familiar
- 7 to me and I know that I have looked through at
- 8 least the 2016 one.
- O. But it's the kind of document that
- 10 you would expect a director of public health to
- 11 have seen and read?
- 12 A. To have seen, yes.
- 13 Q. Okay. Would you have expected the
- 14 director at the time in 2010 to have read the
- 15 2010 report?
- MR. PIFKO: Objection. Calls for 16
- 17 speculation.
- 18 A. I can't speak to that.
- Q. Do you think if you were the 19
- 20 director at the time you would have been aware
- 21 of it?
- 22 MR. PIFKO: Objection. Calls for
- 23 speculation. Incomplete hypothetical.
- A. There are a number of reports that
- 25 come out on a regular basis that I receive, and

1 column, it says, "The Cuyahoga County Opiate

Page 292

Page 293

- 2 Task Force was formed in 2010 to find solutions
- 3 to the increasing number of accidental
- 4 drug-related deaths."
- 5 A. Okay.

6

8

- Q. Did I read that right?
- A. You read what was on the document. 7
 - Q. Does that suggest to you that in
- 9 2010 Cuyahoga knew that opioids were a problem
- 10 in the county?
- MR. PIFKO: Objection. Speculation. 11
- 12 Foundation.
- A. Based --13
- 14 MR. PIFKO: Incomplete hypothetical.
- 15 A. Based on what's written here, trying
- 16 to find solutions to the increasing number of
- 17 accidental drug-related deaths, and that's what
- 18 the task force -- why the task force was formed.
- Q. Right. So the task force was formed
- 20 in 2010?
- 21 A. In 2010.
- 22 Q. To solve a problem related to
- 23 opioids?

1

- 24 MR. PIFKO: Objection. Foundation.
- 25 Speculation.

- 1 I would imagine that my predecessors had
- 2 received as well.
- 3 Q. So is that a yes, that you expect
- 4 that they would have seen it?
- A. I can't speak to that. 5
- 6 Q. Would you expect, if you were the
- 7 director, that you would have seen it?
- 8 MR. PIFKO: Objection. Incomplete
- 9 hypothetical. Speculation.
- 10 A. Honestly, I don't know how it was
- 11 distributed. I don't know what the involvement
- 12 of the director at the time was with whether or
- 13 not a task force was formed or whether or not
- 14 they were on the receiving end of this document
- 15 or would have had knowledge of it.
- Q. Well, let's look at the -- let's 16
- 17 look at the 2016 report. If you could turn
- 18 to -- these don't have page numbers on them, but 18 left-hand corner, there are page numbers. If
- 19 they do have the Bates numbers at the bottom
- 20 right-hand corner.
- 21 A. Okay.
- 22 And it ends in 268. Do you see Q.
- 23 that?
- 24 A. I do.
- 25 And if you look on the left-hand

- A. Well, it says here to find
- 2 solutions, yes.
- 3 Q. And that suggests that they thought
- 4 there was a problem in 2010, right?
- 5 MR. PIFKO: Objection. Speculation.
- 6 Foundation.
- A. Well, they're responding to deaths,
- 8 and yeah, public health is -- part of it is
- 9 working around issues related to why people are
- 10 dying, yes.
- Q. And if you turn to the 2014
- 12 report -- I'm sorry. I mean the 2015 report.
- 13 Apologies.
- A. 2015? 14
- 15 Q. Yes.
- 16 A. Um-hum.
- 17 And if you look on the bottom
- 19 you go to page 4 of that report.
- 20 A. Okay.
- 21 Q. And there it says at the top, first
- 22 paragraph, "Cuyahoga County was recognized in
- 23 2010 as one of the top five areas in Ohio being
- 24 impacted by prescription drug abuse." Do you
- 25 see that?

Page 294 Page 296 1 A. I do. 1 MR. PIFKO: Objection. Foundation. Q. And does that suggest to you that 2 2 Speculation. 3 they knew this was a problem in 2010? A. Well, in an e-mail that I received 4 MR. PIFKO: Objection. Speculation. 4 back in 2016, this individual did put this in 5 Foundation. 5 this e-mail, so I suspect we could draw that A. It would suggest to me that it 6 conclusion. 7 was -- they were one of the top five areas in 7 Q. Do you have any reason to doubt what 8 Ohio being impacted by prescription drug abuse, 8 he wrote to you? 9 just as it states here in the document that I MR. PIFKO: Objection. Foundation. 10 had nothing to do with writing. 10 Speculation. Q. And would you expect them to know 11 A. I do not. 12 that they -- that they were one of the top five 12 Q. Is it fair to say that Cleveland --13 areas in Ohio being impacted? 13 the City of Cleveland knew there was an opioid 14 MR. PIFKO: Objection. Speculation. 14 problem in their city since at least 2010? 15 Foundation. 15 MR. PIFKO: Objection. Vague. A. I can only assume that the reason 16 Overbroad. Speculation. Foundation. 17 why they would write it in a publication that 17 A. Repeat your question, please. 18 was widely distributed or was distributed -- I Q. Is it fair to say that the City of 19 can't say if it was widely distributed -- that 19 Cleveland knew that there was an opioid problem 20 they would put an assertion like this in based 20 in the city in -- at least as early as 2010? 21 on something. 21 MR. PIFKO: Same objections. 22 Q. And the Cleveland Department of 22 A. I don't know when they first --23 Public Health was a part of this task force 23 first recognized it. What is stated in here is 24 since at least 2010, right? 24 that David Gretick, who was the program director 25 A. I do not know that. I do not know 25 for the Office of Mental Health and Substance Page 295 Page 297 1 when the Cleveland Department of Public Health 1 Abuse, stated that he was one of the founding 2 was part of -- invited to be part of the 2 members of the task force. 3 Cuyahoga County Opiate Task Force. 3 Q. Well, let's break it down a little 4 4 bit. 5 (Thereupon, Deposition Exhibit 19, 5 So we know in 2010 Ohio issued a 6 E-Mail String Beginning Bates Stamp 6 report on opioid abuse, prescription abuse, 7 CLEVE_000187408, was marked for 7 prescription drug abuse in the State of Ohio; is 8 purposes of identification.) 8 that right? 9 9 MR. PIFKO: Objection. Foundation. 10 Q. Well, let's look at what I've marked 10 A. Are you referring to this report 11 as Exhibit 19, which is an e-mail from David 11 here? 12 Gretick to you, and it is CLEVE 187408. 12 O. Yes. 13 A. Okay. MR. BOEHM: Can you just say what 13 14 Q. And if you look at the second e-mail 14 you're referring to on the record? 15 in the chain, which is also from David Gretick 15 MR. PIFKO: She's looking at Exhibit 16 to you, in the second paragraph, the second 16 2. 17 sentence, he writes, "My current affiliations 17 A. Again, your question? 18 and activities related to the opiate issue 18 Q. So we know that the State of Ohio 19 include the Cuyahoga County Opiate Task Force. 19 issued that report in 2010, right? 20 (I represented CDPH as one of the founding 20 MR. PIFKO: Objection. Foundation. 21 members when it was known as 'Prescription for 21 A. That's the date on the report, yes. 22 Prevention' in 2010, and continue to attend 22 Q. And we looked at a document, one of

75 (Pages 294 - 297)

25 well, right?

23 the Ohio task reports, that said that the

24 Cuyahoga County Task Force was set up in 2010 as

23 bi-monthly meetings)." Does that mean that the

24 Department of Public Health was a part of the

25 task force since at least 2010?

Page 298

- 1 A. Right. You're asking me a lot of
- 2 questions about dates that precede my time at
- 3 the Cleveland Department of Public Health and I
- 4 can't speak to how any decisions were made or
- 5 what our engagement was prior to that.
- Q. Well, let's just back up. I'm not
- 7 asking you that. I'm just asking, in 2010 Ohio
- 8 issued the final report that is Exhibit 2,
- 9 right?
- 10 That is the date on the document,
- 11 yes.
- 12 Q. And then we also looked at one of
- 13 the Cuyahoga County Task Force reports that said
- 14 that the Cuyahoga County Task Force was set up
- 15 in 2010?
- 16 A. Right.
- 17 Q. And we also just looked at an e-mail
- 18 where someone who works for the Department of
- 19 Public Health said that the department has been
- 20 part of the Cuyahoga County Task Force since
- 21 2010?
- 22 A. Right.
- Q. Is it fair to say that the City of
- 24 Cleveland by 2010 knew there was an opioid
- 25 problem in the city?

Page 300

- 1 that hydrocodone combination products have a 2 lower risk for abuse than other -- than schedule
- 3 II drugs?
- 4 A. I am not aware of a memo of that 5 nature, no.
- 6 Q. And you don't know anything about 7 the analysis they did of abuse data; is that
- 8 right?
- 9 A. I'm not aware of that, no.
- 10 And you're not aware that they found
- 11 that hydrocodone products -- hydrocodone 12 combination products are abused at rates more
- 13 similar to other schedule III drugs rather than
- 14 schedule II drugs?
- 15 A. This is an area that I am not
- 16 familiar so I cannot answer that question. I
- 17 don't know.
- Q. And so you don't know how many
- 19 people in the City of Cleveland overdose from
- 20 hydrocodone combination products?
- 21 A. I don't know, no.
- 22 You haven't done anything to trace
- 23 the deaths in your city to hydrocodone
- 24 combination products?
- 25 No. I have not.

Page 301

- Page 299 MR. PIFKO: Objection. Foundation.
- 2 Speculation.
- 3 A. By 2010?
- 4 Q. At least.
- 5 A. By 2010, yeah, you could make that 6 assumption.
- 7 Q. Okay. Now I'm going to transition 8 to something different.
- Do you know what a hydrocodone
- 10 combination product is?
 - A. I do not.
- 12 Q. Have you ever heard the term?
- A. I can't say that I have or have not.
- 14 I've heard a lot of terms pertaining to this
- 15 issue. That specifically I can't speak to.
- Q. So you can't name any examples of a
- 17 hydrocodone combination product?
- 18 A. I'm not a pharmacist.
- 19 Q. You don't know how they are
- 20 scheduled by the DEA?
- 21 A. I do not.
- 22 Q. So I'm guessing that you don't know
- 23 that in 2008 the U.S. Department of Health and
- 24 Human Services and the Food and Drug
- 25 Administration issued a memo where they found 25 distributed by Wal-Mart?

- Q. To trace opioid addiction to
- 2 hydrocodone combination products?
- 3 A. Not that I'm aware of, to anything
- 4 specific like that, no.
- Q. Okay. Part of what this lawsuit is 5
- 6 about is to -- the City of Cleveland is trying
- 7 to collect -- is alleging damages based on the
- 8 cost to the city from the opioid -- from opioid
- 9 use in the city; is that correct?
- MR. PIFKO: Objection. Calls for a 10
- 11 legal opinion, legal conclusion.
- 12 Aside from conversations with
- 13 counsel, you can answer.
- A. That's basically what I've come to 14
- 15 understand, yes.
- 16 Q. Okay. Can you connect any costs
- 17 from opioid use in your city to any drug
- 18 distributed by a CVS company?
- MR. PIFKO: Objection. Foundation.
- 20 Objection to the extent the question calls for
- 21 an expert opinion.
 - You can answer.
- 23 A. That's not in my purview.
- 24 Q. Okay. Can you do that for any drug

22

	Page 302		Page 304
1	MR. PIFKO: Same objections.	1	A. I have no knowledge of that.
2	A. That's not in my purview.	2	Q. Have you ever reached out to
3	Q. Can you do that for any drug		Rite-Aid?
4		4	A. I did not.
5	MR. PIFKO: Same objections.	5	Q. To Walgreens?
6	A. It's not in my purview.	6	A. I did not.
7	Q. Can you do that for any drug	7	Q. To Wal-Mart?
	distributed by Rite-Aid?	8	A. I did not.
9	MR. PIFKO: Same objections.	9	Q. Do you know if your department has
10	A. It's not in my purview.	-	ever done that?
11	Q. Can you identify a single medication	11	A. I do not have knowledge of that
	that was inappropriately prescribed by a doctor?		specifically, no.
13	MR. PIFKO: Objection. Foundation.	13	Q. Why not?
14	A. I'm sorry. I don't understand your	14	MR. PIFKO: Objection.
	question.	15	A. I don't understand your question.
16	Q. Can you identify any medication, any	16	Q. Well, CVS and Rite-Aid and
1	instance in which a medication was prescribed by		Walgreens I'll just leave it to CVS. There
	a doctor that was done inappropriately?		are a lot of CVS pharmacies in the City of
19	MR. PIFKO: Objection. Foundation.		Cleveland, right?
20	A. I don't know of one instance	20	MR. PIFKO: Objection. Foundation.
	specifically, no.		Vague.
22		22	A. There are some to my knowledge.
1	in which a pharmacy dispensed an opioid	23	Q. Okay. Why wouldn't you if you
1	inappropriately?		have a problem and you believe that that problem
25	MR. PIFKO: Objection. Foundation.	25	is related to prescription drugs, and you say
	Page 303		Page 305
1	A. I do not know.		that you don't have the resources to deal with
2	A. I do not know.Q. I want to talk about what the	2	that you don't have the resources to deal with the problem, why wouldn't you go to these
2 3	A. I do not know. Q. I want to talk about what the Department of Public Health has done to	3	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who
2 3 4	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in	2 3 4	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription
2 3 4 5	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city.	2 3 4 5	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting
2 3 4 5 6	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done	2 3 4 5 6	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city?
2 3 4 5 6 7	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot	2 3 4 5 6 7	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound.
2 3 4 5 6 7 8	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms	2 3 4 5 6 7 8	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence.
2 3 4 5 6 7 8 9	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with	2 3 4 5 6 7 8 9	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood.
2 3 4 5 6 7 8 9 10	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint.	2 3 4 5 6 7 8 9 10	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and
2 3 4 5 6 7 8 9 10 11	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know	2 3 4 5 6 7 8 9 10 11	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and
2 3 4 5 6 7 8 9 10 11 12	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything,	2 3 4 5 6 7 8 9 10 11	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're
2 3 4 5 6 7 8 9 10 11 12 13	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem	2 3 4 5 6 7 8 9 10 11 12 13	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these
2 3 4 5 6 7 8 9 10 11 12 13 14	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city?	2 3 4 5 6 7 8 9 10 11 12 13 14	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to be able to bring these programs to the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these corporations and ask, Hey, look, we're really
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to be able to bring these programs to the community.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these corporations and ask, Hey, look, we're really strapped for resources here and we could really
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to be able to bring these programs to the community. Q. Did you ever reach out to CVS for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these corporations and ask, Hey, look, we're really strapped for resources here and we could really use your help in making sure that this opioid
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to be able to bring these programs to the community. Q. Did you ever reach out to CVS for help?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these corporations and ask, Hey, look, we're really strapped for resources here and we could really use your help in making sure that this opioid problem doesn't get worse, that it gets better.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I do not know. Q. I want to talk about what the Department of Public Health has done to investigate the cause of the opioid problem in your city. Can you tell me what they've done so I know that there we've talked a lot already about what the department does in terms of education in schools, what they do with Project DAWN and treatment and with CenterPoint. I'm not talking about that. All I want to know is, what has the department done, if anything, to investigate the causes of the opioid problem in your city? A. You know, I really wish I had the resources and the staffing available to do that kind of research and to provide that kind of data so we can really target interventions and programs and apply for additional resources to be able to bring these programs to the community. Q. Did you ever reach out to CVS for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that you don't have the resources to deal with the problem, why wouldn't you go to these corporations who are in your neighborhood, who are involved with dispensing drugs, prescription drugs, and ask for their help in fighting whatever opioid problem there is in the city? MR. PIFKO: Objection. Compound. Assumes facts not in evidence. A. The stores are in the neighborhood. The corporation if I had the resources and the staffing available to to do that, and we're battling this on the front line. We're battling addiction. We're battling all these other public health issues on the front line. I often don't have the luxury of time to to do that kind of thing specifically. We're dealing real time with real issues. Q. And so you couldn't pick up the phone and try to place a call to one of these corporations and ask, Hey, look, we're really strapped for resources here and we could really use your help in making sure that this opioid

77 (Pages 302 - 305)

Page 306
A. I didn't realize there was a

- 2 telephone number to call for that kind of --
- 3 that kind of -- those kinds of resources.

1

- 4 Again, we are -- we are trying our best to
- 5 address all the public health issues in this
- 6 city and have staff trying to develop ways that
- 7 we can with the resources we have to battle
- 8 these -- these issues. These are huge issues in
- 9 our community. Trying to find resources to
- 10 address them is -- it's a huge part of our work.
- 11 Q. Okay. Well, let's look at the 2014
- 12 Cuyahoga Task Force report again, which is Bates
- 13 number CUYAH 18534. And that's Exhibit 16.
- If you go to page 4, at about the
- 15 middle of the page, the last paragraph before
- 16 the next section, it says, "We have also
- 17 partnered with Discount Drug Mart and Marc's to
- 18 provide outreach to their pharmacy customers."
- 19 So the task force that your department is a part
- 20 of has partnered with some pharmacies, right?
- 21 MR. PIFKO: Objection. Foundation.
- A. Well, if you read the top of this,
- 23 it's CCBH. It's the Cuyahoga County Board of
- 24 Health had partnered with several members of the
- 25 task force to fulfill the goals of this grant.
- Page 307
- 1 I can't say for sure that the Cleveland
- 2 Department of Public Health was affiliated with
- 3 this particular issue. It doesn't state so in
- 4 the document.
- 5 Q. So -- okay. But you could have
- 6 called someone at -- and I'm sorry. What does
- 7 that stand for, the Cuyahoga County Board of
- 8 Health?
- 9 A. Correct.
- 10 Q. You could have called someone at the
- 11 Cuyahoga County Board of Health and asked, Hey,
- 12 you guys have partnered with these pharmacies,
- 13 we think that's a really great idea, could you
- 14 tell me how you did that?
- 15 MR. PIFKO: Objection. Speculation.
- 16 Foundation.
- 17 A. I suppose I could have found one
- 18 sentence in a report that was dated prior to my
- 19 joining the Cleveland Department of Public
- 20 Health, but -- I'm sorry. You have to rephrase
- 21 your question or state your question again,
- 22 please.
- 23 O. Sure.
- You could have called someone at the
- 25 Cuyahoga County Board of Health and said, Look,

Page 308

- 1 this is really interesting that you guys are 2 partnering with pharmacies to help provide
- 3 outreach, how can we do something like that?
- 4 MR. PIFKO: Objection. Foundation.
 - A. I suppose we could have. I just
- 6 know that I have staff who are -- limited staff
- 7 at that, who are out there working on this
- 8 issue. Any one particular method of
- 9 intervention or programs specific to addressing
- 10 this mammoth issue -- I suppose we could have
- 11 done that.

5

- 12 Q. And, in fact, that would maybe have
- 13 helped your ability to combat the problem
- 14 because it would -- you would have another
- 15 partner helping you in the city, right?
- MR. PIFKO: Objection. Speculation.
- 17 Assumes facts not in evidence. Incomplete
- 18 hypothetical.
- 19 A. With the number of people who have
- 20 died, the number of non-fatal overdoses that
- 21 were occurring in the city, just the enormity of
- 22 the issue, the amount of resources necessary to
- 23 combat this issue -- I'm not entirely sure --
- 24 connecting with two local organizations perhaps
- 25 would have been a drop in the bucket.
- 1 Q. So you don't think that this
 - 2 partnership is useful?
 - 3 A. I did not say that.
 - 4 Q. Well, you think it's a drop in the
 - 5 bucket?
 - 6 A. I did not -- I used those terms. I
 - 7 think you're mischaracterizing what I'm saying
 - 8 here, but this is one -- one intervention in a
 - 9 document that, again, precedes me, and I cannot
 - 10 say for sure that, again, the Cleveland
 - 11 Department of Public Health partnered
 - 12 specifically on -- on this particular
 - 13 intervention. This document doesn't state it
 - 14 and I do not have that knowledge.
 - 15 Q. I want to ask you about -- earlier
 - 16 today you said that pill mills may have
 - 17 contributed to the opioid problem in your city;
 - 18 is that right?
 - MR. PIFKO: Objection to the extent 20 the question mischaracterizes the record.
 - Q. Well, let me just ask it again, if 22 that's okay.
 - Do you believe that pill mills may
 - 24 have contributed to the opioid problem in your

25 city?

Page 310

1

MR. PIFKO: Objection. Foundation.

- 2 Objection to the extent the question calls for 3 expert opinion.
- 4 You can answer.
- 5 A. I don't have that expert opinion. I
- 6 don't -- it's been a long day, so how I answered
- 7 one question in this long day -- a lot of
- 8 contributing factors to -- to this issue.
- 9 Q. Okay. Do you know what diversion of
- 10 drugs is? Do you know what that means, to
- 11 divert drugs?
- 12 A. I -- I don't know that I do.
- 13 Q. Okay. Do you know what doctor
- 14 shopping is?
- 15 A. I don't know if that's a technical
- 16 term. I don't -- I don't have familiarity with
- 17 that.
- 18 Q. Have you ever heard of an internet 19 pharmacy?
- A. An internet pharmacy?
- 21 Q. Of internet pharmacies generally.
- A. Very, very, very generally.
- Q. Okay. Do you think they had any
- 24 impact on the opioid issue in your city?
- 25 MR. PIFKO: Objection. Calls for

- Page 312
- MR. PIFKO: Same objection.
- 2 Speculation. Expert opinion. Legal conclusion.3 Foundation.
- 4 A. Again, it's part of the narrative of
- 5 the addiction crisis that is happening in this 6 community.
- 7 Q. Okay. What about counterfeit drugs; 8 is that part of the problem?
- 9 MR. PIFKO: Objection. Foundation.
- 10 A. I don't know what the legal
- 11 description of counterfeit drug is.12 Q. Okay. What about patients faking
- 13 injuries to get drugs; is that part of the
- 14 problem?
- MR. PIFKO: Objection to the extent the question assumes facts not in evidence.
- 17 Speculation. Foundation.
- 18 A. I don't have any direct knowledge on
- 19 that.
- Q. What about illegal drugs?
- 21 MR. PIFKO: Same objections.
- A. Illegal drugs, broadly. We have a
- 23 lot of data here that indicates how people have
- 24 in that -- the pipeline, and the issue of them
- 25 becoming addicted to painkillers and opiates,

- 1 speculation. Foundation. Expert opinion.
- 2 Legal conclusion.
- 3 A. I do not know.
- 4 Q. Okay. I think earlier you said that
- 5 when you were on the city council, you would
- 6 hear stories of people breaking into homes
- 7 looking for pills; is that right?
- 8 A. Yes. Yeah. We've heard lots of
- 9 stories from people, yes.
- 10 Q. Is theft of prescription drugs a
- 11 contributing factor to the opioid problem?
- 12 MR. PIFKO: Objection. Calls for
- 13 expert opinion. Legal conclusion. Speculation.
- 14 Foundation.
- You can answer.
- 16 A. I think hearing firsthand stories
- 17 from individuals and how desperate people became
- 18 because of their addiction by resorting to
- 19 breaking into people's homes and medicine
- 20 cabinets to try to find painkillers and other --
- 21 other opiates and other drugs is part of the
- 22 narrative of how significant and pervasive this
- 23 issue is in our community.
- Q. My question was, do you think it
- 25 contributed to the opioid problem in your city?

- Page 313 1 that they had to resort to illegal drugs to get
- 2 their fix and, unfortunately, lead to ODs, both
- 3 fatal and non-fatal, and the addiction crisis
- 4 we're in.
- 5 Q. Now I want to ask you -- I'm not
- 6 going to ask you about anything -- specifically
- 7 to read anything in the Cuyahoga Task Force
- 8 reports that we've looked at already, but I just
- 9 want to ask -- so we looked at an Ohio report in
- 10 2010; is that right? Exhibit 2 is a 2010
- 11 report?
- 12 A. Correct.
- 13 Q. And the last one that we looked at
- 14 is a 2016 Cuyahoga Task Force report; is that
- 15 right?
- 16 A. It's one of the exhibits you handed
- 17 me.
- 18 Q. It's the one right there on top,
- 19 Exhibit 18.
- A. Um-hum.
- Q. So for at least six years the County
- 22 of Cuyahoga and the City of Cleveland, as part
- 23 of that task force, has been studying the opioid
- 24 problem in Ohio, in Cuyahoga County, in the City
- 25 of Cleveland?

Page 314 Page 316 1 MR. PIFKO: Objection. Foundation. 1 compliance standards." 2 A. At least, yes. 2 MR. PIFKO: On my version there's Q. Okay. Would you be surprised to 3 3 actually blank of 11 pages. 4 know that none of those reports identify the MR. RUIZ: You're right. It's 8 of 5 failure to detect suspicious orders as a cause 5 11. Thank you. 6 of the opioid problem? 6 Q. So, first, this article came out 7 MR. PIFKO: Objection. Speculation. 7 around the time that you started as director, is 8 Foundation. Argumentative. 8 that right, in June 2016? 9 9 A. Am I surprised? Not necessarily. A. Yes. It's dated -- yeah, June of 10 10 2016. Yes. Q. Okay. MR. PIFKO: Can we take a break so Q. And if you -- if you actually look 11 12 at the bottom of page 7, going onto page 8, it 12 we can figure out this air conditioning issue? 13 MR. BOEHM: Just before we do that, 13 quotes you as saying that you hope to, quote, 14 I think the air conditioning issue, my sense is 14 reestablish a high level of service credibility 15 and integrity back to the, bracket, health 15 was largely because the windows were not 16 covered. 16 department, closed bracket, and to, quote, 17 MR. RUIZ: Can we go off the record? 17 institute rigorous compliance standards, closed 18 THE VIDEOGRAPHER: Off the record 18 quote, in a department that has, quote, 19 19 struggled to be more preventive, proactive and (Recess had.) 20 THE VIDEOGRAPHER: Back on the 20 prospective. Did I read that right? 21 record, 6:37. 21 A. You read what is stated here in this 22 BY MR. RUIZ: 22 document, yes. 23 Q. Do you have any reason to disagree Q. Director Gordon, I want to show you 24 a -- an article from the Plain Dealer. It does 24 with that quote that you gave in 2016? 25 A. I don't recall what I said exactly 25 not have any Bates stamps, but it is -- was Page 315 Page 317 1 posted on June 15th, 2016. The title is 1 at my swearing in on that day, but it sounds 2 about right. 2 "Cleveland's New Health Director, Merle Gordon, Q. And if you look on page 3, I think 3 Faces a Daunting Task," and it's Exhibit 19. 4 you mentioned earlier today that prior to you 4 MR. PIFKO: I think it should be 20. 5 becoming the director, that position had been 5 MR. RUIZ: It's 20. I'm sorry. 6 vacant for about a year; is that right? 6 That's Exhibit 20. 7 7 A. I believe it was about a year, yeah. 8 8 Q. Okay. And then if you see right (Thereupon, Deposition Exhibit 20, 9 there, about a third of the way down in the 9 Article Entitled "Cleveland's New 10 article, it says, "Gordon's two predecessors had 10 Health Director, Merle Gordon, Faces 11 relatively short tenures and little to no public 11 a Daunting Task," was marked for 12 purposes of identification.) 12 health or medical training." Is that your 13 impression or understanding of what the 13 14 14 situation was like before you joined? A. I don't recall reading it when it 15 came out, but I knew it came out, so I'll read 15 A. I know that the previous director 16 had a short tenure. At this precise moment I 16 it now. 17 Q. I've only got two or three questions 17 don't remember who preceded her, but it states 18 about it. 18 here that my immediate predecessor lasted only 19 18 months in the position here in this document. 19 A. Okay. 20 Q. Okay. You can put that document to 20 Okay. 21 Q. If you could turn -- these aren't 21 the side. I just want to ask you -- I want to 22 numbered, but if you could turn to what's page 22 go back to when we were talking about damages 23 and the costs to the city, and when I asked if 23 7. It's the third to last page. 24 A. What's at the top? 24 you could trace any of the costs to, for Q. At the top it says, "Rigorous 25 instance, CVS, you said that's not in my 25

80 (Pages 314 - 317)

Page 318	Page 320
1 purview. What do you mean by that?	1
2 A. It's not in my purview. I don't	2 Whereupon, counsel was requested to give instruction
3 I don't I don't know that it does or doesn't.	3 regarding the witness' review of the transcript
4 It's not something that I know.	4 pursuant to the Civil Rules.
5 Q. Okay. And it's not something you've	5
6 tried to figure out?	6 SIGNATURE:
7 A. No.	7 Transcript review was requested pursuant to the
8 MR. RUIZ: Then I would like to just	8 applicable Rules of Civil Procedure.
9 join the other questioners earlier today who	9
10 said that we object to the late production of	10 TRANSCRIPT DELIVERY:
11 documents, which I did not receive until after I	11 Counsel was requested to give instruction regarding
12 got off the plane yesterday, and I'd like to	12 delivery date of transcript.
13 reserve the opportunity to recall you. But	13
14 other than that, I am I have no further	14
15 questions.	15
MR. PIFKO: Does anyone before we	16
17 go off the record, does anyone else have	17
18 questions?	18
19 All right. We're going to go off	19
20 the record. I don't think we have any	20
21 questions, but I just want to talk to my	21
22 colleagues real quick.	22
THE VIDEOGRAPHER: Off the record	23
24 6:45.	24
25 (Recess had.)	25
Page 319	Page 321
1 THE VIDEOGRAPHER: Back on the	1 REPORTER'S CERTIFICATE
2 record. The time is 6:49.	2 The State of Ohio,)
3 MR. PIFKO: We don't have any	3) SS:
4 questions for the reasons we stated at the	4 County of Cuyahoga.)
5 beginning of the record. Among other things, we	5
6 believe there's no further basis to recall the	6 I, Renee L. Pellegrino, a Notary Public
7 witness. So that concludes the deposition. And	7 within and for the State of Ohio, duly commissioned
8 we reserve the right to review and sign the	8 and qualified, do hereby certify that the within
9 transcript.	9 named witness, MERLE GORDON, was by me first duly
10 THE VIDEOGRAPHER: We're off the	10 sworn to testify the truth, the whole truth and
11 record. The time is 6:50.	11 nothing but the truth in the cause aforesaid; that
12 (Denocities annolated at (.50 a.m.)	12 the testimony then given by the above referenced
13 (Deposition concluded at 6:50 p.m.)	13 witness was by me reduced to stenotypy in the
14	14 presence of said witness; afterwards transcribed,
15	15 and that the foregoing is a true and correct
16	16 transcription of the testimony so given by the above
17	17 referenced witness.
10	10 T1 C d d d d 1 1 1
18	18 I do further certify that this deposition
19	19 was taken at the time and place in the foregoing
19 20	19 was taken at the time and place in the foregoing20 caption specified and was completed without
19 20 21	19 was taken at the time and place in the foregoing20 caption specified and was completed without21 adjournment.
19 20 21 22	 19 was taken at the time and place in the foregoing 20 caption specified and was completed without 21 adjournment. 22
19 20 21 22 23	 19 was taken at the time and place in the foregoing 20 caption specified and was completed without 21 adjournment. 22 23
19 20 21 22	 19 was taken at the time and place in the foregoing 20 caption specified and was completed without 21 adjournment. 22

81 (Pages 318 - 321)

P 222		D 224
Page 322 I do further certify that I am not a	1 DEPOSITION REVIEW	Page 324
2 relative, counsel or attorney for either party, or	CERTIFICATION OF WITNESS 2	
3 otherwise interested in the event of this action.	ASSIGNMENT REFERENCE NO: 2959486	
4 IN WITNESS WHEREOF, I have hereunto set my	3 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018	
•	4 WITNESS' NAME: Merle Gordon	
5 hand and affixed my seal of office at Cleveland,	5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of	
6 Ohio, on this 24th day of July, 2018.	6 my testimony or it has been read to me.	
7	7 I have made no changes to the testimony as transcribed by the court reporter.	
8	8	
9	9 Date Merle Gordon	
10	10 Sworn to and subscribed before me, a Notary Public in and for the State and County,	
11 line L. Pelligria	11 the referenced witness did personally appear	
12 Renee L. Pellegrino, Notary Public	and acknowledge that: 12	
13 within and for the State of Ohio	They have read the transcript;	
14	13 They signed the foregoing Sworn Statement; and	
15 My commission expires October 12, 2020.	14 Their execution of this Statement is of	
16	their free act and deed.	
17	I have affixed my name and official seal	
18	16 this day of, 20	
19	17	
20	Notary Public	
21	Commission Expiration Date	
22	20	
23	21 22	
24	23	
25	24 25	
Page 323		Page 325
		1 450 323
1 Veritext Legal Solutions	1 DEPOSITION REVIEW	1 age 323
1 Veritext Legal Solutions 1100 Superior Ave 2 Suite 1820	1 DEPOSITION REVIEW CERTIFICATION OF WITNESS 2	1 age 323
1100 Superior Ave 2 Suite 1820 Cleveland, Ohio 44114	CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 2959486	1 age 323
1100 Superior Ave 2 Suite 1820	CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 2959486 3 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018	Tage 323
1100 Superior Ave 2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018	CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 2959486 3 CASE NAME: In Re: National Prescription Opiate Litigation	Tage 323
1100 Superior Ave 2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4	CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of	rage 323
1100 Superior Ave 2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6	CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil	1 age 323
1100 Superior Ave 2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq.	CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as	1 age 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486	CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 2959486 3 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 4 WITNESS' NAME: Merle Gordon 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me. 7 I have listed my changes on the attached Errata Sheet, listing page and line numbers as 8 well as the reason(s) for the change(s). 9 I request that these changes be entered	1 age 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 Phone: 216-523-1313 July 24, 2018 To: Mark Pifko, Esq. Case Name: In Re: National Prescription Opiate Litigation v. Veritext Reference Number: 2959486 Witness: Merle Gordon Deposition Date: 7/19/2018	CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s).	rage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 Phone: 216-523-1313 July 24, 2018 To: Mark Pifko, Esq. Case Name: In Re: National Prescription Opiate Litigation v. Veritext Reference Number: 2959486 Witness: Merle Gordon Deposition Date: 7/19/2018	CERTIFICATION OF WITNESS ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony.	rage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony.	rage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness	CERTIFICATION OF WITNESS 2 ASSIGNMENT REFERENCE NO: 2959486 3 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 4 WITNESS' NAME: Merle Gordon 5 In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. 7 I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). 9 I request that these changes be entered as part of the record of my testimony. 10 I have executed the Errata Sheet, as well 11 as this Certificate, and request and authorize that both be appended to the transcript of my 12 testimony and be incorporated therein.	rage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein.	rage 323
2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein.	rage 323
2 Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. Inave executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. The Merle Gordon Merle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County,	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. The Merle Gordon Merle Gordon Notary Public in and for the State and County, the referenced witness did personally appear	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. The Merle Gordon Werle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript;	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. They have Island Before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections in the appended Errata Sheet;	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown 17 above, or email to production-midwest@veritext.com. 18	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Merle Gordon Merle Gordon Merle Gordon Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections	Tage 320
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown 17 above, or email to production-midwest@veritext.com.	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Date Merle Gordon Merle Gordon Merle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections in the appended Errata Sheet; They signed the foregoing Sworn Statement; and Their execution of this Statement is of	Tage 320
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown 17 above, or email to production-midwest@veritext.com. 18 If the errata is not returned within thirty days of your receipt of 19 this letter, the reading and signing will be deemed waived.	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Thate Merle Gordon Merle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections in the appended Errata Sheet; They signed the foregoing Sworn Statement; and	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown 17 above, or email to production-midwest@veritext.com. 18 If the errata is not returned within thirty days of your receipt of	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Thate Merle Gordon Merle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections in the appended Errata Sheet; They signed the foregoing Sworn Statement; and Their execution of this Statement is of their free act and deed. I have affixed my name and official seal this	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address shown 17 above, or email to production-midwest@veritext.com. 18 If the errata is not returned within thirty days of your receipt of 19 this letter, the reading and signing will be deemed waived. 20 21 Sincerely, 22 Production Department	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Date Merle Gordon Sworn to and subscribed before me, a Notary Public in and for the State and County, the referenced witness did personally appear and acknowledge that: They have read the transcript; They have listed all of their corrections in the appended Errata Sheet; They signed the foregoing Sworn Statement; and Their execution of this Statement is of their free act and deed. I have affixed my name and official seal this day of, 20 Notary Public	Tage 323
1100 Superior Ave Suite 1820 Cleveland, Ohio 44114 3 Phone: 216-523-1313 4 July 24, 2018 5 To: Mark Pifko, Esq. 6 Case Name: In Re: National Prescription Opiate Litigation v. 7 Veritext Reference Number: 2959486 8 Witness: Merle Gordon Deposition Date: 7/19/2018 9 10 Dear Sir/Madam: 11 Enclosed please find a deposition transcript. Please have the witness 12 review the transcript and note any changes or corrections on the 13 included errata sheet, indicating the page, line number, change, and 14 the reason for the change. Have the witness' signature notarized and 15 forward the completed page(s) back to us at the Production address 16 shown 17 above, or email to production-midwest@veritext.com. 18 If the errata is not returned within thirty days of your receipt of 19 this letter, the reading and signing will be deemed waived. 20 21 Sincerely,	ASSIGNMENT REFERENCE NO: 2959486 CASE NAME: In Re: National Prescription Opiate Litigation DATE OF DEPOSITION: 7/19/2018 WITNESS' NAME: Merle Gordon In accordance with the Rules of Civil Procedure, I have read the entire transcript of my testimony or it has been read to me. I have listed my changes on the attached Errata Sheet, listing page and line numbers as well as the reason(s) for the change(s). I request that these changes be entered as part of the record of my testimony. I have executed the Errata Sheet, as well as this Certificate, and request and authorize that both be appended to the transcript of my testimony and be incorporated therein. Date Merle Gordon Merle Gordon Merle Gordon Merle Gordon They have read the transcript; They have listed all of their corrections in the appended Errata Sheet; They signed the foregoing Sworn Statement; and Their execution of this Statement is of their free act and deed. I have affixed my name and official seal this day of, 20	Tage 323

82 (Pages 322 - 325)

		Page 326
1	ERRATA SHEET	
	VERITEXT LEGAL SOLUTIONS MIDWEST	
2	ASSIGNMENT NO: 7/19/2018	
3	PAGE/LINE(S) / CHANGE /REASON	
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20	Date Merle Gordon	
	SUBSCRIBED AND SWORN TO BEFORE ME THIS	
	DAY OF, 20	
23	,20	
23	Notary Public	
24	Notary Fublic	
24		
o -		
25	Commission Expiration Date	

[& - 18265] Page 1

&	000298750 8:9	118 12:13	150 13:9 284:2
	35:13	119 8:17	150 13.9 264.2 151 13:10
& 1:20 2:4,9,18	000299033 8:11	11:32 110:11	152 13:10,11,11
3:10 4:4,13,18 5:3	36:21	11:52 110:11	15219-6401 6:10
5:12,17 6:8,13	000299083 8:14	12 9:18 187:2	153 13:12,12,13
18:9,19,23 19:4,12	38:21	248:14,20 254:10	154 13:13,14,14
19:16,21,24 20:3	09 282:19	322:15	155 13:15,15
20:15,17 21:6		120 12:14,14	156 13:16,16
22:3 62:2	1	120 12:14,14 121 12:15	150 13:10,10
0	1 8:5,7,10,12,16,22	121 12.13 1211 6:14	157 13.17 158 8:22
000018265 10:9	18:3 34:16 35:8	1211 0.14 123 12:15	150 8.22 159 13:17
286:19	35:18 36:1,2,18	123 12.13 124 12:16	159 13.17 15910 2:6
000018534 10:5	37:1 38:17 39:1	124 12:16 125 12:16	15910 2:6 15th 315:1
286:7	39:11 41:6 85:18		16 10:4 285:23
000183257 9:3	146:3 147:17	126 12:17,17,18 127 12:18,19	
189:15	157:22 159:3	′	286:2,4,23 306:13
000187408 10:10	176:5	128 12:19,20	160 13:18,18
295:7	10 9:13 229:11,16	129 12:20,21,21,22	134:24 279:24
000187508 9:17	231:5 233:4	12:30 144:18	1600 2:6
	100 12:7	12:35 144:23	161 13:19,19
239:6 000187871 10:7	1000 6:5	12th 5:18	162 13:20,20
	10036-8704 6:14	13 9:20 255:11,19	164 13:21
286:13	103 12:7,8,8	130 12:22,23,23,24	166 13:21,22
000187960 8:21	104 12:9	131 12:24	169 13:22,23
148:14	105 12:9	133 12:25	17 1:7 10:6 18:8
000187963 9:12	106 3:4	134 13:2	286:2,10
228:3	107 12:10	13th 74:14 83:15	170 13:23
000188104 9:5	108 12:10	14 9:23 259:16,23	171 13:24
224:3	100 12:10 109 12:11	140 13:3	1717 4:9
000188105 9:7,9	10:21 71:9	141 13:3,4	172 13:24
224:10,22	10:40 71:12	142 13:4	173 13:25
000188213 9:24	11 7:5 9:15,23	143 13:5 16:2	175 14:2
259:19	238:24 239:1,17	144 13:5,6	179 14:3
000189085 9:14	259:18 316:3,5	145 13:6,7	18 8:5 9:6,8 10:8
229:13	1100 3:13 323:1	147 13:7	34:18 224:8,20
000189292 8:23	110 3:13 323:1	148 8:19	286:2,16 287:3
157:24	112 12:11 113 12:12	149 13:8,8,9	313:19 317:19
000191543 9:22		15 10:2 54:8 58:21	1800 4:14 6:4
255:15	1144 5:8	59:3,5,21 71:18	182 14:3
000298635 10:3	116 12:12	72:23 231:4,16	1820 323:2
271:10	117 12:13	232:16 233:3	18265 287:4
	11747 2:15	271:8,13,18	
		, -,	

[184 - 238] Page 2

101 111	0.50 1.5 10 0.54 10	2017 10 6 20 6 12	2020 202 17
184 14:4	252:17,18 254:12	2015 10:6 286:12	2020 322:15
185 14:4	254:13 255:5	287:1 293:12,14	203 14:14
18534 286:25	256:25 288:24	2016 8:22 9:7,9,11	205 2:11 14:15
306:13	297:16 298:8	9:16,18,21,24 10:8	207 7:9 14:15
186 14:5	313:10	74:14 83:15,19	209 14:16,16
187 14:5	20 10:11 18:18	87:13 88:6,23	21 7:8 101:19
187408 295:12	93:9 315:4,5,6,8	89:21 90:16 98:1	104:3,7 105:25
187508 239:10	324:16 325:22	98:4,14 101:8,14	210 14:17,17
187871 287:2	326:22	103:8,11,17 104:2	211 14:18
187963 228:9	200 1:21 14:12,12	104:24 105:9,19	212 6:15 14:18,19
188104 223:22	2000 282:19	106:14,23 107:4	14:19,20
188105 223:22	20001-3743 4:5	109:5 118:10	213 14:20
188213 260:2	20005 5:18	146:14 148:3	215 4:10
189 9:2 14:6	2000s 23:10	157:22 177:9,10	216 2:20 3:5,14,19
189085 229:20	20036-5807 6:5	224:8,20 225:9	216-523-1313
19 1:17 10:10	2005 54:5 60:23	228:2 239:4,11	323:3
295:5,11 315:3	71:17 73:18 74:3	247:11,23 248:15	216-9140 3:9
191 14:6	2006 264:2	248:21 250:16	219 14:21
19103 4:10	2007 60:22	252:20 254:15	220 14:21
191543 255:21	2008 299:23	255:13 258:12	221 14:22,22
192 14:7,7	201 14:13,13	259:18 262:4	222 14:23,23,24
193 14:8,8	2010 8:16 85:19	282:19 286:18	2222 2:19
194 14:9	177:18 200:12,20	287:3 290:8	223 14:24,25
196 14:9,10	201:22,25 202:3	291:17 296:4	224 9:4,6,8
197 14:10	202:22 203:7,12	313:14 315:1	224-1133 2:16
198 14:11	204:22 252:20	316:8,10,24	226 15:2,3,3,4
199 14:11	288:24 289:12,16	2017 53:8 93:20,23	227 15:4
1990s 173:24	290:14,15 292:2,9	95:14,22 96:4	228 9:10
195:25 196:2	292:20,21 293:4	97:20 101:15,16	229 9:13
1997 54:5 60:23	293:23 294:3,24	101:18,22 102:25	23 11:2,3
71:17 73:18 74:3	295:22,25 296:14	103:2,7,16 104:2	231 15:5,5
19th 18:3	296:20 297:5,19	104:24 190:19	232 15:6,6,7
1:18 1:12	297:24 298:7,15	202:22 203:7	233 15:7,8,8
1:32 145:2	298:21,24 299:3,5	2018 1:17 8:5,11	233-4000 5:10
2	313:10,10	18:3 34:18 36:20	2332 2:10
2 7:3 8:15 36:1	2011 249:21 250:3	37:17 93:21 95:14	234 15:9,9
85:15,23 86:6	250:12,13 252:25	101:3 103:7	235 15:10
126:9,18,20	253:10	179:25 180:5	236 15:10
120.9,18,20	2014 10:4 84:18	181:1 322:6 323:4	237 15:11
159:19 229:21	286:6,23 288:9,13	202 4:6 5:19 6:6	238 15:11,12
230:2 236:9 242:1	293:11 306:11	14:14	
230.2 230.9 242.1			

[239 - 5:46] Page 3

239 9:15	279 16:12,13	307 17:8	44 11:10
24 11:3 264:10	28 3:8 11:5	308 17:8,9	44113-1901 2:20
323:4	280 16:13,14	309 17:9	44113-7213 3:14
241 15:12,13,13	2804 1:6,7 18:8	31 11:6 239:16	44114 3:4 22:10
242 15:14	281 16:14,15	310 17:10	323:2
243 15:14	282 16:15,16	3100 4:9	44114-1190 3:19
244 15:15	283 16:16	311 17:10,11	44720 5:14
245 15:15	284 7:10	312 4:20 17:11,12	45132 1:12
246 15:16	286 10:4,6,8	17:12,13	46 11:11
248 9:18 15:16	29 9:16 11:5 239:4	314 17:13,14	47 11:11
249 15:17	290 16:17,17	315 10:11	471-3490 6:10
24th 322:6	291 16:18	318 17:14	48 11:12,12
25 9:21 11:4	292 16:18	321 7:12	49 11:13
255:13	293 16:19,19	33 11:6	4:37 254:4
250 15:17,18	294 16:20,20	330 5:14	4:58 254:7
251 15:18	29464 3:8	34 8:5	5
252 15:19	295 10:10	35 5:4 8:7 86:22	
253 15:19,20,20	2959486 323:7	3500 1:21	5 8:22 157:20
254 15:21	324:2 325:2	35203 2:10	158:3 272:4
255 9:20	296 16:21,21,22,22	35th 6:9	50 173:16
257 15:21,22	297 16:23,23	36 8:10 11:7	509 240:16
259 9:23	298635 271:18	38 8:12	51 11:13 514 239:13
26 11:4	299 16:24	3:05 199:16	514 239:13 52 11:14
26003 5:9	29th 239:11	3:25 199:19	52 11.14 53 11:14
261 15:22	2:16 178:12	3:35 206:22	543 257:24
262 15:23	2:32 178:15	3:48 206:25	544 257:1
263 15:23	2nd 2:10	4	55 2:19 11:15
264 15:24	3	4 8:19 148:9,18	56 11:15,16
265 15:24	3 8:17 41:10,16,17	149:7 152:2	57 11:16
266 15:25	42:3 119:10,16	153:17 155:4	58 11:17
268 16:3 291:22	237:14 317:3	250:9 252:3	586-3939 3:19
269 16:3	30 134:25 215:12	293:19 306:14	59 11:17,18
271 10:2 16:4	300 4:19	40 11:7,8	591-6000 5:5
272 16:4	301 6:9 16:24,25	400 2:14 5:9,13	592-5000 3:14
273 16:5	302 17:2,3,3,4,4	41 11:8	596-9000 6:15
274 16:5,6,6,7	303 17:5	412 6:10	5:04 259:2,5
275 16:7,8	304 5:10 17:5,6	415 5:5	5:33 284:6
276 16:8,9,9	305 2:15 17:6	42 11:9,9	5:46 284:9
277 16:10,10	305-6400 5:14	43 11:10	
278 16:11,11,12	306 17:7,7	434-5000 5:19	

[6 - accurate] Page 4

6	8	9:53 43:5	190:16 194:11,23
6 8:11 9:2,11	8 7:4 9:6,8 101:2	a	195:5,8,9,11 196:1
36:20 37:16 38:8	103:2,6 223:21	a.m. 1:17	260:7 263:16
189:12,19 228:2	224:7,19 225:1,6	a.m. 1.17 aaron 1:8	265:22 288:25
250:10 252:2	226:5 316:4,12	abbreviations	293:24 294:8
60 11:18,19	800,000 180:21,21	127:24	297:1,6,6,7 300:2
600 4:14 34:10	8040 5:13	abide 62:22 67:22	300:7
284:4	818 2:7	abiding 67:25 68:2	abused 177:18
601 3:4 4:5	83 11:23	ability 57:13 80:6	187:24 300:12
60654 4:19	830-0600 4:15	110:3 214:20	abusers 138:11
61 11:19	839-2333 2:7	215:5 232:5	164:4,6,22 165:10
631 2:16 250:16,22	843 3:9	308:13	166:10 167:8
250:25 251:5,17	85 8:15 231:9	able 34:11 79:22	168:16 169:13
251:25	233:7	93:17 95:24 97:2	178:2 186:15
664-3727 3:5	851-8100 4:10	117:19,20 118:14	188:10
6:37 314:21	861-0804 2:20	139:24 169:18	accept 22:1,4
6:45 318:24	862-2000 4:20	170:7 174:19	76:24
6:49 319:2	88 11:24	180:17 181:20	access 94:25 95:2
6:50 319:11,13	9	182:1 191:16,18	113:7,9,13,19
7		196:24 245:3	116:16,19 117:18
	9 9:10 180:3,25	262:20 278:2,22	164:17 174:20
7 9:4 103:11	227:24	303:20	198:22 221:25
146:14 148:2	90,000 180:23	absent 30:16	222:8,24 223:2,7,7
223:21,25 315:23	900,000 181:2	48:10	223:11,13 262:20
316:12 7/19/2018 323:8	901 3:18 91436 2:6	absolute 59:25	263:3 265:9,14
324:3 325:3 326:2	91430 2:0 92 11:24	abuse 8:15 49:24	267:9,13 269:10
700 180:21	92 11:24 92626-7653 4:15	55:5,19,23 58:11	269:16 270:22
714 4:15	92020-7055 4:15 93 12:2	58:23 59:4,20	277:14,15 278:14
714 4:13 72 11:20		60:20,20,21 61:14	280:12,17
72 11.20 725 5:18	94 12:3,3,4 94111-5356 5:5	71:18,19,25 72:6,9	accidental 292:3
73 11:20	94111-3330 3.3 942-5392 4:6	72:14,17,24 81:8	292:17
73 11.20 732 251:5,17		85:11,16 104:20	accompany
732 231:3,17 74 11:21	95 12:4,5 950 3:13	111:10,16,24,25	209:25
	96 12:5,6	112:25 113:1,5	account 130:14
75 11:21,22 22:9 778-1800 6:6	96 12:3,6 964 236:10	114:1,20 115:12	accountable 143:6
78 11:22,23	904 230.10 97 12:6	117:1,24 123:20	accounts 73:2
782 250:14,22,25	983-7985 2:11	124:1 131:23	accuracy 253:16
251:25	9:15 1:17 18:2	133:18 138:18	accurate 51:23
7th 177:9	9:43 43:2	141:19 151:5,6	54:2,3 255:7
1 (H 1 1 1 3	7.73 73.4	165:23 166:19	256:10,17,18
		170:5 180:12	
		10.14	

[accurately - ahead]

accurately 69:24	59:13,14,16,20	151:10 164:21,21	affiliation 18:16
acknowledge	60:6 61:2,14 73:3	166:6 169:1	affiliations 295:17
324:11 325:16	81:8 104:21	170:24 190:11,14	affirmatively 82:7
acronym 190:1	111:10,16,19,25	191:5 228:11	affixed 322:5
273:1	112:1 113:1,5	230:17,22 263:22	324:15 325:21
act 242:2 284:22	114:1,20 115:12	265:21 306:5,10	aforesaid 321:11
324:14 325:20	117:1,24 123:16	323:15	afternoon 145:4
action 8:7,13 9:3	125:2 132:12	addressed 119:25	284:12,13
35:10 38:19 189:6	133:10 139:9	240:11	ag's 142:18
189:13,24 322:3	140:21,22 141:20	addresses 237:23	age 21:9 121:5
actions 31:14	146:9 163:24	addressing 64:12	agenda 8:8 35:11
actively 113:21	164:21 168:11	64:14,16 70:5	146:8 163:11
activities 42:3	170:24 184:14,19	73:20 139:16,22	177:5 185:10
107:23 242:12	193:10 194:10,23	223:4 308:9	aggregated 167:19
287:22 295:18	195:5 204:16	adjournment	168:24
acts 242:9	205:23 228:12	321:21	ago 28:24 35:6
actual 29:17 51:4	231:5,11,17 232:6	adjust 96:25	37:8 39:8 43:10
91:21 114:22	232:18 233:4,13	administer 91:13	135:11 146:25
115:24 116:8,11	233:17,18,23,24	135:14	176:13 258:13
218:10 247:7	234:3,18 235:23	administered 82:3	agree 24:22,24
249:24 255:1	240:16 258:2	91:21	25:3,23 130:8
acute 63:4	301:1 305:13	administering	142:6 151:7 152:8
ad 86:19	311:18 312:5	135:24 221:14	152:10 192:24
adamhs 180:14	313:3	administration	209:11,18,24
186:23	addictions 163:2,4	49:20 90:7 99:2	212:24 220:12,19
added 244:23	addictive 164:13	240:22 241:2	221:24 222:10
addict 170:15,18	235:8,8	299:25	228:22 231:24
addicted 48:8	addicts 48:6 55:11	administrative	233:12 247:10,19
49:10,10 73:2	186:15 231:4,10	99:1,7	254:18 273:14,22
140:10,11 161:24	232:17 233:3,7	admitted 48:9,15	274:4,11,17,24
161:25 162:24	247:5	advance 87:1	275:7,11 276:3,10
164:7 167:3,8,17	additional 33:7	adverse 43:22	276:13,19 277:8
168:17 169:13	102:7 105:20	46:17 47:3,12	277:20 278:4,11
170:9,20 172:9,16	106:13 107:12	advocacy 240:2	280:11
172:22 205:22	133:9,19 140:2,21	241:14	agreed 21:24 22:1
232:4,13 234:9,25	204:3 303:19	advocate 241:15	153:10
274:19 275:1,9,15	address 21:25	advocating 110:3	agreement 70:23
275:25 312:25	22:8 40:10 55:15	affairs 77:19 80:8	71:1
addiction 49:1,5	57:22 58:1 64:11	98:12	agrees 22:3
49:14 55:5,19,24	72:5 84:20 106:5	affiliated 307:2	ahead 23:4 43:11
58:11,23 59:4,8,12	106:18 110:4		63:22 67:19 68:4

[ahead - approach]

68:17 222:21	180:18 187:10	197:22 198:5	anton 4:14
aid 302:8 304:3,16	245:23 246:11	199:9 201:1,16	anybody 21:2
air 99:18 314:12	247:7 265:1	202:10 207:14,17	32:12 46:24 47:8
314:14	308:22	207:21,22 209:1	79:23 93:14
akearse 3:9	amphetamine	213:22 214:14	164:25 169:17
akron 3:6 19:2	124:18	215:14,21,22	171:14 177:1
27:18	analysis 109:18	216:17,18 217:17	184:10 211:8,10
al 1:10	130:5 147:10,10	217:25 219:9,21	220:9 243:19
alabama 2:10	300:7	220:16 222:20	245:5 263:2 283:8
alcohol 129:19,23	analysts 171:21	234:10,14,20,23	283:15
130:8,21 180:15	172:3	235:17 237:12	apadukone 5:6
allan 8:5 34:17	analytics 191:7	238:15 242:7,14	apologies 293:13
allege 245:4	analyze 52:5 56:23	243:25 244:2,10	apologize 24:11
alleged 219:2	118:17 168:1	244:22,25 245:10	78:7 274:10
alleging 301:7	analyzed 117:15	245:12,15,17,19	apparently 65:20
allergan 4:17	124:5	246:19,24 247:16	69:5 149:23
20:15	analyzing 52:13	248:3 249:18	266:22 272:8
allergies 47:9	109:16,25 121:6	251:24 254:24	appear 67:2 87:3
allocate 181:17	anecdotally 60:4	266:20 267:5	129:23 147:7
allocated 99:21	170:15 242:25	268:19,21 273:19	159:4 253:23
100:7 102:23	anne 3:7 18:25	277:4 278:17	324:11 325:15
103:20	announced 21:3	285:10,15 300:16	appearances 2:1
allowed 62:6	annual 100:12,21	301:13,22 310:4	3:1 4:1 5:1 6:1 7:3
66:14 67:11,20,21	182:20	311:15	appears 38:4
69:3	answer 23:2 25:11	answered 47:15	appended 325:11
alternative 147:9	25:13,22 26:11	103:15 120:6	325:18
147:14	29:9,11,19 30:4,13	166:13 169:21	applicable 320:8
ambiguous 24:23	31:12 44:3,10,18	214:15 232:11,21	application 83:1
57:9	44:20,25 45:3,16	232:24 233:9	84:15 262:16,18
american 239:17	45:21 46:13,22	234:13,15 246:17	269:8 271:4
americas 6:14	47:18 51:16 72:15	251:7 273:17	applied 74:22 78:1
amerisourceberg	86:23 92:20,22	310:6	80:5 83:22
1:10 4:7 20:5	100:11 109:14	answering 112:21	apply 74:15 83:3
208:10	118:14 124:23	215:4	83:17 303:19
amount 40:7,21	125:12,13,16	answers 24:19	applying 272:3
51:7 57:12 94:6	126:12 130:2	190:21	appointment
100:14,15,22,23	133:1 141:10	anthony 6:4 20:6	185:23 186:8
101:7 102:17,23	143:12,18 145:16	284:14	appreciate 162:14
103:5 108:1	149:6 156:23	anti 270:10	204:19
139:11 163:20	162:18 166:15	anticipation	approach 77:25
168:12 173:20	175:18 194:16,25	262:19	78:8

[approached - attorney]

approached 74:16	aside 26:10 143:18	220:17 226:23	assumption 299:6
appropriate 66:18	148:7 194:15,24	229:5 251:8,16,18	attached 8:6,8
71:3 96:21 191:21	195:5 199:8	251:19,21,22	34:18 35:11 325:7
192:4 260:15	200:13,25 201:16	256:18,23 267:17	attaching 260:16
approved 210:1	202:10 207:14	284:16 298:1,7,7	attachment 225:2
274:5,12	208:24 213:21	assert 45:13	attachments 8:23
approximately	217:16,24 219:8	asserting 45:20	157:23
282:19	219:20 220:1	assertion 294:20	attack 278:13
arch 4:9	238:19 242:6,13	assess 263:14	attacking 270:12
arcos 285:8	244:1 285:9,11	assessing 71:21	attempt 84:20
area 31:24 56:9,10	301:12	assessments	attempted 245:20
83:10 108:1,3	asked 24:10 46:5	115:25	262:12
135:22 165:21	47:15 81:18 86:23	assigned 104:9,14	attend 86:22 87:2
279:14 300:15	87:13,15 99:24	104:15 107:19	109:21 136:14
areas 56:5,13 57:3	103:14 105:1	assignment 324:2	139:2 146:10
58:7 106:4 293:23	118:12 120:5	325:2 326:2	163:7 171:21
294:7,13	124:17 126:22	assistant 80:10	172:4 173:5 193:5
arguably 182:5	127:6 146:2	assistants 77:20	193:18 202:13
argumentative	148:19 154:1,4,10	associated 150:21	214:9,17 261:10
33:4 105:14 127:1	156:24 160:11	265:9 267:11	295:22
140:4 153:24	163:11 166:12	assume 25:11 36:7	attended 40:8 48:5
226:22 251:2	169:20 204:24	37:23 72:12 148:1	50:8 73:11 167:24
252:8 314:8	214:24 216:6,9	190:20 281:19	226:15,18 260:25
arms 168:7	225:17 230:15,20	282:2 294:16	261:14,15
arnold 4:4 19:24	232:11,20 233:8	assumes 83:5	attending 18:15
arnoldporter.com	234:12 246:5	121:17 123:12	226:12
4:6	251:20 255:6	126:8 143:8	attends 40:7 172:5
arresting 243:16	258:7,17 263:2	147:13 154:8	attention 109:23
arrests 41:11	269:5,10,16	155:5 171:7	118:23,23 133:24
237:15	272:10,17 273:16	175:17 205:20	attorney 22:25
arrived 288:4	277:7 307:11	209:22 211:22	26:8 28:20 29:7
arrows 41:5	317:23	226:22 236:23	29:21 31:7 82:20
article 10:11	asking 29:25	237:11 241:3	83:24 84:13 85:2
314:24 315:9	30:21,23 33:25	242:23 249:13	88:16 163:18
316:6 317:10	40:12 51:3 57:3	265:3 266:18	175:4 194:13
articulate 57:21	58:13 65:10 66:8	267:4 269:14	197:19 198:14
216:6,7	67:16 68:22 70:18	271:1 276:8 278:8	200:23 201:14
articulation 57:20	70:24 95:5 96:22	305:8 308:17	202:8 207:12,20
aruiz 6:6	107:7 126:23	312:16	219:7 244:1 288:9
aseem 5:4 19:20	127:19 170:14	assuming 209:15	288:12 322:2
	196:21 207:6	222:16,22 281:23	

[attorney's - behalf]

-			
attorney's 146:9	aviation 54:25	267:16 278:20	bates 8:9,11,13,20
163:12 165:25	avoid 268:14	280:23 284:1,8	8:23 9:3,5,7,9,12
167:25 175:3	avoided 91:4	288:23 289:14	9:13,17,21,24 10:2
177:5 193:7	aware 21:21,22	296:4 298:6	10:5,7,9,10 35:12
203:23	27:18,21 35:3,5	314:20 316:15	36:20 38:20
attorneys 20:24	42:5,12,13 47:22	317:22 319:1	148:13 157:23
27:17,20 28:16	48:16,21,22,23,24	323:15	189:14 223:21
33:8 207:4 214:3	49:2,4 55:17	background	224:2,9,21 228:2,9
attracting 147:19	71:17 78:2 82:14	150:16	229:12,20 236:10
attributable	83:22 84:2,14	backing 271:23	239:5,13 240:16
252:24 253:8	102:17 110:2,5	backwards 46:14	255:14,21 257:1
attributed 43:22	136:22 137:9	bad 244:6	257:24 259:19
46:17 47:4,13	181:6 190:9	ballot 101:17	260:1 271:9 286:6
180:7	192:18 211:9,12	barnes 6:8 19:16	286:12,18,25
audience 260:14	216:23 217:8,13	19:16	287:2 291:19
august 9:6,8,21	218:9 242:2,8,12	baron 2:4 18:18	295:6 306:12
224:8,20 225:9	242:17 255:4	21:6 22:3	314:25
255:13 258:12	285:19 290:20	baronbudd.com	bathrooms 61:6
author 39:21	300:4,9,10 301:3	2:7,8	243:5
authority 80:23	awareness 77:24	barry 77:13,21	battle 306:7
192:21	axis 250:12	based 56:25 58:4	battling 305:12,13
authorize 325:11	b	96:25 142:24	305:13
authorized 62:17	b 3:12 4:4 8:10	153:12 202:5	becoming 94:9
63:25 64:1 65:5	36:18 37:1	203:14 217:1	107:4 186:10
68:18 93:7	bachelor's 49:19	234:1 243:2	275:25 312:25
automated 260:17	49:21	249:22 253:21	317:5
264:1 285:13	back 28:21 34:4	255:1 292:13,15	began 74:14
autopsy 205:7	41:12 42:7,21	294:20 301:7	167:17 195:13
available 75:1,5	43:4 71:11 76:13	basic 217:1,18,22	beginning 8:8,13
78:3 82:13,23	84:2 95:13 98:7	218:1,4	8:20,23 9:3,7,9,12
89:9 100:14,16	98:18 103:8	basically 216:23	9:13,17,21 10:2,4
117:18 139:13,20	106:11 108:15	301:14	10:6,8,10 35:12
165:5 167:12	110:13 117:16	basis 29:20 46:15	38:20 93:21
186:25 195:14,21	145:1 148:20	56:3,22 118:7	148:13 157:23
202:16 263:10	166:8 178:14	119:7 120:8 163:5	189:14 224:9,21
264:15,23 265:6	183:22 199:18	170:3 211:17	228:2 229:12
266:12 267:7	203:12,25 204:22	216:7,10 253:15	239:5 255:14,22
303:16 305:11	206:24 219:12	257:9,16,21	271:9 286:6,12,18
ave 323:1	230:7 233:2 236:2	287:25 290:25	295:6 319:5
avenue 2:10 3:4,13		319:6	behalf 2:3,12 3:6
	244:13 249:25	01910	The state of the s
3:18 4:5 5:13 6:14	244:13 249:25 254:6 259:4		3:10,16 4:2,7,12

[behalf - budgeting]

4:17 5:3,7,11,16	263:9 264:20	biweekly 127:4	brent 260:1
6:3,7,12 18:19	273:21 276:25	black 248:9	bretton 5:13
19:1,4,6,8,19,21	287:12 288:8,13	blank 316:3	bridgeside 3:8
19:24 20:10,12,15	304:24 309:23	blocked 263:21	brief 22:20
20:17,19 22:4	317:7 319:6	blood 174:5 205:5	briefly 49:16
31:25 44:16 70:25	beneficial 222:5	board 180:15,15	79:21
239:15	benefit 25:3	181:13 186:23	bring 58:2 88:3
belief 142:25,25	196:10 221:25	263:24 285:18,19	109:22 303:20
169:3	273:15 282:16	306:23 307:7,11	bringing 88:12
believe 24:4 32:24	benefits 104:5	307:25	118:22 133:23
34:10 39:19 41:7	181:19 277:22	bockius 4:13	241:14
42:14 44:4 53:8	best 24:25 53:19	boehm 5:17 20:2,2	broad 198:17,19
57:23 66:25 68:22	92:14 110:3	20:22 61:17,25	broader 29:15
71:15 75:20 78:16	118:21 168:8	62:2,8,15,19,24	108:4 124:11,25
78:22,25 84:17	169:1 215:4	63:4,8,14,18,23	166:2
93:20 96:20 101:1	277:21 280:1	64:1,4,8,12,16,23	broadhollow 2:14
103:9 112:18	306:4	65:1,7,12,17,22	broadly 159:3
117:3 118:2	better 52:4 178:24	66:1,8,21 67:3,8	182:8 193:19
124:13 136:14	222:8,11 305:23	67:13,18,24 68:4,7	198:15 209:2
140:23 145:10,20	beyond 197:10	68:15 70:9,14	312:22
145:24 146:19	bi 8:17 119:11	71:4 207:16	broken 61:5
147:1 148:21,24	295:23	216:20 270:3,16	brooklyn 54:13,13
151:22 153:2	bias 44:5,19,24	297:13 314:13	55:6 58:21
155:21 156:1,19	45:9	boop 3:3 19:9,9	brought 33:7
160:15 161:2	big 38:8 132:14	27:2	80:12 82:7 125:2
165:13 166:17,22	223:2 240:1,2,3,6	bottom 130:3	136:18 142:2,3
167:18 168:19	241:13	239:20 240:20	188:16
172:20 177:11,24	bigger 247:12	257:2 291:19	bucket 308:25
180:16,20 184:23	bill 179:9,10	293:17 316:12	309:5
187:1,2,14 188:1,3	billing 184:3	boulevard 2:6 3:8	budd 2:4 18:19
190:18 192:7	billion 38:8	4:14	21:6 22:3
193:15,24 195:24	billions 38:9	bracket 316:15,16	budget 55:14
196:12 200:8	birmingham 2:10	break 25:19,21	99:19 100:12,18
201:9,17 202:24	birth 131:25	26:1,2 42:24	100:21,23 101:3
204:13 205:8,21	bit 29:14 138:1	110:7,17 144:18	102:14 106:9
218:20 224:13	142:11 162:9,11	144:20 145:7	139:22 179:25
226:15 230:10	162:15 178:18	178:9 199:13,21	180:5,19 181:2,17
233:25 234:7,24	195:2 199:22	253:25 297:3	182:11,19,20
235:12,18 240:5	230:25 269:25	314:11	183:3,13
245:1 247:20,23	284:19 297:4	breaking 242:18	budgeting 104:25
249:6,18 261:20		243:5 311:6,19	

[bullet - changed] Page 10

bullet 41:10 152:1	141:8 143:10	234:8 289:12	cdph 8:17 119:11
155:2,16 156:7,16	144:4 145:14	caption 321:20	272:25,25 295:20
bulleted 240:23	149:3 152:20	card 281:13,18	center 54:14
bullets 241:19	153:19 154:14,20	cardinal 5:16 20:3	centerpoint
burden 140:7	157:4 160:10,22	208:12	138:20 186:16,18
burling 5:3 19:21	160:23 161:9	cardiovascular	186:20 187:25
business 64:22,23	162:22 164:10	221:9	303:10
68:13,15 72:13	172:24 185:7	care 62:16 210:12	centers 167:21
208:20	191:24 192:6,11	266:2	185:16
busy 185:19	193:2,13 194:13	career 51:21	centre 6:9
	197:19 199:6	289:21	certain 56:16 57:3
C	200:23 201:14	carefully 66:14	100:13 265:8
c 8:12 38:17 39:1	202:8 207:12	carfentanil 116:1	certainty 59:25
41:15	213:2 219:5	152:5 153:9 154:5	certificate 7:12
ca 323:25	221:19 222:19	156:2,10,24	321:1 325:11
cabinet 86:12,15	231:13 232:1,10	157:15,17 159:15	certificates 131:25
86:21,22 87:7	233:15,16 234:5,6	159:22 160:8,13	certification 324:1
88:10 89:10 90:3	235:15 237:10	160:21 161:6	325:1
90:15 150:8,10	238:4,14 241:24	162:5,10,12 276:6	certifications
230:19	243:23 244:18	carolina 3:8	278:1
cabinets 61:7	245:9,9 246:22	case 1:7,12 18:7	certified 21:12
243:6 311:20	250:5,21 253:2	20:23 23:3,22	certify 321:8,18
calculation 181:22	257:12,20 264:17	24:1,9 30:11 44:2	322:1
calendar 8:22	265:5 266:18	69:16 88:9 141:9	cetera 87:18 181:8
157:22 158:8	272:19 273:17	196:14 207:5,9,10	279:19
california 2:6 4:15	274:1 275:3	216:3 241:21	chain 198:12
5:5	278:15 280:14	242:5 245:2 278:6	208:23 209:2,4,7
call 34:3 71:7	290:16,22 301:10	323:6 324:3 325:3	218:7 295:15
305:19 306:2	301:20 310:2,25	cases 114:13	chaired 54:20,22
called 21:9 76:11	311:12	268:11,15	chance 249:17
76:13,18 88:9	cameron 271:25	cash 212:20	271:16
138:20 186:17	271:25 272:1	category 272:4	change 101:9
240:3 307:6,10,24	campbell 5:12,12	cause 303:4 314:5	120:16 285:14
calls 22:25 24:3 26:8 28:19 29:7	19:11,11,12	321:11	323:13,14 325:8
30:13 31:7 41:21	cancer 212:16	caused 212:16	326:3
42:11 43:18 46:20	candidate 76:21	233:23 247:25	changed 101:9,10
47:5 49:6,7 51:15	candidates 80:15	248:1	101:16 187:5
53:12 57:7 74:18	canton 5:14	causes 303:13	200:11,20 201:21
	capacity 168:23	ccbh 306:23	203:6 204:21,25
75:2,9 78:14 95:19 100:10	184:23 185:1	cdc 163:15 166:5	205:1
118:1 130:9,23	214:18 217:4	167:11,22 175:1	
110.1 130.9,23			

[changes - cleveland]

changes 323:12	cities 239:17 240:3	166:20 170:8	clean 178:18 231:6
324:7 325:7,9	240:8	176:4 177:17	233:5
characterization	citizen 84:11	179:1 183:24	cleaning 33:5
66:13 123:21	citizens 71:17	184:1 190:6 191:1	35:22 36:9 88:18
124:2	184:6 202:21	200:11,20 201:3	clear 30:20 34:2
characterize 69:24	221:24 222:7,10	202:17 203:4	38:13 41:25 45:19
70:3 229:1	239:17 280:5	214:22 223:1,6	63:17 66:19 67:11
characterizing	city 1:10 2:3 3:3,6	225:20 228:10	69:9,10 77:23
62:14	8:22 18:19 19:1,9	230:17,19,23	97:19 124:10,11
charge 133:14,25	21:6 23:8,11,12,25	237:3 240:3,6	132:3 177:7
134:4	26:22 29:1 32:8	241:21 242:5	251:15 268:22,22
charles 4:4	34:4 41:19 44:17	247:1 249:10	270:9
charles.weinograd	52:12,24 53:1,6	261:25 263:15	clearly 68:2,2
4:6	54:2,10,15 55:18	269:24 273:8	cleve 8:9,11,14,21
charlie 19:23	55:22 56:5,8,13,18	280:10 288:16,21	8:23 9:3,5,7,9,12
chart 250:12	58:7,20 59:5,9,21	296:13,14,18,20	9:14,17,22,24 10:3
251:8 252:14	60:13,14,22,23	298:23,25 300:19	10:7,10 35:13
253:9	61:13 71:16,20,25	300:23 301:6,8,9	36:21 38:21
check 69:16	72:5,14,22 73:8,17	301:17 303:5,14	148:14 157:24
chicago 4:19	73:22 74:2,9,21,23	304:18 305:6	189:15 224:3,10
chief 9:10 77:18	76:16 77:3,6 78:4	306:6 308:15,21	224:22 228:3,9
80:8 98:12 227:25	78:7 79:4,17,24	309:17,25 310:24	229:13,20 239:6
236:24	81:5,19 82:2	311:5,25 313:22	255:15,21 259:19
china 155:1,18	83:13 84:3 89:13	313:24 317:23	271:10 286:13
157:7	91:4 92:3,4,10	city's 196:9	287:2 295:7,12
choice 76:24,24	94:18 96:7 97:7	city.cleveland.o	cleveland 1:10,22
cholesterol 278:12	100:6,17,25	3:5	2:3,20 3:3,4,14,19
278:14	102:18,24 105:1	ciullo 4:18 20:14	5:13 8:22 9:2
choose 188:22	107:11 108:13	20:14	18:10,19 19:10
chosen 140:5	111:5 122:13	civil 21:11 23:16	21:6 22:9 23:8,12
chris 19:14	123:14,15,20,25	320:4,8 324:5	23:25 26:22 37:14
christopher 3:17	124:8,19 125:2,4	325:5	39:16 41:19 42:1
chronic 191:21	125:19,21 132:15	claim 245:24	42:5,8 52:12,16,25
192:4 212:15	140:5 141:15	246:12	53:2,7 54:2,10
276:11	142:6 143:5,24	claims 218:25	55:18,23 56:8,14
ciaccio 2:14 19:5,5	145:11,21 146:1	clarify 207:16	56:18 58:7,8,8
circumstance	150:19 151:13	clarity 57:17	60:14,22 74:9,10
222:6	155:12 157:21	63:11 66:15 71:2	75:8 76:16 77:3,6
circumstances	158:8,12,22 164:6	72:19	78:8,19 79:4,18,24
33:23 40:1 97:12	164:23 165:1,8,11	classified 285:5	81:5,19 82:2
	165:12 166:10,18		83:14 84:3 86:10

[cleveland - committee]

			_
89:14 91:5 92:3,4	260:12 263:12	coached 66:19	69:22 74:15 87:4
92:7,10,12,23 93:1	271:17,18 273:1,9	coaching 63:14,16	87:15 89:7 92:4
93:5,24 94:7,9,18	276:11,14,16	coalition 240:2,4,7	104:8 114:15
94:19,24 95:3,16	278:7,25 279:9	cocaine 125:7	125:3 152:18
96:3,7 97:8,21	280:5 288:16	254:17,19	154:13,17 168:3
98:8,20 99:20,22	294:22 295:1	cocktails 173:8	169:10 174:23
100:6,7,25 102:8	296:12,13,19	174:2	181:12 186:20
102:10,18,24,25	298:3,24 300:19	code 121:4 130:19	193:17 204:10
103:19 104:8,25	301:6 304:19	codes 56:4,4,22,25	221:21 225:18
105:2,21,24	307:1,19 309:10	coding 248:11	236:7 243:8 284:1
107:10,11,15,22	313:22,25 322:5	cohen 63:19 70:16	289:6 290:25
108:2,8,13 111:5	323:2	71:1	301:14
112:25 121:11	cleveland's 10:11	colleagues 318:22	comes 91:6 115:4
124:19 125:19,21	29:2 32:8 99:23	collect 28:16 31:3	136:8 219:22
128:2 131:12,13	103:20 151:16	31:19 168:1,6,25	256:12
140:5 141:15	262:1 315:2,9	301:7	coming 63:4 177:1
142:6 143:5,24	clevelander 58:5	collected 28:17	249:9 258:22
145:12,22 146:1	client 22:25 26:8	31:16 117:14	289:7
149:16 151:13	28:20 29:7,21	collecting 31:10	commander 37:15
153:25 157:21	31:7 62:20 65:18	99:5	comment 275:21
158:8,12,22 164:6	188:5 194:13	collection 130:16	comments 67:21
164:23 165:1,11	197:19 198:14	collective 40:19	67:22
165:12 166:10,18	200:23 201:14	collectively 33:20	commission
166:20 170:9	202:8 207:12,20	113:23 202:16	322:15 324:19
175:24 177:16,17	219:7 244:1	279:24	325:25 326:25
179:1,14 183:25	clients 187:2	collects 264:3	commissioned
184:2,6 185:24,25	clinic 91:17,20	college 49:22,24	321:7
189:5,13,23 190:6	93:12 138:10	colon 239:18	commissioner
191:1 200:11,21	139:4 175:24	240:22	80:2 95:11 99:14
201:4 203:4 207:9	184:11,17 276:16	color 248:10,11	114:4 115:14
214:18,23 217:5	clinics 89:8 91:5	column 239:19	128:4 133:21
220:14,18,23	91:11,12 92:3,12	254:16 255:3	168:24
221:18,25 222:7	92:24 93:6,12,25	292:1	commissioner's
223:1,22 225:20	132:1 137:12,15	combat 308:13,23	118:23
228:11,12,23,24	181:8 184:9,13,18	combination	commissioners
229:2,7,22 230:2	closed 316:16,17	299:10,17 300:1	135:1 239:16
230:23 236:4	closely 89:18	300:12,20,24	committed 242:3
239:10 241:21	clr 1:25	301:2	committee 2:3
242:5 247:13	cmmclaughlin	combined 180:19	8:22 18:20 54:21
249:21 252:4	3:20	come 24:20 28:14	54:23,23,25 55:1,1
256:3 260:1,7,10		31:3 42:21 65:10	112:5 157:21

[committee - continue]

150 0 0 10 10 14	1(2 22 1(4 2	106 20 205 7	G: 4 070 (
158:8,9,10,10,14	163:23 164:2	196:20 305:7	conflict 272:6
158:17	168:13 181:8,25	concern 272:22	conflicts 185:8
committees 54:16	182:7 185:13	concerned 83:8	conjunction 89:16
54:18	236:25 241:15	84:11	connect 301:16
common 37:25	247:4,22 280:2	concerning 25:24	connecting 308:24
279:21	282:16 289:24	64:15	connection 30:1
commons 5:13	303:21 306:9	concerns 45:13	connolly 5:17 20:3
communicable	311:23 312:6	concluded 319:13	62:2
279:19	companies 4:3	concludes 319:7	conscious 227:9
communication	140:1 208:3	conclusion 24:3	consequences
23:1 26:9 30:25	237:24	141:9 144:4 149:4	278:24 279:8
31:7 200:24 202:9	company 6:7	153:19 156:17,22	consider 52:8,10
communications	19:17 43:14 47:20	156:25 160:24	97:15 181:9 241:2
26:10 28:20 29:8	208:14 245:6	161:9 213:2 219:5	considering
29:22 30:16,24	280:12,16,24	238:4 243:23	254:25
143:16 194:14,15	281:2 283:16	244:19 245:10,13	consists 259:12
194:25 197:20,21	301:18	246:23 274:2	consolidated
198:6 199:6,8	compare 247:13	296:6 301:11	285:14
200:14,25 201:15	254:17	311:2,13 312:2	constantly 115:10
202:11 207:13,15	compared 257:4	conclusions	134:25
207:20,22 208:25	complaint 29:5,17	143:10 257:10	consulted 28:25
213:22 217:17,25	30:2,2,5,10,18	condition 44:1	consume 232:15
219:7,8,21 220:1	31:2 144:1,6,7,9	46:3 210:13	consumed 232:6
242:7,14 244:2	144:12,15 196:13	conditioning	consumer 82:16
285:10,11	196:16,19,25	314:12,14	83:22 84:14
communities 54:9	197:1,11,17 198:1	conditions 221:17	142:13,22 289:22
55:18 57:1 58:15	completed 321:20	277:13	cont'd 3:1 4:1 5:1
58:22,24 60:8	323:15	conduct 69:13	6:1 9:1 10:1 12:1
168:10 174:13	completely 215:12	73:23 213:6,11,19	13:1 14:1 15:1
community 40:10	216:15 237:4	215:7 216:24	16:1 17:1
40:20 54:22 59:10	compliance 316:1	227:5 237:24	contain 36:13
59:24 60:4 73:10	316:17	241:20 243:20	contained 201:18
73:11,14,16 82:17	compliant 63:5	244:15 245:5	240:14 262:13
82:24 83:8,9	comply 63:2	246:1,14 276:1	contention 211:18
84:22 85:7,8 92:8	components 66:11	conducted 73:8	context 126:11
106:6 108:5	comport 62:12	275:22	131:10 166:2
109:20 110:6	compound 40:16	confidential 45:22	200:7
111:21 117:21	42:10 58:12 60:24	143:16	continue 57:19
118:18 137:13	83:4 93:8 94:21	confirm 21:24	66:17,21 70:19
139:2,3,7,16 140:8	112:10 116:5	157:5 278:23	80:16 216:19
140:13 141:21	120:1 125:8		268:20 295:22

[continued - course] Page 14

	20.27.240.10	222.12	222.2
continued 145:5	38:25 248:10	corrections 323:12	322:2
continues 123:14	corap 9:3 189:14	325:17	counseling 138:19
193:16	189:25 262:18	correctly 79:8	138:21,21
continuing 123:18	269:9 271:4	89:15 160:1 230:3	counselor 187:1
contractor 136:17	corner 39:11	264:12	counselors 187:3
contractors	291:20 293:18	correlate 173:22	187:11 188:6,9
135:17 136:12	corp 1:10	correlation 174:15	counterfeit 312:7
contribute 275:19	corporation 19:22	correlations 174:6	312:11
contributed	305:10	cost 265:14 301:8	counties 239:18
140:24 141:5	corporations	costa 4:15	countless 34:9
143:2,3 145:11,21	305:3,20	costs 265:9 301:16	61:8
148:22 149:1	correct 23:13	317:23,24	country 175:1
247:22 309:17,24	26:15 28:7 37:18	council 8:22 23:12	196:4
311:25	53:20 83:16 86:8	54:2,15,16 58:20	county 2:12 3:6
contributing	87:5 90:10 91:13	59:6,21 60:14,23	8:13 10:4,6,8 19:1
145:25 203:24,24	91:19,22 92:15	61:13 71:16,20	19:4,6,8 27:17,20
204:5 206:1 310:8	96:5,14 97:23	72:1,5,14,23 73:8	38:18 42:7 90:10
311:11	98:2 99:15 101:5	73:17,22 74:2	90:11,14 111:18
contributor 40:18	101:23,24 102:10	157:21 158:8	112:2,15 113:8,12
control 64:17,20	103:7,7 104:5	159:7 311:5	166:1 171:14,18
64:20 167:22	109:9 111:5,6,8	counsel 5:16 18:14	184:22 186:6,10
185:16	115:15 128:2,5,6	21:24 23:3 25:1	203:4 231:3,21
controlled 264:4,8	128:11,12,15,16	25:19 26:11,12,13	233:1 249:9 273:9
284:20,22	130:5,6 131:9	26:16,17,22 27:14	286:5,11,17,24
conversation	134:15,16 137:17	27:24 28:2 29:11	288:20 290:2
88:23 133:8	138:4,6 146:7,20	30:1,3,14,17,24	292:1,10 293:22
conversations	147:11 148:4,5	31:1,10,12 35:6	295:3,19 297:24
23:3 29:10 31:9	151:13,14 159:11	37:8 39:8 43:10	298:13,14,20
31:14 49:11 70:12	159:15 160:19	64:10 65:14,24	306:23 307:7,11
114:4 115:17	206:5,9 221:3,12	67:16 69:12 70:23	307:25 313:21,24
128:10,13 143:14	221:14 223:8	127:3 143:14,17	321:4 324:10
243:9,11,14	225:22 238:11	146:25 197:22	325:15
301:12	240:17 241:8,18	198:7,8 199:7,9	county's 232:18
convey 127:18,20	243:17 255:23	200:14 201:1	couple 27:15
copied 264:19,21	257:15 266:7,15	202:11 210:25	28:24 32:16 33:6
266:21 268:5	268:2 269:6	213:22,24 217:17	43:10 83:20,21
copies 32:4,7	271:20 281:15	217:25 218:21	122:18 146:25
33:10,11 34:13	287:18 301:9	219:21,23 220:2	238:22 284:16
227:11 248:9,10	307:9 313:12	242:7,14 244:2	course 33:12 48:4
copy 31:21,23	321:15	249:7 285:10,12	51:6,20 84:6
32:19 37:10 38:5		301:13 320:2,11	174:6 203:6,20
		cal Calutions	

[course - daunting] Page 15

204:7 210:12,17	204:11 225:19	298:13,14,20	201:11,12 202:5
227:20 271:15	230:22 247:4	306:12,23 307:7	202:24,25 204:8
282:5	312:5 313:3	307:11,25 313:7	204:23 206:5
courses 49:25 50:6	critical 176:2	313:14,22,24	233:21 248:6,16
50:8,20,23 53:22	279:15,20	321:4	248:21 253:20
court 1:1 7:14	current 55:2 74:8	cvs 6:3,3 20:7,7	255:4 262:7,12
18:6,12 20:20	101:8,12 103:6	284:15,15 301:18	263:10,14 264:10
21:7 24:21 25:3	173:24 295:17	303:22 304:16,17	265:17 269:5,11
35:17 36:24 38:24	currently 41:18,24	304:18 317:25	269:11 270:23,23
138:20 188:2,13	52:18 55:10 56:17	cycle 234:2	272:7,9,16 273:5
188:17 267:19	58:7 91:24 100:23	d	280:13,19,20,21
270:14 324:7	104:19,19 106:10		282:3 300:7
cov.com 5:6	108:16,24 109:3	d.c. 4:5 5:18 6:5	303:18 312:23
cover 282:23	134:2 164:23	62:3	database 116:25
coverage 281:24	186:24 187:4	daily 56:2,21 118:7 170:3	117:11 259:8,10
covered 314:16	190:6 262:6 288:7		259:13 262:3,7,13
covington 5:3	custodian 183:1	damages 140:7 144:1 245:24	264:11,23 267:17
19:21	183:12	246:12 301:7	databases 113:19
crack 160:1	custody 7:14	317:22	116:10,15,18
created 149:14,19	customers 306:18	dan 1:8	118:16 263:9
150:16,18 183:13	cut 209:6 214:10	data 9:19 52:5,6,7	265:7 267:6,12
204:16 263:24	215:24 216:8	56:2,3,21 57:8	date 18:2 37:16
creating 91:8	235:5	58:14,16 60:3,9,10	41:2 51:4 146:11
credentials 267:9	cuts 106:2	82:22 89:14,22	149:10 226:8
credibility 316:14	cutting 215:9,11	90:5,13,15,23	249:24 297:21
criminal 23:15	216:1 235:4	94:16,17 95:5,9	298:10 320:12
242:2,9,12 244:16	cuyah 10:5,9	109:16 112:20,25	323:8 324:3,9,19
crisis 56:17 57:5	286:7,19,25 287:4	113:3,8,13,23	325:3,13,25
58:9 104:21	306:13	116:6,9,16 117:12	326:20,25
107:24 108:8	cuyahoga 2:12	117:14,19,23	dated 8:5,10,16,22
109:12 123:17	8:12 10:4,6,8 19:4	118:12 120:9,14	9:11,16,21,23
124:3,8,10,12,14	19:6,8 27:20	120:16,18,19,20	34:18 36:20 85:18
124:15,18,19,23	38:18 42:7 90:14	121:6,6 122:11	157:22 228:1
124:24 125:1,12	111:18 112:2,14	125:25 126:22	239:4,11 255:13
125:16,21 132:4	113:8 166:1	127:14,16,16,20	259:18 307:18
132:10,23 140:24	184:22 186:6,10	130:4,19 165:4,17	316:9
141:6,24 143:2,4,6	203:4 273:9 286:5	166:4 167:11,14	dates 93:22 282:18
144:1,2 145:11,21	286:11,17,24	167:25 168:5,6	298:2
146:1 148:23	287:13 290:2	169:4 170:2 171:5	daunting 10:12
149:1 151:17,23	292:1,9 293:22	171:9,12 177:13	315:3,11
169:11 176:3	295:3,19 297:24	177:15 191:6	

[david - department]

david 9:23 96:2	dear 323:10	deemed 323:19	99:3,20,22 100:7
97:6 259:17,24	death 116:1	defendant 24:1	100:15 101:19
260:5 271:20	131:25 165:20	197:5 207:5 211:6	102:8,10,14,19,25
295:11,15 296:24	170:25 171:3	211:10 212:4	103:19,21 104:8
davis 183:16	172:20 174:9,9	218:22	105:1,7,17,21,24
dawn 89:8 90:22	205:6 255:2	defendants 5:16	106:2,17 107:10
91:1,3,3,6,6,15,24	deaths 87:17 89:2	33:20 68:25 70:7	107:15,22 108:17
92:3,6 93:7,25	90:19 91:4 114:14	70:25 141:23	109:24 110:24
97:22 98:5 138:23	115:7 172:14	196:18 197:10,15	113:17,22 114:12
184:15,16 303:10	174:2,16 175:14	198:3 199:2 207:9	115:3,22 116:7,12
day 3:17 19:15	203:3,6,16 204:6,9	208:6 209:8,19	121:11,14,20
32:25 55:3 105:16	204:18 205:17	210:5 211:18	124:6 131:12
115:1 119:7,7	206:3,9,10,12,14	213:6,11,12 215:8	132:7 134:2,11,19
166:22 173:24	247:24 252:19,24	218:18 219:1	134:22 135:5
174:8 244:9	253:7 254:14,19	220:20 241:20	137:2,21 139:20
249:16 270:21	257:4,5,6 292:4,17	242:4 246:1 249:8	141:14,19 146:16
271:14 274:5,10	293:7 300:23	278:6	148:4 149:16,20
274:13 310:6,7	debrosse 2:9,9	defending 26:14	150:19,22 151:12
317:1 322:6	18:22,23	defense 65:13	151:15 153:22
324:16 325:22	decade 195:16,20	definitely 232:22	154:1 155:11
326:22	289:20	degree 49:19	166:3 168:3 169:9
dayno 4:13 20:18	december 8:22	88:25 142:11	169:19 170:1
20:18	157:22	214:21 225:15	171:11 175:2
days 35:6 37:8	decide 65:14	234:8,25	176:20 177:12,16
39:8 43:10 146:25	decided 105:3	delivered 284:3	177:23 178:1,4,20
323:18	decides 191:20	delivery 320:10,12	178:23 179:7,14
dea 210:7 217:13	192:3	demands 185:20	180:1,10 181:18
217:20 218:18,23	deciding 83:2	demise 204:18	182:12,18,23,24
299:20	106:8	dennis 3:12 20:9,9	183:2,3,11,13,21
deal 136:20	decision 78:13,17	department 9:18	183:23 184:5,12
139:24 140:21,22	78:18,23 235:3,7	29:2 31:25 37:14	184:17 185:19,25
202:17 221:2	235:10	42:2,6,8,20 52:16	186:8,15 187:7,9
225:19 305:1	decisions 105:4	52:19 53:4 55:10	187:15,22 188:7
dealer 174:25	298:4	55:17 74:11 75:8	188:22 189:2
314:24	decline 106:7	76:1 79:3,11 82:4	190:18,22 191:18
dealers 242:11,19	declined 253:9	83:14 86:10 89:15	195:4,7 211:9,11
dealing 41:12 73:5	257:5	89:18 92:7,12,23	214:19 217:5
115:13 176:2	deed 324:14	93:1,5,24 94:7,10	220:10 228:25
182:8 247:4	325:20	94:19,24 95:4,6,9	245:5,25 246:13
275:17 305:16	deem 66:18	95:16,22 96:4	247:1,11 248:15
		97:10,21 98:8,20	248:22 256:3,13

[department - disclose]

256:21 257:14	65:4 66:9,13 69:1	detect 314:5	181:4 198:22
258:1,16,22 260:8	69:6,7,11,17 85:15	determination	199:3 256:20
262:1,6,11,17	85:23 97:1 119:10	245:21,22	director 8:20 9:11
263:13 264:24	119:16 148:9,18	determine 171:2	10:12 29:9 55:17
266:6,8 267:1	157:20 158:3	194:9,20	58:6 74:10,16
268:9,24 269:1,9	169:10 178:22	determining 210:6	75:13 76:1,8 78:9
269:24 271:6	189:12,19 215:19	develop 306:6	78:19 79:2,18
272:16,22 273:1	223:25 224:7,19	development	81:3 83:14 94:9
278:25 279:9,24	227:12,24 229:11	54:22	98:8 102:9 105:8
280:4 287:17	239:1 248:14	devoted 111:15	118:5 128:2 134:7
294:22 295:1,24	255:11 259:16	diabetes 221:7	134:14 135:8
298:3,18,19	271:8,15 286:4,10	diagnosis 212:5,11	137:2 141:14
299:23 303:3,8,12	286:16 295:5	diandra 2:9 18:22	148:12 149:20
303:25 304:9	315:8 319:7,13	die 171:1	150:21 151:12
306:19 307:2,19	321:18 323:8,11	died 165:18	153:25 155:15
309:11 316:16,18	324:1,3 325:1,3	170:16 308:20	169:9 183:7,9,14
323:22	describe 51:2 76:9	difference 101:18	185:24 186:8,11
department's	117:9 135:18	different 89:14	187:6,12,13
151:24 180:19	136:2 230:12	116:7 117:12	190:15 214:18
departments	255:6 259:11	118:3 121:4,5	217:4 219:25
89:17 117:17	described 81:17	126:1 156:16	220:10 225:11
182:25 240:5	141:18 142:10	166:7 168:6 207:5	228:1,24 229:3
departure 97:16	190:25 219:19	243:4 253:5 299:8	230:20 236:25
depend 58:19	265:14	differently 32:2	254:9 258:1 259:7
dependence	describes 130:4	83:12	259:24 260:6
192:25	describing 84:13	difficult 24:21	262:4 263:12
depending 33:24	266:22	direct 59:16 98:16	264:24 269:22,23
depo 43:12	description 8:3	116:16 164:24	270:24 284:12
deposed 21:12	22:21 186:14	181:23 312:18	287:23 288:8
22:14 24:14	264:19 312:11	directed 73:19,19	289:13 290:10,14
deposition 1:15	deserve 276:20	102:18 126:17	290:20 291:7,12
18:4,8 20:23,25	277:9	127:10	296:24 314:23
21:20 22:13 23:7	designed 241:11	directing 139:10	315:2,10 316:7
23:9 24:16 26:6	266:8,14	direction 31:11	317:5,15
27:24 28:2,10,15	designee 183:8	directly 42:18	directorship 75:23
30:11,15,19 33:12	desire 232:13	44:5 98:9 109:23	109:8
33:24 34:1,12,16	desk 290:3	112:12 113:13	disagree 211:17
35:8,18 36:18	desperate 139:15	114:3 117:8	216:14,16 257:9
37:1 38:17 39:1	174:12 311:17	118:25 119:4	257:17 316:23
44:6 57:11 58:1	details 29:1 79:22	138:10 163:14	disclose 46:2
61:19 62:13 63:2		169:16 173:1	

[discloses - doing] Page 18

discloses 188:5	dispute 149:18,23	diversion 242:3	228:8,15,18,20
disclosing 23:2	253:15 257:16	263:23 265:22	229:25 230:8
discount 306:17	disrespectful 68:8	310:9	231:15 232:25
discovered 146:24	68:12	divert 310:11	236:9 238:2,12
discuss 73:18	distribute 138:22	division 1:3 99:12	241:5,6,7,22
113:25 114:17,20	209:16 237:25	99:14,17,17	248:22,23,25
120:9 136:19	256:4,8,11,24	104:10,16 107:20	250:10,20 251:18
169:11	distributed 39:22	108:22 115:14	251:23 252:3
discussed 40:15	91:15 183:23	131:11,18 133:22	253:1,12 254:22
51:10 86:16	218:2 245:6	divisions 98:23,25	255:20,22 256:25
120:11 136:5	249:20 278:5	99:10,16 104:14	257:24 287:1,3
150:8 151:16	291:11 294:18,18	116:12	289:8,12 290:9
155:22 158:24	294:19 301:18,25	doctor 212:5	291:14 292:7
172:7,13 203:22	302:4,8	278:22 281:22	294:9 297:22
220:8 262:18	distributes 221:16	302:12,18 310:13	298:10 307:4
discussing 29:25	distribution 91:9	doctors 192:20,22	309:9,13 316:22
123:24 144:2	198:12 208:14	210:16 222:13	317:19,20
discussion 22:21	287:15	277:20 278:1	documented
30:3 81:1,3,7,11	distributor 5:16	document 1:9 8:7	193:16
81:13,24 90:19	207:8 208:6,22	8:12,19 9:6,8 35:9	documents 28:12
106:15 107:10	209:8,18 210:5	35:17 37:2 38:10	28:16 31:4,11,16
260:14	211:5,10,18 212:4	38:18 39:2,5,11,18	31:19,21,23,24
discussions 60:13	212:10,14,19	39:20,22,24 40:3	32:5,8,19,20 33:21
61:13 74:2 125:17	213:6,11,12 215:8	40:14,21,25 41:3	34:7,24 35:21
136:24 147:4	218:11,13,17,22	119:17 126:14	36:8,12,13,15 37:6
193:5 198:6,8	219:1 220:20	127:21 128:21	37:22 38:14 39:6
218:21 233:22	227:5 241:20	129:6 131:7 146:7	40:11 43:8 52:23
243:4	242:4 246:1 278:5	146:13,21,23	115:24 116:9
disease 167:22	distributors	147:22 148:10	147:2 149:13
185:16 221:9	198:20 209:3,11	149:8,9,11,19	150:16,17 155:9
279:15,16	209:15,24 210:11	150:1,7 151:4	156:14 182:19,22
diseases 279:19	210:16,21,25	153:17 155:8,13	182:23 183:3,13
disgruntled 97:16	211:13,24 212:24	155:20 156:12	202:25 223:20
dispense 93:7,13	213:20 214:5	158:4,5 159:17,18	249:2 271:14
95:17	216:25 217:14	159:20 160:3	283:24 284:2
dispensed 90:24	218:6,14 220:12	176:9 189:20	286:22 288:18
92:11,25 94:18	220:21 227:21	190:25 191:4	318:11
250:11 252:6,12	238:5 241:25	194:5 202:19,25	doing 62:10 63:13
264:5 302:23	246:14	224:8,14,20	65:16,21 66:22,25
dispensing 305:4	district 1:1,2 18:6	225:23 226:6,8,11	68:12 83:7 94:3
	18:7 23:20 54:6	227:2,4,7,15,22	104:19 106:22

[doing - employees]

118:20 122:16	188:2,13,17 195:8	37:16,24,24 38:1	191:8 237:16
143:5	237:15 242:3,11	40:25 112:18	303:9
dollar 101:18	248:16,21 252:19	123:4 183:17,18	effect 190:6
247:6,9	254:14,19 263:16	185:10 224:1	effective 274:6,12
dollars 101:2	263:25 264:7	225:2,4 229:12,17	efficiently 24:17
102:2,5 103:3,6,10	265:22 266:2,15	229:19 230:5	efforts 32:9 34:3
103:11 104:3	268:1 288:25	255:12,20,22	139:6
180:3 181:1,23	292:4,17 293:24	256:7 257:13	eight 34:8
door 159:25 161:7	294:8 297:7	258:10,12 259:17	either 22:13 39:21
161:13,14,18	299:24 301:17,24	259:23 261:7,19	40:3,14 53:22
dose 250:24 251:4	302:3,7 306:17	261:21 268:6	161:19 205:6
252:10,16	312:11	271:9,19 273:4,12	219:1 267:9 322:2
doses 89:4 250:10	drugs 61:6 121:23	295:6,11,14 296:3	elect 9:16 239:3,12
250:13 252:6	123:16 125:3,5,19	296:5 298:17	240:12
double 69:16,18	140:11 159:23	earlier 83:19	element 233:12
227:8,11,18	165:19 173:9	108:23 124:14	234:2,17 235:12
doubt 296:7	174:5,18,20,21	150:8 176:18	elements 117:12
dr 39:14,15,23	178:3 200:4,7	178:22 196:12	130:15
40:2,7,17 91:7	231:25 232:9	221:4 230:11	elena 3:3 19:9 27:2
172:2 258:2	235:22 243:16	249:6 260:24	eligible 188:23
260:14,20,21,25	244:16 247:12,20	262:18 263:8	ellis 3:11 4:18
261:11	252:20 254:15	283:23 284:19	20:10,12,15
draft 30:5,9	263:23 285:1,4	287:12 288:5	email 323:17
149:15 209:25	300:3,13,14	309:15 311:4	emergency 8:13
dramatic 280:10	304:25 305:4,5	317:4 318:9	38:19 132:1
draw 156:17,22	310:10,11 311:10	early 23:10 53:8	emerging 60:3,9
245:13 296:5	311:21 312:7,13	87:12,13 95:14	employ 52:15
drive 4:19	312:20,22 313:1	106:14 110:16	137:11
driven 162:23	due 56:24 106:16	190:19 266:2,15	employed 23:6
driving 205:16	245:25 246:13	268:1 296:20	52:24 53:1 83:13
drop 308:25 309:4	duly 21:11 321:7,9	east 3:18	94:9 97:25,25
dropped 161:13	dumas 183:10	eastern 1:3	98:14 107:4
dropping 38:8	duties 279:1,10	eboop 3:5	108:24 109:4,4
drug 1:10 8:15,17	duty 280:4	economic 54:22	110:23
9:19 41:11 60:21	dying 162:7	educate 105:10	employee 96:7
85:16 119:11	163:23 174:7,7	288:19	97:16 113:12
121:3,22 127:4	204:12,12 293:10	educating 82:25	136:17 181:18
128:20 138:20	e	105:15	196:9 256:2
140:1 151:6	e 5:12,17 8:10 9:4	education 49:18	employees 77:3
167:23 173:2,7	9:13,20,23 10:2,10	50:11,13,15 53:21	93:6 108:6,16,21
178:2 180:15	30:17 36:19 37:10	74:4 151:20 180:9	134:10,22,24

[employees - executive]

	T	T	T
135:15,16,18	entry 187:24	erstankewicz 5:10	305:8 308:17
188:6	188:15	escalate 122:6,10	312:16
employer 22:22	environment	escalated 114:6,9	exact 182:3 287:19
employment 23:16	99:17 227:10	116:20	exactly 40:22
48:11,17,25 50:17	279:18	especially 82:19	93:22 94:5 101:13
50:18 53:19 54:1	epicenter 116:23	203:22	103:3 113:20
54:25 58:6 96:13	116:24 117:5,8,9	esq 2:4,5,9,13,14	251:20,21 260:11
97:7,13 106:14	118:9	2:18 3:3,7,12,12	272:1 316:25
ems 90:8	epidemic 158:11	3:17 4:4,8,13,18	examination 7:7
encino 2:5,6	165:8 190:11	5:4,8,12,17 6:4,8	21:10,14 69:14
enclosed 323:11	202:17 228:12	6:13 323:5	145:5 207:1
encompass 54:9	237:2 266:2,15	essentially 100:13	284:10
endo 4:2,2 19:24	268:1	100:15,22 101:6	examiner 90:11
19:25	epidemics 266:9	117:19 173:24	113:8 171:20,25
ends 291:22	267:2 268:10,25	established 102:11	172:1 203:12
enforcement	epidemiologist	146:19 236:5	206:4,7,13 231:4
243:12,13,15	52:9,11 53:3	264:2	232:19 233:1
engaged 82:17	epidemiologists	estimate 28:9	examiner's 90:9
engagement 298:5	51:8,11,21,25	182:4	90:14 168:4
enhanced 106:9	52:13,15 108:23	et 1:10 87:18	171:15,18 204:10
enormity 308:21	109:11,15 110:23	181:8 279:19	231:21
entail 54:11	112:14 113:4	evaluate 277:21	examiners 89:1
entered 20:23	114:2,10 115:21	evaluation 199:25	example 36:1,8
189:1 325:9	116:15 117:22	event 322:3	79:7 90:19 104:1
entering 243:5	118:25 119:4	events 139:2,4	115:21 132:21
entire 54:1 56:11	122:4 131:14	214:2	143:1 241:17
59:9 86:22 204:8	165:22 170:4,7	everybody 177:1	276:15 278:13
204:11 218:7	190:14	222:22	280:22 281:4
324:5 325:5	epidemiology 50:7	evidence 83:6	examples 299:16
entirely 29:19	50:9,21,23,25	121:17 123:12	excluded 282:24
47:16 77:22	51:13 108:3,10,15	126:8 143:8	excuse 120:20
170:13 204:14	108:17 117:13	147:13 154:8	141:11 174:3
253:22 308:23	er 8:17 119:11	155:6 171:8	231:2,10 238:7
entirety 196:15	121:3,22 127:4,20	175:17 205:20	249:9 250:2 253:6
258:11	127:25 128:20	209:22 211:22	259:25 271:23
entitled 8:7,12,19	129:1,4,19,24	226:22 236:23	282:6,21
9:6,8 10:11 35:9	130:8,15	237:11 241:4	executed 325:10
38:18 57:18	erieview 22:9	242:23 249:14	execution 324:14
148:10 224:8,20	erin 5:8 19:18	265:4 266:19	325:19
315:9	errata 323:13,18	267:4 269:14	executive 2:3
	325:7,10,18 326:1	271:2 276:8 278:9	18:20

[exhibit - familiarity]

exhibit 7:14 8:5,6	experience 234:1	185:18 194:12	265:4 266:18
8:7,10,12,15,17,19	282:10	197:18 199:5	267:4 269:14
8:22 9:2,4,6,8,10	expert 46:20 47:6	200:22 201:14	271:2 276:8 278:9
9:13,15,18,20,23	49:8 145:14 149:4	202:8 205:18	305:8 308:17
10:2,4,6,8,10,11	161:22 162:22	207:11 209:5	312:16
34:16,19 35:8,18	164:10 172:24	211:21 219:4	fail 280:3
36:18,25 37:1	191:24 192:6	236:22 238:3,13	failed 219:1
38:17 39:1 85:15	222:19 233:16	241:23 242:22	fails 279:1,10
85:23 86:6 119:10	234:6 235:16	243:21 244:18	failure 314:5
119:16 146:3	245:9 246:22	289:25 301:20	fair 40:7,21 51:7
148:9,18 149:7	253:18 273:17	309:19 310:2	55:12,20,21 72:12
152:2 155:4	275:3 301:21	312:15	94:6 97:5 107:25
157:20 158:3	310:3,5 311:1,13	extremes 233:24	123:21 124:1
176:5 189:12,19	312:2	f	139:11 142:4
223:25 224:7,19	experts 163:9	f 6:13	170:13 173:20
225:1,1,6 226:5	173:5 174:14	faced 81:5	208:2 214:6 220:2
227:24 229:11	175:12,25 204:2	faces 10:12 315:3	220:3 223:15
238:24 239:1	261:16	315:10	225:3,9 226:17
248:14,20 254:10	expiration 324:19	facilitated 185:14	227:1 232:9
255:11,19 259:16	325:25 326:25	facing 55:19 81:19	236:13,15 241:2
259:23 271:8,13	expires 322:15	84:4 123:15,20	252:14 258:14
271:18 286:1,4,10	explain 216:12	263:15	261:5 265:2
286:16,23 287:3	218:3 232:16	fact 67:1 108:17	266:24 280:3
288:24 295:5,11	234:18,19	149:18 155:3	283:14 296:12,18
297:15 298:8	explanation	157:7 226:19	298:23
306:13 313:10,19	226:24	231:17 262:24	fairs 139:3
315:3,6,8	express 283:8	274:16 275:5,7	faking 312:12
exhibits 7:4 8:1	extensively 174:22	308:12	fall 87:12,13 88:6
9:1 10:1 146:4	extent 21:1 22:24	factor 145:25	88:23 89:21 90:16
285:25 313:16	24:2 25:18 26:7	206:1 311:11	93:20,23 95:14,22
exist 196:1	28:19 29:6 30:13	factors 203:25	96:4 97:20 203:21
exists 95:5 151:5	31:6 41:21 43:24	275:19 310:8	falls 265:11,13
expect 289:9	46:19 49:7 57:6	facts 83:6 121:17	familiar 35:19,20
290:10 291:3,6	58:13 61:15 83:5	123:12 126:8	37:5 39:5 56:12
294:11	95:18 100:9	143:8 147:13	57:24 120:13
expectations	121:15 123:10	154:8 155:6 171:7	158:5 197:2
272:12	126:7 128:17	175:17 205:20	208:18 259:7
expected 272:9	141:8 143:7,10,13	209:22 211:22	285:17 287:8
273:4 290:13	145:13 147:12	226:22 236:23	290:6 300:16
expense 245:4	149:3 153:18	237:11 241:4	familiarity 259:9
	159:16 175:16	242:23 249:13	259:12 287:10
		272.23 279.13	

[familiarity - force]

210.16	154.5 10 12 17	6 J 05-0 165-1 10	£4 71.5
310:16	154:5,10,12,17	find 95:9 165:1,10	fit 71:5
familiarize 288:15	155:23 156:20,25	166:9,11 170:20	five 27:25 28:5
288:19	157:11,12 159:14	170:23 292:2,16	175:9 240:23
families 60:5,7	159:22 160:17,21	293:1 306:9	241:19 293:23
61:1,3 73:4,4,13	161:6 162:4,6	311:20 323:11	294:7,12
132:18 223:5	164:14 170:22	finding 170:14	fix 164:21 313:2
family 43:16 45:5	173:7 174:10	findings 9:19	fixation 163:3
45:10,25 46:8	203:3,16 204:6,21	248:17,21	fixing 163:1
133:7,11	205:14,14,16,25	fine 51:5 66:24	flask 77:13,20
family's 163:25	206:3,9,10,12,14	67:4 68:23 83:18	flip 231:11
far 70:20 84:2	206:15,15 276:5	144:20 216:2	floor 6:9
107:18 122:18	fgallucci 2:21	270:4	flu 132:9,22 133:3
151:6 179:12	field 51:8,13 82:18	finger 270:18	133:15 134:1,6,9
184:3,8 254:16	193:8 289:20	fingers 269:20	135:4,10,14
289:14	fighting 305:5	fingertips 165:18	136:12,18,20
fast 247:17,18	figure 168:9 169:1	finish 214:12,14	137:8,15 221:14
274:8	182:3 247:6,9	287:5	focused 108:12
fatal 308:20 313:3	250:10 252:2,18	fire 90:8	139:5
313:3	254:13 255:5	fired 53:16,17	folks 119:23 134:1
fatalities 87:18	314:12 318:6	76:5 96:10,11	134:9 137:14
fatals 56:24,24	file 140:6	firm 27:15	227:3
115:7,8 165:6,16	filed 18:6 24:6	firms 174:24	follow 177:22
168:2,3	28:23 29:17 30:6	207:25	178:21 215:23
fda 210:1 274:6,12	31:3	first 21:11 24:18	273:5
federal 21:10	files 33:7	28:1,22 76:23,24	following 124:16
179:23 180:13,22	filibustering 215:2	85:25 90:8 131:17	239:16 264:19
213:16,18 214:4	filing 29:4	147:17 150:24	follows 21:13
214:25 215:7	fill 74:21 78:4	152:1 158:7 160:4	food 279:18
216:24 241:16	210:21 222:11	175:21,22 188:17	299:24
285:5	filled 222:24 281:6	193:21 224:14	force 8:15,16 10:4
fee 267:11	281:23	230:25 231:3	10:6,8 42:6 85:11
feed 140:20 163:3	filling 75:6 282:4	235:11 257:1,23	85:17,17 111:19
205:23 233:24	282:12	258:9 263:20	112:6,8,9,12,15,18
feel 233:7,10,11	final 8:15 76:21	277:8 284:18,21	112:19 113:1
feels 140:12	78:18 80:11 85:17	286:23 293:21	146:9 163:18
fees 100:18 179:2	149:15 298:8	296:22,23 316:6	165:25 166:1
179:4 183:19,21	finalists 76:14,15	321:9	177:6 184:22
fentanyl 48:18	80:11,13	firsthand 73:2	185:5,14 186:6,10
60:20 129:15	finance 54:23	311:16	286:5,11,17,24
147:19 152:5,11	182:24 183:2,7,9	fiscal 100:23 101:8	287:14,16,20
152:12,17 153:2,9	183:14	101:12	288:25 290:2

[force - gathered] Page 23

291:13 292:2,18	75:10 78:15 92:5	293:6 294:5,15	full 21:17 110:17
292:18,19 294:23	94:4,11 95:1,19	296:1,9,16 297:9	function 99:1
295:3,19,25 297:2	96:8,17,21 107:16	297:20 299:1	functions 90:4
297:24 298:13,14	108:9 113:14	301:19 302:13,19	104:20 131:10,18
298:20 306:12,19	117:25 124:20	302:25 304:20	266:1
306:25 313:7,14	125:24 128:22	305:25 306:21	fund 42:18 92:15
313:23	141:1,7 143:9	307:16 308:4	99:23 100:14,24
forces 109:21	144:3,10 149:2,12	310:1 311:1,14	101:20 102:19,24
111:13,15,23	149:22 150:14	312:3,9,17 314:1,8	179:7,22
112:1 167:24	151:8,10 152:9,14	foundational	funded 180:14
foregoing 321:15	152:19 153:4	96:22	181:14 186:22,23
321:19 324:13	154:7,15,19	founding 295:20	190:23 191:10
325:18	155:24 156:11	297:1	262:20
forgotten 66:10	157:3 160:9,23	four 27:4 77:10	funding 74:3
form 132:8 149:15	161:8,21 162:21	146:15 148:3	91:23 92:2 100:18
149:15 170:21	164:9 166:21	176:20,21	180:1 181:10,14
182:6	172:23 189:3	fourth 257:5	183:20 186:19
formed 291:13	191:23 192:6,10	frame 73:23	190:10,17 262:16
292:2,18,19	193:3,14 196:3	203:11	funds 92:10 99:21
former 260:21	201:23 209:13,21	francisco 5:5	100:6 102:18
formerly 53:3	210:2,8 212:8,12	frank 2:18 19:3	103:24 178:23
formulary 196:9	212:17,22 213:1	228:11	186:22
282:20,22 283:5,7	219:6 220:15,24	free 25:25 79:2	funneled 41:12
283:10,16	221:20 222:19	324:14 325:20	furnished 264:6
forward 8:8 35:10	226:4 231:12	frequency 172:6	further 24:14
105:9 115:23	232:2,11,21	frequently 171:23	43:11 57:22 81:21
191:1 256:19	233:14 234:4	friday 146:13	206:19 318:14
258:7,17 323:15	235:14 241:12	friends 43:16 45:5	319:6 321:18
forwarding	245:8 246:23	45:10,25 46:8	322:1
256:14,22 258:19	248:2 250:4,21	47:10	future 22:2 140:10
foster 52:21	253:2,11,17	front 5:4 66:23	g
found 33:6 34:25	254:23 257:11,19	167:13 169:16,23	gain 263:3
35:22 36:9,13	264:16 265:5	169:25 171:9	0
37:7,23 39:7 43:9	266:17 267:3	173:20 248:6	gallucci 2:18,18
88:15 161:14	268:3 269:14	305:12,14	19:3,3,4
299:25 300:10	272:20 273:17	fryerson 52:22	games 270:17,19
307:17	274:7,14,20 275:2	fu 2:9	gary 8:10 36:19
foundation 41:20	276:7,17,22	fulfill 279:1,10	37:11
42:11 53:13 55:8	277:25 280:15	280:4 306:25	gather 163:21
56:1,19 58:25	281:9,25 282:8	fuli 2:11	170:2,3
59:7 72:25 75:3	283:1 292:12,24		gathered 217:2
			233:20

[gatherings - grants]

gatherings 163:9	134:1,6,9 135:10	250:19 265:25	35:16 36:24 38:24
gender 121:5	137:8 166:14	going 23:22 24:18	43:7 49:16 55:9
general 9:19 23:14	182:2,4 185:3	25:7,11 30:4,12	56:7 71:14 110:21
42:18 51:22 56:8	215:21 249:17	42:1 43:1 44:2,5	124:16 126:22
56:10 79:6 82:20	269:25 287:5	44:17 45:2,15	128:1 134:14
83:24 84:13 99:23	320:2,11	46:1 57:10,18	140:14 145:5,7
100:14,24 101:20	given 56:6 81:21	58:19 60:25 61:5	148:11,20 151:11
101:21 102:19,24	112:5,7 115:3	62:1,8,9,21,24	155:14 158:2
103:20 163:18	118:6 136:13	63:8 64:4,7 65:1,3	178:17 191:20
176:16,17 177:9	169:8 173:6 181:2	65:4,7,14,15 66:16	199:21 204:20
183:22,24 184:1	231:22 290:1	66:16,17,22 67:1,6	207:1,3 224:1,2
186:22 248:16,21	321:12,16	67:9 68:9 69:24	227:25 254:9
260:21 261:17	gives 219:2	70:20,24 71:1,4,6	255:12 259:7,18
272:24 283:3	giving 89:10	71:7 73:15 89:6	259:24 269:22
288:9,12	112:12 136:20	95:13 97:1 98:7	271:19 284:10,12
general's 85:2	263:11	99:25 100:21	314:23 315:2,10
175:5,23	go 23:4 43:10	105:5 106:11,17	321:9 323:8 324:4
generalities 133:4	45:14 46:14 53:25	110:2,6,10 123:15	324:9 325:4,13
generally 54:12	63:22 67:19 68:4	124:3 133:4 137:1	326:20
59:14,19 60:12,19	68:17 70:9,16	140:8 143:15	gordon's 317:10
81:16 98:7 106:24	71:1,6 105:5	145:17 148:17	gotten 90:13 162:2
110:25 111:1	110:16 119:22	162:14 174:21	govern 213:5,10
128:20 157:11	131:1 163:8,12	178:11,17 199:15	213:19 216:24
310:21,22	164:25 165:11	204:22 206:21	governing 215:7
generate 169:18	166:11 172:25	207:6 215:12,25	government
generated 100:19	176:23 183:19,22	223:19,20 228:7	179:24 213:17
109:25 116:11	187:17 206:19	244:7 249:17	governor 9:15
124:5 179:4	222:13,21,23	254:3 270:6,17	239:3,11 240:11
183:21	230:7 233:24	274:8 283:21,25	graduate 49:17
geographic 56:13	261:2 276:4	284:16 286:1	50:14 53:23
germane 115:2	283:22 293:19	289:14 299:7	grand 260:14
getting 34:23 61:5	305:2 306:14	313:6 316:12	261:10,15
69:22 163:1 174:8	314:17 317:22	318:19	grant 6:9 100:18
288:6	318:17,19	good 18:1,17	180:13,13 190:16
gilson 172:1,2	goal 269:1,3	21:16 223:7,11,14	190:21 262:16
gingell 8:10 36:19	goals 267:1 268:24	284:12,13	263:4,5 269:6,9
37:12,13	306:25	gordon 1:15 7:7	271:4 272:12
give 22:7,20 24:15	goes 33:24 44:4,19	8:20 9:4,5,10,20	306:25
27:1,4 80:23	44:24 45:9 58:1	9:23 10:12 18:4	grants 179:1,12,15
91:10 94:13 98:19	181:3,19 182:12	21:9,14,18,19 22:7	179:19 180:2,4,18
114:16 132:21	182:25 203:12	26:5 29:9 34:25	181:1,12 272:8

[gray - hearings] Page 25

gray 6:13 20:17	handwriting 36:1	107:11,15,20,23	258:23 260:7,8
great 22:6 33:19	36:4,5,14 39:10,12	108:22 109:19,19	262:1,11 263:13
307:13	39:13 41:8 176:8	109:24 110:24	264:24 266:7
greater 98:22	handwritten 8:8	113:18 114:4,12	268:9,25 269:2,24
173:16	35:11 88:1,2,6,11	115:14,17,22	270:25 273:2
gretick 9:23 96:2,3	88:18 146:20	116:7,13 117:13	277:12,14 279:1
97:6 259:17,24	147:3,18,23	117:16 118:5,17	279:10,21,22
260:4,5 261:19,22	happen 67:9 76:20	121:12,20 128:2,5	280:5,5 289:12,20
271:20 295:12,15	237:20	131:11,12,18,23	290:10 293:8
296:24	happened 87:11	132:7 133:18	294:23 295:1,24
griffin 9:11 228:1	237:21 252:23	134:11,15,19,22	296:25 298:3,19
ground 24:15	happening 42:15	135:5 137:2,21	299:23 303:3
group 121:5	61:3 230:19 312:5	138:9,17 139:1,3,7	305:14 306:5,24
261:16	happens 42:12	141:14 146:17	307:2,8,11,20,25
growing 263:22	157:7	148:4,12 149:17	309:11 315:2,10
guess 185:17	happy 33:10 34:13	149:20 150:20	316:15 317:12
guessing 299:22	272:6	151:12,15 153:22	health's 42:2
guys 65:13,14	harassing 234:13	154:1 155:11,15	92:24
67:19 230:12	251:2,6	158:9 165:23	healthcare 223:8
270:16 307:12	hard 31:21,23	166:3 168:5 169:9	223:11 277:15,16
308:1	32:4,7,19	169:19 170:1,5	healthy 108:2,8
h	hardest 175:10	171:12 175:2	131:13
halfway 64:21	hbc 6:7 19:17	176:20 177:16	hear 60:5 89:15
hampshire 49:22	head 47:18	178:20,23 179:14	125:14 185:16
49:24	health 4:3 5:16	180:11 183:4,12	311:6
hand 36:25 38:25	8:20 9:18 10:12	184:9,13,17	heard 34:6 61:10
123:2 148:17	19:24 20:3 29:2	185:24,25 186:9	70:2 73:15 89:12
	42:8,19 50:2	187:15,22 188:7	90:25 116:23,24
123:2 148:17 291:20,25 293:18 322:5	42:8,19 50:2 52:16 54:20 58:6	187:15,22 188:7 189:2 190:15	90:25 116:23,24 140:16,18 189:6
291:20,25 293:18	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8	187:15,22 188:7 189:2 190:15 193:19 195:4,8	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18
291:20,25 293:18 322:5	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9
291:20,25 293:18 322:5 handed 35:16	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16 handing 39:23	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4 95:10,16 96:4	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25 229:2,6,22 230:2	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18 311:8
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16 handing 39:23 85:22 119:15	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4 95:10,16 96:4 97:21 98:9,20	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25 229:2,6,22 230:2 236:4,21 239:16	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18 311:8 hearing 61:1,1,4,7
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16 handing 39:23 85:22 119:15 158:2 189:18	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4 95:10,16 96:4 97:21 98:9,20 99:3,12,20,22	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25 229:2,6,22 230:2 236:4,21 239:16 240:3,6 247:11	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18 311:8 hearing 61:1,1,4,7 73:2 163:13,19
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16 handing 39:23 85:22 119:15 158:2 189:18 255:19	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4 95:10,16 96:4 97:21 98:9,20 99:3,12,20,22 100:8 102:8,10,25	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25 229:2,6,22 230:2 236:4,21 239:16 240:3,6 247:11 248:15,23 252:4	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18 311:8 hearing 61:1,1,4,7 73:2 163:13,19 243:2 311:16
291:20,25 293:18 322:5 handed 35:16 39:20 40:14,23 284:3 286:22 313:16 handing 39:23 85:22 119:15 158:2 189:18 255:19 handling 64:17	42:8,19 50:2 52:16 54:20 58:6 74:11,17 75:8 76:2 78:10,20 79:3,19 80:2 81:4 82:4 83:15 86:10 92:7,13 93:2,6,24 94:8,10,20,24 95:4 95:10,16 96:4 97:21 98:9,20 99:3,12,20,22	187:15,22 188:7 189:2 190:15 193:19 195:4,8 211:11 214:19 217:5 219:25 220:10,14,18,22 223:3,15,18 225:11 228:23,25 229:2,6,22 230:2 236:4,21 239:16 240:3,6 247:11	90:25 116:23,24 140:16,18 189:6 193:9,23 196:18 200:6 208:9 214:11 232:3 242:24 261:18 284:21,23 285:7 299:12,14 310:18 311:8 hearing 61:1,1,4,7 73:2 163:13,19

[heart - illicit] Page 26

heart 278:13	higher 55:23	hosted 185:13	i
held 18:8	58:10,22 254:19	hour 110:17	idea 211:16 233:6
hello 229:21	highlight 38:1,14	hours 28:11	307:13
260:13	highlighting 38:5	264:10 284:1	identification
help 24:16 113:22	38:7,10	house 163:17	34:20 35:14 36:22
140:7 168:10,10	highly 130:11	houses 61:4	38:22 85:20
174:13,13 190:11	hire 78:13,19 79:2	huge 123:14	119:13 148:15
204:4 278:6	79:23 80:23 104:3	139:23 140:7	157:25 189:16
303:23 305:5,22	105:2 106:15	163:20 168:12	224:4,11,23 228:4
308:2	187:9	174:7,11 175:7	229:14 239:7
helped 308:13	hired 75:13 79:17	306:8,10	248:18 255:16
helpful 222:5	81:2 93:12 108:18	hugh 172:5,7,13	259:21 271:11
helping 308:15	109:7 118:21	huh 24:23	286:8,14,20 295:8
helps 113:23	hiring 76:9	hum 55:4 99:8	315:12
hereinafter 21:12	history 45:2,11	126:19 185:2	identified 34:8
hereunto 322:4	54:1 58:5	289:1 293:16	227:21
heroin 8:7 35:9	hit 175:10	313:20	identify 21:1
heroine 44:22 45:6	hiv 108:3,11	human 158:10	27:10 196:24
46:9 48:3,9,12	131:15 137:23	299:24	302:11,16,22
60:20 129:11	138:2 268:11	hundred 162:5	314:4
151:5 152:3	hoc 86:19	182:11 187:3	identifying 139:8
159:14,22 160:5	hold 92:18 127:11	189:9	identity 49:4
160:20 161:5	143:6 228:14	hungry 110:18	211:14,19
162:16,20 164:4,6	229:18 237:10	hurst 257:25	ii 300:3,14
164:7,14,22	239:9 246:3	258:2	iii 2:18 300:13
165:10 166:10,20	247:15	hydrocodone	illegal 161:12,13
167:2,7,17 168:16	holding 269:20	299:9,17 300:1,11	161:15,16,16
168:18 169:13	holds 86:13	300:11,20,23	162:2 174:18
170:8,15,18,21	hollister 1:20 18:9	301:2	205:24,25 232:14
171:1 172:8,14,20	home 133:5	hypothetical	235:8,11 247:12
173:1,7 174:9,9,16	homes 61:10 311:6	104:12 130:23	247:20,25 276:5
175:14 196:1,6	311:19	132:25 160:24	312:20,22 313:1
276:5	honestly 216:2	161:10 192:11	illegally 155:19
heroine's 161:20	291:10	222:3,18 223:10	156:9 157:2,8,12
hey 265:16 305:20	hooked 204:14	223:17 233:15	178:3 243:1
307:11	hop 258:24	234:5 235:15	illicit 48:18 129:15
high 34:4 121:19	hope 316:13	273:18 276:22,23	152:24,25,25
163:1 170:19	hopefully 38:9	277:25 278:16	154:12,17 160:18
185:3 278:12	191:8	279:3,12 281:17	162:2 174:18
316:14	hospital 39:16	290:23 291:9	205:15 206:15
	92:1	292:14 308:18	

[illicitly - information]

Page 27

illicitly 152:13	inappropriately	increased 202:22	265:8 278:12
154:6,11	302:12,18,24	249:21	311:17
illinois 4:19	incapable 234:25	increasing 292:3	industries 4:12
imagine 55:16	incidence 58:22	292:16	infant 132:2 139:6
232:12 291:1	incident 115:6	incredibly 279:20	268:14
immediate 75:13	incidents 58:10,17	incurable 212:15	infections 221:11
98:10 317:18	130:21	incurred 245:5	influenza 111:7
immersed 51:8	include 155:22	indented 263:22	135:24
immunizations	260:15 283:16	independent	information 40:2
138:5	295:19	137:10 147:10	40:15 48:10 81:22
impact 61:2 85:7	included 129:24	263:4,5	81:25 82:17,21
117:20 132:15	130:1,5 245:2	index 7:1,4,5 8:1	83:2 84:10,19
164:1 168:12	269:7,8 283:10	9:1 10:1 11:1 12:1	88:10 89:1,3,9,11
173:2 175:7 191:9	323:13	13:1 14:1 15:1	89:25 90:2 94:23
247:5 280:10	includes 25:1	16:1 17:1	97:12 106:12
310:24	72:15 156:1	indiana 6:3 20:7	109:22 112:5,8,9
impacted 56:6,17	including 223:13	284:15	112:12,17 113:10
57:1,5 58:9,15	263:16 266:1	indicate 272:15	113:17,18,22
59:24 140:13	277:17	indicated 253:19	114:11,16 115:4,9
182:7 293:24	income 101:17	indicates 177:16	116:6 117:1 118:3
294:8,13	184:8	226:9 254:13	118:6,17,22
impacting 59:10	incomplete 104:11	312:23	120:12 123:6,7
60:7,13 133:6	130:22 132:24	indicating 107:12	124:4,7 125:9,17
280:2	160:24 161:10	323:13	126:10 127:17
impacts 83:9	192:11 222:2,18	indirect 181:9,22	130:16 150:9,17
109:20	223:10,16 233:15	indirectly 181:4	153:12,20 154:21
implementation	234:5 235:15	individual 44:16	159:4,5 163:15,19
272:5	273:18 276:21	95:20,23 133:2	163:21 165:2,4,15
implications 108:4	277:24 278:16	188:4 211:14	165:16,24 166:1
important 66:10	279:3,12 281:16	240:5 296:4	166:24 167:19
176:24 220:13,22	290:23 291:8	individuals 73:3	168:19,21,22,24
240:9 279:18	292:14 308:17	73:10 76:12 91:10	168:25 169:8,15
289:24	incorporated	132:18 135:24	169:18,22,24
importantly	325:12	139:9 140:10,19	170:3 171:15
131:22	incorrectly 267:22	165:6 174:19	173:4,5,19 175:13
impression 317:13	increase 101:17	198:21 204:2	177:19 178:7
improper 57:23	103:9,16 107:2	205:4,7 221:23	187:16 188:4
242:10	139:21 173:22	223:5 225:5 226:9	193:4 194:5,11,20
improving 236:20	201:25 202:1	231:25 240:4	194:22 198:7
inappropriate	205:16 249:23	242:11,20 243:3	201:3,6,9,17
244:5 270:13		245:2 261:17	202:12,15 204:3

Veritext Legal Solutions

[information - issues]

206:13 213:23	instrumental 40:9	288:6	85:9 87:14 89:19
214:8 217:2,3,6,7	91:8	interviewed 77:2	97:22 101:17
217:8 231:21,23	insurance 179:10	80:7	105:16 107:9
233:21 249:23,25	212:21 280:12,16	interviewing	108:4,11 113:24
256:9,12,14,17,20	280:24 281:1,12	77:16 80:25	114:18 123:14
258:21 260:17	281:18,24 282:6	introduction	132:7,17 133:23
262:2,21,24 263:3	282:17	263:21	139:17,23,25
264:3,8,14 265:1	insurmountable	invades 43:25	141:9 143:15,17
266:23,25 275:16	140:12	44:14	159:2 162:7
281:21 287:16	integrity 316:15	invest 181:5	163:22 166:6
288:11,15 289:14	intended 25:13	invested 163:20	168:8,11 169:2
initial 81:1 136:16	73:19 160:15,19	investigate 275:13	174:12 175:10
initially 195:13	160:25 161:4,11	303:4,13	181:6,11 182:7
initiated 137:5	161:17,20 162:16	investigation	185:17 190:14
initiatives 105:11	162:19,20 273:20	275:23 276:2	191:6,9 193:9,18
105:19 190:25	intensive 138:19	investigations	201:19 202:14
191:2,14	138:21	72:8 73:23	223:2 230:17
inject 91:17	interact 135:1	invited 185:11	233:22 240:7,13
injection 152:3	210:11,16 285:21	295:2	243:10 247:2,22
injuries 312:13	interaction 73:9	involve 49:24	270:20 275:17
inquiry 265:13	97:9	involved 29:16	295:18 299:15
insert 193:22	interactions 68:23	69:22 71:21	307:3 308:8,10,22
194:22	interested 78:9	107:22 108:11	308:23 310:8,24
inside 194:1	322:3	111:18,20 188:20	311:23 312:24
insight 196:8	interesting 308:1	193:6 254:14	314:12,14
inspections 279:17	internal 26:21	305:4	issued 297:5,19
instance 80:22	80:4	involvement 185:4	298:8 299:25
88:5 235:11	internet 159:25	185:10,23 186:6,7	issues 22:21 32:9
302:17,20,22	160:21 161:3	291:11	52:14 55:19 59:20
317:25	310:18,20,21	involves 240:1	60:20 71:18,19
instances 114:13	interpret 252:5,13	involving 252:19	72:6,10,14,15,17
institute 316:17	interrupting	254:19,20	72:18,24 73:20,25
instruct 30:12	268:19	ish 284:2	81:4,8,19 82:14,15
44:2,17 45:3,15	intervention	isolate 164:11	82:24 83:9 86:11
143:15	279:15 308:9	issuances 89:4	86:16 87:4,8 99:4
instructing 44:9	309:8,13	issue 23:15,16,16	99:11 106:6,8,17
44:20,25 45:20	interventions	40:10,19 44:1	108:13 109:18
207:17,19	303:18	55:6,15 59:5,9	110:5 114:9,21
instruction 29:18	interview 76:11,15	60:1,21 69:5	115:2,11,13,18
219:6 320:2,11	76:17 78:16 80:13	71:24,24 73:5	117:2 119:24
	81:9,14 82:8	81:22 84:3,7,21	122:12 123:19,25

[issues - know] Page 29

132:12 135:19	job 48:4 68:13,14	289:17	315:15
136:7 137:9 139:9	68:16 73:13 84:11	katherine 52:22	know 24:5,9 25:8
140:12 141:20	96:6 105:12 111:4	kathie 259:25	25:19 26:3 31:15
142:14 150:20	119:6 225:10	kearse 3:7 18:25	33:1,9,22 34:14
153:16 181:19	241:13 288:7	18:25	39:21 41:23 42:14
182:13 214:21,22	johnson 3:10,10	kec 5:15	42:17 45:16 46:16
221:3 223:5	134:8 135:9	keep 44:6 57:14	46:24,25 47:2,7,11
230:19 240:14,15	join 318:9	65:5 68:5 270:17	47:17,19,21 48:2
241:14 263:15	joined 101:14	289:23	48:11 49:2,12
265:15 280:1	175:21 317:14	kelly 5:7 19:19	53:9,14,15 61:21
288:16,20 289:23	joining 105:4,6	kevin 2:13 19:7	68:25 69:4 70:7
293:9 305:14,17	307:19	key 77:21 127:24	74:25 75:4,7,11,12
306:5,8,8	joint 158:9	killers 173:10	75:15,19,21,25
issuing 94:8	jointly 159:6	killing 158:12,21	76:3,4,6,20,22,25
item 41:15 102:23	jones 3:17 19:15	kimberly 183:16	77:1,14 78:18,21
items 40:21	jonesday.com	kind 68:8 87:22	79:8,21 84:5 85:1
178:19 237:23	3:20	88:17 109:17,17	86:4 87:3 96:9,15
240:23	joseph 2:14 19:5	114:9 116:2	96:18,20,25 98:3
j	judge 1:8 58:3	118:12 120:11	101:7 102:3 103:3
j 4:8	216:1	166:4 173:2	104:22,23 107:20
j&j 20:12	july 1:17 8:5 9:23	176:25 179:21	107:21 109:19
jackson 5:7 19:19	18:3 34:18 259:18	194:5 272:7	110:19 111:17,19
80:22 81:2,23	322:6 323:4	280:20 290:9	111:25 112:11,24
86:11,20 122:8	jump 61:18	303:17,17 305:16	113:2,3,6,15,19,20
228:11	june 74:14 83:15	306:2,3	114:5 116:15,18
jackson's 78:12,23	97:25 98:3,14	kinds 115:25	117:7,17 118:15
jacksonkelly.com	105:9,19 106:14	306:3	118:21 120:22
5:10	107:4 109:5	kirkland 4:18	121:22,24,25
jana 9:20 52:24	118:10 177:9	20:15	126:5 130:24,25
255:12,23 256:2	315:1 316:8,9	kirkland.com 4:20	131:3 132:19
258:7 259:25	jurisdiction 201:5	kit 91:14	134:21 135:8,21
271:19	201:8	kits 90:24 91:6,9	136:3,4 140:9,14
janssen 3:10 20:10	jurisdictions	91:22 92:6,11,25	141:3,4,11,12
20:12	201:8	93:7,13,16,25 94:8	142:9,11 144:5,13
jciaccio 2:17	justice 190:18,22	94:18 95:17,21,25	144:14 153:13
jeannie 134:8	262:17 269:9	97:22 98:5 138:23	154:16 156:25
135:9	271:6	184:15,16	157:15,18 160:8
jeff 6:17 18:11	k	knew 74:20 83:2	160:13 161:1
jessica 6:13 20:16	kaiser 281:3,4,7,7	160:12 211:5	162:9,11 163:7
jessica.soricelli	282:10,15,17,22	292:9 294:3	164:11 166:5
6:15	282:25 283:9,15	296:13,19 298:24	168:2 171:13,16

[know - letter] Page 30

173:3 178:5	276:12,18 278:10	l	leave 53:6,11
181:21 182:2	279:23 282:12	1 1:25 2:14,18	62:22,25 65:10
188:3,3,14 189:4,5	283:21 284:18,24	75:20,20 183:17	67:7,23 68:9
191:22 192:13,14	285:1,3,4 287:19	183:17,18,18	276:15 283:25
192:17,22 193:22	289:13 290:6,7	321:6 322:12	304:17
195:12,15,16,20	291:10,11 294:11	lack 178:24	leaving 67:24
195:23 196:17	294:25,25 296:22	lakeside 3:4,18	215:18
197:4,6,12 198:9	297:5,18 299:9,19	landed 271:16	led 187:24 204:17
199:1,10,25 201:2	299:22 300:6,17	landfill 23:20	left 53:8,14,15
203:10,19 204:22	300:18,21 302:20	language 24:23	75:8,25 76:5
204:25 207:8,24	303:1,7,11,15	large 173:8,11	95:21,23 96:3
207:25 208:2,5,19	304:9 308:6 310:9	180:12 234:7,25	97:10 187:8
208:22 209:5,14	310:10,12,13,15	largely 314:15	239:19 291:25
209:23 210:3,4,9	311:3 312:10	lasalle 4:19	293:18
210:10,14,15,19	314:4 317:15	lasted 317:18	legal 24:3 141:9,9
210:20,23,24	318:3,4	late 33:21,22	143:10 144:4
211:2,13,14,19,23	knowledge 53:19	34:24 87:13	145:14 149:4,4
211:24 212:4,9,10	91:20 92:15 96:7	283:24 318:10	153:2,19 157:16
212:13,14,18,19	112:4 151:22	law 27:14 69:16	160:4,5,13,18,20
212:23 213:4,9,13	153:16 167:1	242:18 243:11,13	160:23 161:2,3,5,9
213:13,14,15,17	168:15 197:8,14	243:14	199:10 207:12
213:24 216:3,22	198:2 200:9,18	law.com 5:15	213:2 219:5 238:4
217:9,10,11	203:5 208:20	lawful 21:9	238:14 241:24
218:10,12,15,16	213:3,25 214:4	lawfully 245:6	242:21 243:23,23
218:17,19,21,24	216:7,8,10,11	273:23	244:18,19 245:9
218:25 219:16	219:15,19,22,24	laws 213:18	245:10 246:22
227:12 233:10,11	220:4 221:1	lawsuit 24:6 28:23	274:2 301:11,11
236:20 237:7	284:19 291:15	43:13 208:7 211:6	311:2,13 312:2,10
242:24 246:19,24	304:1,11,22	218:22,25 219:3	323:1 326:1
248:3 249:3,22,23	309:14 312:18	243:20,24 245:25	legally 155:17
250:6,24 251:4,12	known 189:25	246:2,13,14 301:5	156:8 157:1,6
251:13 252:10,11	192:25 193:11	lawyers 27:14	192:8 199:2
252:13,16 255:9	220:5 264:1	194:16,25 207:15	205:15
256:15 258:2	295:21	208:25	legislation 72:4
260:9,11,22	knows 46:12	lead 138:3 313:2	73:18
261:25 262:9	218:13	leadership 271:24	legitimate 174:15
263:1 265:6,11	koishor 6:17 18:11	leading 235:21	175:14
267:10 272:7	kristen 5:12 19:11	leaflet 194:1	legitimately
273:3,8,10,11	ksusman 2:16	leana 9:15 239:2	167:15 170:10
274:3,15 275:5,12		learn 28:22	letter 8:5 9:15
275:20,22 276:9		100011	34:17 74:23

[letter - lot] Page 31

238:20 239:2,11	308:6	lived 56:7,10	248:11 250:9
239:23,25 240:10	limiting 125:12	lives 133:5 163:25	252:2,17 253:23
272:6 273:6	limits 188:25	163:25 278:7	254:12,15 255:18
323:19	line 36:2 102:22	living 278:12	257:23 263:8,10
lettered 41:6	147:17,21,22	llc 3:7 6:3 20:7	263:13 288:23
letterhead 156:14	228:9 271:22	284:15	290:6 291:16,17
letters 238:23	305:12,14 323:13	llp 1:20 3:11 4:8	291:25 293:17
272:10,18	325:7 326:3	4:13,18 5:3,17	295:10,14 305:20
letting 67:13	lines 266:25	6:13	306:11 307:25
level 34:4 114:16	link 245:4	local 82:22 83:24	316:11 317:3
117:16 131:1	list 236:10,14,19	84:9 114:15	looked 58:16
132:16 136:22	237:6,23 238:17	117:23 174:25	59:23 60:1 121:3
159:1 167:21	240:23,25	180:14 201:10	124:5 150:11
185:3 197:6	listed 81:20	308:24	194:4 201:19
198:16 214:4,21	108:23 131:20	locally 200:11	203:19 288:4
219:17 241:16	150:3 159:10,19	located 18:9 23:20	290:7 297:22
285:5 316:14	178:20 207:25	logan 4:9	298:12,17 313:8,9
leveling 257:6	225:6 226:18	logo 121:8,9,12,19	313:13
levels 151:5	239:19 325:7,17	long 22:1 56:7	looking 40:9 61:6
leverage 262:12	listening 20:25	69:23 75:21 94:2	61:9 74:21 78:4
lewis 4:13 20:19	21:2 163:10	94:5 98:3 166:15	85:8 109:16,17
liability 219:3	185:17	196:7 249:16	111:3 119:22
liaison 5:16	listing 325:7	260:9,11 270:21	127:13 130:3,25
licensed 218:18	listservs 256:22	274:10 282:5	131:3 139:21
264:5,6,9 273:24	258:20	310:6,7	175:6 190:10,13
licenses 100:19	literally 246:7	longer 36:3 53:1	203:2 223:19
179:5 183:19	litigation 1:7 18:6	147:24 152:2	287:5 297:15
265:8	21:21 31:5,17,21	164:17 174:19	311:7
licensing 279:17	32:13,21 169:5	176:11 244:4	looks 35:19 39:13
life 48:16,25 49:13	323:6 324:3 325:3	289:20	147:15,15 204:9
56:11 133:6 162:3	little 29:14 32:1	look 35:20 56:22	225:5
232:7 279:22	41:5 83:11 101:1	56:24 57:2,4 69:9	lost 232:5
lifelong 58:5	101:2 103:2	82:23 111:3 113:4	lot 34:5 60:25
lifetime 171:4	110:16 137:25	119:19 120:7,17	61:10,11 70:7
likelihood 121:19	142:11 162:9,11	125:22 126:4,9,17	82:18 84:18
limit 198:5	162:15 180:3	126:20 127:13,16	109:21 115:3,5
limitations 184:8	195:2 199:22	128:24 146:22	118:6 125:9 139:1
limited 125:23	269:25 284:19	163:11 165:4	141:17 142:16
126:6,13,23 127:7	297:3 317:11	168:1,2 170:4	150:15 163:7,8,15
127:8 139:18,19	live 163:24 276:11	179:19,21 202:15	163:16 165:20
227:19 266:11		227:2 239:12	167:10 168:5,6,6

[lot - mean] Page 32

-			_
169:8 171:22	271:9,19 273:4,12	manufactures	massive 84:21
173:3 174:23	295:6,11,14 296:3	197:5	master 58:3 63:19
175:6 176:23	296:5 298:17	manufacturing	66:23 70:16
185:20,20 202:14	mailed 161:18	196:18 197:10,15	master's 49:20
214:8,11,17,22	mailing 225:4	198:3 199:2	matched 139:13
233:21 243:4	mails 37:24,24	marc's 306:17	materials 87:7,22
249:2 258:10	38:1 112:18	march 8:10 36:20	88:15,17,19 136:1
267:12 275:16	185:10 258:10	37:16	136:4,19 159:10
279:13,16 298:1	main 3:13	marcus 6:8,11	matter 18:5 22:18
299:14 303:7	maintain 32:4,7	19:16	22:18,19 23:14,19
304:18 310:7	187:16,23	mark 2:4 8:5	79:6 85:4
312:23	maintained	18:18 34:17	mayor 76:16
lots 311:8	264:11	223:20 228:8	77:20 78:12,17,22
loved 73:4	majority 103:24	238:24 248:8,12	80:10,12,12,22
lower 250:22,25	173:18 274:17,24	257:25 259:14	81:2,15,23 86:11
251:5,17,25 300:2	275:7 276:3	286:1 323:5	86:13,20 87:16
luken 5:7 19:19	makers 241:16	marked 8:3 34:19	89:10 122:7
lunch 110:16,18	making 110:5	35:13,17 36:21	225:18 228:7,11
144:18	124:6 139:12	37:1 38:21,25	230:15 236:8
luncheon 144:25	174:6 235:1	85:19,22 119:12	237:2
luxury 305:15	305:22	119:15 146:4	mayor's 90:3
m	mallinckrodt 6:12	148:14,18 157:24	225:17 230:8,10
m 3:12,17 6:4,4,8	20:17	158:3 189:15,18	mcginness 3:7
9:10 227:25	mammoth 308:10	224:3,10,13,22	mcgrath 9:11
m.d. 9:15 239:2	managed 186:21	228:3 229:13	227:25
madam 323:10	manager 282:16	239:6 248:17,20	mckesson 5:3
madeline 3:12	managers 135:2	255:15,19 259:20	19:21 208:16,17
20:9	managing 214:22	259:23 271:10,17	mclaughlin 3:17
madeline.dennis	manufacture	286:7,13,19 295:7	19:14,14
3:15	209:12,16,17	295:10 315:11	mcnamee 271:25
mail 8:10 9:4,13	manufactured	market 5:8 209:19	271:25 272:2
9:20,23 10:2,10	152:13,22,22	marketed 195:13	md 1:7 18:8
30:17 36:19 37:10	153:3 154:6	marketing 197:9	mdl 1:6 2:3 18:21
37:16 40:25 123:4	159:24	marking 34:22	21:20
224:1 225:2	manufacturer	271:13	mean 30:2 72:18
229:12,17,19	157:16 249:8	mart 19:15 301:25	98:21 120:18,20
230:5 255:12,20	manufacturers	304:7 306:17	137:7 140:17
255:22 256:7	194:9,20 196:24	martin 77:13,13	173:11 209:6
257:13 258:12	198:11,19 199:22	77:19,19 80:9	214:10 216:22
259:17,23 261:7	209:3	massachusetts 4:5	230:10 231:9
261:19,21 268:6			235:5 293:12

[mean - minutes] Page 33

295:23 318:1	medicines 221:22	members 45:10	meth 124:18
means 37:23 141:3	meds 278:14	46:9 72:23 104:4	method 161:15
147:25 164:20	meet 27:23 73:13	133:16 134:6,10	308:8
184:4 205:24	114:17,19 272:11	240:6 258:17	metro 39:15 91:25
285:3 310:10	meeting 40:13	281:5 295:21	metrohealth 92:9
meant 25:9 72:5	87:23 88:7,9	297:2 306:24	mexico 154:25
mechanism 80:4	89:21 114:24	memo 9:10 227:25	miami 5:7 19:19
media 18:3	146:12 147:5,8,16	299:25 300:4	michael 4:8
medical 43:25	148:6 158:14,17	memory 27:6	microphone 207:7
44:1,15 45:2,4,11	158:19,25 159:8	289:2	middle 41:6
45:17,22 46:2	163:12 176:13,15	mental 50:2	306:15
50:4,5 89:1 90:9	176:17,18 177:4,6	131:23 133:18	midnight 271:17
90:11,14 113:7	177:8 185:9,11	138:17 165:23	midwest 323:17
168:4 171:14,18	214:3 225:5,14,22	170:5 180:11	326:1
171:20,24 172:1	225:25 226:10,13	190:15 258:1	migrate 58:18
179:11 192:7,14	226:15 228:7	260:6 296:25	mike 9:16 20:4
192:20,25 203:12	261:2,15	mentioned 90:22	207:3 239:4,12
204:10 206:4,7,13	meetings 40:8,18	111:12 112:2	240:12
222:24 231:4,21	48:5 51:11,21	124:13 131:12,14	mill 140:15 144:9
232:18 233:1	52:2 60:4,25	131:15 159:14	144:15
257:25 277:13	61:10 73:11,14	178:25 179:1,2	million 101:2,18
281:21 317:12	86:13 87:2,8	181:15 186:13	102:2,5 103:3,6,10
medication 194:1	109:21 122:24	202:13 221:12	103:11,16 104:2
194:2 211:1,25	133:22 136:6,15	228:6 238:16	180:3 181:1
218:11 222:14	163:8,8 167:24	241:25 263:4	239:17
302:11,16,17	171:22 172:4	317:4	millions 250:13
medication's	173:4 175:20,22	merle 1:15 7:7	mills 140:23 141:5
277:21	176:23,25 185:12	8:19 9:4,5,20,23	142:9,15,20 143:1
medications	193:5,17 202:14	10:12 18:4 21:9	143:25 145:8
162:19,25 184:13	203:23 204:3	21:14,18 145:5	309:16,23
184:18 197:4	214:9,11,16,17	148:11 155:14	mind 44:7 232:8
210:1,18 216:25	215:11 217:3	207:1 224:1,1	273:13
220:13,21 221:17	233:21 243:2,9	255:12 259:17	mine 146:22 227:8
222:1,9,12 223:14	295:23	284:10 315:2,10	minimum 225:25
237:25 238:1	meets 86:21	321:9 323:8 324:4	minor 77:12,18
245:7 278:5	melanie 229:21	324:9 325:4,13	98:11 122:9 123:9
280:21 281:15	melville 2:15	326:20	125:18 126:5
282:23	member 54:1	mesa 4:15	128:15
medicine 61:6	184:21 287:13,17	met 26:12 28:1,5	minutes 18:18
243:6 278:2	287:19	28:11 48:4 51:24	135:11
311:19		73:12 90:1 172:6	

[mischaracterizes - need]

mischaracterizes	morning 18:1,17	69:8,11,18,23 70:4	napolilaw.com
47:15 61:16	21:16	71:13 72:21 96:19	2:16,17
121:16 123:11	mortality 132:2	96:24 97:5 100:2	narcan 89:4 91:13
128:18 142:1	139:6 268:15	110:19,20 144:11	91:17 92:25
159:17 169:7	motion 215:16,23	144:19 145:6	narrative 74:19
170:12 171:7	motion 213.16,23 motley 3:7 18:25	160:11 178:16	185:7 311:22
173:14 182:15	motleyrice.com	186:3 196:22	312:4
186:2 205:19	3:9	199:14,20 206:18	narrow 80:6
241:4 243:22	mountains 34:5	270:10	164:12
249:13 265:4	mouthpiece	naloxone 41:13	nation 175:9
309:20	153:22	89:5 91:4,13,21	nation 175.5
mischaracterizing	move 43:11 69:25	92:25	114:15 323:6
309:7	145:9 187:20	name 18:11,16	324:3 325:3
misuse 263:23	198:11 214:25	21:17,18 24:5	nationally 167:21
mitigation 200:1	234:22 235:25	39:17,20 52:23	201:9
mixes 152:6 153:9	236:1 237:4 247:8	62:1 75:15,16,17	nationwide 267:7
173:8	267:14 268:13	75:18 79:7 80:21	natoya 77:12,18
mobile 139:4	moved 34:5 191:1	96:1,2 122:8	98:11
moment 169:16	moving 8:7 35:10	134:1,8 149:14	nature 61:11
317:16	mpifko 2:7	150:3,5,20 154:5	300:5
moms 139:5	msalimbene 4:11	155:8,9,10 156:13	necessarily 47:10
money 42:5	mt 3:8	156:14,15 166:16	79:5 123:3 170:17
102:23 103:19	mujumdar 2:9	171:24 175:20	208:15,21 258:19
105:2 237:15	18:23	183:10,16 207:3	314:9
monies 41:11	multi 180:20	208:9,12,17	necessary 191:8
42:17	multiple 73:14	225:23 226:10,18	308:22
monitoring 263:25	106:5 151:5 266:1	226:20 239:20	need 24:18 25:18
272:4	murthy 260:20,21	281:1 284:14	26:2 33:11 40:19
month 83:18	260:25 261:11	299:16 323:6	42:21 61:22 62:21
176:21 190:9	murthy's 260:14	324:3,4,15 325:3,4	63:19,20 64:17,20
monthly 114:25	n	325:21	64:25 65:14 66:12
136:5,5,6 295:23	n 4:19	named 208:6	67:5,23 68:5,7,24
months 28:24	n.d. 1:12	238:5 321:9	69:4 70:2,7 86:4
32:17 83:20,21	naeem 3:12 7:8	names 27:1,5,6	94:14 101:7 106:4
146:16 148:3	20:11,11 21:15	46:6 52:20 77:7	106:15,19 107:12
176:20 317:19	22:6 29:20,23	116:21 144:8	109:23 117:20
morgan 4:13	31:13 33:14,19	166:14 175:11	119:24 139:24
20:19	42:25 43:6 44:4,9	196:19,23 197:2	167:3 168:11
morganlewis.com	44:19,24 45:8,19	208:3 239:19	189:8 191:5
4:16	45:24 46:5 57:10	napoli 2:13 19:5,7	216:20 251:23
	57:25 68:20 69:2		268:20 272:8

[need - objection] Page 35

277.12	56.04.115.0	172 22 175 25	11000
277:13	non 56:24 115:8	173:22 175:25	objection 11:2,3,3
needed 95:8 106:9	154:12 165:6,16	178:2 190:12	11:4,4,5,5,6,6,7,7
132:13,16,16	168:3 215:1,13	200:10,19 201:20	11:8,8,9,9,10,10
166:9	221:2 234:23	202:1,12,20 206:3	11:11,11,12,12,13
needing 164:16	235:25 237:5	207:24 208:5	11:13,14,14,15,15
needs 65:9 110:4	267:15 268:13	217:3 221:2 228:9	11:16,16,17,17,18
124:7 133:9	308:20 313:3	229:21 230:2	11:18,19,19,20,20
277:12,14	north 2:10 3:18	237:14 240:13,13	11:21,21,22,22,23
neighborhood	5:14	249:8,19 250:2,12	11:23,24,24 12:2,3
55:6 58:24 305:3	northern 1:2 18:7	250:19 251:17,23	12:3,4,4,5,5,6,6,7
305:9	nos 24:22	252:1 257:6 263:9	12:7,8,8,9,9,10,10
neighborhoods	notarized 323:14	265:7 267:6	12:11,11,12,12,13
54:13 56:16,25	notary 321:6	275:18,18 286:25	12:13,14,14,15,15
58:8,17 61:2	322:12 323:25	287:2 288:14	12:16,16,17,17,18
73:16	324:10,18 325:15	290:24 292:3,16	12:18,19,19,20,20
never 272:17	325:23 326:23	306:2,13 308:19	12:21,21,22,22,23
273:13 276:4	notation 159:21	308:20 323:7,13	12:23,24,24,25
283:14	note 20:22 147:23	numbered 315:22	13:2,3,3,4,4,5,5,6
new 2:15 6:14,14	271:24 323:12	numbers 203:21	13:6,7,7,8,8,9,9,10
10:12 101:19	notes 8:8 9:7,9	218:5,8 219:16	13:10,11,11,12,12
104:3,7 105:25	35:12 36:14 87:25	291:18,19 293:18	13:13,13,14,14,15
107:19 108:21	88:1,2,7,11,12	325:7	13:15,16,16,17,17
114:14 115:23	146:21 147:3,4,7	nurses 137:11	13:18,18,19,19,20
136:17,17 240:22	147:15,18 148:6	nursing 132:1	13:20,21,21,22,22
241:1 256:13	159:4 185:11	134:7 135:9	13:23,23,24,24,25
315:2,9	224:9,15,21 225:4	nw 4:5 5:13,18 6:4	14:2,3,3,4,4,5,5,6
news 82:16 83:23	225:21,25 226:9	0	14:6,7,7,8,8,9,9,10
83:25 84:14,14	226:19	o 183:17,18 259:8	14:10,11,11,12,12
142:13,21,22	notified 76:18	oarrs 259:8	14:13,13,14,14,15
289:23	272:10,17	260:18 261:18	14:15,16,16,17,17
newsletters	november 9:16	262:2,7,13,24	14:18,18,19,19,20
258:16	239:4,11	263:3 264:2,2,20	14:20,21,21,22,22
newspaper 82:22	number 8:3 18:7	264:22,23 265:12	14:23,23,24,24,25
82:22 84:9	41:10 48:5 89:2,4	265:17,21 266:21	15:2,3,3,4,4,5,5,6
newspapers 175:1	101:25 104:1,23	267:17,25,25	15:6,7,7,8,8,9,9,10
night 35:4 116:2	106:3 111:20	269:5,10 270:23	15:10,11,11,12,12
284:3	114:22 118:15	271:24 272:8,9,17	15:13,13,14,14,15
nine 237:23	130:14 164:24	271.24 272.8,9,17	15:15,16,16,17,17
nods 24:19	165:10 166:9		15:18,18,19,19,20
noloxone 237:17	167:4,5,15 168:15	object 33:21 45:3 63:10 94:14	15:20,21,21,22,22
	169:12 172:14,18	318:10	15:23,23,24,24,25
		J10.1U	

[objection - office] Page 36

			_
16:2,3,3,4,4,5,5,6	126:7,15,25	234:4,12 235:14	231:19 233:19
16:6,7,7,8,8,9,9,10	127:21 128:17,21	236:22 238:2,3,13	244:3,8 246:22
16:10,11,11,12,12	129:6,12,16,21,25	241:3,12,22,23	275:10 277:3,11
16:13,13,14,14,15	130:9,13,22 131:7	242:22 243:21	296:21 302:1,5,9
16:15,16,16,17,17	132:24 134:12	244:17,21 245:8	312:21
16:18,18,19,19,20	140:3 141:1,7,8,25	246:21 248:2	objectives 195:7
16:20,21,21,22,22	143:7,9,13 144:3	249:12 250:4,20	268:8
16:23,23,24,24,25	144:10 145:13	251:1 252:7 253:1	observe 135:23
17:2,3,3,4,4,5,5,6	147:12 149:2,3,12	253:11,17 254:22	obtain 217:7
17:6,7,7,8,8,9,9,10	149:22 150:14	257:11,19 261:13	273:23
17:10,11,11,12,12	151:8,11 152:9,14	262:14 263:18	obtained 219:24
17:13,13,14,14	152:19 153:4,18	264:16 265:3	262:2,7
22:24 23:17 24:2	153:23 154:7,14	266:17 267:3	obviously 177:2,3
24:7 25:15 26:7	154:19 155:5,24	268:3 269:13	216:17 221:21
28:18,19 29:6	156:3,11 157:3	271:1 272:19	occasion 40:11
31:6 33:3 36:11	159:16 160:9,22	273:16 274:1,7,14	272:11
40:5,16 41:20,21	161:8,21 162:17	274:20 275:2	occasionally 38:3
42:10 43:18,24	162:21 164:9	276:7,17,21 277:2	38:14
44:8,14,23 45:7	166:12,21 169:6	277:24 278:8,15	occur 95:15
46:19 47:5,14,24	169:20 170:11	279:2,11 280:7,14	occurring 308:21
48:13 49:6,7	171:6 172:23	281:9,16,25 283:1	october 8:16 85:18
51:14,15 52:3	173:13 175:16	283:23 290:16,22	146:14 148:2
53:12 55:7,25	179:16 182:14	291:8 292:11,24	177:9 322:15
56:19 57:6,17	184:7 185:6 186:1	293:5 294:4,14	od 36:3,6 114:14
58:12,13,25 59:7	187:18 189:3	296:1,9,15 297:9	115:7 147:24,25
60:16,24 61:15,18	191:23 192:5,10	297:20 299:1	174:9,9 176:11
61:20 62:9 63:11	193:2,13 194:12	301:10,19,20	ods 115:8 313:2
65:8 72:2,25	196:3,20 197:18	302:13,19,25	offer 279:13
74:18 75:2,9	198:13 199:5	304:14,20 305:7	offered 76:18
78:14,24 83:4,5	200:2,22 201:13	305:25 306:21	offering 93:16
88:20 92:5 93:8	201:23 202:7	307:15 308:4,16	offers 92:8
94:4,11,21 95:1,18	203:8 205:18	309:19 310:1,2,25	offhand 208:1,4
96:8,16,21 97:17	207:11 209:13,21	311:12 312:1,9,15	office 31:16,18
100:9 103:1,14,22	210:2,8 211:21	314:1,7	32:5,10 33:6
104:11 105:13	212:8,12,17,22	objections 7:5	35:23 36:10 85:2
107:16 108:9	213:1 219:4	11:1 12:1 13:1	88:18 90:14
109:13 112:10	221:19 222:2,15	14:1 15:1 16:1	131:23 133:18
113:14 116:4	222:18 223:16	17:1 42:16 44:7	138:17 142:18
117:6,25 120:1,5	226:2,4,7,21 227:7	57:12,15,20 62:10	146:9 165:23,25
121:15 123:10	231:12 232:1,10	63:6 64:15 66:15	167:25 168:4
124:20 125:8,24	232:20 233:8,14	70:19 71:5 145:23	170:4 171:15,18

[office - opioid] Page 37

	I	I	I	
172:15 175:3,5,23	322:6,13 323:2	239:22 241:18	111:18 148:10	
177:6 180:11	ohio's 263:24	243:18 249:5	150:2 151:4	
190:15 193:7	okay 25:14,22	250:9 254:2	152:12 155:3,14	
203:23 204:10	26:3,4 32:1 33:14	255:18 256:16,25	155:16 157:1	
231:22 260:6	40:12 45:24 52:17	257:23 260:24	163:17 165:25	
296:25 322:5	57:2,25 61:22	261:21 263:2	177:6 184:22	
offices 98:21	62:4 64:20,22	265:12,20 269:4	230:22 286:5,11	
official 34:4 44:17	65:3,9,15 68:6	272:3 273:3,12	286:17,24 287:13	
184:23,25 220:18	69:15 70:3 71:6	277:7 281:4	292:1 295:3,18,19	
228:23 229:2,6,22	77:14 78:6 86:4	282:20 283:20	323:6 324:3 325:3	
230:3 236:4 252:4	92:10 96:24 102:9	285:4,7,17 287:7	opiates 85:6 87:17	
324:15 325:21	118:24 120:25	287:21 288:5,23	155:17,22 156:18	
oftentimes 116:9	121:25 122:19	289:15,19 290:13	156:21 157:9,10	
oh 114:8 143:13	123:18 124:9	291:21 292:5	158:21,24 159:9	
243:25 259:14	125:5,22 126:3,12	293:20 295:13	161:24 162:1,25	
283:21	128:1 133:14,25	299:7 301:5,16,24	205:22 252:12	
ohio 1:2,12,22	135:4,8 136:9	302:22 304:23	311:21 312:25	
2:20 3:4,14,19	143:23 147:9,17	306:11 307:5	opinion 46:20 47:6	
5:14 8:15 9:18,19	149:7 150:23	309:22 310:9,13	49:8 145:14,15	
18:7,10 22:10	151:2 152:24	310:23 311:4	149:4,5 161:22	
82:19,20 83:24	155:13 158:6,13	312:7,12 314:3,10	162:22 164:10	
84:12 85:2,11,16	159:13 164:4,22	315:19,20 317:8	172:24 191:24	
109:24 113:17	166:17,25 170:6	317:20 318:5	192:6 222:19	
114:12 116:12	177:12 178:10	old 54:13 55:6	233:16 234:6	
142:18 163:18	179:6 180:25	58:21 121:11	235:16 238:14	
166:3 175:2,4,8,8	181:16 182:18	261:6	241:24 243:23	
192:15 201:12,21	183:11 184:12	once 76:7 79:1	245:9,10 246:22	
202:3,21 213:5,10	188:9,18 191:13	234:9,24	253:18 273:18	
248:15,15,21,22	196:17 198:17,23	ones 192:18	275:3 301:11,21	
250:2,11 252:6	201:20 203:13	ongoing 123:19,25	310:3,5 311:1,13	
256:12,21 257:5	204:19 205:8,12	147:4	312:2	
257:14 258:1,16	206:2,8 208:2,9,16	online 155:18	opinions 143:11	
258:22 260:17	209:17 211:24	op 1:12	244:19	
263:24 264:1,5,7,9	212:10 213:4,16	open 78:1 215:19	opioid 8:7 9:2	
264:15 265:2	215:25 217:12,21	opened 194:2	21:21 32:9 35:9	
266:8,14 267:7	219:18,24 225:9	operations 179:8	42:2 52:14 55:5	
281:3 285:18,20	225:13,21,24	186:23 208:20	55:11,19,23 56:17	
288:12,25 293:23	227:1,14,16 228:6	operators 143:25	57:5 58:9,10,23	
294:8,13 297:5,7	229:19 230:7,24	144:9,15	59:4,13,16,20	
297:18,23 298:7	233:6 236:3,7	opiate 1:7 8:19	60:10,19 61:14	
313:9,24 321:2,7	237:14,22 238:7	10:4,6,8 18:5	72:15,18,24 73:20	

[opioid - page] Page 38

73:25 74:4 81:8	276:4 281:15	opportunity	116:4 179:16
83:23 85:11 86:11	288:20 296:13,19	318:13	185:6 200:2 203:9
86:16 87:4,8,17	297:6 298:24	opposed 86:19	220:24 222:3
89:22 90:19 99:4	301:1,8,8,17	oral 40:4 87:24	223:9,17 226:7
99:11 104:20	302:23 303:4,13	orange 254:16	279:3,12 280:8
106:16 107:13,14	305:6,22 309:17	255:3	296:16
107:23 108:8	309:24 310:24	order 110:4 159:6	overdose 9:19
109:11 111:4,9,16	311:11,25 313:23	159:24 160:20	36:6 87:17 89:2
111:24,25 112:15	314:6	161:2,5 220:5,9	147:25 172:8,14
112:25 113:5,25	opioids 29:3 44:13	238:11	174:2 203:3
114:20 115:12	47:23 60:13 84:3	ordering 285:14	204:17 205:17
116:16 117:1,23	115:18 121:23	orders 218:14	240:17 248:16,21
124:12,14,14,24	125:3,6,10,13,23	314:5	252:19 253:7
125:20 127:20	126:6,13,23 127:7	organization	254:14,19 257:4
131:5 132:4,9,23	127:9 129:1,5	98:22	300:19
135:19 137:9	131:19,19 136:19	organizations	overdoses 56:24
138:10,14 140:24	136:25 145:10,20	82:23 163:16	85:8 91:18 129:10
141:6,19,24	148:22,25 156:8	207:25 308:24	129:15 174:1
142:14 143:2,3,6	164:8 167:3,8,16	organized 98:20	204:13,13,21
144:2 145:11,21	168:17,18 169:14	original 38:10	308:20
145:25 146:9	170:10 171:4	153:6,8	overseas 154:24
148:23 149:1	170:10 171.4	originally 148:19	155:18 156:9
151:17,23 152:1	175:15 177:18	168:16 169:13	157:1
169:11 174:16	188:11 191:20	170:9 172:9,16,21	oversee 135:2
180:8,9 181:3,19	192:3,16 193:11	outlets 140:19	oversight 79:3,23
182:12 183:20	194:10,21 195:13	195:4	overview 185:4
184:14,19 186:15	195:21 196:24	outpatient 264:3	oxford 6:9
189:6,13,23 192:8	198:11 199:23	outrageous 61:17	
192:24 194:6	202:2,20 204:15	62:12	p
195:5,9,10 198:4	209:12,19 211:15	outreach 191:7	p 2:4 75:20
199:2,3 200:10,19	227:6 242:10,19	306:18 308:3	p.c. 2:4
201:20 210:1,6	247:14,25 248:1	outs 163:13	p.m. 319:13
211:20 221:2	250:3 252:24	outside 30:23,25	package 193:22
224:15 228:12	253:8 254:17,21	45:16 198:6,7	194:22
233:18 235:11	265:2 273:15	outweigh 277:22	padukone 5:4
237:25 238:1	274:5,11,25 275:1	overall 100:17	19:20,20
240:16 245:7	275:8,9,15,25	253:6	page 32:3 36:1,1,2
249:19 250:2,10	283:9,17 292:9,23	overbroad 23:18	39:11 41:6 126:9
252:5 257:3	opportunities	40:6 46:21 47:25	126:18,20 127:13
260:15 273:23	190:11,13	56:20 60:17 74:19	130:3 147:17
274:18 275:14,24	,	103:22 109:13	158:7 159:3,19
			230:25 236:9

[page - people] Page 39

239:13,14 240:16	84:10 86:9 91:14	partnering 308:2	pdmp 263:25
240:20,24 242:1	93:3 100:17	partnership 309:2	pelini 5:12,15
250:9 252:2,17	143:25 147:1	parts 54:10 55:22	19:12
254:12 256:25	151:16 170:1	party 322:2	pellegrino 1:25
257:23 291:18	173:9 180:14	party's 46:2	18:13 321:6
293:18,19 306:14	204:8,11 205:3	passed 72:4	322:12
306:15 315:22,23	209:2,4 223:18	patch 165:15	pence 9:16 239:4
316:12,12 317:3	237:14 240:1,2	pathway 172:18	239:12 240:12
323:13,15 325:7	241:13 258:20	173:1 174:18	pencil 269:20
326:3	262:15 266:8	204:16 235:18,20	pending 25:21
pages 34:10 316:3	269:7 271:3	235:24	127:2
paid 101:20	279:23 283:11,12	pathways 164:13	pennsylvania 4:10
pain 140:20,22	287:20,22 288:13	164:15 173:6	6:10
162:24 164:16	288:19 293:8	176:1 205:23	penny 103:4
173:10 191:21	294:23 295:2,2,24	233:23 247:21	people 34:8,9 47:9
192:4 212:16	298:20 301:5	patient 91:21	47:11,17 48:5
276:11,14,15,20	306:10,19 311:21	172:21 189:1	49:2,5,13 60:5
276:20,25 277:1,9	312:4,8,13 313:22	212:1,7,15,20	61:5,9 73:1,11,11
277:10,18	325:9	266:1 277:23	77:15 79:2 86:22
painkillers 61:8	participate 54:18	280:12,18	92:24 103:25
161:24,25 164:18	111:12 112:1	patient's 212:11	106:16 110:18
173:23 205:22	185:18	280:11,16,18	132:13 134:5
311:20 312:25	participates	patients 89:7	135:10,13 137:8
panel 76:12 77:2,3	243:19	90:24 91:18	139:12 147:20
81:1,13	particular 36:14	132:13 135:23	156:15 158:12,21
panelists 77:10	87:14 89:19 104:9	172:15 192:8	161:23 162:7,23
81:23	107:9 130:19	195:14,22 198:12	163:9,14,22
paper 116:8	154:4 183:1	199:4 210:11,18	164:15 165:18,21
papp 39:14,15,23	202:18 206:2	210:25 250:11	165:24 166:19
40:2,7,17 91:7	210:12 211:20	252:6 273:14	167:2,4,5,15
par 4:3,3 19:25	212:1,6 218:12	276:19,25 277:9	168:10 170:16,18
paragraph 150:24	230:17 275:20	277:17 282:4,5	171:1 172:25
231:2,3 257:2	277:22 287:16	312:12	173:3 174:7,7,13
263:20 265:20	289:8 307:3 308:8	paul 5:17 20:2	174:17 175:6
293:22 295:16	309:12	62:2	176:24 177:17
306:15	particularly 62:11	pause 199:13	178:6 186:25
parens 264:1	partner 308:15	paused 65:22	187:17 188:23
parilla 75:17,25	partnered 306:17	pay 109:23 282:7	202:2 204:11,12
part 34:23 43:13	306:20,24 307:12	pays 212:20	205:21 221:18
50:10,12,14,17,18	309:11	pboehm 5:19	222:5 231:10
73:12 82:25 84:9			232:3,4,8 233:23

[people - pifko] Page 40

224 24 242 17	• 70 0 00 21	4. 02.24	100 7 102 22
234:24 242:17	persis 79:8 80:21	pertinent 82:24	189:7 193:23
243:16 270:6	95:12 128:4	pervasive 311:22	200:6 279:21
274:18,25 275:7	person 23:12	pglawyer.com	physical 115:24
275:24 277:12	54:16 58:21 59:6	2:21	physician 39:15
293:9 300:19	59:22 60:15,23	pharma 38:8	273:25
308:19 311:6,9,17	61:23 62:5 65:16	pharmaceutical	physicians 209:20
312:23	67:2,11 70:24	4:3,12 43:14,23	210:22
people's 45:16	75:12 97:22 98:4	46:18,23 47:4,13	pick 305:18
61:4,9 174:5	98:13 128:14	47:20 208:23	piece 165:14
311:19	165:14 166:25	213:19 214:5	pieces 288:14
percent 173:16	183:6 256:23	216:25 217:14	pifko 2:4 8:5 18:17
182:11 187:3	273:23	220:13,21 221:22	18:18 22:3,24
189:10 231:4,5,9	person's 75:15,16	237:25	23:17 24:2,7
231:17 232:17	96:1,2 175:19	pharmaceuticals	25:15,23 26:7
233:3,5,7	personal 21:25	3:11 4:2,3 6:12	28:18 29:6,18,21
percentage 167:7	22:17 43:25 44:15	19:25 20:1 218:6	29:24 30:12,20,23
173:12 252:18,23	48:16,25 49:13	pharmacies	31:6 32:22 33:3,9
253:6,7 254:13,18	142:25 153:16	198:20 209:4	33:16 34:2,17
254:20 257:3	168:15 187:16	218:7 264:5	36:11 37:3 39:3
275:14,23	197:8,13,14 198:1	282:11 304:18	40:5,16 41:20
perfect 64:19	220:4 233:13	306:20 307:12	42:10,16,23 43:18
217:12	234:2,17 235:12	308:2 310:21	43:24 44:8,11,14
perfectly 270:4	personally 48:2	pharmacist	44:21,23 45:1,7,12
performed 131:11	184:21 258:3	250:23 251:3	45:22 46:1,10,19
performing	264:6 275:23	252:10,16 299:18	47:5,14,24 48:13
104:19	324:11 325:15	pharmacology	49:6 51:14 52:3
period 76:17	perspective 191:6	53:23	53:12 55:7,25
95:13 176:21	perspectives 166:7	pharmacy 164:19	56:19 57:6,10,16
periodic 86:20	pertain 117:12	218:12,13 222:13	58:12,25 59:7
periodically	214:5 217:14	222:23 263:24	60:16,24 61:15,21
119:21	pertained 89:3	264:9 281:6	62:4,14,16,21 63:1
peripheral 219:15	272:25	285:18,20 302:23	63:7,10,16,21,24
permanente 281:3	pertaining 23:19	306:18 310:19,20	64:3,6,10,14,19,24
281:5 289:17	31:24 83:9 87:16	philadelphia 4:10	65:3,9,13,19,24
permission 46:4	105:16 108:13	philanthropy	66:5,12,24 67:5,10
permit 61:19	109:18 118:17	179:24	67:15,20 68:1,5,11
permits 100:19	150:19 202:14	phone 20:13 30:17	68:18,21 69:2,4,10
179:3,4 183:19	299:14	305:19 323:3	69:15,21 70:1,6,11
permitted 57:15	pertains 163:22	phrase 38:7	70:22 71:6 72:2
69:13 192:16	201:19 208:13	124:23 125:11	72:19,25 74:18
		140:15,16,18	75:2,9 78:14,24
		. ,	, ,

[pifko - point] Page 41

83:4 88:20 92:5 92:18 93:8 94:4 194:24 196:3,5,20 95:18 96:8,16,19 95:18 96:8,16,19 95:18 200:2,13 95:18 96:8,16,19 95:51 200:2,13 95:23 97:3,17 200:22 201:13,23 103:14,22 104:11 105:13 107:16 208:24 209:13,21 210:2,8 211:21 210:3,9 15:11 210:13 14 210:2,8 211:21 210:2,8 211:21 210:3,9 14,20 212:3,1,21 214:13 216:5,12,16 217:2,11 214:13 216:5,12,16 227:2,12 28:1,22 291:8 228:17 229:2,15 220:1,5 121:15 216:5,12,16 221:15,21 12:15 216:5,12,16 221:10,222:2,15 221:12,16,21,25 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 223:1,21 29:26 223:1,23 270:2,5 276:21,27 277:,17 277:24 278:8,15 279:2,11 280:7,14 281:9,16,25 282:8 290:16,22 291:8 290:16,22 201:5 290:16,22 201:5 290:16,22 201:5 290:16,22 201:5 290:16,22 2				1
94:11,13,21 95:1 95:18 96:8,16,19 96:23 97:3,17 99:24 100:9 103:1 103:14,22 104:11 105:13 107:16 208:24 209:13,21 108:9 109:13 210:2,8 211:21 2119:15 210:2,8 211:21 211:21 113:14 213:1,21 214:13 216:4 117:6,25 215:3,9,14,20 217:16,24 219:4 212:8,12,17,22 210:1,5 121:15 212:10 22:21,15 212:10 22:21,15 212:10 22:21,15 212:11,21 22:119 22:22,15 22:17 223:9,16 229:17,10,15,21 231:12,16,21,25 231:12,19 22:21,15 230:12,14,72 22:18 230:13,21 214:13 230:10,19,30:10,19 24:20 217:16,24 219:4 297:9,15,20 299:1 297:9,15,20		· · · · · · · · · · · · · · · · · · ·	·	1
95:18 96:8,16,19 96:23 97:3,17 200:22 201:13,23 275:2,10 276:7,17 99:24 100:9 103:1 202:7 203:8 207:11,19 105:13 107:16 208:24 209:13,21 279:2,11 280:7,14 108:9 109:13 210:2,8 211:21 281:9,16,25 282:8 110:9,15 112:10 212:8,12,17,22 281:9,16,25 282:8 116:4 117:6,25 215:39,14,20 290:16,22 291:8 120:1,5 121:15 216:5,12,16 293:5 294:4,14 233:10 124:20 217:16,24 219:4 296:1,9,15,21 128:17,21 129:6 222:17 223:9,16 229:12,16,21,25 226:2,4,7,21 227:7 130:9,13,22 131:7 227:14,17 228:14 132:24 134:12 228:17 229:18,24 140:3 141:1,7,25 23:12,19 232:1 143:7 144:3,10,17 232:10,20,24 14:21 145:13,23 149:22 150:14 235:14 236:22 151:8 155:24 156:3,11 242:22 243:61 155:24 156:3,11 242:22 243:61 155:24 156:3,11 242:22 243:61 155:15 166:12,21 169:6 249:12 250:4,20 170:11 251:16,611,15,22 171:61 172:23 25:7 253:1,11,17 271:61 172:23 25:7 253:1,11,17 271:61 172:23 25:12 25:12 25:13 18:20 270:17 271:24 278:10 179:16 253:25 254:22 178:10 179:16 253:25 254:22 178:10 179:16 253:25 254:22 178:10 179:16 251:16,2113 226:17 207:17 191cs 32:11 204:13 224:17 229:18,14 189:3 266:17 267:3,19 266:17 267:3,19	92:18 93:8 94:4	194:24 196:3,5,20	270:12,19 271:1	114:5 185:12
96:23 97:3,17 99:24 100:9 103:1 103:14,22 104:11 105:13 107:16 108:9 109:13 110:9,15 112:10 110:9,15 112:10 110:9,15 112:10 110:9,15 112:10 110:9,15 112:10 110:9,15 112:15 110:15:3,9,14,20 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,5 121:15 110:1,10 124:20 117:1,6,24 129:4 129:1,1,1,21 125:8,24 126:7,15 128:17,21 129:6 129:12,16,21,25 129:13,14,24 129:11,14,24 120:11,15,22 121:14,17,21 121:15,15,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12 121:15,12,12,12,12 121:14,17,11 121:15,12,12,12 121:14,17,11 121:15,12,12,12 12		·	272:19 273:16	
99:24 100:9 103:1 103:14,22 104:11 205:18 207:11,19 205:18 207:11,19 205:18 207:11,19 210:2,8 211:21 210:3,101:10 210:2,8 211:21 221:13:14 210:2,8 211:21 221:13:14 213:1,21 214:13 213:1,21 214:13 220:1,5 12:15 216:5,12,16 221:1,6,21,25 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 223:10,21,24 233:1,21 212:14 233:1,21 212:15 226:2,4,7,21 227:7 230:1,2,12 231:1,2,12 22:13 221:19 222:2,15 220:1,5,12,16 229:1,5,20 299:1 221:1,14,24 296:1,9,15,21 297:9,15,20 299:1 297:0,10,10,10,10,10,10,10,10,10,10,10,10,10	95:18 96:8,16,19	199:5,12 200:2,13	274:1,7,14,20	305:19 321:19
103:14,22 104:11	96:23 97:3,17	200:22 201:13,23	275:2,10 276:7,17	placed 285:1
105:13 107:16 208:24 209:13,21 279:2,11 280:7,14 281:9,16,25 282:8 314:24 281:9,16,25 282:8 290:16,22 291:8 290:16,22 291:8 290:16,22 291:8 290:16,22 291:8 290:16,22 291:8 290:16,22 291:8 290:11,14,24 293:5 294:4,14 293:9,13,19,25 190:8 189:6,14,24 190:5 190:8 189:6,14,24 190:5 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 189:9,13,19,25 190:8 190:8 189:9,13,19,25 190:8 190:8 190:8 189:9 196:10 194:2 20:13,21 194:11 194:15,23 151:8 152:9,14,19 235:14 236:22 235:4 236:18 155:24 156:3,11 242:22 243:21 157:3 159:16 244:6,17,23 245:8 145:5 142:9,14,20 169:20 170:11 251:1,6,11,15,22 176:6 172:23 252:7 253:1,11,17 173:13 175:16 253:25 254:22 178:0 179:16 257:11,19 261:13 182:14 184:7 262:14 263:18 187:18 189:3 266:17 267:3,19 191:8 and 174:25 314:24 146:12 24:6 43:13 212:6 148:15 246:6,12,16 249:12 220:15,24 290:16,22 291:8 18:20 189:6,14,24 190:5 189:6,14,24 1	99:24 100:9 103:1	202:7 203:8	276:21 277:2,11	places 154:25
108:9 109:13 210:2,8 211:21 281:9,16,25 282:8 314:24 110:9,15 112:10 212:8,12,17,22 283:1 285:9,25 plaintiff 24:6 112:21 113:14 213:1,21 214:13 290:16,22 291:8 plaintiff 24:6 110:9,15 12:15 215:3,9,14,20 292:11,14,24 plaintiff 24:6 123:10 124:20 217:16,24 219:4 293:5 294:4,14 plaintiff 23:3 125:8,24 126:7,15 219:20 220:15,24 299:19,15,20 299:1 plaintiff 23:3 126:25 127:11,21 221:19 222:2,15 301:10,19 302:1,5 302:19,13,19,25 128:17,21 129:6 222:17 223:9,16 302:9,13,19,25 304:14,20 305:7 130:9,13,22 131:7 227:14,17 228:14 305:25 306:21 190:8 132:24 134:12 228:17 229:18,24 307:15 308:4,16 play 209:9 210:5 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 312:21 314:1,7,11 144:21 145:13,23 233:8,14,19 234:4 318:16 319:3 318:16 319:3 155:4 156:3,11 237:10 238:2,12 323:5 218:16 29:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 323:5 218:16	103:14,22 104:11	205:18 207:11,19	277:24 278:8,15	plaguing 122:13
110:9,15 112:10	105:13 107:16	208:24 209:13,21	279:2,11 280:7,14	plain 174:25
112:21 113:14 213:1,21 214:13 290:16,22 291:8 43:13 212:6 116:4 117:6,25 215:3,9,14,20 292:11,14,24 293:5 294:4,14 293:5 294:4,14 293:5 294:4,14 293:5 294:4,14 293:5 294:4,14 293:5 294:4,14 296:1,9,15,21 297:9,15,20 299:1 297:9,15,20 299:1 188:6,14,24 190:5 18:20 188:6,14,24 190:5 189:6,14,24 190:5 190:8 190:0 </td <td>108:9 109:13</td> <td>210:2,8 211:21</td> <td>281:9,16,25 282:8</td> <td>314:24</td>	108:9 109:13	210:2,8 211:21	281:9,16,25 282:8	314:24
116:4 117:6,25 215:3,9,14,20 292:11,14,24 293:5 294:4,14 296:1,9,15,21 296:25 127:11,21 221:19 222:2,15 221:7 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 222:17 223:9,16 302:9,13,19,25 302:9,13,19,25 302:9,13,19,25 304:14,20 305:7 305:25 306:21 307:15 308:4,16 309:19 310:1,25 220:13,21	110:9,15 112:10	212:8,12,17,22	283:1 285:9,25	plaintiff 24:6
120:1,5 121:15	112:21 113:14	213:1,21 214:13	290:16,22 291:8	43:13 212:6
123:10 124:20	116:4 117:6,25	215:3,9,14,20	292:11,14,24	plaintiffs 2:3
125:8,24 126:7,15	120:1,5 121:15	216:5,12,16	293:5 294:4,14	18:20
125:8,24 126:7,15	123:10 124:20	217:16,24 219:4	296:1,9,15,21	plan 8:7 9:3 35:10
128:17,21 129:6 222:17 223:9,16 302:9,13,19,25 304:14,20 305:7 304:14,20 305:7 304:14,20 305:7 304:14,20 305:7 305:25 306:21 196:10 19ay 209:9 210:5 196:10 19ay 209:9 210:5 220:13,21 19ay 209:9 210:5 220:13,21 19ay 209:9 210:5 220:13,21 19ay 209:9 210:5 220:13,21 19ay 209:9 210:5 19ay 209:9 210:5 220:13,21 19ay 209:9 210:5 19ay 209:9 210:	125:8,24 126:7,15	219:20 220:15,24	297:9,15,20 299:1	_
129:12,16,21,25 226:2,4,7,21 227:7 304:14,20 305:7 plans 189:9 130:9,13,22 131:7 227:14,17 228:14 305:25 306:21 196:10 132:24 134:12 228:17 229:18,24 307:15 308:4,16 19ay 209:9 210:5 140:3 141:1,7,25 231:12,19 232:1 309:19 310:1,25 220:13,21 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 play 209:9 210:5 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 plaza 2:5 22:9 147:12 149:2,12 234:12,20 235:4 315:4 316:2 plasm 189:9 151:8 152:9,14,19 237:10 238:2,12 318:16 319:3 plaza 2:5 22:9 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 please 18:15 20:21 155:24 156:3,11 242:22 243:21 pilfered 243:6 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 200:16 252:18 160:9,22 161:8,21 247:15 248:2 pills 61:9 140:11 269:17 271:24 169:20 170:11 251:1,6,11,15,22 311:7 243:1,7 249:9,20 311:7 173:13 175:16 253:25 254:22 311:7 pinched 269:20	126:25 127:11,21	221:19 222:2,15	301:10,19 302:1,5	190:8
130:9,13,22 131:7 227:14,17 228:14 305:25 306:21 196:10 132:24 134:12 228:17 229:18,24 307:15 308:4,16 play 209:9 210:5 140:3 141:1,7,25 231:12,19 232:1 309:19 310:1,25 220:13,21 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 playing 270:16,19 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 playing 270:16,19 147:12 149:2,12 234:12,20 235:4 315:4 316:2 playa 209:9 210:5 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 playa 209:9 210:5 144:21 149:2,12 234:12,20 235:4 312:21 314:1,7,11 playa 209:9 210:5 144:21 149:2,12 234:12,20 235:4 312:21 314:1,7,11 playa 209:9 210:5 147:12 149:2,12 233:8,14,19 234:4 312:21 314:1,7,11 playa 209:9 210:5 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 playa 209:9 210:5 142:21 149:2,12 233:8,14,19 234:4 312:21 314:1,7,11 playa 209:9 210:5 142:21 149:2,12 233:12,20 235:4 315:4 316:2 please 18:15 20:21 151:8 152:9,14,19 237:10 238:2,12 pille 254:10 288:24 pille 254:10 288:24	128:17,21 129:6	222:17 223:9,16	302:9,13,19,25	plane 318:12
132:24 134:12 228:17 229:18,24 307:15 308:4,16 play 209:9 210:5 140:3 141:1,7,25 231:12,19 232:1 309:19 310:1,25 220:13,21 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 playing 270:16,19 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 playing 270:16,19 147:12 149:2,12 234:12,20 235:4 315:4 316:2 playing 270:16,19 149:22 150:14 235:14 236:22 318:16 319:3 play 209:9 210:5 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 playing 270:16,19 149:22 150:14 235:14 236:22 318:16 319:3 playing 270:16,19 149:22 150:14 235:14 236:22 318:16 319:3 playing 270:16,19 149:22 150:14 235:14 236:22 318:16 319:3 please 18:15 20:21 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 please 18:15 20:21 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 166:12,21 169:6 249:12 250:4,20 249:12 250:4,20 249:12 250:4,20 243:1,7 249:9,20 307	129:12,16,21,25	226:2,4,7,21 227:7	304:14,20 305:7	plans 189:9
140:3 141:1,7,25 231:12,19 232:1 309:19 310:1,25 220:13,21 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 playing 270:16,19 144:21 145:13,23 234:12,20 235:4 312:21 314:1,7,11 plaza 2:5 22:9 147:12 149:2,12 234:12,20 235:4 315:4 316:2 pleasant 3:8 149:22 150:14 235:14 236:22 318:16 319:3 21:8,16 22:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pilfered 243:6 77:9 80:20 100:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 pills 61:9 140:11 278:20 296:17 173:13 175:16 253:25 254:22 311:7 pinched 269:20 270:17 pleases 215:15 178:10 179:16 262:14 263:18 262:14 263:18 270:17 plexin 2:18 19:4 182:14 184:7 264:16 265:3 pipeline 312:24 plus 86:18 103:16 </td <td>130:9,13,22 131:7</td> <td>227:14,17 228:14</td> <td>305:25 306:21</td> <td>196:10</td>	130:9,13,22 131:7	227:14,17 228:14	305:25 306:21	196:10
140:3 141:1,7,25 231:12,19 232:1 309:19 310:1,25 220:13,21 143:7 144:3,10,17 232:10,20,24 311:12 312:1,9,15 playing 270:16,19 144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 plaza 2:5 22:9 147:12 149:2,12 234:12,20 235:4 315:4 316:2 plaza 2:5 22:9 149:22 150:14 235:14 236:22 318:16 319:3 please 18:15 20:21 151:8 152:9,14,19 237:10 238:2,12 323:5 please 18:15 20:21 153:4,18,23 154:7 239:9,24 241:3,12 pille 254:10 288:24 please 18:15 20:21 155:4156:3,11 241:22 242:6,13 pille 254:10 288:24 pilfered 243:6 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178: 9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 166:12,21 164:9 249:12 250:4,20 143:1,25 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 311:7 243:1,7 249:9,20 311:7 173:13 175:16 257:11,19 261:13 262:14 263:18 270:17 pileases 215:15 182:14 184:7 262:14 263:18 262:14 263:18 270:17 pleases 215:15 <td>132:24 134:12</td> <td>228:17 229:18,24</td> <td>307:15 308:4,16</td> <td>play 209:9 210:5</td>	132:24 134:12	228:17 229:18,24	307:15 308:4,16	play 209:9 210:5
144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 plaza 2:5 22:9 147:12 149:2,12 234:12,20 235:4 315:4 316:2 pleasant 3:8 149:22 150:14 235:14 236:22 318:16 319:3 please 18:15 20:21 151:8 152:9,14,19 237:10 238:2,12 323:5 21:8,16 22:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pilfered 243:6 77:9 80:20 100:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 247:15 248:2 143:1,25 144:8,15 200:16 252:18 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 243:1,7 249:9,20 307:22 323:11,11 173:13 175:16 253:25 254:22 311:7 pinched 269:20 270:17 178:10 179:16 257:11,19 261:13 262:14 263:18 262:14 263:18 270:17 plexin 2:18 19:4 185:6 186:1 266:17 267:3,19 266:17 267:3,19 pittsburgh 6:10	140:3 141:1,7,25	231:12,19 232:1	309:19 310:1,25	_ •
144:21 145:13,23 233:8,14,19 234:4 312:21 314:1,7,11 plaza 2:5 22:9 147:12 149:2,12 234:12,20 235:4 315:4 316:2 pleasant 3:8 149:22 150:14 235:14 236:22 318:16 319:3 please 18:15 20:21 151:8 152:9,14,19 237:10 238:2,12 323:5 21:8,16 22:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pile 254:10 288:24 77:9 80:20 100:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 247:15 248:2 143:1,25 144:8,15 200:16 252:18 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 pills 61:9 140:11 278:20 296:17 173:13 175:16 253:25 254:22 311:7 pinched 269:20 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plexin 2:18 19:4 182:14 184:7 264:16 265:3 pipeline 312:24 plus 86:18 103:16	143:7 144:3,10,17	232:10,20,24	311:12 312:1,9,15	playing 270:16,19
147:12 149:2,12 234:12,20 235:4 315:4 316:2 pleasant 3:8 149:22 150:14 235:14 236:22 318:16 319:3 21:8,16 22:7 25:7 151:8 152:9,14,19 237:10 238:2,12 323:5 21:8,16 22:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 141:5 142:9,14,20 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 173:13 175:16 253:25 254:22 pills 61:9 140:11 278:20 296:17 173:13 175:16 253:25 254:22 311:7 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plevin 2:18 19:4 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	144:21 145:13,23	233:8,14,19 234:4	312:21 314:1,7,11	
149:22 150:14 235:14 236:22 318:16 319:3 please 18:15 20:21 151:8 152:9,14,19 237:10 238:2,12 323:5 21:8,16 22:7 25:7 153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pile 254:10 288:24 25:10 27:5 39:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 243:1,7 249:9,20 307:22 323:11,11 173:13 175:16 253:25 254:22 311:7 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plevin 2:18 19:4 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	147:12 149:2,12	234:12,20 235:4	315:4 316:2	_
153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pilfered 243:6 77:9 80:20 100:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plexin 2:18 19:4 182:14 184:7 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	149:22 150:14	235:14 236:22	318:16 319:3	1 -
153:4,18,23 154:7 239:9,24 241:3,12 pile 254:10 288:24 25:10 27:5 39:3 154:14,19 155:5 241:22 242:6,13 pilfered 243:6 77:9 80:20 100:3 155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plexin 2:18 19:4 182:14 184:7 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	151:8 152:9,14,19	237:10 238:2,12	323:5	21:8,16 22:7 25:7
155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 178:10 179:16 257:11,19 261:13 311:7 plenty 244:7 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	153:4,18,23 154:7	239:9,24 241:3,12	pile 254:10 288:24	1
155:24 156:3,11 242:22 243:21 pill 140:15,23 110:8 134:1 151:2 157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 307:22 323:11,11 178:10 179:16 257:11,19 261:13 311:7 pleases 215:15 182:14 184:7 262:14 263:18 270:17 plevin 2:18 19:4 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	154:14,19 155:5	241:22 242:6,13	pilfered 243:6	77:9 80:20 100:3
157:3 159:16 244:6,17,23 245:8 141:5 142:9,14,20 178:9 187:21 160:9,22 161:8,21 246:3,7,11,17,21 143:1,25 144:8,15 200:16 252:18 162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 173:13 175:16 253:25 254:22 311:7 pleases 215:15 178:10 179:16 257:11,19 261:13 262:14 263:18 270:17 plevin 2:18 19:4 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10		·	-	110:8 134:1 151:2
162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 173:13 175:16 253:25 254:22 311:7 pleases 215:15 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	157:3 159:16	244:6,17,23 245:8	141:5 142:9,14,20	178:9 187:21
162:17,21 164:9 247:15 248:2 145:8 309:16,23 269:17 271:24 166:12,21 169:6 249:12 250:4,20 pills 61:9 140:11 278:20 296:17 169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 173:13 175:16 253:25 254:22 311:7 pleases 215:15 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	160:9,22 161:8,21	246:3,7,11,17,21	143:1,25 144:8,15	200:16 252:18
169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 173:13 175:16 253:25 254:22 311:7 plenty 244:7 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	162:17,21 164:9		145:8 309:16,23	269:17 271:24
169:20 170:11 251:1,6,11,15,22 140:21 242:20 307:22 323:11,11 171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 173:13 175:16 253:25 254:22 311:7 plenty 244:7 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10		249:12 250:4,20		278:20 296:17
171:6 172:23 252:7 253:1,11,17 243:1,7 249:9,20 pleases 215:15 173:13 175:16 253:25 254:22 311:7 plenty 244:7 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	·	· · · · · · · · · · · · · · · · · · ·	*	
173:13 175:16 253:25 254:22 311:7 178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	171:6 172:23		243:1,7 249:9,20	
178:10 179:16 257:11,19 261:13 pinched 269:20 plevin 2:18 19:4 182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10				_
182:14 184:7 262:14 263:18 270:17 pllc 2:13 5:7 185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10	178:10 179:16	257:11,19 261:13	pinched 269:20	1 0
185:6 186:1 264:16 265:3 pipeline 312:24 plus 86:18 103:16 187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10		*	*	A
187:18 189:3 266:17 267:3,19 pittsburgh 6:10 point 3:18 27:10				_
, 1				_
				_
	, ,	·		

[point - presentation]

89:9 93:9 106:11	postoperative	prepared 121:14	211:20 212:6,20
120:21 130:24	276:15	149:11 150:13	222:1,8,23 223:13
149:19 152:2	potent 162:5	155:9 159:7	227:5 242:10,18
155:2,16 156:7,16	potential 278:24	preparedness	242:20,21 243:1
162:3 164:16	279:8	132:1	245:7 247:13
187:5 191:13	potentially 150:6	prepares 122:4	248:1 249:20
202:19 235:21	powerpoint 87:19	preparing 29:4,16	250:3 252:24
256:14 268:21	practice 37:25	30:1,2,15 102:13	253:8 254:17,20
269:17 270:21	199:11 258:15,23	prescribe 184:18	257:3 263:16,23
pointed 127:5	278:2	prescribed 167:16	263:25 265:1,22
pointing 269:21	practices 36:3	168:16 170:10	272:4 273:15,23
270:4,5,7,7,8,10	85:6 147:24	171:4 205:15	273:24 274:4,11
270:20	176:11 197:9	211:25 222:12	274:18,25 275:8,9
points 91:9 120:16	260:16	302:12,17	275:14,24 276:4
120:19 130:4,19	pre 261:15	prescriber 264:10	281:6,14,22 282:7
police 37:15 42:6,6	precede 185:23	prescribers	282:13 283:9,17
90:7 168:3	186:7 298:2	197:16 198:3	288:25 293:24
policy 241:16	preceded 317:17	210:17 264:6	294:8 295:21
polster 1:9	precedes 309:9	prescribing 36:2	297:6,7 304:25
porter 4:4 19:24	precise 317:16	85:6 147:23	305:4 311:10
portion 106:14	precursor 36:3	176:10 192:21	323:6 324:3 325:3
position 34:3	147:24 176:11	209:20 210:17	prescriptions
42:14 45:17 67:18	predecessor 75:7	260:16	173:23 192:16
68:17,19 70:19	317:18	prescription 1:6	199:3 200:10,19
74:20,22 75:14,22	predecessors	5:11 8:15 18:5	201:21 210:21
76:1,8,19,25 77:21	291:1 317:10	19:12 21:20 44:12	222:11 264:4
77:25 78:1,2,5	predetermined	47:23 60:21 85:16	282:5
80:2,3,5 83:3,17	105:6	129:5 145:10,20	presence 21:3
90:10,12 101:8	predictive 191:6	148:22,25 164:8	174:5 321:14
105:18 106:23	pregnancy 137:20	167:3,8,16 168:17	present 6:17 18:14
108:18 109:5	137:22	169:14 171:4	86:15,23 87:14
118:10 277:21	pregnant 139:5	172:10,16,22	88:9 89:21 90:2
317:5,19	prejudice 34:11	173:9,10 174:16	133:2 135:23
positions 105:4,5	preparation 28:9	174:20 175:14	159:7 222:13
possible 24:17	28:15 29:4	177:18 178:2	226:20 237:1
87:5 166:7 179:22	prepare 26:6	192:9 193:25	presentation 8:19
possibly 55:14	27:24 28:2 34:12	194:6,9,21 195:8,9	40:4 87:20 88:24
89:11 139:18	87:19,23 88:8	195:10,12,21	90:15 148:11
post 49:17	117:23 132:13	198:4,11 200:4,7	150:2 154:4 155:4
posted 80:3 315:1	182:18,20	202:2,20 206:15	155:8,14 260:25
		209:12,19 210:1	

[presentations - protocol]

presentations	privacy 44:1,15	167:20 169:5	programs 41:13
87:24 150:7	45:18	218:2 225:2	41:14 42:9,19
presented 40:2	private 179:24	271:14	55:13 82:3 134:25
86:12,14 89:13,24	privilege 25:25	product 30:14	135:3,5 138:19
173:4	45:4,9,20,23	43:23 46:18,23	141:18 179:22
presenting 87:6	198:14 244:1	47:4 152:23	180:8,9 181:24,24
88:25 236:8	privileged 29:19	194:11,21 299:10	183:20 185:20
president 9:16	proactive 316:19	299:17	237:16,17 279:13
239:3,12 240:12	probably 18:18	production 31:4	303:19,20 308:9
presidential	28:24 180:21	31:17,20 32:13,20	project 89:8 90:22
238:21	236:1 244:4	33:17,21 34:24	91:1,3,6,6,15,23
pretty 69:8 132:6	problem 57:19	88:15 283:24	92:3,6,16 93:7,25
prevent 266:9	82:2 247:12,21	318:10 323:15,17	97:22 98:5 138:22
267:2 268:9,25	292:9,22 293:4	323:22	184:15,16 303:10
preventing 63:13	294:3 296:14,19	products 47:9,13	proliferation
prevention 41:13	298:25 303:4,13	192:9 197:16	176:3
138:24 151:20	304:24,24 305:2,6	198:4 199:3 210:6	promoting 220:14
167:22 180:8	305:23 308:13	217:15 300:1,11	220:22 223:15
237:16 279:14,14	309:17,24 311:11	300:12,20,24	promotion 139:1
295:22	311:25 312:8,14	301:2	pronounce 79:7
preventive 316:19	313:24 314:6	professional 192:7	proper 211:1
previous 106:2	problems 57:22	professionally	properly 218:23
317:15	68:24	258:3	proportion 165:8
print 38:14	procedure 21:11	professionals	245:23 246:12,15
printed 37:24 38:2	320:8 324:5 325:5	192:15 193:1,8	proposal 190:17
	_	1 -	· · · · · · · · · · · · · · · · · · ·
printed 37:24 38:2	320:8 324:5 325:5	192:15 193:1,8	proposal 190:17
printed 37:24 38:2 38:11 227:10	320:8 324:5 325:5 proceeded 74:24	192:15 193:1,8 222:25	proposal 190:17 191:10 271:5 proposals 241:1 242:1
printed 37:24 38:2 38:11 227:10 prior 30:10,18	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3	192:15 193:1,8 222:25 program 91:7,25	proposal 190:17 191:10 271:5 proposals 241:1
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2	proposal 190:17 191:10 271:5 proposals 241:1 242:1
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2 245:21 246:21	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25 52:6	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24 programming	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24 61:19 62:4,13
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2 245:21 246:21 261:18 277:3	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25 52:6 produced 32:19	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24 programming 106:16 107:14	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24 61:19 62:4,13 63:2,7 66:9,13
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2 245:21 246:21 261:18 277:3 298:5 307:18	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25 52:6 produced 32:19 33:2 35:4 37:7	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24 programming 106:16 107:14 108:2 131:13	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24 61:19 62:4,13 63:2,7 66:9,13 67:10 69:12
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2 245:21 246:21 261:18 277:3	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25 52:6 produced 32:19 33:2 35:4 37:7 39:7 40:22 43:9	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24 programming 106:16 107:14	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24 61:19 62:4,13 63:2,7 66:9,13
printed 37:24 38:2 38:11 227:10 prior 30:10,18 75:13,22 81:2 83:2,20,21 90:1 93:23 94:2,8 97:16,20 98:3 101:11 103:10 105:3,6 107:3 163:10 186:10 190:20 196:2,19 205:19 214:2 245:21 246:21 261:18 277:3 298:5 307:18	320:8 324:5 325:5 proceeded 74:24 proceeding 46:3 proceedings 22:2 process 76:9 80:1 81:9,17 82:8 83:1 84:15 99:19 100:12 104:25 179:13 182:21,25 196:9 282:6 processed 281:23 produce 33:25 52:6 produced 32:19 33:2 35:4 37:7	192:15 193:1,8 222:25 program 91:7,25 92:8 106:4 135:2 137:4,7 138:20,24 180:22 186:13,17 186:21,25 187:11 187:17,25 188:20 188:23 189:1 260:6 262:17 263:25 266:13 272:5 296:24 programming 106:16 107:14 108:2 131:13	proposal 190:17 191:10 271:5 proposals 241:1 242:1 propose 240:21 prospective 316:20 protect 45:9 57:18 66:17 protecting 97:3 protocol 20:23 44:7 57:11,24 61:19 62:4,13 63:2,7 66:9,13 67:10 69:12

[provide - question]

			· ·
provide 32:12	74:17 76:1 77:19	293:8 294:23	315:12
33:10 55:11,13	78:10,20 79:19	295:1,24 298:3,19	pursuant 320:4,7
91:17,22 93:17	80:8 81:4 82:4	303:3 305:14	pursued 195:7
95:21,24 98:5	83:15 86:10 87:14	306:5 307:2,19	purview 301:23
112:8,20,25	89:5,17,23 90:4,7	309:11 317:11	302:2,6,10 318:1,2
113:23 133:15	92:7,13,24 93:2,6	321:6 322:12	put 39:20 82:21
137:15,15 138:2	93:24 94:8,10,20	324:10,18 325:15	114:22 118:18
138:21 150:7	94:24 95:4,10,16	325:23 326:23	148:7 149:14
151:17 165:24	96:4 98:8,12,20	public's 236:21	159:5 163:15,18
169:25 184:13,15	99:3,20,22 100:8	publication	164:12 167:19
184:18 188:9	102:8,10 103:19	294:17	168:7 175:4,5
194:21 204:3	104:8 105:1,8,21	publications	190:8,16,18 191:9
207:20 218:6	105:24 107:11,15	174:24,25	230:12,16,21
264:25 303:17	107:23 109:19	publicity 84:18	236:14,18 237:6
306:18 308:2	110:24 115:5,6,17	pull 146:3 176:5	238:18 241:1
provided 21:10	117:13,18 118:5	pulled 116:10	247:6,9 281:12,18
35:5 38:6 56:2	118:17 121:12	purchase 92:11	294:20 296:4
89:6 90:1,5	128:2 133:16	161:17 178:3	317:20
112:17 113:12	134:6,10,15 137:2	purchased 155:18	puts 40:11
114:11 116:6	141:14 148:12	156:9 157:8	putting 195:5
117:16 126:10	149:16 150:20	161:14	q
127:15 133:21	151:12 153:22	purported 253:13	qualified 321:8
134:18 136:1,19	154:1 155:15	purpose 51:12	quality 99:18
138:10 141:20	168:5 171:12	52:1 110:1 160:15	quarterly 136:6
150:10 153:13,21	176:20 185:24,25	160:19 161:1,4,11	quarterly 130.0 question 22:25
154:22 166:4	186:9 187:15	161:18,20 162:16	23:5 24:3 25:6,9
167:10 168:23	188:7 193:19	162:20 225:14	25:12,12,13,20,22
186:14 193:4	211:11 214:19	230:9 237:8	25:24 26:8,11
195:3 202:2,12,20	217:5 219:25	239:22 262:8	29:7,12,13,24
213:23 217:4	220:10,14,18,22	283:6	31:12 32:23 41:21
221:22	223:3,15,18	purposes 31:4,20	46:13,20 47:2,18
provider 164:19	225:11 228:23,25	34:19,22 35:14	48:21 50:19 51:18
provides 91:23	230:21 236:4,24	36:22 38:22 85:19	57:7 58:4 61:16
116:25 135:6	247:11 252:4	119:13 148:15	69:19 75:4 83:5
184:5	256:3 260:8 262:1	157:25 162:19	95:19 96:20,22
providing 91:5	262:11 263:13	189:16 224:4,11	100:3,10 106:19
93:25 99:4 132:22	266:7 268:9,24	224:23 228:4	120:2 121:16
public 1:21 2:19	269:1,24 270:24	229:14 239:7	123:11 124:17
8:20 29:2 42:2,8	273:1 279:1,10,21	248:17 255:16	125:14 126:1,8,24
49:20 52:16 54:20	279:21 280:4	259:20 271:11	127:2 128:18,23
58:6 73:24 74:11	289:20 290:10	286:8,14,20 295:8	130:3 134:3 141:8

[question - recall] Page 45

143:8,10,19,22 145:14,18 147:13 445:14,18 147:13 448:19,24 149:3 153:7,8,19 156:5 157:11 159:17 40estioner 64:25 40estioner 318:9 45:11 175:17 46:9 170:13 166:9 170:13 172:11 175:17 47:21 175:17 47:21 175:17 47:21 175:17 47:21 175:17 47:21 175:18 44:7 267:20 46:17 47:3,12 46:17 47:3,12 46:11 47:3,12 47:3,13 47:3,12 47:3,13 47:3,13 47:3,13 47:3,13 47:3,13 47:3,13	142.0 10 10 22	312:16		malified 05:02
148:19,24 149:3 153:7,8,19 156:5 157:11 159:17 162:13,15 165:9 166:9 170:13 177:8,22 179:18 186:24,45 192:1 194:13 195:18 196:21 197:19,23 199:6,23 200:15 2098:2 315:17 200:23 201:14 200:8 203:17 200:23 201:14 200:8 203:17 200:23 201:14 201:24 151:2 214:15 211:25 214:15 211:22 214:15 211:23 213:5 238:4,14 241:24 242:15,23 237:5 238:4,14 241:24 242:15,23 237:5 238:4,14 241:24 242:15,23 243:12 244:17 23 243:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 300:12 300:12 300:12 306:21 300:12 316:13 300:12 306:21 300:12 306:21 307:13 308:1 7eason 26:3 7eason 26:3 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 211:25 212:5 221:25 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 212:5 221:125 21:25 226:25 221:125 212:5 226:25 221:125 212:5 226:25 221:125 212:5 226:25 226				
153:7,8,19 156:5 157:11 159:17 questioners 318:9 questions 45:1 reach 303:22 reached 265:15 303:15,18 305:20 306:21 307:13 306:22 reaction 43:22 reaction	· · · · · · · · · · · · · · · · · · ·	_		
157:11 159:17	_	_		
162:13,15 165:9	, , ,	_		
166:9 170:13 168:22 69:3,22 70:24 72:16,20 70:25 70:24 72:16,20 70:24		•		
172:11 175:17	· · · · · · · · · · · · · · · · · · ·			,
177:8,22 179:18 86:24 96:25 99:25 46:17 47:3,12 reason 26:3 186:3,4,5 192:1 118:14 207:6 244:7 267:20 61:18 63:7 66:8 211:25 212:5 196:21 197:19,23 268:17 284:2,17 66:14 84:7 88:4 294:16 296:7 199:6,23 200:15 298:2 315:17 142:14,16,17,20 316:23 323:14 200:23 201:14 318:15,18,21 142:24 151:2 325:8 326:3 207:12,18,21,22 318:22 197:10,17,25 reasonsble 226:24 207:21,18,21,22 318:22 197:10,17,25 reasons 73:12 211:22 214:15 216:21,23 219:5 229:1 228:13 229:23 recall 24:8 37:9,19 219:10 230:1 64:25 65:2 67:6 237:17 244:12,14 226:25 238:4,14 241:24 242:15,23 243:22 244:41:11,18,24 245:17,19 246:4,6 246:8 250:14,17 39:25 40:20,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 267:16,18 272:13 72:13,22 73:21 253:4 254:9 7 7:8:8 75:20 259:8,8 278:19,21 290:11 84:25 85:12 87:6 266:17 297:17 300:16 301:20 302:15 304:15 302:15		·		
186:3,4,5 192:1 118:14 207:6 read 42:4 57:23 126:21 174:20 194:13 195:18 244:7 267:20 61:18 63:7 66:8 211:25 212:5 199:6,23 200:15 298:2 315:17 142:14,16,17,20 316:23 323:14 200:23 201:14 318:15,18,21 142:24 151:2 325:8 326:3 202:8 203:17 319:4 160:1 174:22 reasonable 226:24 204:20 205:19 quick 110:15 176:7 196:15 226:25 207:12,18,21,22 318:22 197:10,17,25 reasonable 226:24 219:10 230:1 64:25 65:2 67:6 233:25 234:11,15 233:25 234:11,15 233:25 234:11,15 233:25 234:11,15 233:25 234:11,15 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,182,0,25 257:7 258:8,11,16 59:17,18,19 60:2 59:17,18,19 60:2 247:16 248:4 251:8,17,23,24 27:2 27:23 274:9 74:5 77:5 84:23 251:8,17,23,24 7 7 5:8 75:20 259:8,8 315:15 316:20,21 324:5,6,12 325:5,6 325:17 72:13,22 73:21 72:13,22 73:21 72:13,22 73:21 72:13,22 73:21 72:13,22 73:21				
194:13 195:18 244:7 267:20 61:18 63:7 66:8 294:16 296:7 199:6,23 200:15 298:2 315:17 142:14,16,17,20 316:23 323:14 318:15,18,21 142:24 151:2 325:8 326:3 202:8 203:17 204:20 205:19 207:12,18,21,22 211:22 214:15 211:22 214:15 211:22 214:15 211:22 214:15 211:22 214:15 211:22 214:15 211:23 214:15 219:10 230:1 64:25 65:2 67:6 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 251:8,17,24 251:8,17,24 251:8,17,24 251:8,17,24 251:8,17,24 251:8,17,24 25	/		,	
196:21 197:19,23 268:17 284:2,17 298:2 315:17 142:14,16,17,20 316:23 323:14 325:8 326:3 142:24 151:2 325:8 326:3 160:1 174:22 176:7 196:15 176:7 196:15 177:0,17,25 211:22 214:15 218:22 214:15 219:14,13 224:16 228:13 229:23 216:21,23 219:5 219:10 230:1 230:1 230:1 230:23:25 234:11,15 236:16,23 237:5 238:4,14 241:24 244:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 251:8,17,23,24 276:23 277:3 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 302:15 304:15 302:15 304:15				
199:6,23 200:15 298:2 315:17 318:15,18,21 325:8 326:3 142:24 151:2 325:8 326:3 162:3 323:14 325:8 326:3 162:3 201:14 318:15,18,21 319:4 160:1 174:22 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 176:7 196:15 177:0,17,25 179:10,17,25				
200:23 201:14 202:8 203:17 204:20 205:19 207:12,18,21,22 211:22 214:15 215:4,15,23 216:21,23 219:5 219:10 230:1 233:25 234:11,15 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 266:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 318:15,18,21 319:4 160:1 174:22 176:7 196:15 176:10,17,25 179:4 170:17,25 179:10,17,25 179:10,17,25 179:10,17,25 179:10,17,25 179:10,17,25 18	,	·		
202:8 203:17 204:20 205:19 207:12,18,21,22 211:22 214:15 215:4,15,23 216:21,23 219:5 219:10 230:1 233:25 234:11,15 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 319:4 160:1 174:22 176:7 196:15 179:10,17,25 219:11,13 224:16 228:13 229:23 129:11,13 224:16 228:13 229:23 230:3 231:7 233:2 249:41,13 224:16 228:13 229:23 230:3 231:7 233:2 246:8 250:14,17 246:8 250:14,17 257:7 258:8,11,16 260:18 264:12,21 260:18 264:12,21 276:23 277:3 278:18 279:5 278:18 279:5 278:18 279:5 276:23 277:3 278:18 279:5 278:18 279:5 278:18 279:5 278:19 279:17 300:16 301:20 302:15 304:15 307:21,21 309:20 319:4 reasonable 226:24 226:25 reasons 73:12 319:4 recall 24:8 37:9,19 246:12,21 39:25 40:20,24 41:1,2,4 50:3 59:1 257:7 258:8,11,16 260:18 264:12,21 260:18 264:12,21 276:23 274:29 278:19,21 290:11 278:19 240:4 242:15,23 269:15 278:19 240:4 242:15,23 269:15 278:18 279:1 278:18 279:5 278:18 279:5 278:18 279:5 278:18 279:5 278:18 279:6 278:19 24:16 228:13 229:13 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 233:2 230:3 23:17 244:12,14 246:8 250:14,17 257:7 258:8,11,16 260:18 264:12,21 279:17	199:6,23 200:15	298:2 315:17	142:14,16,17,20	316:23 323:14
204:20 205:19 quick 110:15 176:7 196:15 226:25 reasons 73:12 207:12,18,21,22 318:22 197:10,17,25 319:4 recall 24:8 37:9,19 215:4,15,23 279:4 228:13 229:23 319:4 recall 24:8 37:9,19 219:10 230:1 64:25 65:2 67:6 237:17 244:12,14 39:25 40:20,24 233:25 234:11,15 68:6 246:8 250:14,17 39:25 40:20,24 238:4,14 241:24 quotas 210:6 260:18 264:12,21 60:12,18,19,25 244:4,11,18,24 316:13,16,18,18 267:16,18 272:13 72:272:3,7,9,11 244:4,11,18,24 316:13,16,18,18 267:16,18 272:13 72:13,22 73:21 245:17,19 246:4,6 246:9,15,18,20,25 316:24 272:23 274:9 74:577:5 84:23 247:16 248:4 251:8,17,23,24 316:13 290:14 292:6,7 87:10 88:5,14,22 256:23 268:19 75:8 75:20 259:8,8 315:15 316:20,21 315:15 316:20,21 315:14 323:19 324:56,12 325:5,6 325:17 102:4 106:23 269:12 274:22 276:23 277:3 278:18 279:5 315:14 323:19 126:23 127:6 136:7 141:21	200:23 201:14	318:15,18,21	142:24 151:2	325:8 326:3
207:12,18,21,22 211:22 214:15 215:4,15,23 216:21,23 219:5 219:10 230:1 233:25 234:11,15 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 266:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 318:22 219:10,17,25 219:11,13 224:16 228:13 229:23 230:3 231:7 233:2 230:3 231:7	202:8 203:17	319:4	160:1 174:22	reasonable 226:24
211:22 214:15 quickly 168:8 219:11,13 224:16 319:4 recall 24:8 37:9,19 215:4,15,23 279:4 228:13 229:23 37:21 38:12 39:9 37:21 38:12 39:2 37:13 32:2 37:13 38:12 39:2 37:13 38:12 39:2 37:13 38:12 39:2 37:21 38:12 39:2 37:21 38:12 39:2 37:21 38:12 39:2 37:	204:20 205:19	quick 110:15	176:7 196:15	226:25
215:4,15,23 216:21,23 219:5 219:10 230:1 233:25 234:11,15 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 279:4 quite	207:12,18,21,22	318:22	197:10,17,25	reasons 73:12
216:21,23 219:5 quiet 61:23 62:18 230:3 231:7 233:2 37:21 38:12 39:9 219:10 230:1 64:25 65:2 67:6 237:17 244:12,14 39:25 40:20,24 233:25 234:11,15 68:6 246:8 250:14,17 41:1,2,4 50:3 59:1 238:4,14 241:24 quotas 210:6 260:18 264:12,21 59:17,18,19 60:2 242:15,23 243:22 quote 257:1,13,18 265:23 266:3 71:22 72:3,7,9,11 244:4,11,18,24 316:13,16,18,18 267:16,18 272:13 72:13,22 73:21 245:17,19 246:4,6 316:24 272:23 274:9 74:5 77:5 84:23 247:16 248:4 316:13 290:14 292:6,7 87:10 88:5,14,22 253:4 254:9 7 306:22 313:7 89:24 90:18 93:21 266:21,23 269:15 75:8 75:20 259:8,8 73:5:15 316:20,21 74:5,17,22 101:13 269:22 274:22 76:23 277:3 73:25 289:3 73:5:14 323:19 72:23 27:2 276:23 277:3 73:25 296:15 73:25 289:3 73:5:14 323:19 73:5:17 10:24 296:17 297:17 73:0:16 301:20 73:5:14 323:19 73:5:17 10:24 205:1,2,8 73:5:13 62:9 73:5:14 32	211:22 214:15	quickly 168:8	219:11,13 224:16	319:4
219:10 230:1 233:25 234:11,15 236:16,23 237:5 238:4,14 241:24 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 272:23 274:9 278:19,21 290:11 290:14 292:6,7 306:22 313:7 306	215:4,15,23	279:4	228:13 229:23	recall 24:8 37:9,19
233:25 234:11,15 236:16,23 237:5 quite 171:23 quotas 210:6 quote 257:1,13,18 242:15,23 243:22 244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 68:6 quite 171:23 quotas 210:6 260:18 264:12,21 265:23 266:3 260:18 27:38 266:18 272:13 265:23 266:3 267:16,18 272:13 265:23 266:3 278:19,21 290:11 290:14 292:6,7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 315:15 316:20,21 316:13 278:19,21 290:11 290:14 292:6,7 306:22 313:7 315:15 316:20,21 315:15 316:20,21 324:5,6,12 325:5,6 325:17 284:9 283:23 284:4,11,16 260:12,18,19,25 71:22 72:3,7,9,11 72:13,22 73:21 72:1	216:21,23 219:5	quiet 61:23 62:18	230:3 231:7 233:2	37:21 38:12 39:9
236:16,23 237:5 quite 171:23 257:7 258:8,11,16 59:17,18,19 60:2 238:4,14 241:24 quotas 210:6 260:18 264:12,21 60:12,18,19,25 244:4,11,18,24 316:13,16,18,18 265:23 266:3 71:22 72:3,79,11 245:17,19 246:4,6 316:24 272:23 274:9 74:5 77:5 84:23 246:9,15,18,20,25 quotes 263:21 278:19,21 290:11 84:25 85:12 87:6 251:8,17,23,24 r 290:14 292:6,7 87:10 88:5,14,22 253:4 254:9 r 306:22 313:7 89:24 90:18 93:21 267:16,23 268:19 67:1,3 324:5,6,12 325:5,6 325:17 102:4 106:23 269:22 274:22 67:1,3 324:5,6,12 325:5,6 325:17 107:5,17 110:24 269:22 274:22 67:1,3 315:14 323:19 126:23 127:6 269:17 297:17 300:16 301:20 302:15 304:15 305:17,17 318:22 136:13 290:14 292:274:22 276:23 277:3 278:18 279:5 325:17 126:23 127:6 290:17 297:17 300:16 301:20 305:17,17 318:22 126:23 127:6 305:17,17 318:22 126:23 127:6 <t< td=""><td>219:10 230:1</td><td>64:25 65:2 67:6</td><td>237:17 244:12,14</td><td>39:25 40:20,24</td></t<>	219:10 230:1	64:25 65:2 67:6	237:17 244:12,14	39:25 40:20,24
238:4,14 241:24 quotas 210:6 260:18 264:12,21 60:12,18,19,25 242:15,23 243:22 quote 257:1,13,18 265:23 266:3 71:22 72:3,7,9,11 244:4,11,18,24 316:13,16,18,18 267:16,18 272:13 72:13,22 73:21 245:17,19 246:4,6 316:24 272:23 274:9 74:5 77:5 84:23 246:9,15,18,20,25 quotes 263:21 316:13 278:19,21 290:11 84:25 85:12 87:6 251:8,17,23,24 r 306:22 313:7 89:24 90:18 93:21 89:24 90:18 93:21 253:4 254:9 r5:8 75:20 259:8,8 324:5,6,12 325:5,6 325:17 102:4 106:23 266:17 297:17 raised 283:23 raised 283:23 315:14 323:19 126:23 127:6 296:17 297:17 rate 204:21,25 305:17,17 318:22 136:16:16 136:7 141:21 300:16 301:20 302:15 304:15 305:17,17 318:22 159:1 186:16 159:1 186:16 307:21,21 309:20 187:1 187:1 187:13 201:10	233:25 234:11,15	68:6	246:8 250:14,17	41:1,2,4 50:3 59:1
242:15,23 243:22 quote 257:1,13,18 265:23 266:3 71:22 72:3,7,9,11 244:4,11,18,24 316:13,16,18,18 267:16,18 272:13 72:13,22 73:21 245:17,19 246:4,6 316:24 272:23 274:9 74:5 77:5 84:23 246:9,15,18,20,25 quotes 263:21 278:19,21 290:11 84:25 85:12 87:6 247:16 248:4 316:13 290:14 292:6,7 87:10 88:5,14,22 251:8,17,23,24 r 306:22 313:7 89:24 90:18 93:21 253:4 254:9 75:8 75:20 259:8,8 315:15 316:20,21 94:5,17,22 101:13 266:23 274:22 276:23 277:3 325:17 102:4 106:23 266:17 297:17 300:16 301:20 315:14 323:19 11:13 112:22 296:17 297:17 205:1,2,8 315:14 323:19 126:23 127:6 302:15 304:15 205:1,2,8 305:17,17 318:22 149:10 158:16 307:21,21 309:20 187:1 187:13 201:10	236:16,23 237:5	quite 171:23	257:7 258:8,11,16	59:17,18,19 60:2
244:4,11,18,24 245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:13,16,18,18 272:23 274:9 278:19,21 290:11 290:14 292:6,7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 reading 37:20 196:25 289:3 118:8 122:16,21 126:23 127:6 ready 68:20 288:6	238:4,14 241:24	quotas 210:6	260:18 264:12,21	60:12,18,19,25
245:17,19 246:4,6 246:9,15,18,20,25 247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:24 272:23 274:9 278:19,21 290:11 290:14 292:6,7 306:22 313:7 306:22 313:7 306:22 313:7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 3278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:24 278:19,21 290:11 290:14 292:6,7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 reading 37:20 196:25 289:3 315:14 323:19 ready 68:20 288:6 real 110:15 117:19 305:17,17 318:22 realize 223:1 74:5 77:5 84:23 84:25 85:12 87:6 87:10 88:5,14,22 94:5,17,22 101:13 102:4 106:23 107:5,17 110:24 111:13 112:22 118:8 122:16,21 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 187:13 201:10	242:15,23 243:22	quote 257:1,13,18	265:23 266:3	71:22 72:3,7,9,11
245:17,19 246:4,6 316:24 272:23 274:9 74:5 77:5 84:23 246:9,15,18,20,25 quotes 263:21 278:19,21 290:11 84:25 85:12 87:6 247:16 248:4 316:13 290:14 292:6,7 87:10 88:5,14,22 251:8,17,23,24 r 306:22 313:7 89:24 90:18 93:21 253:4 254:9 r 5:8 75:20 259:8,8 315:15 316:20,21 94:5,17,22 101:13 268:21,23 269:15 67:1,3 324:5,6,12 325:5,6 102:4 106:23 269:22 274:22 raised 283:23 raising 62:11 reading 37:20 111:13 112:22 278:18 279:5 196:25 289:3 118:8 122:16,21 126:23 127:6 296:17 297:17 rate 204:21,25 205:1,2,8 100:15 117:19 149:10 158:16 302:15 304:15 rates 55:23 300:12 305:17,17 318:22 159:1 186:16 187:13 307:21,21 309:20 187:1 187:1 187:1 187:1	244:4,11,18,24	316:13,16,18,18	267:16,18 272:13	72:13,22 73:21
247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:13 290:14 292:6,7 306:22 313:7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 324:5,6,12 325:5,6 325:17 326:23 277:3 3278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:13 290:14 292:6,7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 326:23 325:17 3278:18 279:5 328:18 279:5 329:14 292:6,7 329:14 292:4 90:18 29 102:4 106:23 107:5,17 110:24 111:13 112:22 118:8 122:16,21 126:23 127:6 126:23 127:6 127:13 201:10 126:23 127:6 127:13 201:10 127:13 201:10 128:10 24 129:10 24	245:17,19 246:4,6	316:24	272:23 274:9	74:5 77:5 84:23
247:16 248:4 251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:13 290:14 292:6,7 306:22 313:7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 324:5,6,12 325:5,6 325:17 326:23 277:3 3278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 316:13 290:14 292:6,7 306:22 313:7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 326:23 325:17 3278:18 279:5 328:18 279:5 329:14 292:6,7 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 315:14 323:19 316:13 324:5,6,12 325:5,6 325:17 315:14 323:19 316:13 324:5,6,12 325:5,6 325:17 315:14 323:19 316:13 324:5,6,12 325:5,6 325:17 315:15 316:20,21 324:5,6,12 325:5,6 325:17 315:15 316:20,21 324:5,6,12 325:5,6 325:17 310:24 106:23 111:13 112:22 118:8 122:16,21 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 159:1 186:16 159:1 186:16 187:13 201:10	246:9,15,18,20,25	quotes 263:21	278:19,21 290:11	84:25 85:12 87:6
251:8,17,23,24 253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 r 5:8 75:20 259:8,8 raise 57:13 62:9 67:1,3 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 306:22 313:7 315:15 316:20,21 324:5,6,12 325:5,6 325:17 reading 37:20 196:25 289:3 315:14 323:19 ready 68:20 288:6 ready 68:20 288:6 ready 68:20 288:6 136:7 141:21 149:10 158:16 159:1 186:16 159:1 186:16 187:13 201:10	247:16 248:4		290:14 292:6,7	87:10 88:5,14,22
253:4 254:9 267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 r 5:8 75:20 259:8,8 raise 57:13 62:9 67:1,3 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 ratio 187:1 ratio 187:1 r 5:8 75:20 259:8,8 raise 57:13 62:9 67:1,3 reading 37:20 102:4 106:23 107:5,17 110:24 111:13 112:22 196:25 289:3 315:15 316:20,21 324:5,6,12 325:5,6 325:17 reading 37:20 196:25 289:3 315:14 323:19 ready 68:20 288:6 136:7 141:21 149:10 158:16 159:1 186:16 159:1 186:16 187:13 201:10	251:8,17,23,24	r	306:22 313:7	89:24 90:18 93:21
267:16,23 268:19 268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 7 3.8 73.20 239.8,8 raise 57:13 62:9 67:1,3 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 7 324:5,6,12 325:5,6 324:5,6,12 325:5,6 325:17 reading 37:20 196:25 289:3 315:14 323:19 ready 68:20 288:6		_	315:15 316:20,21	94:5,17,22 101:13
268:21,23 269:15 269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 raise 57:13 62:9 67:1,3 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 raise 57:13 62:9 67:1,3 reading 37:20 107:5,17 110:24 111:13 112:22 118:8 122:16,21 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 187:13 201:10	267:16,23 268:19	· ·	324:5,6,12 325:5,6	
269:22 274:22 276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 reading 37:20 111:13 112:22 118:8 122:16,21 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 159:1 186:16 187:13 201:10	· ·			107:5,17 110:24
276:23 277:3 278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 raised 283:23 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 196:25 289:3 315:14 323:19 ready 68:20 288:6 read 110:15 117:19 305:17,17 318:22 realize 223:1 118:8 122:16,21 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 187:13 201:10	· · · · · · · · · · · · · · · · · · ·	· ·	reading 37:20	_
278:18 279:5 296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 raising 62:11 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 315:14 323:19 ready 68:20 288:6 read 110:15 117:19 305:17,17 318:22 realize 223:1 126:23 127:6 136:7 141:21 149:10 158:16 159:1 186:16 187:13 201:10	276:23 277:3			118:8 122:16,21
296:17 297:17 300:16 301:20 302:15 304:15 307:21,21 309:20 range 137:16 rate 204:21,25 205:1,2,8 rates 55:23 300:12 ratio 187:1 ready 68:20 288:6 read 110:15 117:19 305:17,17 318:22 realize 223:1 136:7 141:21 149:10 158:16 159:1 186:16 187:13 201:10				· · · · · · · · · · · · · · · · · · ·
300:16 301:20 302:15 304:15 307:21,21 309:20				
302:15 304:15 307:21,21 309:20		· ·		
307:21,21 309:20				
' rano 8/:1			· ·	
202.21200.11	ĺ	ratio 187:1		
	, · · · · · · · · · · ·			

[recall - reimbursed]

211:4 225:13	recollection 40:13	258:25 259:1,5	reflect 191:3 255:3
226:3,12 238:18	59:8 61:12 73:1,6	265:5 267:18	269:19
238:20,22 258:7	74:1 82:5 86:6	269:19 278:21	refresh 146:6
261:4,9,11,14,23	105:23 150:13	281:7,11 284:5,9	regard 30:14
261:24 262:5,15	158:18 201:24	297:14 309:20	regarding 29:1
263:11 271:3	202:23 205:2,10	314:17,18,21	36:14 57:12 73:24
272:1 315:14	220:11 250:7	318:17,20,23	94:17 97:13
316:25 318:13	263:7 265:18	319:2,5,11 325:9	105:24 112:25
319:6	283:18,19 289:7	recorded 18:4	117:1 125:16
recalling 175:19	recommendation	226:1	127:20 129:18
receipt 323:18	80:14 283:15	records 187:23	133:13 151:23
receive 112:18	recommendations	redirected 42:7	153:16 154:22
113:16,17 135:19	8:16 80:7,11	reduce 195:8	167:1,14 168:15
258:10 272:9,16	85:18 87:16	reduced 321:13	175:13 177:13
273:5 287:25	225:19 227:3	reduction 253:24	187:16,23 193:18
290:25 318:11	228:10 230:13,16	reed 4:8 20:5	194:22 197:9,14
received 41:3	230:22 236:8,10	reedsmith.com	198:2,4 200:9,18
50:24 97:11 180:1	236:14,19 237:1,6	4:11	203:5 205:13
180:4 181:1	238:6,10,17	reestablish 316:14	237:2 240:12
193:25 218:14	reconsider 44:6	refer 108:14 124:9	320:3,11
261:19,22 287:21	record 18:2,16	156:10,20 158:6	registered 218:23
291:2 296:3	21:17,23 33:15,18	229:5	registrar 131:24
receives 211:14	34:23 43:2,5,8	reference 323:7	regular 120:8
receiving 37:19	57:14,18 63:17	324:2 325:2	133:22 258:23
185:10 256:15	65:8 66:3,6,18,18	referenced 60:10	287:25 290:25
291:14	69:3 70:1,10,12,16	321:12,17 324:11	regularity 230:18
recess 43:3 71:10	71:7,8,12,16 97:4	325:15	regularly 114:17
110:12 144:25	110:11,14,22	referencing	163:12 171:22
178:13 199:17	121:16 123:11	127:24	172:3 214:20
206:23 254:5	124:10 127:1	referrals 188:2,13	230:15
259:3 284:7	128:18 144:22	referred 84:12	regulated 212:25
314:19 318:25	145:2 148:20	124:17 125:15	regulation 216:24
recipients 8:10	151:3 170:12	142:22 189:23	218:9,10 284:20
36:20	171:7 173:14	229:4,8	regulations 213:5
recognize 119:16	176:7 178:12,15	referring 84:16	213:10,18 214:4
121:7,9 132:12	191:3 199:16,19	85:25 86:3,7	214:25 215:7
139:17 149:8,9	206:20,22,25	108:15 124:11,24	217:10,13
150:6 181:7	219:13 226:20	125:1,6,18 297:10	rehabilitation
189:22 206:16	241:5 243:22	297:14	230:24 231:1
recognized 293:22	244:14 249:13	refers 36:6 140:15	reimbursed 281:7
296:23	251:16 254:4,7		

[reiterate - research]

			_
reiterate 283:23	rely 119:23	129:24 130:1	174:3,8,23 175:2,5
reject 34:3	remain 274:5	131:4 163:13,19	201:18 202:15
rejected 190:21	remaining 95:16	230:8,10,18	203:11,20 205:4
relate 22:17 23:15	remains 149:6	253:14,16,21	206:4,6,8,11
128:19 131:19	remember 39:23	255:2 286:6,12,18	285:13 287:9,11
138:13	40:1,22 54:24	286:24 287:1,4	287:22,25 290:2
related 8:17 21:20	61:4,7 116:21	288:9,25 290:15	290:24 297:23
22:22 29:3 32:8,9	143:19 180:24	291:17 293:12,12	298:13 313:8
42:2 52:14 60:10	249:10,15 282:18	293:19 297:6,10	314:4
61:14 71:25 72:9	317:17	297:19,21 298:8	represent 38:6
72:15,18 73:20,25	remind 57:11	306:12 307:18	45:24 224:25
74:4 83:23 86:11	282:15	313:9,11,14	284:15
86:16 87:4,8,17	remotely 18:15	reported 118:13	representative
89:22 90:23 99:4	rems 200:6	120:14,23 121:1	59:23 185:15
99:11 104:20	renee 1:25 18:13	167:23 253:20	represented 23:21
106:12,16 107:13	321:6 322:12	264:10	59:11 73:10 255:5
107:13,14,23	reorganizing 33:6	reporter 7:14	295:20
113:5 116:16	repeat 51:18 120:2	18:13 20:21 21:7	representing
119:11 121:3,22	123:22 145:18	24:21 35:18 36:25	62:19 239:16
123:16,16 125:2	148:23 153:6	38:25 267:19	represents 207:5
127:4 128:20	156:4 179:18	270:14 324:7	reputable 163:16
129:1,5,10,20,23	197:23 219:10	reporter's 7:12	174:24
130:8,21 131:5	233:2 242:15	25:3 321:1	request 66:2
135:19 136:25	244:11 274:21	reporting 121:6	105:20 107:2
137:9 149:15	296:17	127:25 170:18	325:9,11
174:4 175:21,22	repeating 231:22	217:19 219:16	requested 270:22
180:8,9 181:3,10	rephrase 23:5	220:6,9 238:11	320:2,7,11
181:19 182:12	25:8,10 106:19	260:17 264:1	requesting 105:25
183:3,20 203:25	143:21 212:2	reports 79:15	requests 106:13
204:6,12 242:3,9	307:20	83:24,25 98:16	require 20:24
257:3 288:16	report 8:15,18	109:17,25 114:14	265:8
292:4,17,22 293:9	10:4,6,8 82:21	115:6,6,21,23,25	required 28:16
295:18 304:25	84:13,16,19,24	116:2,11,19 117:4	264:7 323:25
relates 1:9 172:18	85:1,1,4,17,24	117:7,23 118:4,9	requirements
200:3 241:19	86:1,3,7 98:9	118:13 119:19,19	188:14 217:19
relations 237:1	114:3 116:1	119:23 120:4,7,14	265:11
	1	120:17,18,23	reread 216:21
relatively 317:11	122:4 123:8,19	122:7,10,11	rereview 63:9
		· · · · · · · · · · · · · · · · · · ·	research 194:8,19
· ·			303:17
164:16	128:24,25 129:3	170:25 171:3	
relative 322:2 relatively 317:11 release 84:19 relief 140:20,20	119:12,18 121:13	120:17,18,23 122:7,10,11 128:11 142:17,21 165:19 167:20	reread 216:21 rereview 63:9

[reserve - rosen] Page 48

210.12	• 1 • 1 • 4 •		200 22 200 0
reserve 318:13	responsibilities	reviewed 80:5	298:22 300:8
319:8	102:15,20 119:7	107:8 169:12	304:19 306:20
reserving 33:23	responsibility	193:20 196:13	308:15 309:18
residents 221:6	133:17 141:24	258:8 283:4 288:8	311:7 313:10,15
276:10,13 278:7	233:13 234:2,17	290:1,4	313:18 316:4,8,20
278:25 279:9	235:13 283:12	reviewing 106:12	317:2,6,8 318:19
resolved 24:10	responsive 215:1	109:16,25 118:8	319:8
resort 313:1	215:13 234:23	191:4 196:19	rigorous 315:25
resorted 164:20	235:25 237:5	288:18 289:2	316:17
205:24	267:15 268:13	rice 3:7 19:1	rise 203:21 214:3
resorting 311:18	rest 181:10	right 28:8,14,25	219:2,2 250:8
resource 279:25	restate 100:3	31:2,22 39:10	risk 162:3 192:24
resourced 247:3	172:11	41:25 51:9 62:6	193:10 194:10,23
resources 106:5	result 101:16	63:25 66:6,7	199:25 300:2
139:11,13,15,19	115:8 168:13	67:15,21 68:19	risks 277:22
139:24 140:2	174:2,19	70:15,21 80:18	rite 302:8 304:3,16
168:10 174:12	resulted 172:21	93:19 98:18	road 2:14
178:5 191:5,11,17	resume 74:23 76:7	101:11,25 102:13	robert 6:8 19:16
241:14 266:11	resumes 80:5	102:22 107:7	role 74:13,16,25
303:16,19 305:1	retained 7:14	108:6 115:16	75:5,6 77:6 78:9
305:10,21 306:3,7	returned 323:18	121:10,21 122:6	78:13 79:1 86:9
306:9 308:22	reveal 143:15	122:15 130:25	98:7 99:3 109:10
respect 32:9 42:3	revealing 29:10	131:3,6 140:9	112:14 134:17
45:10,17 109:11	49:3 207:21	141:13 142:2,6,10	209:8 210:5
185:22 190:24	revenue 100:5,14	142:18 144:21	219:25 220:9,14
198:14 219:6	101:20,21 102:24	146:15 153:8,11	220:22 260:10
227:17 242:18	103:20 178:25	154:3 159:21	262:3
250:1 265:12	179:7,21 183:22	165:17 166:8	roles 77:15 102:14
269:25	183:24 184:1	167:13 175:11	102:20
respectively	186:22	184:3 186:19	romig 52:22
223:23	review 28:12 37:3	190:5 215:20	room 3:4 18:14
respond 40:19	39:4 105:19 118:4	221:4 229:16	25:1 26:16,18
85:9 132:20 141:2	126:13 228:17	236:9 240:15,25	27:7,9,16 34:9
141:4 247:2	229:24 239:24	249:19 254:1,11	62:22,25 67:7,23
responders 90:8	261:21 262:12	254:16 266:13	68:10 166:19
responding 293:7	264:25 271:16	281:20 285:24	175:25 270:6,11
response 8:19 9:2	275:16 283:6	287:14 288:10,17	ropes 6:13 20:17
34:24 148:10	288:2,3,14 319:8	289:17 291:20	ropesgray.com
150:2 151:17,24	320:3,7 323:12	292:6,19 293:4	6:15
155:14 189:6,9,13	324:1 325:1	294:24 297:8,19	rosen 259:25
189:23		297:25 298:1,9,16	

[rothenberg - seen] Page 49

250.25	1. 1. 4.0.7.0	257 2 24 25 262 5	41 17 (0 10 71 7
rothenberg 259:25	salimbene 4:8 7:9	257:2,24,25 260:5	41:17 69:12 71:5
roughly 103:5,11	20:4,4 207:2,4	260:13 263:22	117:4,19 119:20
146:15,18 148:3	214:24 215:6,10	264:18 265:20	119:21 120:4,7,9
180:25 181:2	215:18 216:2,9,14	271:22,23 272:3	150:23 152:3,6
rounds 260:15	219:11,14 227:9	272:24 292:1	174:1 180:23
261:10,15	227:16,19 228:16	293:1,21 306:16	189:8 194:4
route 74:24	232:22 234:22	315:25 317:10	203:19 214:15
rpr 1:25	235:5 244:3,9,12	scenes 34:9	224:15 225:6
ruiz 6:4 7:10 20:6	244:20 246:5,10	schedule 86:24	227:21 228:13,19
20:6 284:11,14	247:18 248:8	300:2,13,14	229:23 231:7
285:23 286:1	251:10,13,19	scheduled 30:11	236:11 237:17
314:17,22 315:5	254:2,8 258:24	30:22 86:20,25	248:23 249:2
316:4 318:8	259:6 267:14,21	146:12 299:20	250:11,14,16
rule 244:5	270:1 278:19	schedules 285:2	252:20 255:23
rules 21:10 24:15	283:20	school 56:11	257:7 260:2,18
55:1 62:22 67:23	samhsa 180:12,13	138:23	265:23 266:3
67:25 68:3 320:4	san 5:5	schools 138:23	272:12 291:22
320:8 324:5 325:5	sat 23:7 51:10,20	303:9	293:25 317:8
run 49:16 92:12	54:23	scope 82:1	seeing 78:8 88:14
134:24 185:19	satiate 235:22	screenings 138:3	88:16 174:3
rush 9:21 52:24	satisfy 97:1	script 222:14	202:23
255:13,23 256:1,2	save 278:7	seal 322:5 324:15	seek 113:18
259:25 271:19	saved 279:22	325:21	132:18 268:11
rx 6:3 20:8 260:17	saw 81:18 144:11	search 80:16	seeking 76:8
264:1 284:15	saying 25:16 42:13	170:19	113:21 133:3
S	70:14,21,22	second 36:2 54:21	140:6,20 144:1
	111:13 119:1	147:21,22 150:25	162:25 165:7
s 9:15 183:17,18	124:21 155:7	155:2,16 156:7	179:15 235:22
239:2 259:8	176:24 267:24	176:8 196:21	seen 30:18 37:1
323:15 325:8,8	309:7 316:13	239:19 247:15	39:1 52:23 84:7
326:3	says 38:6 41:10	258:25 263:20	85:25 89:7 106:2
safe 274:5,12	121:2,21 127:23	265:20 286:25	106:6 117:8
safety 87:14 89:5	146:13 147:19,23	287:5 295:14,16	119:18 144:6,7,8
89:17,23 90:5,7	152:2 155:4,20	295:16	144:14 146:6
115:5,7 158:10	156:17,21 159:23	seconds 215:12	158:3 167:14
230:21 236:25	176:10 226:9	section 99:2,7	189:8,19 201:9,10
279:18	227:12 228:21	241:11 306:16	201:12 202:6
sake 236:1	229:20,21 230:2	sections 41:6	203:11 204:23
salaries 104:5	231:1 239:13,14	secure 264:11	206:4,6 248:25
181:18	239:15 240:21	see 30:5,9,10	290:11,12 291:4,7
sale 242:25 244:16	246:11 250:13,16	35:25 38:4 41:14	
	, ,		

[seized - sorry] Page 50

seized 41:11 42:5	195:3 258:2	shortly 76:13	sitting 26:13 27:13
237:15	284:15 299:24	show 34:6 226:6	64:21
selected 67:2	serving 237:8	314:23	situation 80:17
252:20 254:15	session 145:4	showed 30:15	97:24 133:5,12
selecting 170:17	set 87:15 204:8	shown 323:16	317:14
self 170:17	210:7 225:18	shows 202:19	six 26:20 313:21
selling 242:19	230:16,21 237:1	shrugs 24:19	skip 178:17
243:16	238:6,9 242:1	side 41:5 231:11	slow 279:6,7
sells 218:11	297:24 298:14	282:17 317:21	slower 274:9
send 119:23 123:4	322:4	sided 227:8,11,11	smith 4:8 20:5
199:2	sets 119:6	sidedness 227:18	sold 155:17 156:8
sense 25:10 98:19	seven 104:17,18	sign 319:8	157:1,5 243:7
165:7 198:19	107:18 108:21	signature 320:6	264:9
236:15,20 237:7	284:1	322:11 323:14	solid 250:10,13,24
314:14	severe 43:21 46:17	signed 241:7,9	251:4 252:5,10,16
sent 37:11 107:10	47:3,12	324:13 325:18	solutions 4:3
161:13 230:5	sexually 221:11	significant 40:10	19:25 292:2,16
sentence 150:23	shannon 172:5,8	40:18 145:25	293:2 323:1 326:1
150:25 176:8,10	172:14	162:6 173:22	solve 292:22
231:2 240:21	shape 132:8	201:25 202:1	somebody 32:20
272:23 295:17	170:21 182:6	240:7 311:22	77:25 78:4,7
307:18	shapira 6:8 19:17	signing 238:20,22	89:13,22 95:24
separate 98:21	shapira.com 6:11	323:19	132:21 135:9
september 9:11	shared 48:7 214:8	similar 300:13	166:23 171:17
228:2	sharon 183:10	simple 66:1	226:1 232:13
sersis 80:18	sheena 52:22	251:17,22	265:15
serve 54:6,15	sheer 115:7	simply 124:22	somewhat 101:10
181:24 184:10	sheet 323:13 325:7	165:9 232:25	208:17
266:15	325:10,18 326:1	sims 2:5 21:5,5	soon 207:7 225:10
serves 266:1	shipped 155:19	sincere 239:14	soricelli 6:13
service 6:7 19:17	157:2,8,12 159:25	sincerely 239:15	20:16,16
22:1,4 267:11	161:6	323:21	sorry 30:8,9 41:16
316:14	ships 211:15	single 105:16	50:18 51:17 60:22
services 6:3 20:8	shirley 27:2	165:13 166:22	99:24 112:7 120:2
132:19 134:18	shkolnik 2:13 19:6	227:11 302:11	122:8 134:3
137:16 138:9,13	19:8	sir 68:22 69:7	145:17 156:4
141:20 151:18,20	shopping 310:14	251:19 323:10	172:11 179:17
158:10 178:24	short 42:23 57:14	sit 65:11 94:17	184:25 186:7
179:10,11,11	199:13 259:3	116:14 211:3	191:25 194:17
181:3 184:4,5,9	317:11,16	245:3 249:18	200:12 209:7
186:14 188:10,15		262:8	212:2 219:12

[sorry - square] Page 51

222:21 245:15	220:17 247:18	76:6 78:21 79:22	96:16 100:10	
247:19 248:11	290:18 291:5	84:5 85:3 86:2	118:1 130:10,23	
253:4 258:3	298:4 299:15	88:24 90:18,25	143:9 152:20	
259:14 269:18	speaking 64:7,8,9	92:9 95:3 102:3	153:5 154:15,20	
274:8,9,21 275:4	65:5,17,18,20,20	104:22,23 107:2	157:4 160:10,23	
277:5 278:18	66:6 68:21,25	107:17,25 112:11	161:9 192:11	
279:6 282:21	69:21 92:19	112:23 113:20	193:3,14 196:5	
293:12 302:14	158:16,18 247:17	116:22 129:22	221:20 231:13	
307:6,20 315:5	279:4	130:2 132:4	232:2,11,21	
sort 40:3 73:24	speaks 57:8 58:14	133:15 138:14	233:15 234:5	
173:24 175:9	61:23 62:5 86:24	158:11 159:10	235:15 237:11	
243:20 244:15	125:25 127:22	164:3 166:23	245:11 250:5	
sorts 59:24	128:22 129:7	167:12 175:13	253:3,18 257:12	
sosiak 79:8 80:21	131:8 227:4,8	176:1 177:25	257:20 264:17	
80:23 95:12 99:13	238:3,10,13	195:10,11,15,23	265:5 266:18	
114:10,20 115:13	241:23 243:24	197:5 198:9 201:7	267:4 268:4	
115:23 119:3	250:21 253:2,12	208:1,8 209:10	269:13 272:20	
120:10 122:1	254:23	210:9 214:1	274:2 276:8	
128:4,10	special 58:2 63:19	217:11 233:11	278:16 280:15	
sought 205:23	66:23 70:16 77:20	238:6,16 265:19	281:10 282:1,9	
sounds 317:1	80:9	272:22 282:13	283:2 290:17,23	
source 179:6	specialists 111:9	299:15 302:21	291:9 292:11,25	
205:13 206:17	specific 40:13	304:12 305:16	293:5 294:4,14	
219:18 253:19,21	46:11 50:22 57:21	309:12 313:6	296:2,10,16 299:2	
253:22 254:25	61:12 72:13 78:6	specificity 49:9	307:15 308:16	
sources 113:3	80:17 81:4,7	57:17 59:2,15,17	311:1,13 312:2,17	
118:3,19 127:14	84:15 89:20	60:11,18 63:12	314:7	
127:16 142:21	104:14 121:23	66:15 131:2	speed 106:22	
154:22,23,23	130:16 136:3	136:23 159:2	107:9	
166:5 168:7	150:12 165:14	197:7 198:16	spell 75:18	
181:14 202:13	166:16 172:18	209:23 219:17	spelling 190:1	
205:25	178:19 187:20	274:3	spent 28:9 51:7	
south 3:8	188:4 198:23	specifics 154:16	181:18	
sowell 183:16	201:3 203:10	209:8	spike 114:14	
spaeder 6:3 20:7	247:7 255:2	specified 321:20	spoke 271:24	
speak 57:7,13	267:17 280:12,18	spectrum 265:14	spoken 123:8	
61:22 62:1,6,8,17	301:4 308:9	speculation 41:22	174:14	
63:25 64:2,5,6	specifically 28:3	42:11 43:19 47:6	spots 186:24	
65:6,15,23 67:2,11	29:3 47:8 50:16	49:7 51:15 53:13	spread 279:16	
68:8 70:25 86:11	51:3 60:2 72:3,7	56:1 75:3,10	square 1:21 2:19	
92:6 158:13 201:7	72:11 73:21 75:14	78:15,24 95:19	4:9	
Varitant Lagal Calutions				

[ss - submitted] Page 52

ss 321:3	standard 258:15	statement 51:22	strap 207:7
stack 146:3	standards 316:1	151:7 152:8,10	strapped 178:4
staff 92:15,24 93:6	316:17	156:8,10,20 163:6	279:25 305:21
93:9,17 101:20	standing 114:24	211:4 246:8	strategy 200:1
102:7 104:3 105:2	185:9	272:24 274:15	strategy 200.1 street 4:9 5:4,8,18
102.7 104.3 103.2	stands 44:8 91:3	275:20 278:23	6:4,9 73:15
118:16,20 132:11	285:13	324:13,14 325:19	242:11,19
132:15 133:3,13	stankewicz 5:8	324.13,14 323.19	streets 243:8
132:15 133:3,13	19:18,18	statements 197:14	stretched 191:18
137:14 139:3,4,19	start 29:14 63:6	198:2 211:9	strict 57:12
150:18 159:6	74:7 99:21 108:19	states 1:1 151:4	strictly 127:20
181:5,5,10,23	126:24 167:2	157:2,17 160:6,14	252:1
186:21 187:8	168:14 173:9	161:7 175:9	strike 59:3 71:23
190:12 256:23	207:6 223:19		74:6 82:11 106:10
258:21 266:11	started 68:12	195:14,22 294:9 317:17	107:21 108:18
267:10 306:6	146:16 148:3	statewide 117:15	126:2 134:13
	164:15 174:10		177:13 193:21
308:6,6		stating 57:16	
staffers 104:7	195:24 204:14	231:20 232:25	214:25 218:16
105:25 107:12,19	225:10 316:7	statistics 82:1 99:5	222:9,9 234:22
staffing 103:25	starting 60:5	117:13 131:25	235:9,25 237:4
105:20 106:5,13	100:5 173:21	stenotypy 321:13	238:8 247:8
107:3 303:16	174:1 247:24	step 98:18	267:14 268:13
305:11	starts 150:24	steps 8:13 38:19	string 9:13 10:2,10
stakeholders	state 8:13 18:15	stettinius 1:20	229:12 271:9
261:16	21:17 38:19 45:8	18:9	295:6
stamp 8:9,13,20	63:11 65:7 66:15	stimulants 125:6	strive 266:10
8:23 9:3,7,9,12,14	114:16 117:11,16	stis 132:2 268:14	struggled 316:19
9:17,21 10:3,5,7,9	167:21 179:23	stop 62:9 63:19,23	studies 49:23
10:10 35:12 38:20	192:15 201:12,21	64:7,9 65:10 68:7	studying 173:21
148:13 157:24	202:3,21 213:4,9	70:15 231:25	313:23
189:14 224:9,21	250:1 252:12	235:4 268:11	styer 260:1
228:3 229:12	263:24 297:7,18	stopped 64:8	subcategories
239:5 255:14	307:3,21 309:13	stopping 279:16	240:19
271:9 286:6,12,18	321:2,7 322:13	stored 182:22	subdepartments
295:6	324:10 325:15	stores 305:9	98:22
stamped 8:11 9:5	stated 18:24	stories 61:4,11	subgroup 69:13
9:24 36:21 224:2	158:20 231:14,16	311:6,9,16	subject 85:4
259:19	257:10,17 267:25	story 48:6,7	224:15 228:9
stamps 314:25	268:5,8,24 269:1	straight 152:6	submit 264:8
stand 307:7	296:23 297:1	153:10 257:5	submitted 31:23
	316:21 319:4		74:22 76:7 240:10

[submitted - talk] Page 53

271.5	152 15	147 (15((150 1	
271:5	suggesting 153:15	147:6 156:6 159:1	synthetic 152:12
subpoenas 22:4	153:20 182:11	168:22 172:12	152:23 159:23
subscribed 324:10	suggests 255:5	174:22 177:21	204:15
325:14 326:21	293:3	178:5,6 181:5	system 165:20
substance 49:12	suing 140:1	187:3 188:14	260:18 264:2
49:24 71:18,19,25	141:23	189:10 192:2,13	266:2,16 268:2
72:6,9,14,17	suit 140:6	192:23 195:19	285:14
123:20 124:1	suite 1:21 2:6,15	196:22 197:24	t
131:23 133:18	2:19 3:13 4:9,14	199:14 200:17	table 64:21 82:7
138:18 160:5	5:9,13 6:5 323:2	209:14 210:3	tables 139:3
161:12,13,16	summer 87:13	212:3 213:8 223:4	tad 8:5 34:17
165:23 170:5,23	summit 3:6 19:1	228:16 229:19	taft 1:20 18:9
180:12 187:23	27:17	230:14 236:6,17	27:14
188:16 190:16	superior 323:1	240:9 242:16	take 18:18 21:19
232:14 235:8,9	supervise 118:24	243:13 249:24	24:21 25:25 37:3
260:7 276:5	supervises 119:4	252:1 253:5	39:3 42:23 53:21
296:25	supervisor 98:10	258:21 260:23	63:18,22,22 68:19
substances 49:3,4	128:14	261:6,8 274:23	70:15 74:12,12
145:9,19 148:21	supply 5:11 19:13	277:19 278:3	96:6 98:18 110:7
148:24 162:2,4	208:23 209:2,4	281:13 289:11	114:5 123:1
163:3 164:14	support 42:19	305:22 307:1,23	134:17,21 144:19
188:10,19 198:22	80:15 237:15	308:23 309:10	162:4 178:8
264:4,8 284:20,22	272:7,11,18	surely 222:4	185:12 199:13
substantive 29:10	supporting 42:18	surgeon 175:23	226:19 228:17
30:3	181:23	176:16,17 177:8	229:24 239:24
sued 43:14 47:19	suppose 147:14	260:21 261:17	270:14 274:18,25
143:24 207:9,9	307:17 308:5,10	surmise 103:12,13	275:8 314:11
241:21 242:4	sure 32:2 37:9	surprised 314:3,9	taken 1:19 22:12
243:19 278:6	39:25 41:9 42:25	surveillance	48:7 50:20,22
suffer 49:13	47:16 51:19 54:24	117:14	144:25 147:7,16
221:18 276:14	72:21 73:6 76:10	susman 2:13 19:7	163:25 168:12
278:13 280:6	77:12,17,22,23	19:7	232:6 243:7
suffered 43:21	85:13 90:2 91:2	suspect 296:5	321:19
46:17 47:3,12	94:13 100:4	suspend 93:16	takes 41:23 130:14
49:1,5 245:25	106:20 108:10	suspicious 220:5,8	talk 25:2 33:16
246:13	110:2 113:2,6	238:11 314:5	47:10 63:24 65:11
suffering 72:23	114:8 116:17	swear 20:21 21:8	111:24 115:1
73:3 91:18 212:15	118:11 120:3	swearing 317:1	122:1 123:5,13
277:9,17	121:18,24 124:6	sworn 21:11	132:17 133:4,23
suggest 292:8	131:21 132:19	321:10 324:10,13	152.17 153.4,25
294:2,6	134:7 139:12,22	325:14,18 326:21	164:3 170:25
			107.3 1/0.23

[talk - third] Page 54

171:22 269:19	146:9 163:17	temporary 276:14	teva 4:12 20:19
303:2 318:21	165:25 166:1	ten 175:9	thank 22:11 70:12
talked 97:6 104:4	167:23 177:6	tenure 59:5,21	108:20 219:14
122:12 137:25	184:22 185:5,14	60:14 71:16 73:8	267:22 269:4
141:17,23 144:17	186:6,10 286:5,11	73:17 87:12	283:20 287:7
159:6 160:17	286:17,24 287:13	317:16	316:5
162:18 172:17	287:16,20 288:25	tenures 317:11	theft 311:10
174:17 175:25	290:2 291:13	term 54:21 140:19	theodore 4:13
178:19,25 195:2,6	292:2,18,18,19	173:15,17 285:7	20:18
243:3 284:18	294:23 295:3,19	287:20 299:12	thing 25:20 190:3
303:7	295:25 297:2,23	310:16	223:7,12,14 261:5
talking 31:13,14	297:24 298:13,14	terminal 212:16	266:14 305:16
31:22 40:20 43:8	298:20 306:12,19	terminate 65:4	things 51:9 55:9
55:2 59:13 60:6	306:25 313:7,14	terminated 53:18	59:24 103:18
63:23 86:5 97:20	313:23 315:3,11	96:12 97:7,13	109:22 111:2,20
101:22 106:21,24	tasked 109:15	terms 89:1 109:22	115:25 133:20
107:1 110:22	tax 101:17	179:14 219:16	142:16 178:18
115:9,20,24 116:2	tb 138:7,8	223:2,2,14 236:20	193:18 203:22
124:4 125:20	tdayno 4:16	243:3 299:14	214:20 221:6
127:12 132:5,12	team 69:16 238:21	303:8 309:6	222:25 319:5
136:9 140:24	238:23 240:10	tested 205:7	think 25:8 46:11
141:6 145:8	256:5,9,12,19,24	testified 22:23	51:22 67:10 69:8
155:23 157:10	258:17	128:9 221:3	69:9 71:15 72:19
161:23 178:23	teaming 69:19	226:13 230:10	82:8 85:10,23
190:2 199:22	technical 310:15	249:6 262:23	141:2,5 153:10
214:16 215:10	telephone 2:5 4:12	263:8	214:12 221:3,16
270:15 303:11	4:17 6:12 20:25	testify 24:11 44:16	222:6 228:8
317:22	306:2	260:24 321:10	234:16 254:10
talks 129:14	telephonically	testimony 22:12	256:9 267:21
target 303:18	21:3	34:7 47:15 61:16	268:21 269:11
targeting 168:9	tell 34:14 35:19	163:10 164:5	280:9 283:21,25
targets 179:13,19	77:9 129:18 131:4	169:7 182:15	285:23 288:5
tariq 3:12 20:11	166:18 169:17	186:2 205:19	289:5 290:19
65:9,18	170:7 180:17	243:2 249:11,15	307:13 309:1,4,7
tariq.naeem 3:15	216:1 258:11	252:3 256:16	310:23 311:4,16
task 8:15,15 10:4	303:6 307:14	263:11 321:12,16	311:24 314:14
10:6,8,12 85:11,16	telling 42:4 66:20	324:6,7 325:6,9,12	315:4 317:3
85:17 109:20	70:18 137:18	testing 137:20,22	318:20
111:13,15,19,23	207:23	137:23 138:2,7,8	third 46:2 150:25
112:1,6,8,9,12,15	tells 128:25 129:4	tests 184:4	179:2 271:22
112:17,19 113:1	129:9 243:15		287:2 315:23

[third - transition] Page 55

	I	I	I
317:9	199:16 200:15	317:4 318:9	track 118:16
thirty 323:18	203:7,10,20 204:7	toinette 75:17	165:3,22 174:1
thomas 2:5 21:5	204:22 205:5	told 48:6 51:23	177:12,19,24
172:2	206:19,22,25	100:13,20 135:11	178:1 206:10,12
thompson 77:13	215:1 220:1	135:20 142:18	tracked 168:20
77:19 80:9	228:17 229:24	154:24 175:13	tracking 56:4
thought 89:12	236:1 239:24	196:12	116:13 178:7
110:16 226:13	252:6 254:4,7	tom 172:1	tracks 177:23
236:15,19 237:7	255:1 261:19	tomasello 27:3	tracy 77:12,19
240:9 270:23	262:3 270:15	tone 68:9,12 270:2	80:8
293:3	275:4 277:8	270:3	trafficking 41:11
three 4:9 52:18,21	282:24 283:25	tool 265:21 266:2	155:3,17
98:25 99:10	284:6,9 288:3	top 39:10,18 74:7	train 51:12 132:11
108:16 109:7	289:15 290:14,20	80:13 81:19	133:12
159:13 286:22	291:12 298:2	102:22 121:7	trained 93:10,14
287:8 315:17	305:15,17 316:7	175:9 220:17	93:17 95:21,24
threefold 173:25	319:2,11 321:19	225:6 226:8	97:22 98:4 133:8
thumb 244:5	times 22:15 27:23	228:22 229:2,6,22	139:8 181:7
tie 71:14	27:25 28:6 61:8	230:2 236:3	training 50:4,5,6
time 18:2 22:16	73:14 86:17	248:23 252:4,22	50:24 133:14,19
23:6 25:19 26:1,2	122:18 154:2	289:23 293:21,23	133:25 135:19,22
28:1,8,11 31:17	162:5 185:11	294:7,12 306:22	136:10,11,13,16
32:18 33:23 37:3	204:6 214:8	313:18 315:24,25	136:25 137:8
39:3 43:2,5 51:7	218:23	topic 23:14 86:25	317:12
54:7 56:6 58:18	title 74:8 77:22	88:22 261:11	trains 134:5
58:20 59:17 61:23	84:23,25 85:13	topical 199:12	135:10
62:5 64:11 65:16	127:3 149:25	topics 51:11	transaction 281:8
65:25 67:12 69:15	196:25 315:1	total 28:6	281:12
71:9,12 73:22	titled 155:13	totality 223:3	transcribed
75:1 76:17 77:15	today 26:6 27:8,9	252:11	321:14 324:7
82:20 90:20 93:11	33:13 34:6 116:14	touch 99:11	transcript 7:1
93:15 94:6,14,19	124:14 140:25	131:19 132:7,9,23	24:20 246:8 319:9
106:11 109:4	150:13,24 151:4	141:19	320:3,7,10,12
110:14,21 117:19	154:2 164:5	touches 108:7	323:11,12 324:5
120:16 122:15,19	166:19 169:10	touching 132:4	324:12 325:5,11
133:7 144:23	181:16,20 182:1	tour 185:18	325:17
145:2 156:15	211:3 214:8 221:4	town 261:3	transcription
163:21 165:20	226:3 245:3,21	toxicology 165:19	321:16
176:16 178:12	262:8,18,25	174:3 204:9 205:3	transition 238:21
185:21 187:6	279:22 283:24	trace 300:22 301:1	238:23 240:10
191:13 196:7	284:1 309:16	317:24	299:7

[transmit - united] Page 56

transmit 122:22	263:17 264:15,24	two 26:25 35:6	understand 25:7
transmitted	266:5,16 267:2	37:8 39:8 51:6	25:16,17 32:22
221:11	268:10,23 270:22	69:12 76:15 80:11	52:4 57:2 72:18
transportation	280:24 281:14,20	80:13 86:18 99:16	91:16 124:22
54:25	321:15	99:24 109:3	126:21 127:15
traub 5:12	trust 118:20	135:11 176:13	133:9 134:18
treat 184:13,19	truth 321:10,10,11	187:3,14 248:9	154:3 163:22
221:17	try 25:1 43:11	258:13 308:24	176:22,25 182:10
treated 276:20	55:11,13 57:20	315:17 317:10	190:1 204:4
277:1,10	84:20 163:3	type 61:20 81:25	214:21 246:6
treatment 41:13	165:21 168:7	88:3 120:13 123:7	263:14 267:23
42:9 55:11 74:4	169:1 178:18	189:1 191:7,11	269:15 279:5
82:2 99:5 133:10	185:18 202:14	233:17	301:15 302:14
138:14,18,22	204:4 223:3	typed 88:7,13	304:15
139:16 151:18	268:12 276:4	types 122:7 140:12	understanding
165:7 180:9	305:19 311:20	192:14 204:2	33:22 111:23
191:21 192:4	trying 68:7 96:25	u	112:13,16 132:17
195:3 237:16	124:22 126:21		152:15,21 153:1
303:10	127:17 135:1	u.s 156:9 u.s. 18:6 38:7	154:9 157:7,13
trend 203:13	139:17 163:21,24	146:8 155:19	188:12 192:12
252:5	164:20 165:3,4,7	157:9,12 163:11	198:10,18,24,25
trends 56:23 57:4	165:15 166:6	165:24 167:25	203:15 205:13
109:16 111:3,4,7	168:1,25 170:20	175:3,4,23 177:5	217:1,19,22,23
113:4 114:1	170:23 191:19	193:7 203:23	218:1,5 241:10
117:13 168:2	202:16 216:5,7,12	299:23	259:13 267:20
204:5	237:8 251:7	uh 24:23	268:16 283:3
trial 22:13 23:23	268:18 279:5,25	ultimately 78:12	317:13
24:11	292:15 301:6	um 55:4 99:8	understood 25:12
trick 251:7	306:4,6,9	126:19 185:2	76:14 77:24 96:23
tried 318:6	tsims 2:8	289:1 293:16	undertaken
trouble 267:20	tucker 3:11 20:10	313:20	105:11
268:16	20:11	unable 93:13	unfortunately
true 115:19 128:3	tucker.com 3:15	252:5 272:11	185:8 204:17
221:7,9 223:7	tuckerellis.com	undergraduate	313:2
228:20 230:5	3:15	49:17 50:10,12	unh 24:23,23
231:18 236:4	turn 62:6 291:17	53:23	unintentional
237:9 239:20,21	293:11 315:21,22	underlined 231:1	252:19 254:14,18
240:23 243:12,16	turned 88:16	underlying 51:12	257:4
243:18 250:19	146:24 162:1	underlying 31.12 underneath 150:3	unit 18:3
253:10,22 256:5	163:2	150:5 155:16	united 1:1 157:2
261:1 262:25		130.3 133.10	157:17 160:6,14

[united - way] Page 57

161:7 195:14,22	58:13 60:16 72:2	71:11 110:10,13	77:23 89:20
unofficial 185:22	88:20 97:17 103:1	144:22 145:1	111:22,25 144:19
updates 86:20	103:23 117:6	178:11,14 199:15	156:25 199:13
use 33:12 42:8	126:15 134:12	199:18 206:21,24	215:16,17,24
117:22 152:1	184:7 187:18	254:3,6 259:1,4	231:5,10,17,25
156:15 164:6	203:8 220:25	284:5,8 314:18,20	232:17 233:4
174:16 196:1,6	223:9,17 261:13	318:23 319:1,10	251:11,13,15
211:1 235:7,10	262:14 263:18	videotaped 1:15	270:9 272:7
242:10 269:5	277:2 279:2,11	virginia 5:9	283:22 303:2,11
273:20 275:24	280:7 296:15	visited 91:10	309:15 313:5,9
282:6 301:9,17	304:21	visits 8:18 119:12	314:23 317:21,21
305:22	valid 242:21	121:3,22 127:4,20	318:21
useful 269:12	273:24	127:25 128:20	wanted 105:10
270:24 309:2	variety 73:12	129:1,4,19,24	121:25 145:8
user 211:19	116:7 117:11	130:8,15	165:10 171:17
users 170:8 275:14	118:3 166:5	vital 131:24	237:7 256:4
276:4	167:20	vocal 40:17	272:16 284:20
uses 103:19	various 8:10 36:19	volume 115:7	wanting 258:21
118:16 179:7	51:11 56:13	218:1	wants 215:21
267:25	116:12 195:4	voluntarily 53:18	234:21
utilize 262:7	227:3	76:5 96:12	ward 54:8 58:21
utilizing 262:2	vehicle 113:15	W	59:3,5,21 71:17
V	ventura 2:6	w 183:17,18	72:23
v 1:10 323:6	verbalize 24:19	wait 222:17,17,17	warning 266:2,15
vacant 74:21	verbatim 217:10	waived 323:19	268:1
75:22 317:6	264:19,21 266:25	wal 19:15 301:25	warnings 209:25
vacated 78:3	268:5	304:7	washington 4:5
vaccinations	veritext 18:12,13	walgreens 302:4	5:18 6:5 62:3
135:25	323:1,7 326:1	304:5,17	waste 215:1
vaccine 132:22	veritext.com.	walker 77:12,18	way 64:17 65:12
133:3 136:21	323:17	98:11 122:7,9	66:22 70:20 132:8
vaccines 132:9	version 123:1	123:9 125:18	140:1 164:12,15
133:16 134:1,6,9	287:1,4 316:2	126:5 128:15	170:21 182:6,9
135:4,10,14	versus 131:5	walks 184:10	188:18 210:4,10
136:13,18 137:8	vice 9:15 239:3,12	walmart 3:16	210:15,20,24
137:15 221:14	240:12	want 33:11,14,16	213:14,15,17
vague 23:17 25:15	victims 172:8	34:14 43:10 45:14	238:10 241:15
, ugue 23.11 23.13	video 18:4		247:2 249:3 253:5
28.18 36.11 40.5	video 10.4	46:10 11 23:72	1
28:18 36:11 40:5 46:20 47:24 48:13	videographer 6:17	46:10,11 53:25 62:1 64:6 65:11	257:17,21 261:10
46:20 47:24 48:13	videographer 6:17 18:1,12 20:13,20	62:1 64:6 65:11	257:17,21 261:10 262:10,23,24
	videographer 6:17	ĺ ,	· ·

[way - zachary] Page 58

		100016555	
275:12 276:24	wheeling 5:9	103:8 106:21	y
277:7 317:9	whereof 322:4	109:23 138:23	y 250:12
ways 40:9 85:8	white 163:17	139:5,11 149:15	yeah 33:17 44:11
116:8 121:4,5	248:10	163:14 165:21	52:7 64:24 112:4
139:21 163:1	wholesalers 264:7	179:13 181:7	112:6 133:12
288:22 306:6	widely 294:18,19	191:12 240:1,8	142:19 147:15
wc.com 5:19	wildlife 208:13	268:12 279:17,20	187:19 278:2
we've 58:16	williams 5:12,17	282:17 283:13	293:8 299:5 311:8
102:11 106:21,24	19:12 20:2 62:2	306:10	316:9 317:7
118:21 132:4,13	windows 314:15	worked 89:18	year 51:5 75:24
133:12,19 144:2	wish 303:15	280:23 282:18	83:18 100:15,16
146:4,19 148:17	withdrawal	289:19	100:23 101:4,8,12
151:16 155:23	184:14,19	workers 139:8	103:6,10 122:18
172:17 178:19	withers 77:13,21	working 108:1,7	180:5,20 181:2
187:9 195:6	witness 2:3 18:20	115:10 139:8,10	190:9 200:20
203:19 232:3	20:21 21:8 22:5	211:5 289:16	202:21 206:2
242:24 243:3	25:24 31:8 33:25	293:9 308:7	231:6 233:5
275:17 303:7	34:4 43:25 44:10	works 128:7	247:24 250:11
311:8 313:8	44:15,20 57:7	298:18	252:20 253:9
website 264:20,22	63:15,17 64:11,13	worse 305:23	254:15 257:6
266:22 268:1	64:15 66:19 69:14	wrap 168:7	317:6,7
week 28:4,6 73:14	69:19 92:21 110:7	write 39:17 176:24	years 51:7 54:4
130:20,20	178:8 191:4	192:16 241:6	84:6 86:18 106:3
weekend 33:5 35:1	207:17 270:13	272:6,10,18	133:24 168:20
35:22 37:7 39:7	319:7 320:3 321:9	294:17	176:13 193:1,12
43:9 88:16 146:24	321:13,14,17	writer 190:16	203:14 204:24
weekly 8:17 56:3	322:4 323:8,11	writes 212:5	258:13 275:18
56:22 86:13,21	324:1,4,11 325:1,4	295:17	282:14 313:21
114:25 119:11	325:15	writing 273:6	yeses 24:22
weinograd 4:4	witness' 323:14	281:22 294:10	yesterday 32:25
19:23,23	woman 27:13	written 82:19 84:8	32:25 33:22
wen 9:15 239:2	women 139:6	87:7 88:17 136:1	271:14 318:12
wendy 52:21	word 125:15	136:4,18 160:2	york 2:15 6:14,14
went 21:23 43:7	178:24 267:22	174:22,24 210:21	younger 147:20
61:10 71:15 73:13	words 127:24	233:3 292:15	youth 138:24
76:9 104:2 106:8	268:6	wrong 66:25 90:25	
110:21 175:22	work 22:8,18,19	122:8 146:20	Z
281:5	30:14 31:24 52:4	wrote 156:13	zac.ciullo 4:20
west 5:9	52:13 79:11,13	176:13 177:4	zachary 4:18
whacked 38:9	80:1 83:10 89:16	273:3,12 296:8	20:14
	92:16 93:4 99:19		

[zarsaur - zuckerman.com]

Page 59

zarsaur 2:9
zarzaur 18:23
zarzaur.com 2:11
zimmermann 2:9
18:22,23
zip 56:4,4,22,25
121:4 130:19
zuckerman 6:3
20:7
zuckerman.com
6:6

Veritext Legal Solutions

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF SEPTEMBER 1,

2016. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.